0001558370-23-014250.txt : 20230809 0001558370-23-014250.hdr.sgml : 20230809 20230809160601 ACCESSION NUMBER: 0001558370-23-014250 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC CENTRAL INDEX KEY: 0001621227 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37368 FILM NUMBER: 231155109 BUSINESS ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX BUSINESS PHONE: 44 1235 430000 MAIL ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX FORMER COMPANY: FORMER CONFORMED NAME: Adaptimmune Ltd DATE OF NAME CHANGE: 20141001 10-Q 1 adap-20230630x10q.htm 10-Q
110816696096279407210500714349514745460001621227--12-312023Q200-0000000Non-accelerated Filer13518280449871098900.020.050.020.1021389000445200002035300094785000false0001621227us-gaap:CommonStockMember2022-01-012022-03-310001621227us-gaap:CommonStockMember2023-01-012023-03-310001621227us-gaap:CommonStockMember2022-04-012022-06-300001621227us-gaap:CommonStockMember2023-04-012023-06-300001621227us-gaap:RetainedEarningsMember2023-06-300001621227us-gaap:AdditionalPaidInCapitalMember2023-06-300001621227us-gaap:RetainedEarningsMember2023-03-310001621227us-gaap:AdditionalPaidInCapitalMember2023-03-310001621227us-gaap:RetainedEarningsMember2022-12-310001621227us-gaap:AdditionalPaidInCapitalMember2022-12-310001621227us-gaap:RetainedEarningsMember2022-06-300001621227us-gaap:AdditionalPaidInCapitalMember2022-06-300001621227us-gaap:RetainedEarningsMember2022-03-310001621227us-gaap:AdditionalPaidInCapitalMember2022-03-3100016212272022-03-310001621227us-gaap:RetainedEarningsMember2021-12-310001621227us-gaap:AdditionalPaidInCapitalMember2021-12-310001621227us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EmployeeSeveranceMember2023-01-012023-06-300001621227us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:EmployeeSeveranceMember2023-01-012023-06-300001621227adap:ResearchServiceRightsGrantedForPersonalizedTherapiesMemberadap:StrategicCollaborationAndLicenseAgreementMember2023-06-300001621227adap:ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMemberadap:StrategicCollaborationAndLicenseAgreementMember2023-06-300001621227adap:MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMemberadap:StrategicCollaborationAndLicenseAgreementMember2023-06-300001621227adap:MaterialRightForSecondOptionExtendResearchTermMemberadap:StrategicCollaborationAndLicenseAgreementMember2023-06-300001621227adap:MaterialRightForFirstOptionExtendResearchTermMemberadap:StrategicCollaborationAndLicenseAgreementMember2023-06-300001621227adap:StrategicCollaborationAndLicenseAgreementMember2023-06-300001621227adap:LtfuMember2023-06-300001621227adap:IgnyteMember2023-06-300001621227adap:GskTerminationAndTransferAgreementMember2023-06-300001621227adap:GSKCollaborationAndLicenseAgreementMember2023-06-300001621227adap:DevelopmentRevenueMember2023-04-012023-06-300001621227adap:DevelopmentRevenueMember2023-01-012023-06-300001621227adap:DevelopmentRevenueMember2022-04-012022-06-300001621227adap:DevelopmentRevenueMember2022-01-012022-06-300001621227us-gaap:OneTimeTerminationBenefitsMember2023-03-310001621227us-gaap:EmployeeSeveranceMember2023-01-012023-06-300001621227us-gaap:ResearchAndDevelopmentExpenseMember2023-06-022023-06-300001621227us-gaap:GeneralAndAdministrativeExpenseMember2023-06-022023-06-300001621227us-gaap:OneTimeTerminationBenefitsMember2023-06-300001621227us-gaap:ContractTerminationMember2023-06-300001621227us-gaap:OneTimeTerminationBenefitsMember2022-12-310001621227us-gaap:ContractTerminationMember2022-12-310001621227us-gaap:OneTimeTerminationBenefitsMember2023-04-012023-06-300001621227us-gaap:OneTimeTerminationBenefitsMember2023-01-012023-03-310001621227us-gaap:ContractTerminationMember2023-01-012023-03-310001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-04-012022-06-300001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001621227us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001621227us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001621227us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001621227us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001621227us-gaap:RetainedEarningsMember2023-04-012023-06-300001621227us-gaap:RetainedEarningsMember2023-01-012023-03-310001621227us-gaap:RetainedEarningsMember2022-04-012022-06-300001621227us-gaap:RetainedEarningsMember2022-01-012022-03-310001621227us-gaap:USTreasuryBillSecuritiesMember2023-06-300001621227us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001621227us-gaap:CorporateDebtSecuritiesMember2023-06-300001621227us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001621227us-gaap:CorporateDebtSecuritiesMember2022-12-310001621227adap:GskTerminationAndTransferAgreementMember2023-04-012023-06-300001621227adap:GskTerminationAndTransferAgreementMember2023-01-012023-06-300001621227us-gaap:CommonStockMember2023-06-300001621227us-gaap:CommonStockMember2023-03-310001621227us-gaap:CommonStockMember2022-12-310001621227us-gaap:CommonStockMember2022-06-300001621227us-gaap:CommonStockMember2022-03-310001621227us-gaap:CommonStockMember2021-12-3100016212272022-06-3000016212272021-12-310001621227adap:Tcr2TherapeuticsMemberus-gaap:RestrictedStockUnitsRSUMember2023-06-012023-06-010001621227adap:Tcr2TherapeuticsMember2023-05-310001621227adap:Tcr2TherapeuticsMember2023-06-012023-06-010001621227adap:Tcr2TherapeuticsMember2023-05-312023-05-310001621227us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-06-300001621227us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001621227us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001621227us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-06-300001621227us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-06-300001621227us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001621227us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001621227us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001621227us-gaap:FairValueMeasurementsRecurringMember2023-06-300001621227us-gaap:DebtSecuritiesMemberadap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember2023-06-300001621227adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember2023-06-300001621227adap:AgencyBondMaturityPeriodLessThanThreeMonthsMember2023-06-300001621227us-gaap:DebtSecuritiesMemberadap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember2023-06-300001621227us-gaap:CashAndCashEquivalentsMemberadap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember2023-06-300001621227us-gaap:DebtSecuritiesMember2023-06-300001621227us-gaap:CashAndCashEquivalentsMember2023-06-300001621227adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember2023-06-300001621227adap:TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember2023-06-300001621227adap:ReplacementAwardsGrantedToTcr2GrantholdersMember2023-01-012023-06-300001621227adap:EmployeeConsultantsAndDirectorsStockOptionsMember2023-01-012023-06-300001621227adap:EmployeeConsultantsAndDirectorsStockOptionsMember2022-01-012022-06-300001621227us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001621227us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001621227us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001621227us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001621227adap:Tcr2TherapeuticsMember2023-01-012023-05-310001621227us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001621227us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001621227us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001621227us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001621227adap:Tcr2TherapeuticsMember2022-01-012022-06-300001621227us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001621227us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001621227us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001621227us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016212272022-01-012022-03-310001621227us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300001621227us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001621227us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001621227us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300001621227us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310001621227us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001621227us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001621227us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001621227us-gaap:CustomerConcentrationRiskMember2022-12-3100016212272023-08-0700016212272023-03-310001621227adap:MDAndersonStrategicAllianceMember2017-01-012017-12-310001621227us-gaap:CollaborativeArrangementMember2023-06-300001621227adap:GskTerminationAndTransferAgreementMember2023-04-060001621227adap:SalesAgreementMember2023-01-012023-06-300001621227adap:SalesAgreement2022Member2023-01-012023-06-300001621227srt:MaximumMemberadap:SalesAgreement2022Member2022-04-082022-04-080001621227srt:MaximumMemberadap:SalesAgreementMember2020-08-102020-08-100001621227adap:ReplacementAwardsGrantedToTcr2GrantholdersMember2023-06-012023-06-010001621227adap:GSKCollaborationAndLicenseAgreementMember2022-12-190001621227adap:Tcr2TherapeuticsMember2023-03-060001621227adap:GskTerminationAndTransferAgreementMember2023-06-012023-06-3000016212272023-06-022023-06-300001621227adap:UniversalCellsIncMemberadap:CollaborationAndLicenseAgreementMember2023-06-300001621227us-gaap:CustomerConcentrationRiskMember2023-06-3000016212272023-04-012023-06-3000016212272022-04-012022-06-300001621227us-gaap:CollaborativeArrangementMember2023-01-012023-06-300001621227adap:MDAndersonStrategicAllianceMember2022-01-012022-12-310001621227adap:MDAndersonStrategicAllianceMember2021-01-012021-12-310001621227adap:MDAndersonStrategicAllianceMember2020-01-012020-12-310001621227adap:MDAndersonStrategicAllianceMember2018-01-012018-12-310001621227adap:MDAndersonStrategicAllianceMembersrt:MinimumMember2016-09-260001621227adap:UniversalCellsIncMemberadap:CollaborationAndLicenseAgreementMember2015-11-012015-11-300001621227adap:UniversalCellsIncMemberadap:CollaborationAndLicenseAgreementMember2018-01-012018-12-310001621227adap:UniversalCellsIncMemberadap:CollaborationAndLicenseAgreementMember2017-01-012017-12-310001621227adap:UniversalCellsIncMemberadap:CollaborationAndLicenseAgreementMember2016-02-012016-02-290001621227adap:UniversalCellsIncMemberadap:CollaborationAndLicenseAgreementMember2022-12-3100016212272023-01-012023-03-3100016212272022-01-012022-12-310001621227adap:Tcr2TherapeuticsMember2023-06-010001621227adap:Tcr2TherapeuticsMember2023-06-010001621227adap:AdaptimmuneMember2023-06-010001621227adap:Tcr2TherapeuticsMember2023-01-012023-06-3000016212272023-06-010001621227srt:MaximumMemberus-gaap:DebtSecuritiesMemberadap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember2023-01-012023-06-300001621227srt:MaximumMemberus-gaap:CashAndCashEquivalentsMemberadap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember2023-01-012023-06-300001621227srt:MinimumMemberadap:TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember2023-01-012023-06-300001621227srt:MinimumMemberadap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember2023-01-012023-06-300001621227srt:MinimumMemberadap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember2023-01-012023-06-300001621227srt:MaximumMemberadap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember2023-01-012023-06-300001621227srt:MaximumMemberadap:TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember2023-01-012023-06-300001621227srt:MaximumMemberadap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember2023-01-012023-06-300001621227srt:MaximumMemberadap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember2023-01-012023-06-300001621227srt:MaximumMemberadap:AgencyBondMaturityPeriodLessThanThreeMonthsMember2023-01-012023-06-3000016212272023-01-012023-06-3000016212272022-01-012022-06-3000016212272023-06-3000016212272022-12-31iso4217:GBPxbrli:sharesadap:securityiso4217:USDadap:leasexbrli:pureadap:itemadap:contractadap:customeriso4217:GBPiso4217:USDxbrli:sharesxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number  001-37368

ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of Registrant as specified in its charter)

England and Wales

Not Applicable

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

60 Jubilee Avenue, Milton Park

Abingdon, Oxfordshire OX14 4RX

United Kingdom

(Address of principal executive offices)

(44) 1235 430000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share

ADAP

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes    No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filerx

Smaller reporting company x

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes    No

As of August 7, 2023, the number of outstanding ordinary shares par value £0.001 per share of the Registrant is 1,357,031,946.

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION

4

Item 1.

Financial Statements:

4

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022

4

Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022

5

Unaudited Condensed Consolidated Statements of Comprehensive Profit/Loss for the three and six months ended June 30, 2023 and 2022

6

Unaudited Condensed Consolidated Statements of Change in Equity for the three and six months ended June 30, 2023 and 2022

7

Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022

9

Notes to the Unaudited Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

39

Item 4.

Controls and Procedures

39

PART II — OTHER INFORMATION

40

Item 1.

Legal Proceedings

40

Item 1A.

Risk Factors

40

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

41

Item 3.

Defaults Upon Senior Securities

41

Item 4.

Mine Safety Disclosures

41

Item 5.

Other Information

41

Item 6.

Exhibits

42

Signatures

43

2

General information

In this Quarterly Report on Form 10-Q (“Quarterly Report”), “Adaptimmune,” the “Group,” the “Company,” “we,” “us” and “our” refer to Adaptimmune Therapeutics plc and its consolidated subsidiaries, except where the context otherwise requires.

Information Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” or the negative of these words or other comparable terminology.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those discussed in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2023, those discussed in the section titled “Risk Factors” included under Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 12, 2023 and those discussed in the section titled “Risk Factors” included under Part II, Item 1A below. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources.

3

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

ADAPTIMMUNE THERAPEUTICS PLC

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

June 30, 

December 31, 

    

2023

    

2022

Assets

Current assets

Cash and cash equivalents

$

76,969

$

108,033

Marketable securities - available-for-sale debt securities

127,738

96,572

Accounts receivable, net of allowance for expected credit losses of $0 and $0

2,970

7,435

Other current assets and prepaid expenses

54,094

43,330

Total current assets

261,771

255,370

Restricted cash

3,231

1,569

Operating lease right-of-use assets, net of accumulated amortization of $11,258 and $9,470

22,027

18,019

Property, plant and equipment, net of accumulated depreciation of $40,635 and $38,588

55,492

53,516

Intangible assets, net of accumulated amortization of $5,003 and $4,676

463

442

Total assets

$

342,984

$

328,916

Liabilities and stockholders’ equity

Current liabilities

Accounts payable

$

14,713

$

4,753

Operating lease liabilities, current

4,752

2,728

Accrued expenses and other current liabilities

25,242

31,215

Restructuring provision

2,285

Deferred revenue, current

31,418

23,520

Total current liabilities

76,125

64,501

Operating lease liabilities, non-current

21,590

20,349

Deferred revenue, non-current

117,257

160,892

Other liabilities, non-current

1,361

1,296

Total liabilities

216,333

247,038

Stockholders’ equity

Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,351,828,044 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)

1,851

1,399

Additional paid in capital

1,057,547

990,656

Accumulated other comprehensive loss

(3,092)

(875)

Accumulated deficit

(929,655)

(909,302)

Total stockholders' equity

126,651

81,878

Total liabilities and stockholders’ equity

$

342,984

$

328,916

See accompanying notes to unaudited condensed consolidated financial statements.

4

ADAPTIMMUNE THERAPEUTICS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

Three months ended

    

Six months ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Revenue

$

5,130

$

5,538

$

52,731

$

9,113

Operating expenses

Research and development

(29,965)

(34,740)

 

(55,513)

 

(71,492)

General and administrative

(20,073)

(14,550)

 

(40,470)

 

(31,354)

Total operating expenses

(50,038)

(49,290)

(95,983)

 

(102,846)

Operating loss

(44,908)

(43,752)

 

(43,252)

 

(93,733)

Interest income

1,543

357

 

2,219

 

695

Gain on bargain purchase

22,155

 

22,155

 

Other income (expense), net

501

(655)

 

(170)

 

(643)

Loss before income tax expense

(20,709)

(44,050)

 

(19,048)

 

(93,681)

Income tax expense

(680)

(470)

 

(1,305)

 

(1,104)

Net loss attributable to ordinary shareholders

$

(21,389)

$

(44,520)

$

(20,353)

$

(94,785)

Net loss per ordinary share

Basic and diluted

$

(0.02)

$

(0.05)

$

(0.02)

$

(0.10)

Weighted average shares outstanding:

Basic and diluted

1,108,166,960

962,794,072

 

1,050,071,434

 

951,474,546

See accompanying notes to unaudited condensed consolidated financial statements.

5

ADAPTIMMUNE THERAPEUTICS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS

(In thousands)

Three months ended

Six months ended

June 30, 

June 30, 

    

2023

    

2022

2023

2022

Net loss

$

(21,389)

$

(44,520)

$

(20,353)

$

(94,785)

Other comprehensive (loss)/income, net of tax

Foreign currency translation adjustments, net of tax of $0, and $0

(12,281)

47,694

(29,190)

64,486

Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0

10,590

(39,108)

26,116

(52,916)

Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0

385

(316)

857

(1,471)

Total comprehensive loss for the period

$

(22,695)

$

(36,250)

$

(22,570)

$

(84,686)

See accompanying notes to unaudited condensed consolidated financial statements.

6

ADAPTIMMUNE THERAPEUTICS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY

(In thousands, except share data)

Accumulated

Additional

other

Total

Common

Common

paid in

comprehensive

Accumulated

stockholders'

    

stock

    

stock

    

capital

    

(loss) / gain

    

deficit

equity

Balance as of January 1, 2023

987,109,890

$

1,399

$

990,656

$

(875)

$

(909,302)

$

81,878

Net profit

 

 

 

 

1,036

1,036

Other comprehensive loss

(910)

(910)

Issuance of shares upon exercise of stock options

 

6,035,574

 

7

 

1

 

 

8

Issuance of shares upon completion of public offering, net of issuance costs

554,496

1

187

188

Share-based compensation expense

 

 

 

1,676

 

 

1,676

Balance as of March 31, 2023

 

993,699,960

$

1,407

$

992,520

$

(1,785)

$

(908,266)

$

83,876

Net loss

 

 

 

 

(21,389)

(21,389)

Other comprehensive loss

(1,307)

(1,307)

Issuance of shares upon exercise of stock options

 

698,778

 

1

 

13

 

 

14

Issuance of shares upon acquisition of TCR2

357,429,306

443

60,320

60,763

Share-based compensation expense

 

 

 

4,694

 

 

4,694

Balance as of June 30, 2023

 

1,351,828,044

$

1,851

$

1,057,547

$

(3,092)

$

(929,655)

$

126,651

See accompanying notes to unaudited condensed consolidated financial statements.

7

ADAPTIMMUNE THERAPEUTICS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY

(In thousands, except share data)

Accumulated

Additional

other

Total

Common

Common

paid in

comprehensive

Accumulated

stockholders’

stock

stock

capital

(loss) / gain

deficit

equity

Balance as of January 1, 2022

 

937,547,934

$

1,337

$

959,611

$

(11,142)

$

(743,846)

$

205,960

Net loss

 

(50,265)

(50,265)

Other comprehensive gain

1,829

1,829

Issuance of shares upon exercise of stock options

 

3,318,072

5

30

35

Share-based compensation expense

 

5,586

5,586

Balance as of March 31, 2022

 

940,866,006

$

1,342

$

965,227

$

(9,313)

$

(794,111)

$

163,145

Net loss

 

 

 

 

 

(44,520)

 

(44,520)

Other comprehensive gain

8,270

8,270

Issuance of shares upon exercise of stock options

 

759,336

 

1

 

 

 

 

1

Issuance of shares under At The Market sales agreement, net of commission and expenses

35,134,182

44

9,932

 

9,976

Share-based compensation expense

 

 

 

5,045

 

 

 

5,045

Balance as of June 30, 2022

 

976,759,524

$

1,387

$

980,204

$

(1,043)

$

(838,631)

$

141,917

See accompanying notes to unaudited condensed consolidated financial statements.

8

ADAPTIMMUNE THERAPEUTICS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

Six months ended

June 30, 

    

2023

    

2022

Cash flows from operating activities

Net loss

$

(20,353)

$

(94,785)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

3,824

2,728

Amortization

253

419

Gain on bargain purchase

(22,155)

Share-based compensation expense

5,513

10,631

Unrealized foreign exchange losses/(gains)

377

(108)

(Accretion)/amortization on available-for-sale debt securities

(633)

1,636

Other

663

585

Changes in operating assets and liabilities:

Decrease/(increase) in receivables and other operating assets

1,971

(22,898)

(Decrease)/increase in payables and other current liabilities

(8,801)

12,898

Decrease in deferred revenue

(41,704)

(6,758)

Net cash used in operating activities

(81,045)

(95,652)

Cash flows from investing activities

Acquisition of property, plant and equipment

(3,565)

(16,074)

Acquisition of intangible assets

(199)

Acquired upon acquisition of TCR2 Therapeutics Inc.

45,264

Maturity or redemption of marketable securities

76,119

97,605

Investment in marketable securities

(67,121)

(42,197)

Other

537

Net cash provided by investing activities

51,035

39,334

Cash flows from financing activities

Proceeds from issuance of common stock from offerings, net of commissions and issuance costs

188

9,976

Proceeds from exercise of stock options

22

36

Net cash provided by financing activities

210

10,012

Effect of currency exchange rate changes on cash, cash equivalents and restricted cash

398

(5,836)

Net decrease in cash, cash equivalents and restricted cash

(29,402)

(52,142)

Cash, cash equivalents and restricted cash at start of period

109,602

151,666

Cash, cash equivalents and restricted cash at end of period

$

80,200

$

99,524

See accompanying notes to unaudited condensed consolidated financial statements.

9

ADAPTIMMUNE THERAPEUTICS PLC

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 General

Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients.

The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of $929,655,000 as of June 30, 2023.

Note 2 Summary of Significant Accounting Policies

(a)          Basis of presentation

The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.

The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.

(b)          Use of estimates in interim financial statements

The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

10

(c)          Fair value measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:

Level 1 - Quoted prices in active markets for identical assets or liabilities

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability

The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.

(d)          Significant concentrations of credit risk

The Company held cash and cash equivalents of $76,969,000, marketable securities of $127,738,000 and restricted cash of $3,231,000 as of June 30, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.

The Company had two customers during the three months ended June 30, 2023 which are Genentech and GSK, and three during the six months ended, June 30, 2023, which also includes Astellas. There were accounts receivable of $2,970,000 as of June 30, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no credit losses have been recognized. As of June 30, 2023, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of June 30, 2023 is considered to be remote.

Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.

(e) New accounting pronouncements

Adopted in the current period

Measurement of credit losses on financial instruments

In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.

11

Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition. There was also no impact from adopting this standard on the acquisition accounting for TCR2 Therapeutics Inc. as no contracts with customers were assumed as a result of the business combination.

(f)          Business combinations

The Company determines whether a transaction or other event is a business combination by determining whether the assets acquired and liabilities assumed constitute a business. Business combinations are accounted for by applying the acquisition method as set out by ASC 805 Business combinations. The acquisition method of accounting requires the acquirer to recognize and measure all identifiable assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values, with certain exceptions for specific items.

For leases acquired in a business combination in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The right-of-use asset shall be measured at the same amount as the lease liability, adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. For leases in which the acquired entity is a lessee, the Company has elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less.

Goodwill is measured as the excess of the consideration transferred in the business combination over the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed. If instead the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed exceeds the consideration transferred, a gain on bargain purchase is recognized in the Consolidated Statement of Operations. The consideration transferred in a business combination is measured as the sum of the fair values of the assets transferred by the acquiring entity, the liabilities incurred by the acquiring entity to former owners of the acquired entity, and the equity interests issued by the acquiring entity.

The results of operations of businesses acquired by the Company are included in the Company’s Consolidated Statement of Operations as of the respective acquisition date.

Where the acquiring entity exchanges its share-based payment awards for awards held by grantees of the acquiree, such exchanges are treated as a modification of share-based payment awards and are referred to as replacement awards. The replacement awards are measured as of the acquisition date and the portion of the fair-value-based measure of the replacement award that is attributable to pre-combination vesting is considered part of the consideration transferred. For awards with service-based vesting conditions only, the amount attributable to pre-combination vesting is the fair-value-based measure of the acquiree award multiplied by the ratio of the employee’s pre-combination service period to the greater of the total service period of the original service period of the acquiree award.

Acquisition-related costs, including advisory, legal and other professional fees and administrative fees are expensed as incurred except for the costs of issuing equity securities, which are recognized as a reduction to the amounts recognized in the Statement of Changes in Equity for the respective equity issuance.

12

Note 3 Revenue

The Company had two revenue-generating contracts with customers in the three months, and three in the six months, ended June 30 2023, compared to three in the three and six months ended June 30, 2022: a collaboration agreement with Astellas that was terminated as of March 6, 2023, a strategic collaboration and license agreement with Genentech and a termination and transfer agreement with GSK that was effective on April 6, 2023. The original collaboration and license agreement with GSK was terminated in 2022.

Revenue comprises the following categories (in thousands):

Three months ended

 

Six months ended

 

June 30, 

June 30, 

     

2023

     

2022

2023

     

2022

Development revenue

 

$

5,130

 

$

5,538

$

52,731

 

$

9,113

 

$

5,130

 

$

5,538

$

52,731

 

$

9,113

Deferred revenue decreased by $35,737,000 from $184,412,000 at December 31, 2022 to $148,675,000 at June 30, 2023 primarily due to revenue recognized during the quarter but was partially offset by a $9,613,000 payment from GSK and a $5,890,000 increase caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.21 at December 31, 2022 to £1.00 to $1.26 at June 30, 2023.

As of December 31, 2022, there was deferred revenue of $184,412,000 of which $52,046,000 was recognized as revenue in the six months ended June 30, 2023

The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of June 30, 2023 was $318,107,000.

The Genentech Collaboration and License Agreement

The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Genentech agreement as of June 30, 2023 was $280,250,000. Of this amount $171,816,000 is allocated to the research services and rights granted for the initial ‘off-the-shelf’ collaboration targets, $89,098,000 is allocated to the research services and rights granted for the personalized therapies, $13,052,000 is allocated to the material rights to designate the additional ‘off-the-shelf’ collaboration targets, $5,027,000 is allocated to the material right for the first option to extend the research term and $1,257,000 is allocated to the material right for the option to extend the research term a second time.

The Company expects to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progresses and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expects to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options are exercised and then as development progresses, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expire. The Company expects to satisfy the performance obligations relating to the material rights to extend the research term from the point that the options are exercised and then over the period of the extension, or at the point in time that the rights expire.

The Astellas Collaboration Agreement

The Company and Universal Cells mutually agreed to terminate the Astellas Collaboration Agreement as of March 6, 2023 (the “Termination Date”). In connection with the termination, all licenses and sublicenses granted to either party pursuant to the Collaboration Agreement ceased as of the Termination Date. There were no termination penalties in connection with the termination, however the Company is still entitled to receive reimbursement for research and development work performed up to and including a period of 30 days after the Termination Date.

13

The Company originally satisfied the performance obligations relating to the three co-development targets as development progresses and recognized revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company originally determined that the performance obligations relating to the two independent Astellas targets would be recognized at a point-in-time, upon commencement of the licenses in the event of nomination of the target, since they were right-to-use licenses.

The termination was accounted for as a contract modification on a cumulative catch-up basis. No performance obligations were identified as a result of the modification as there were no further goods or services to be provided by the Company and the modification resulted in the remaining unsatisfied and partially satisfied performance obligations under the collaboration becoming fully satisfied. The aggregate transaction price of the contract modification was $42,365,000 which included the remaining deferred income that had not been recognized as revenue as of the date of the modification and variable consideration from the remaining reimbursement income to be billed under the collaboration at the end of the 30 day period after the Effective Date. The transaction price of the modification was recognized in full in March 2023 and there is no remaining transaction price allocated to performance obligations that are unsatisfied or partially satisfied under, no remaining deferred income relating to, the agreement as of June 30, 2023 and no revenue was recognized in the three months ended June 30, 2023.

The GSK Collaboration and License Agreement

The GSK Collaboration and License Agreement consisted of multiple performance obligations, including the development of a third target, which was the only performance obligation for which revenue was recognized in 2022.

The collaboration was terminated by GSK in October 2022 (effective December 23, 2022). A further amendment to the collaboration agreement was entered into on December 19, 2022 for the deletion of certain provisions relating to GSK’s post termination manufacturing and supply obligations and payment of £5,000,000 by GSK to Adaptimmune. The aggregate transaction price of the contract modification was $6,500,000, which was recognized as revenue on the date of the modification. No revenue was recognized in relation to the GSK Collaboration and License Agreement in 2023.

The GSK Termination and Transfer Agreement

On April 6, 2023, the Company and GSK entered into a Termination and Transfer Agreement (the “Termination and Transfer Agreement”) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program.

As part of the agreement, sponsorship and responsibility for the ongoing IGNYTE and long-term follow-up (“LTFU”) trials relating to the NY-ESO cell therapy program will transfer to Adaptimmune. In return for this, Adaptimmune received an upfront payment of £7.5 million in June 2023 following the signing of the agreement and further milestone payments totalling £22.5 million will be due in relation to successive stages of transfer of the trials.

The Company determined that GSK is a customer and has accounted for the agreement under ASC 606 Revenue from contracts with customers. The agreement is accounted for as a separate contract from the original GSK Collaboration and License Agreement. The Company has identified the following performance obligations under the agreement: (i) to take over sponsorship for the IGNYTE trial and (ii) to take over sponsorship for the LTFU trial.

The aggregate transaction price at inception of the agreement was $37,335,000 comprising the total £30,000,000 upfront and milestone payments. No value was ascribed to non-cash consideration and there was no variable consideration identified. The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the relative standalone selling price, the Company considered the internal pricing objectives it used in negotiating the contract, together with internal data regarding the expected costs and a standard margin on those costs, for completing the trials. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation.

The Company expects to satisfy the IGNYTE performance obligation as sponsorship of the active trials that make up the IGNYTE trial transfers, based on the number of patients transferring to the Company in each trial. The Company considers that this

14

depicts the progress of the transfer of sponsorship of the IGNYTE trial to the Company, as each individual trial comprising IGNYTE transferred represents the transfer of a portion of the sponsorship for IGNYTE.

The Company expects to satisfy the LTFU performance obligation as sponsorship of the trials that make up the LTFU trial transfers, including trials for potential future patients transferring to the LTFU trial from the IGNYTE trial, based on the number of active and potential patients transferring in each trial. The Company considers that this depicts the progress of the transfer of sponsorship of the LTFU trial to the Company, as each individual trial comprising LTFU transferred represents the transfer of a portion of sponsorship for the LTFU trial and the sponsorship of patients transferring from IGNYTE in future is part of the promise to take on the overall LTFU trial.

No revenue was recognized for the agreement in the three and six months ended June 30, 2023. The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of June 30, 2023 was $37,857,000, of which $21,200,000 is allocated to the IGNYTE performance obligation and $16,657,000 is allocated to the LTFU performance obligation.

Note 4 Loss per share

The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):

Three months ended

Six months ended

June 30, 

June 30, 

     

2023

     

2022

     

2023

     

2022

Numerator for basic and diluted loss per share

Net loss attributable to ordinary shareholders

 

$

(21,389)

 

$

(44,520)

 

$

(20,353)

 

$

(94,785)

Net loss attributable to ordinary shareholders used for basic and diluted loss per share

$

(21,389)

$

(44,520)

$

(20,353)

$

(94,785)

Three months ended

Six months ended

June 30, 

June 30, 

 

2023

    

2022

     

2023

     

2022

Denominator for basic loss per share - Weighted average shares outstanding

 

1,108,166,960

 

962,794,072

 

1,050,071,434

 

951,474,546

The dilutive effect of 201,688,491 and 150,711,054 stock options outstanding as of June 30, 2023 and 2022 respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2023 and 2022 because they would have an antidilutive effect on the loss per share for the period. The stock options outstanding as of June 30, 2023 includes a provisional amount of 35,156,344 replacement awards granted to TCR2 grantholders on June 1, 2023.

Note 5 Accumulated other comprehensive loss

The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.

15

The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):

Accumulated

Accumulated

Total

foreign

unrealized

accumulated

currency

(losses) gains on

other

    

translation

    

available-for-sale

comprehensive

adjustments

debt securities

(loss) income

Balance at January 1, 2023

 

$

55

$

(930)

$

(875)

Foreign currency translation adjustments

(16,908)

(16,908)

Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0

15,526

15,526

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

472

472

Balance at March 31, 2023

$

(1,327)

$

(458)

(1,785)

Foreign currency translation adjustments

(12,281)

(12,281)

Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0

10,590

10,590

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

385

385

Balance at June 30, 2023

$

(3,019)

$

(73)

$

(3,092)

Accumulated

Accumulated

Total

foreign

unrealized

accumulated

currency

(losses) on

other

    

translation

    

available-for-sale

comprehensive

adjustments

debt securities

(loss) income

Balance at January 1, 2022

 

$

(10,785)

$

(357)

(11,142)

Foreign currency translation adjustments

16,792

16,792

Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0

(13,808)

(13,808)

Unrealized holding losses on available-for-sale debt securities, net of tax of $0

(1,155)

(1,155)

Balance at March 31, 2022

$

(7,801)

$

(1,512)

(9,313)

Foreign currency translation adjustments

47,694

47,694

Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0

(39,108)

(39,108)

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

(316)

(316)

Balance at June 30, 2022

785

$

(1,828)

(1,043)

16

Note 6 Fair value measurements

Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of June 30, 2023 are as follows (in thousands):

Fair value measurements using

June 30, 

Level 1

Level 2

Level 3

     

2023

    

    

    

Assets classified as cash equivalents:

U.S. Treasury securities

$

29,102

$

$

29,102

$

Assets classified as available-for-sale debt securities:

Corporate debt securities

$

24,928

$

24,928

$

$

U.S. Treasury securities

$

94,917

$

94,917

Agency bonds

 

$

7,893

7,893

 

$

127,738

$

24,928

 

$

102,810

 

$

The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.

Note 7 — Marketable securities – available-for-sale debt securities

As of June 30, 2023, the Company has the following investments in marketable securities (in thousands):

Gross

Gross

Aggregate

Remaining

Amortized

unrealized

unrealized

estimated

    

contractual maturity

    

cost

    

gains

    

losses

    

fair value

Cash equivalents:

 

  

 

  

 

  

 

  

 

  

U.S. Treasury securities

Less than 3 months

29,069

33

29,102

 

  

$

29,069

$

33

$

$

29,102

Available-for-sale debt securities:

 

  

 

  

 

  

 

  

 

  

Corporate debt securities

 

Less than 3 months

$

16,258

$

$

(26)

$

16,232

U.S. Treasury securities

Less than 3 months

41,675

12

(5)

41,682

Agency bonds

Less than 3 months

5,008

(56)

4,952

U.S. Treasury securities

3 months to 1 year

53,225

19

(9)

53,235

Agency bonds

3 months to 1 year

2,949

(8)

2,941

Corporate debt securities

3 months to 1 year

8,726

2

(32)

8,696

 

  

$

127,841

$

33

$

(136)

$

127,738

17

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of June 30, 2023 and December 31, 2022 are as follows:

June 30, 2023

December 31, 2022

     

Fair market value of investments in an unrealized loss position

Number of investments in an unrealized loss position

Unrealized losses

Fair market value of investments in an unrealized loss position

Number of investments in an unrealized loss position

Unrealized losses

Marketable securities in a continuous loss position for 12 months or longer:

Corporate debt securities

$

15,554

4

$

(50)

$

74,481

16

$

(679)

Agency bond

4,952

1

(56)

4,854

1

(154)

Marketable securities in a continuous loss position for less than 12 months:

Corporate debt securities

 

$

6,424

 

2

$

(8)

 

$

11,283

 

2

 

$

(97)

U.S. Treasury securities

$

31,608

 

11

 

(14)

 

 

 

Agency bond

$

2,941

1

(8)

 

$

61,479

 

19

$

(136)

 

$

90,618

 

19

 

$

(930)

As of June 30, 2023, no allowance for expected credit losses has been recognized in relation to securities in an unrealized loss position. This is because the impairments are not severe, do not represent a significant proportion of the total fair market value of the investments and all securities have an investment-grade credit rating. Furthermore, the Company does not intend to sell the debt securities in an unrealized loss position, believes that it has the ability to hold the debt securities to maturity, and it is currently unlikely that the Company will be required to sell these securities before the recovery of the amortized cost.

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):

June 30, 

December 31, 

    

2023

    

2022

Research and development credits receivable

 

$

37,863

$

30,162

Prepayments

 

13,040

9,472

Clinical materials

 

1,334

1,279

VAT receivable

92

490

Other current assets

 

1,765

1,927

$

54,094

$

43,330

Note 9 — Operating leases

The Company has operating leases in relation to property for office, manufacturing and research facilities.

18

The following table shows the lease costs for the six months ended June 30, 2023 and 2022 and the weighted-average remaining lease term and the weighted-average discount rate as at June 30, 2023 and 2022:

Six months ended

June 30, 

     

2023

     

2022

Lease cost:

Operating lease cost

 

$

2,353

 

$

2,285

Short-term lease cost

 

319

 

164

 

$

2,672

 

$

2,449

June 30, 

2023

2022

Weighted-average remaining lease term - operating leases

5.8 years

7.3 years

Weighted-average discount rate - operating leases

8.6%

6.8%

The maturities of operating lease liabilities as of June 30, 2023 are as follows (in thousands):

     

Operating leases

2023

 

$

3,402

2024

 

6,530

2025

 

5,142

2026

 

4,142

2027

 

5,559

after 2027

 

7,637

Total lease payments

32,412

Less: Imputed interest

6,070

Present value of lease liability

$

26,342

The Company has operating leases in relation to property for office, manufacturing and research facilities.

On June 1, 2023, as part of the acquisition of TCR2, the Company became the lessee for three office, manufacturing and research facilities in Cambridge, Massachusetts. The Company retained TCR2’s previous classification for two of these leases as operating leases and, upon acquisition, the lease liabilities were measured at the present value of the remaining lease payments, as if the lease were a new lease of the Company at June 1, 2023. The right-of-use assets were initially measured at the same amount as the respective lease liabilities, adjusted to reflect favorable or unfavorable terms of the leases when compared with market terms.

The third lease had a remaining lease term of less than 12 months as of June 1, 2023, and the Company elected not to recognize a lease liability or right-of-use asset as of June 1, 2023. The rent associated with this lease will be recognized on a straight-line basis over the remainder of the lease term.

The maximum lease term without activation of termination options is to 2041.

19

Note 10 Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

June 30, 

December 31, 

    

2023

    

2022

Accrued clinical and development expenditure

$

12,039

$

16,749

Accrued employee expenses

10,020

8,232

Other accrued expenditure

3,028

4,079

Other

 

155

 

2,155

$

25,242

$

31,215

Note 11 Contingencies and commitments

Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement

On November 25, 2015, the Company entered into a Research, Collaboration and License Agreement relating to gene editing and Human Leukocyte Antigen (“HLA”) engineering technology with Universal Cells, Inc. (“Universal Cells”). The Company paid an upfront license and start-up fee of $2,500,000 to Universal Cells in November 2015, a milestone payment of $3,000,000 in February 2016 and further milestone payments of $200,000 and $900,000 were made in the years ended December 31, 2018 and 2017, respectively.

The agreement was amended and re-stated as of January 13, 2020, primarily to reflect changes to the development plan agreed between the parties. The agreement was further amended as of July 22, 2022, primarily to make certain changes to development milestones and to agree on the status thereof, as agreed between the parties. Following the amendment, milestone payments of $500,000, $600,000 and $400,000 were made in the year ended December 31, 2022. No remaining milestones have been accrued as of June 30, 2023. The upfront license and start-up fee and milestone payments were expensed to Research and development when incurred.

This Agreement was terminated by notice on January 27, 2023, effective 30 days following receipt of notice of termination. As a result of termination, all licenses between the parties to the Agreement will cease and each party is required to return all confidential information of the other party.

Astellas Collaboration Agreement

Under the Astellas Collaboration Agreement, described further in Note 3, if Adaptimmune had unilaterally developed a product with technology contributed by Astellas, Astellas could have been eligible to receive milestones and royalties relating to future commercialization and sales. As a result of the termination of the collaboration, Astellas no longer has the right to receive these milestones or royalties in future.

MD Anderson Strategic Alliance

On September 26, 2016, the Company announced that it had entered into a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center (“MD Anderson”) designed to expedite the development of T-cell therapies for multiple types of cancer. The Company and MD Anderson are collaborating on a number of studies including clinical and preclinical development of the Company’s SPEAR T-cell therapies and will collaborate on future clinical stage first and second generation SPEAR T-cell therapies across a number of cancers.

Under the terms of the agreement, the Company committed at least $19,644,000 to fund studies. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance and the performance of set milestones by MD Anderson. The Company made an upfront payment of $3,412,000 to MD Anderson in the year ended December 31, 2017 and milestone payments of $2,326,000, $3,549,000, $454,000 and $2,326,000 in the years ended December 31, 2018, 2020, 2021, and 2022, respectively. The Company is obligated to make further payments to MD Anderson as certain milestones are achieved. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance.

20

The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, amongst other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.

Note 12 Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):

Three months ended

Six months ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

1,285

$

2,033

$

1,401

$

4,556

General and administrative

 

2,552

 

3,012

 

4,112

6,075

$

3,837

$

5,045

$

5,513

$

10,631

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:

Three months ended

Six months ended

June 30, 

June 30, 

2023

    

2022

    

2023

    

2022

Number of options over ordinary shares granted

30,247,398

1,735,488

52,002,726

24,611,952

Weighted average fair value of ordinary shares options

$

0.05

$

0.25

$

0.08

$

0.41

Number of additional options with a nominal exercise price granted

6,148,186

3,361,728

26,015,098

21,050,160

Weighted average fair value of options with a nominal exercise price

$

0.15

$

0.34

$

0.17

$

0.55

The information above includes the impact of 29,654,742 options over ordinary shares and 5,501,602 options with a nominal exercise price granted on June 1, 2023, as replacement awards as part of the acquisition of TCR2 Therapeutics Inc., as explained further in Note 15. The number and fair value of replacement awards of the Company granted to TCR2 grantholders is provisional.

Note 13 Stockholders’ equity

On August 10, 2020 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) (the “Sales Agreement”) under which we may from time to time issue and sell American Depositary Shares (“ADSs”) representing our ordinary shares through Cowen in at-the-market (“ATM”) offerings for an aggregate offering price of up to $200 million. As of June 30, 2023, $197,360,000 remained available for sale under the Sales Agreement.

On April 8, 2022 the Company entered into a new sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the six months ended June 30, 2023, the Company sold 92,416 ADSs under the agreement representing 554,496 ordinary shares resulting in net proceeds to the Company of $173,430 after deducting commissions payable under the 2022 Sales Agreement and estimated issuance costs. As of June 30, 2023, approximately $186,513,100 remained available for sale under the 2022 Sales Agreement.

21

Note 14 – Restructuring

2022-23 Restructuring programme

On November 8, 2022, the Company announced that in order to extend the Company’s cash runway from early 2024 into early 2025, it was re-focusing the business on core programs and deprioritizing non-core programs and undertaking a restructuring of the Company including a headcount reduction to be completed in the first quarter of 2023.

The redundancy process was completed in the first quarter of 2023 with a reduction of approximately 25% of global headcount. The redundancy packages to be paid to departing staff comprise a combination of contractual termination benefits, relating to payments that arise from terms of employment contracts and statutory redundancy pay, and one-time employee termination benefits that were provided or enhanced specifically for this redundancy process. Due to the structure of the redundancy scheme and the different employment regulations affecting the Company’s U.K. and U.S. employees, some of the expense associated with the one-time employee termination benefits were recognized over the remaining period of employee service to be rendered. Contractual termination benefits and other one-time employee termination benefits were expensed and recognized in the year ended December 31, 2022. All expenses have been recognized in General and administrative expenses in the Statement of Operations.

The amounts incurred in relation to the redundancy programme are as follows:

One-time

Contractual

employee

Total

termination

termination

restructuring

benefits

benefits

costs

Cumulative amount incurred to December 31, 2022

$

1,171

$

1,114

$

2,285

Amount incurred in the three months ended March 31, 2023 and six months ended June 30, 2023

778

925

1,703

Total amount and cumulative amount incurred to March 31, 2023 and June 30, 2023

$

1,949

$

2,039

$

3,988

The table below is a summary of the changes in the restructuring provision in the Consolidated Balance Sheet in the six months ended June 30, 2023:

One-time

Contractual

employee

Total

termination

termination

restructuring

    

benefits

benefits

provision

Provision at January 1, 2023

$

1,171

$

1,114

$

2,285

Costs incurred and charged to General and administrative expenses

670

947

1,617

Costs paid during the period

(1,955)

(1,953)

(3,908)

Adjustments to the liability

108

(22)

86

Effect of foreign exchange rates

6

2

8

Provision at March 31, 2023

$

$

88

$

88

Costs paid during the period

(88)

(88)

Provision at June 30, 2023

$

$

$

The costs incurred during the period includes the element of one-time employee termination benefits that was recognized over the remaining period of employee service. The costs incurred during the six months to 30 June 2023 also include an addition to the provision for costs incurred relating to termination benefits paid to the former Chief Commercial Officer, who left employment with the Company in the first quarter of 2023.

No impairment losses were recognized as a result of the restructuring.

22

TCR2 post-acquisition senior leadership severance

Following the acquisition of TCR2 Therapeutics Inc., the Company made most of the former members of TCR2’s senior leadership team, comprising the executive officers and most vice presidents, redundant and paid severance packages. The redundancy packages are considered contractual termination benefits as they arise from terms of employment contracts including change-in-control ‘dual trigger’ provisions, and were comprised of severance and other payments and accelerated vesting of share option awards.

The amounts incurred in relation to these redundancies in the six months to June 30, 2023, are as follows:

Three and six months ending

June 30, 2023

Severance and other cash payments

$

5,655

Accelerated vesting of share-based compensation awards

835

Total and cumulative amount incurred to June 30, 2023

$

6,490

The expense associated with the accelerated vesting of share-based compensation awards recognized in Research and development and General and administrative expenses in the Consolidated Statement of Operations was $0.2 million and $0.6 million, respectively. The table below is a summary of the changes in the liability in the Consolidated Balance Sheet in the three and six months ended June 30, 2023:

Liability

Liability at June 1, 2023

$

805

Costs incurred and charged to Research and development expenses

1,267

Costs incurred and charged to General and administrative expenses

4,388

Costs paid during the period

(4,823)

Liability at June 30, 2023

$

1,637

The amounts included in the liabilities at June 1, and June 30, 2023 and the cash paid during the period, include amounts relating to accrued payments to these employees for services provided prior to the acquisition of TCR2 by the Company.

Note 15 – Business combinations

On March 6, 2023 the Company announced entry into a definitive agreement under which it will combine with TCR² Therapeutics Inc. (“TCR²”) in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. TCR2 is a Boston, Massachusetts-based T-cell therapy company focused on treating solid tumours, with clinical franchises undergoing trials and a preclinical pipeline. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms.

The transaction was approved by the Company’s shareholders and TCR2 stockholders on May 30, 2023 and the merger became effective on June 1, 2023. The Company issued 357,429,306 shares to TCRstockholders in return for 100% of TCR2’s stock. As a result, TCR2 and all entities within the TCR2 group, became wholly owned by the Company. Following the completion of the transaction, the former TCR2 stockholders held approximately 25% of the Company, whereas the Company’s pre-existing shareholders held approximately 75%.

The Company was identified as the acquirer, with TCR2 as the acquiree, and June 1, 2023 was determined to be the acquisition date.

23

The consideration transferred for TCR2 includes the shares issued by the Company to former TCR2 shareholders, plus the fair value of replacement awards of the Company granted to TCR2 grantholders attributable to pre-combination vesting. The table below summarizes the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date:

Consideration transferred:

Fair value of 357,429,306 ordinary shares issued

$

60,763

Fair value of replacement options and RSU-style options granted attributable to pre-combination service:

857

Purchase consideration

$

61,620

Identifiable assets acquired and liabilities assumed:

Assets acquired

Cash and cash equivalents

$

43,610

Restricted cash

1,654

Marketable securities - available-for-sale debt securities

39,532

Other current assets and prepaid expenses

6,029

Property, plant and equipment

2,712

Operating lease right-of-use assets

5,145

Intangible assets

58

Total assets acquired

$

98,740

Liabilities assumed

Accounts payable

(6,210)

Accrued expenses and other current liabilities

(4,537)

Operating lease liabilities, current

(1,974)

Operating lease liabilities, non-current

(2,244)

Total liabilities assumed

$

(14,965)

Net assets acquired and liabilities assumed

$

83,775

The fair value of the 357,429,306 ordinary shares issued to TCR2 stockholders of $60,763,000 was determined on the basis of the closing market price of $1.02 ($0.17 per ordinary share) of the Company’s ADSs as of May 31, 2023.

The number and fair value of replacement awards of the Company granted to TCR2 grantholders attributable to pre-combination and post-combination vesting is provisional as the Company is still evaluating the total number of replacement awards that were required to be granted on June 1, 2023, their respective exercise prices and the total fair value of replacement options granted.

The assets acquired and liabilities assumed were measured based on management’s estimates of the fair value as of the acquisition date, excluding leases.

The lease contracts acquired by the Company relate to the rental of office and manufacturing spaces in which TCR2 was the lessee. The Company retained TCR2’s previous classification of acquired leases as operating leases as there were no lease modifications as a result of the combination, with the exception of leases with a remaining lease term of 12 months or less at the acquisition date, for which no assets or liabilities were recognized at the acquisition date. The lease liabilities were measured at the present value of the remaining lease payments as if the leases were a new lease as of June 1, 2023, discounted using the incremental borrowing rate. The right-of-use assets were measured at the same amount as the lease liabilities, with adjustments to reflect favorable or unfavorable terms compared to market terms. No intangible assets were identified in relation to lease contracts acquired.

24

The table below summarises the calculation for the gain on bargain purchase, recognized in the Gain on bargain purchase line in the Consolidated Statement of Operations:

Gain on bargain purchase

Purchase consideration

$

(61,620)

Net assets acquired and liabilities assumed

83,775

Gain on bargain purchase

$

22,155

The transaction resulted in a gain on bargain purchase as the purchase consideration included in the agreement on March 6, 2023 comprising Company ADSs was based on a fixed ratio of 1.5117 of the Company’s ADSs to be issued for each TCR2 stock acquired. As the transaction was an all-stock transaction, the value of the consideration was highly sensitive to changes in the Company’s ADS price. The price of a Company ADS fell from a closing price of $1.32 on March 6, 2023 compared to a closing price of $1.02 on May 31, 2023.

The amount of TCR2’s earnings that are included in the Company’s Consolidated Statement of Operations for the six months ended June 30, 2023 was a loss of $11,760,000 which excludes the gain on bargain purchase.

The amount of revenue and earnings of the combined entity for the six months ended June 30, 2023 and 2022, had the acquisition date been January 1, 2022, are as follows:

Six months ended

Six months ended

June 30, 2023

June 30, 2022

Revenue

$

52,731

$

9,113

Net loss

(86,202)

(143,556)

The supplemental pro forma earnings for the six months ended June 30, 2023 were adjusted to exclude the $22.2 million Gain on bargain purchase, the $7.2 million of acquisition-related costs recognized by the Company, as detailed below, and the $7.7 million of acquisition-related costs incurred by TCR2. The pro forma earnings for the six months ended June 30, 2022 were adjusted to include these gains and losses. The supplemental pro forma earnings for both periods were adjusted to include the impact of replacement options issued, as if these had been issued as of January 1, 2022. Accordingly, the share-based compensation expense recognized by TCR2 in the six months ended June 30, 2022, and the five months ended May 31, 2023, prior to the acquisition by the Company, of $6.0 million and $1.0 million, respectively, were excluded from the pro forma earnings.

TCR2 did not generate revenue in the period from January 1, 2022 to June 30, 2023, as it has no contracts with customers, so there was no impact on the revenue included in the Company’s Consolidated Statement of Operations or in the supplemental pro forma revenue and earnings presented above.

The Company incurred the following acquisition-related costs that were recognized as an expense in the six months ended June 30, 2023:

Legal, professional and accounting fees

4,993

Bankers' fees

2,172

Total acquisition-related costs

$

7,165

All acquisition-related costs that were recognized as an expense were recognized in General and administrative expenses in the Consolidated Statement of Operations. No issuance costs were incurred relating to the issuance of shares to TCR2 stockholders.

Note 16 – Subsequent events

None

25

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and the audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2022, included in our Annual Report on Form 10-K that was filed with the SEC on March 6, 2023. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report and our Annual Report on Form 10-K for the year ended December 31, 2022, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.

Overview

We are a clinical-stage biopharmaceutical company focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors and have reported clinical responses in multiple solid tumor indications.

Our proprietary platform enables us to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Our cell therapy candidates include T-cells with genetically engineered T-cell receptors (“TCR T-cells”), TCR Fusion Construct T cells (TRuC-T cells) and HLA-independent TCRs (“HiTs”). Our cell therapies are currently manufactured on an autologous or per patient basis and we have a proprietary preclinical allogeneic platform for the development of “off the shelf” cell therapies.

Strategic Combination with TCR² Therapeutics Inc.

On June 1, 2023, we announced the consummation of the strategic combination between Adaptimmune Therapeutics Plc and TCR² Therapeutics Inc. (“TCR2”). The all-stock transaction created a preeminent cell therapy company focused on treating solid tumors with later stage assets targeting MAGE-A4 and mesothelin expressing tumors and earlier stage assets targeting PRAME and CD-70 expressing tumors. Following the closing of the transaction we currently estimate that the cash runway of the combined company will extend into early 2026

The combined company comprises a team of leading cell therapy experts led by Adrian Rawcliffe, the CEO of Adaptimmune. The Board of Directors is composed of three members from TCR2 and six continuing members from Adaptimmune: David Mott (Chair); Andrew Allen, MD, PhD; Lawrence Alleva; Ali Behbahani, MD; John Furey; Priti Hegde, PhD, Kristen Hege, MD (as of November 1, 2023), Garry Menzel, PhD, Adrian Rawcliffe, Elliot Sigal, MD, PhD. The merger agreement was unanimously approved by the boards of directors of both companies. Following the closing of the transaction, Adaptimmune shareholders own approximately 75% of the combined company and TCR2 stockholders own approximately 25% of the combined company.

We are currently working on integrating the programs and technologies of both companies to ensure prioritization of our clinical portfolio and ongoing development. As part of that integration, we increased our headcount by 39 and are in the process of combining current Boston activities into a single facility in Boston.

BLA Filing for afami-cel

Adaptimmune’s lead product, afami-cel targets the MAGE-A4 antigen. Clinical data from the pivotal SPEARHEAD-1 trial for this product will support the filing of our first BLA submission in Q4 2023. Updated data for afamicel was presented at the American Society of Clinical Oncology’s (ASCO) annual meeting in May 2023, demonstrating people with advanced synovial sarcoma who responded to afami-cel have a 24 month survival probability of 70%. Approximately 39% of patients were reported to have clinical responses after a single dose of afami-cel in cohort-1 of the SPEARHEAD-1 trial, with median duration of response at approximately 12 months and medial overall survival reported at approximately 17 months.

Submission of the preclinical (Part 1) and clinical (Part 2) modules of the BLA to the FDA has been completed and submission of the final modules are targeted for Q4 2023 (previously Q3 2023). The submission to the FDA for the companion diagnostic for the MAGE-A4 antigen has been completed. The FDA has agreed the confirmatory evidence plan, cohort 2 of the SPEARHEAD-1 trial will act as confirmatory evidence for full approval for afami-cel. Mature data from cohort 2 is expected in mid 2024. The FDA has provided feedback

26

on the commercial T-cell potency assay including agreement on the proposed potency dataset for inclusion in the submission. The FDA has not requested any new or additional information on T-cell potency to precede the BLA submission. Method validation for lot release assays, including potency assays, is complete and vector process performance qualification runs (PPQ) have been conducted. T-cell process performance qualification (PPQ) has been initiated.

Clinical progress

Phase 2 clinical programs are ongoing with both our MAGE-A4 targeted TCR T-cell therapies (afami-cel and ADP-A2M4CD8) and our mesothelin targeted TRuC-Tcell (Gavo-cel):

SPEARHEAD-1 Phase 2 Trial with afami-cel (ADP-A2M4) targeting MAGE-A4: A registration directed Phase 2 clinical trial is ongoing in synovial sarcoma in which the MAGE-A4 antigen is expressed. Enrollment in Cohorts 1 and 2 are complete. Updated data were presented at ASCO in May 2023.

IGNYTE Phase 2 Trial with lete-cel targeting NY-ESO: We announced agreement of terms for the transfer of the NY-ESO Target programs back to Adaptimmune from GSK in April 2023. We are currently in the process of transitioning the phase 2 IGNYTE trial in synovial sarcoma and myxoid round cell liposarcoma (MRCLS) from GSK, with completion of transition of IGNYTE trial expected by the end of 2023. An update on data for the trial is anticipated in late 2023.

SURPASS-3 Phase 2 Trial with ADP-A2M4CD8 targeting MAGE-A4. A Phase 2 trial for people with platinum resistant ovarian cancer has been initiated. We have received RMAT designation (Regenerative Medicine Advanced Therapy designation) for ADP-A2M4CD8 for the treatment of this indication from the FDA. In the Phase 1 SURPASS trial an ORR of 43% in ovarian cancer was reported in November 2022. The Phase 2 trial will evaluate ADP-A2M4CD8 in both monotherapy and in combination with a checkpoint inhibitor, nivolumab, in ovarian cancer.

Gavo-cel Phase 1/2 Trial in ovarian cancer. The Phase 2 portion of this trial is ongoing to assess gavo-cel in people with ovarian cancer in combination with Opdivo® (nivolumab). The phase 1 portion of the trial in ovarian cancer, non-small cell lung cancer (NSCLC), malignant pleural/peritoneal mesothelioma or cholangiocarcinoma has been completed. Data from the phase 1 portion of the trial was reported in September 2022. Initial data from the phase 2 portion of the trial will be evaluated later in 2023, which will be determinative of the next steps with gavo-cel. We have enrolled all patients to be included in this interim data review, and further enrolment has been paused pending the outcome of this review.

Earlier stage clinical trials are ongoing with our MAGE-A4 targeted TCR-T-cell therapy (ADP-A2M4CD8) and mesothelin targeted TRuC T-cell therapy, TC510.

SURPASS Phase 1 Trial with ADP-A2M4CD8: Enrolment is ongoing in a Phase 1 trial for ADP-A2M4CD8, focusing on treatment of patients with head and neck and urothelial cancers in which the MAGE-A4 antigen is expressed. Across all indications and as of November 23, 2022, the trial has an overall response rate of 37%. In the focus areas of ovarian, urothelial and head and neck cancers the response rate is 75% in patients with 3 or fewer prior lines of therapy (9 out of 12 patients). The trial includes a combination cohort where participants receive a combination of ADP-A2M4CD8 together with a checkpoint inhibitor (nivolumab). Two new cohorts in urothelial and head and neck cancers for patients with fewer lines of therapy and in combination with standard of care in those settings is initiating.

Phase 1 Trial with TC-510: We are conducting a Phase 1/2 clinical trial for TC-510 focussing on the treatment of patients with mesothelin-expressing MPM, ovarian cancer, pancreatic cancer, colorectal cancer or triple negative breast cancer. The trial is currently in its dose escalation phase and we anticipate output from that dose escalation phase later in 2023.

Outside of the clinical programs, we have a preclinical program for T-cell therapies directed to the PRAME target which is expressed in a broad range of tumors. Dependent on the data arising from the preclinical program, the first cell therapy targeting PRAME is anticipated to be IND-ready by the end of 2023. The PRAME program was previously part of a prior collaboration with GSK. We also have a preclinical program for TC-520, a TRuC T-cell targeting CD70 and enhanced with IL-15. CD70 is expressed in certain hematological malignancies and solid tumours specifically acute myeloid leukemia and renal cell carcinoma. Depending on the data arising from the preclinical program we are targeting IND readiness by the end of 2024.

27

We are also developing allogeneic or “off-the-shelf” cell therapies utilizing a proprietary allogeneic platform. The platform utilizes cells derived from Induced Pluripotent Stem Cells (“iPSCs”), which can be gene-edited to express our engineered TCRs or other constructs and then differentiated into the required end cell type, for example T-cells. The platform is applicable to all of our cell therapies. We have a strategic collaboration with Genentech Inc. (“Genentech”). The collaboration with Genentech covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets (“off-the-shelf” products) and the development of a novel allogeneic personalized cell therapy platform.

We have several other development and research collaborations.

A prior collaboration with GSK terminated in December 2022. On April 11, 2023, we announced the entry into a Termination and Transfer Agreement with GSK (the “Termination and Transfer Agreement”) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program. In addition, under the Termination and Transfer Agreement, Adaptimmune has received an upfront amount of £7.5 million in June 2023 and will receive milestone payments totalling £22.5 million in relation to the transfer of the clinical trials for the NY-ESO cell therapy program.
We have a clinical trial collaboration ongoing with Bristol-Myers Squibb in relation to the phase 1/2 trial evaluating gavo-cel in combination with Opdivo® (nivolumab) and Yervoy® (ipilimumab) in mesothelin-expressing solid tumors.

Financial Operations Overview

Revenue

The Company had two contracts with customers in the three months ended June 30, 2023, and three in the six months ended June 30, 2023: the Astellas Collaboration Agreement (until March 6, 2023), the Genentech Collaboration Agreement and the GSK Termination and Transfer Agreement (from April 11, 2023). A previous collaboration, the GSK Collaboration and License Agreement, was terminated on October 24, 2022 (effective December 23, 2022).

The Astellas Collaboration Agreement

In January 2020, the Company entered into a collaboration agreement with Astellas. The Company received $50.0 million as an upfront payment after entering into the agreement. Under the agreement the parties would agree on up to three targets and would co-develop T-cell therapies directed to those targets pursuant to an agreed research plan. For each target, Astellas would fund co-development up until completion of a Phase 1 trial for products directed to such target. In addition, Astellas was also granted the right to develop, independently of Adaptimmune, allogeneic T-cell therapy candidates directed to two targets selected by Astellas. Astellas would have sole rights to develop and commercialize products resulting from these two targets.

The agreement consisted of the following performance obligations: (i) research services and rights granted under the co-exclusive license for each of the three co-development targets and (ii) the rights granted for each of the two independent Astellas targets. The revenue allocated to the co-development targets was recognized as the development of products directed to the targets progressed up until completion of a Phase 1 trial. The revenue allocated to each of the research licenses for the targets being independently developed by Astellas was to be recognized when the associated license commenced, which was upon designation of a target by Astellas.

The Company and Universal Cells mutually agreed to terminate the Astellas Collaboration Agreement as of March 6, 2023 (the “Termination Date”). In connection with the termination, all licenses and sublicenses granted to either party pursuant to the Collaboration Agreement ceased as of the Termination Date. There were no termination penalties in connection with the termination, however the Company is still entitled to receive reimbursement for research and development work performed up to and including a period of 30 days after the Termination Date.

The termination was accounted for as a contract modification and the modification resulted in the remaining unsatisfied and partially satisfied performance obligations under the collaboration becoming fully satisfied. The aggregate transaction price of the contract modification was $42,365,000, which was primarily comprised of deferred income relating to the third co-development target and the two independent targets, and was recognized in full in March 2023. No revenue was recognized for Astellas in the three months ended June 30, 2023.

28

The Genentech Collaboration Agreement

On September 3, 2021, Adaptimmune Limited, a wholly owned subsidiary of Adaptimmune Therapeutics Plc, entered into a Strategic Collaboration and License Agreement with Genentech, Inc. (“Genentech”) and F. Hoffman-La Roche Ltd. The collaboration has two components:

1)development of allogeneic T-cell therapies for up to five shared cancer targets
2)development of personalized allogeneic T-cell therapies utilizing αβ T-cell receptors (TCRs) isolated from a patient, with such therapies being administered to the same patient.

The parties will collaborate to perform a research program, initially during an eight-year period (which may be extended for up to two additional two-year terms at Genentech’s election upon payment of an extension fee for each two-year term), to develop the cell therapies, following which Genentech will determine whether to further develop and commercialize such therapies. The Company received an upfront payment of $150 million in October 2021 and a $20 million milestone payment in December 2022.

The Company identified the following performance obligations under the agreement: (i) research services and rights granted under the licenses for each of the initial “off-the-shelf” collaboration targets, (ii) research services and rights granted under the licenses for the personalized therapies, (iii) material rights relating to the option to designate additional “off-the-shelf” collaboration targets and (iv) material rights relating to the two options to extend the research term. The revenue allocated to the initial “off-the-shelf” collaboration targets and the personalized therapies is recognized as development progresses. The revenue allocated to the material rights to designate additional ‘off-the-shelf’ collaboration targets is recognized from the point that the options are exercised and then as development progresses, in line with the initial “off-the-shelf” collaboration targets, or at the point in time that the rights expire. The revenue from the material rights to extend the research term is recognized from the point that the options are exercised and then over the period of the extension, or at the point in time that the options expire.

The GSK Termination and Transfer Agreement

On April 11, 2023, the Company announced the entry of the Company and GSK into a Termination and Transfer regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program.

As part of the agreement, sponsorship of the ongoing IGNYTE and long-term follow-up (“LTFU”) trials relating to the NY-ESO cell therapy program will transfer to Adaptimmune. In return for this, Adaptimmune received an upfront payment of £7.5 million in June 2023 following the signing of the agreement and further milestone payments totalling £22.5 million will be due in relation to successive stages of transfer of the trials.

The Company has identified the following performance obligations under the agreement: (i) to take over sponsorship for the IGNYTE trial and (ii) to take over sponsorship for the LTFU trial. The revenue allocated to the IGNYTE obligation is recognized as sponsorship of the active trials that make up the IGNYTE trial transfer, based on the number of patients transferring in each trial. The revenue allocated to the LTFU obligation is recognized as sponsorship of the trials that make up the LTFU trial transfers, including trials for potential future patients transferring to the LTFU trial from the IGNYTE trial, based on the number of active and potential patients transferring in each trial.

No revenue was recognized for the agreement in the three and six months ended June 30, 2023.

Research and Development Expenses

Research and development expenditures are expensed as incurred. Research and development expenses consist principally of the following:

salaries for research and development staff and related expenses, including benefits;
costs for production of preclinical compounds and drug substances by contract manufacturers;

29

fees and other costs paid to contract research organizations in connection with additional preclinical testing and the performance of clinical trials;
costs associated with the development of a process to manufacture and supply our lentiviral vector and cell therapies for use in clinical trials;
costs to develop manufacturing capability at our U.S. facility for manufacture of cell therapies for use in clinical trials;
costs relating to facilities, materials and equipment used in research and development;
costs of acquired or in-licensed research and development which does not have alternative future use;
costs of developing assays and diagnostics;
an allocation of indirect costs clearly related to research and development;
amortization and depreciation of property, plant and equipment and intangible assets used to develop our cells therapies; and
share-based compensation expenses.

These expenses are partially offset by:

reimbursable tax and expenditure credits from the U.K. government.

Research and development expenditure is presented net of reimbursements from reimbursable tax and expenditure credits from the U.K. government.

As a company that carries out extensive research and development activities, we benefit from the U.K. research and development tax credit regime for small and medium sized companies (“SME R&D Tax Credit Scheme”), whereby our principal research subsidiary company, Adaptimmune Limited, is able to surrender the trading losses that arise from its research and development activities for a payable tax credit of up to approximately 33.4% of eligible research and development expenditures, decreasing to 18.6% after April 1, 2023. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which we do not receive income. Subcontracted research expenditures are eligible for a cash rebate of up to approximately 21.7%, decreasing to 12.1% after April 1, 2023. A large proportion of costs in relation to our pipeline research, clinical trials management and manufacturing development activities, all of which are being carried out by Adaptimmune Limited, are eligible for inclusion within these tax credit cash rebate claims.

Expenditures incurred in conjunction with our collaboration agreements are not qualifying expenditures under the SME R&D Tax Credit Scheme but certain of these expenditures can be reimbursed through the U.K. research and development expenditure credit scheme (the “RDEC Scheme”). Under the RDEC Scheme tax relief is given at 13% of allowable R&D costs, which may result in a payable tax credit at an effective rate of approximately 10.5% of qualifying expenditure for the three months ended March 31, 2023. The RDEC Scheme tax relief rate is scheduled to increase to 20% after April 1, 2023, which may result in a payable tax credit at an effective rate of 15%.

On July 18, 2023, the U.K. Government released draft legislation on proposed changes to the U.K. research and development regimes. These changes include combining the current SME R&D Tax Credit Scheme and RDEC Schemes with a single 20% gross rate applying to all claims with an exception for R&D Intensive SMEs. For entities which qualify as R&D Intensive SMEs, a high effective cash tax benefit of 27% will be available. The draft legislation also includes changes to other rules and types of qualifying expenditure, such as the treatment of subcontracted and overseas costs. The Company is currently evaluating the impact of the draft legislation on its future tax credit claims.

30

Our research and development expenses may vary substantially from period to period based on the timing of our research and development activities, which depends upon the timing of initiation of clinical trials and the rate of enrollment of patients in clinical trials. The duration, costs, and timing of clinical trials and development of our cell therapies will depend on a variety of factors, including:

the scope, rate of progress, and expense of our ongoing as well as any additional clinical trials and other research and development activities;
uncertainties in clinical trial enrollment rates;
future clinical trial results;
significant and changing government regulation;
the timing and receipt of any regulatory approvals; and
supply and manufacture of lentiviral vector and cell therapies for clinical trials.

A change in the outcome of any of these variables may significantly change the costs and timing associated with the development of that cell therapy. For example, if the FDA, or another regulatory authority, requires us to conduct clinical trials beyond those that we currently anticipate will be required for regulatory approval, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

Our general and administrative expenses consist principally of:

salaries for employees other than research and development staff, including benefits;
business development expenses, including travel expenses;
professional fees for auditors, lawyers and other consulting expenses, including those incurred in relation to the merger with TCR2;
costs of facilities, communication, and office expenses;
cost of establishing commercial operations;
information technology expenses;
amortization and depreciation of property, plant and equipment and intangible assets not related to research and development activities; and
share-based compensation expenses.

Other (Expense) Income, Net

Other (expense) income, net primarily comprises foreign exchange (losses) gains. We are exposed to foreign exchange rate risk because we currently operate in the United Kingdom and United States. Our expenses are generally denominated in the currency in which our operations are located, which are the United Kingdom and United States. However, our primary U.K.-based subsidiary, Adaptimmune Limited, incurs significant research and development costs in U.S. dollars and, to a lesser extent, Euros. Adaptimmune Limited has an intercompany loan balance in U.S. dollars payable to the ultimate parent company, Adaptimmune Therapeutics plc, which is considered of a long-term investment nature as repayment is not planned or anticipated in the foreseeable future. It is Adaptimmune Therapeutics plc’s

31

intent not to request payment of the intercompany loan for the foreseeable future. The foreign exchange gains or losses arising on the revaluation of intercompany loans of a long-term investment nature are reported within other comprehensive (loss) income, net of tax.

Our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. We seek to minimize this exposure by maintaining currency cash balances at levels appropriate to meet forthcoming expenditure in U.S. dollars and pounds sterling. To date, we have not used hedging contracts to manage exchange rate exposure, although we may do so in the future.

In addition to currency fluctuations, adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs, changes to fiscal and monetary policy, tighter credit, and higher interest rates, could materially adversely affect the Company by, for example, driving higher input costs and/or impacting the Company’s ability to raise future financing.

Taxation

We are subject to corporate taxation in the United Kingdom and the United States. We incur tax losses and tax credit carryforwards in the United Kingdom on an annual basis. No net deferred tax assets are recognized on our U.K. losses and tax credit carryforwards because there is currently no indication that we will make sufficient taxable profits to utilize these tax losses and tax credit carryforwards. On June 10, 2021, the U.K. 2021 Finance Bill received Royal Assent. Under this bill, the rate of U.K. corporation tax will increase to 25% from April 1, 2023, with lower rates and tapered relief to be applied to companies with profits below £250,000.

We benefit from reimbursable tax credits in the United Kingdom through the SME R&D Tax Credit Scheme as well as the RDEC Scheme which are presented as a deduction to research and development expenditure.

Our pre-existing subsidiary in the United States, Adaptimmune LLC, has generated taxable profits due to a Service Agreement between our U.S. and U.K. operating subsidiaries and is subject to U.S. federal corporate income tax of 21%. Due to its activity in the United States, and the sourcing of its revenue, the U.S. subsidiary is not currently subject to any state or local income taxes. The Company also benefits from the U.S Research Tax Credit and Orphan Drug Credit.

TCR2 has incurred net losses since acquisition and generates research and development tax credits. No net deferred tax assets are recognized on our TCR2’s losses and tax credit carryforwards because there is currently no indication that we will make sufficient taxable profits to utilize these tax losses and tax credit carryforwards.

In the future, if we generate taxable income in the United Kingdom on an annual basis, we may benefit from the United Kingdom’s “patent box” regime, which would allow certain profits attributable to revenues from patented products to be taxed at a rate of 10%. As we have many different patents covering our products, future upfront fees, milestone fees, product revenues, and royalties may be taxed at this favorably low tax rate.

U.K. Value Added Tax (“VAT”) is charged on all qualifying goods and services by VAT-registered businesses. An amount of 20% of the value of the goods or services is added to all relevant sales invoices and is payable to the U.K. tax authorities. Similarly, VAT paid on purchase invoices paid by Adaptimmune Limited and Adaptimmune Therapeutics plc is reclaimable from the U.K. tax authorities.

Critical Accounting Policies and Significant Judgments and Estimates

The preparation of our unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the revenues and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are relevant under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies considered to be critical to the judgments and estimates used in the preparation of our financial statements are disclosed in the Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022.

32

Results of Operations

Comparison of Three Months Ended June 30, 2023 and 2022

The following table summarizes the results of our operations for the three months ended June 30, 2023 and 2022, together with the changes to those items (in thousands):

Three months ended

 

June 30, 

    

 

    

2023

    

2022

    

Increase/decrease

 

Revenue

$

5,130

$

5,538

$

(408)

 

(7)

%

Research and development expenses

 

(29,965)

 

(34,740)

 

4,775

 

(14)

%

General and administrative expenses

 

(20,073)

 

(14,550)

 

(5,523)

 

38

%

Total operating expenses

 

(50,038)

 

(49,290)

 

(748)

 

2

%

Operating loss

 

(44,908)

 

(43,752)

 

(1,156)

 

3

%

Interest income

 

1,543

 

357

 

1,186

 

332

%

Gain on bargain purchase

22,155

22,155

%

Other (expense) income, net

 

501

 

(655)

 

1,156

 

(176)

%

Loss before income tax expense

 

(20,709)

 

(44,050)

 

23,341

 

(53)

%

Income tax expense

 

(680)

 

(470)

 

(210)

 

45

%

Profit/(loss) for the period

$

(21,389)

$

(44,520)

$

23,131

 

(52)

%

Revenue

Revenue decreased by $0.4 million to $5.1 million for the three months ended June 30, 2023 compared to $5.5 million for the three months ended June 30, 2022.

Research and Development Expenses

Research and development expenses decreased by 14% to $30.0 million for the three months ended June 30, 2023 from $34.7 million for the three months ended June 30, 2022.

Our research and development expenses comprise the following (in thousands):

Three months ended

 

June 30, 

    

 

    

2023

    

2022

    

Increase/decrease

Salaries, materials, equipment, depreciation of property, plant and equipment and other employee-related costs(1)

$

21,608

$

24,198

$

(2,590)

(11)

%

Subcontracted expenditure

 

9,480

 

14,983

 

(5,503)

(37)

%

Manufacturing facility expenditure

 

1,884

 

1,934

 

(50)

(3)

%

Share-based compensation expense

 

1,285

 

2,033

 

(748)

(37)

%

In-process research and development costs

 

(1,863)

 

408

 

(2,271)

(557)

%

Reimbursements receivable for research and development tax and expenditure credits

 

(2,429)

 

(8,816)

 

6,387

(72)

%

$

29,965

$

34,740

$

(4,775)

(14)

%

(1)These costs are not analyzed by project since employees may be engaged in multiple projects simultaneously.

33

The net decrease in our research and development expenses of $4.8 million for the three months ended June 30, 2023 compared to the same period in 2022 was primarily due to the following:

A decrease of $2.6 million in salaries, materials, equipment, depreciation of property, plant and equipment and other employee-related costs, which is mainly driven by a decrease in the average number of employees engaged in research and development compared to the equivalent period in 2022, including the restructuring programme that was completed in the first quarter of 2023;
A decrease of $5.5 million in subcontracted expenditure due to a decrease in clinical trial expenses and lentiviral vector manufacturing costs; and
a decrease of $2.3 million in in-process research and development costs to a credit of $1.9 million due to the release of a milestone that was previously accrued that is no longer expected to be paid; offset by
A decrease of $6.4 million in reimbursements receivable for research and development tax and expenditure credits due to decreases in the associated research and development costs for which the credits may be claimed and a reduction in the effective rate at which the tax credits can be claimed which was effective from April 1, 2023.

Our subcontracted costs for the three months ended June 30, 2023 were $9.5 million, compared to $15.0 million in the same period of 2022. This includes $5.9 million of costs directly associated with our afami-cel, ADP-A2M4CD8 and ADP-A2AFP SPEAR T-cells and $3.6 million of other development costs.

Our research and development expenses are highly dependent on the phases and progression of our research projects and will fluctuate depending on the outcome of ongoing clinical trials. We expect that our research and development expenses will increase in future periods as we continue to invest in our translational sciences and other research and development capabilities.

General and Administrative Expenses

General and administrative expenses increased by 38% to $20.1 million for the three months ended June 30, 2023 from $14.6 million in the same period in 2022. Our general and administrative expenses consist of the following (in thousands):

Three months ended

 

June 30, 

    

 

    

2023

    

2022

    

Increase/decrease

Salaries, depreciation of property, plant and equipment and other employee-related costs

$

12,296

$

8,559

$

3,737

44

%

Other corporate costs

 

7,703

 

5,323

 

2,380

45

%

Share-based compensation expense

2,552

3,012

(460)

(15)

%

Reimbursements

 

(2,478)

 

(2,344)

 

(134)

6

%

$

20,073

$

14,550

$

5,523

38

%

The net increase in our general and administrative expenses of $5.5 million for the three months ended June 30, 2023 compared to the same period in 2022 was largely due to;

An increase of $3.7 million in Salaries, depreciation of property, plant and equipment and other employee-related costs for the three months ended June 30, 2023 compared to the same period in 2022 due to severance and other related costs for former TCR2 leadership and employees; and
An increase of $2.4 million in other corporate costs due to an increase in accounting, legal and professional fees incurred in relation to entering into the TCR2 Therapeutics Inc. merger agreement.

Gain on Bargain Purchase

34

The gain on bargain purchase of $22.2 million arose in June 2023 from the strategic combination with TCR2 Therapeutics Inc on June 1, 2023.

Income Taxes

Income taxes arise in the United States due to Adaptimmune LLC generating taxable profits. We typically incur taxable losses in the United Kingdom on an annual basis and have incurred losses in TCR2 Therapeutics Inc. since acquisition.

Comparison of six months ended June 30, 2023 and 2022

The following table summarizes the results of our operations for the six months ended June 30, 2023 and 2022, together with the changes to those items (in thousands):

Six months ended

 

June 30, 

    

 

    

2023

    

2022

    

Increase/decrease

 

Revenue

$

52,731

$

9,113

$

43,618

 

479

%

Research and development expenses

 

(55,513)

 

(71,492)

 

15,979

 

(22)

%

General and administrative expenses

 

(40,470)

 

(31,354)

 

(9,116)

 

29

%

Total operating expenses

 

(95,983)

 

(102,846)

 

6,863

 

(7)

%

Operating profit/(loss)

 

(43,252)

 

(93,733)

 

50,481

 

(54)

%

Interest income

 

2,219

 

695

 

1,524

 

219

%

Gain on bargain purchase

22,155

22,155

%

Other (expense) income, net

 

(170)

 

(643)

 

473

 

(74)

%

Profit/(loss) before income tax expense

 

(19,048)

 

(93,681)

 

74,633

 

(80)

%

Income tax expense

 

(1,305)

 

(1,104)

 

(201)

 

18

%

Profit/(loss) for the period

$

(20,353)

$

(94,785)

$

74,432

 

(79)

%

Revenue

Revenue increased by $43.6 million to $52.7 million in the six months ended June 30, 2023 compared to $9.1 million for the six months ended June 30, 2022 primarily due to the termination of the Astellas collaboration, resulting in the release of the remaining deferred income for the collaboration being released as revenue in March 2023.

Research and Development Expenses

Research and development expenses decreased by 22% to $55.5 million for the six months ended June 30, 2023 from $71.5 million for the six months ended June 30, 2022.

Our research and development expenses comprise the following (in thousands):

Six months ended

 

June 30, 

    

 

    

2023

    

2022

    

Increase/decrease

Salaries, materials, equipment, depreciation of property, plant and equipment and other employee-related costs(1)

$

39,715

47,236

$

(7,521)

(16)

%

Subcontracted expenditure

 

20,645

 

29,533

 

(8,888)

(30)

%

Manufacturing facility expenditure

 

3,392

 

4,887

 

(1,495)

(31)

%

Share-based compensation expense

 

1,401

 

4,556

 

(3,155)

(69)

%

In-process research and development costs

 

(1,863)

 

2,253

 

(4,116)

(183)

%

Reimbursements receivable for research and development tax and expenditure credits

 

(7,777)

 

(16,973)

 

9,196

(54)

%

$

55,513

$

71,492

$

(15,979)

(22)

%

35

(1)These costs are not analyzed by project since employees may be engaged in multiple projects simultaneously.

The net decrease in our research and development expenses of $16.0 million for the six months ended June 30, 2023 compared to the same period in 2022 was primarily due to the following:

a decrease of $7.5 million in salaries, materials, equipment, depreciation of property, plant and equipment and other employee-related costs, which is mainly driven by a decrease in the average number of employees engaged in research and development;
a decrease of $8.9 million in subcontracted expenditure due to a decrease in clinical trial expenses;
a decrease of $4.1 million in in-process research and development costs to a credit of $1.9 million due to the release of a milestone that was previously accrued that is no longer expected to be paid; and
a decrease of $3.2 million in share-based compensation expense due to a combination of lower fair value of options granted in the six months ended June 30, 2023 compared to the equivalent period in 2022 and due to high forfeiture credits due to redundancies in the same period; offset by
a decrease of $9.2 million in reimbursements receivable for research and development tax and expenditure credits due to decreases in the associated research and development costs for which the credits may be claimed and a reduction in the effective rate at which the tax credits can be claimed which was effective from April 1, 2023.

Our subcontracted costs for the six months ended June 30, 2023 were $20.6 million, compared to $29.5 million in the same period of 2022. This includes $15.1 million of costs directly associated with our afami-cel, ADP-A2M4CD8 and ADP-A2AFP SPEAR T-cells and $5.5 million of other development costs.

General and Administrative Expenses

General and administrative expenses increased by 29% to $40.5 million for the six months ended June 30, 2023 from $31.4 million in the same period in 2022. Our general and administrative expenses consist of the following (in thousands):

Six months ended

 

June 30, 

    

 

    

2023

    

2022

    

Increase/decrease

Salaries, depreciation of property, plant and equipment and other employee-related costs

$

20,664

$

17,326

$

3,338

19

%

Restructuring charges

1,703

1,703

N/A

%

Other corporate costs

 

16,469

 

10,297

 

6,172

60

%

Share-based compensation expense

 

4,112

 

6,075

 

(1,963)

(32)

%

Reimbursements

 

(2,478)

 

(2,344)

 

(134)

6

%

$

40,470

$

31,354

$

9,116

29

%

The net increase in our general and administrative expenses of $9.1 million for the six months ended June 30, 2023 compared to the same period in 2022 was largely due to:

an increase of $3.3 million in salaries, depreciation of property, plant and equipment and other employee-related costs compared to the equivalent period in 2022, due to severance and other related costs for former TCR2 leadership and employees
Restructuring charges of $1.7 million, relating to the restructuring programme completed in the first quarter of 2023;

36

and
an increase of $6.2 million in other corporate costs due to an increase in accounting, legal and professional fees incurred in relation to entering into the TCR2 Therapeutics Inc. merger agreement; offset by
a decrease in share-based compensation expense of $2.0 million due to a combination of lower fair value of options granted in the six months ended June 30, 2023 compared to the equivalent period in 2022 and due to high forfeiture credits due to redundancies in the same period.

Gain on Bargain Purchase

The gain on bargain purchase of $22.2 million arose in June 2023 from the strategic combination with TCR2 Therapeutics Inc on June 1, 2023.

Income Taxes

Income taxes arise in the United States due to Adaptimmune LLC generating taxable profits. We typically incur taxable losses in the United Kingdom on an annual basis and have incurred losses in TCR2 Therapeutics Inc. since acquisition.

Liquidity and Capital Resources

Sources of Funds

Since our inception, we have incurred significant net losses and negative cash flows from operations. We financed our operations primarily through sales of equity securities, cash receipts under our collaboration arrangements and research and development tax and expenditure credits. From inception through to June 30, 2023, we have raised:

$870.2 million, net of issuance costs, through the issuance of shares;
$402.5 million through collaborative arrangements with Genentech, GSK and Astellas; and
$110.6 million in the form of reimbursable U.K. research and development tax credits and receipts from the U.K. RDEC Scheme.

$45.3 million in cash and cash equivalents and restricted cash and $39.5 million of marketable securities were also acquired as part of the strategic combination with TCR2 Therapeutics Inc.

We use a non-GAAP measure, Total Liquidity, which is defined as the total of cash and cash equivalents and marketable securities, to evaluate the funds available to us in the near-term. A description of Total Liquidity and reconciliation to cash and cash equivalents, the most directly comparable U.S. GAAP measure, are provided below under “Non-GAAP measures”.

As of June 30, 2023, we had cash and cash equivalents of $77.0 million and Total Liquidity of $204.7 million. We regularly assess Total Liquidity against our activities and make decisions regarding prioritization of those activities and deployment of Total Liquidity. We believe that our Total Liquidity will be sufficient to fund the Company’s current operations, based upon our currently anticipated research and development activities and planned capital spending, we currently estimate that the cash runway will extend into early 2026. This belief is based on estimates that are subject to risks and uncertainties and may change if actual results differ from management’s estimates.

37

Cash Flows

The following table summarizes the results of our cash flows for the six months ended June 30, 2023 and 2022 (in thousands):

    

Six months ended

June 30, 

    

2023

    

2022

Net cash used in operating activities

$

(81,045)

$

(95,652)

Net cash provided by investing activities

 

51,035

 

39,334

Net cash provided by financing activities

 

210

 

10,012

Cash, cash equivalents and restricted cash

 

80,200

 

99,524

Operating Activities

Net cash used in operating activities was $81.0 million for the six months ended June 30, 2023 compared to $95.7 million for the six months ended June 30, 2022. Our activities typically result in net use of cash in operating activities. The net cash used in operating activities for the six months ended June 30, 2023 decreased due to a decrease in operating expenditure as a result of the restructuring and re-prioritisation of activities that was initiated in the final quarter of 2022.

Net cash used in operating activities of $81.0 million for the six months ended June 30, 2023 comprised a net profit of $20.4 million and a net cash outflow of $48.5 million from changes in operating assets and liabilities, offset by non-cash items of $12.2 million The changes in operating assets and liabilities include the impact of a $9.2 million increase in reimbursements receivable for research and development tax credits. The non-cash items consisted primarily of a $22.2 million gain on bargain purchase, depreciation expense on plant and equipment of $3.8 million, share-based compensation expense of $5.5 million, unrealized foreign exchange losses of $0.4 million, accretion on available-for-sale debt securities of $0.6 million and other items of $0.9 million.

Investing Activities

Net cash provided by investing activities was $51.0 million for the six months ended June 30, 2023 compared to $39.3 million for the six months ended June 30, 2022. The net cash provided by investing activities for the respective periods consisted primarily of:

purchases of property and equipment of $3.6 million and $16.1 million for the six months ended June 30, 2023 and 2022, respectively; and
cash outflows from investment in marketable securities of $67.1 million and $42.2 million for the six months ended June 30, 2023 and 2022, respectively; offset by
cash inflows from maturity or redemption of marketable securities of $76.1 million and $97.6 million for the six months ended June 30, 2023 and 2022, respectively; and
cash and cash equivalents acquired as part of the strategic combination with TCR2 Therapeutics Inc. of $45.3 million.

The Company invests surplus cash and cash equivalents in marketable securities.

Financing Activities

Net cash provided by financing activities was $0.2 million and $10.0 million for the six months ended June 30, 2023 and 2022, respectively. The net cash provided by financing activities in the six months end June 30, 2023 consisted primarily of net proceeds of $0.2 million from shares issued in an At-The-Market offering, net of commissions and issuance costs. The net cash provided by financing activities in the six months ended June 30, 2022 consisted primarily of net proceeds of $10.0 million from shares issued in an At-The-Market offering, net of commissions and issuance costs.

38

Non-GAAP Measures

Total Liquidity (a non-GAAP financial measure)

Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities. Each of these components appears in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in thousands):

    

June 30, 

    

December 31, 

2023

2022

Cash and cash equivalents

$

76,969

$

108,033

Marketable securities - available-for-sale debt securities

 

127,738

 

96,572

Total Liquidity

$

204,707

$

204,605

We believe that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its management of overall solvency and liquidity, financial flexibility, capital position and leverage. The definition of Total Liquidity includes marketable securities, which are highly-liquid and available to use in our current operations.

Safe Harbor

See the section titled “Information Regarding Forward-Looking Statements” at the beginning of this Quarterly Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

There have been no material changes to the Company’s market risk during the three and six months ended June 30, 2023. For a discussion of the Company’s exposure to market risk, please refer to the Company’s market risk disclosures set forth in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”) as of June 30, 2023.

Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at June 30, 2023.

Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d – 15(e)) under the Exchange Act) occurred during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

39

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

As of June 30, 2023 we were not a party to any material legal proceedings.

Item 1A. Risk Factors.

Our business has significant risks. You should carefully consider the risk factors set out in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, the disclosures set out in our Quarterly Report for the quarter ended March 31, 2023 and the disclosures set out in this Quarterly Report, including our condensed consolidated financial statements and the related notes, before making an investment decision regarding our securities. The risks and uncertainties described are those material risk factors currently known and specific to us that we believe are relevant to our business, results of operations and financial condition. Additional risks and uncertainties not currently known to us or that we now deem immaterial may also impair our business, results of operations and financial condition.

As of and for the period ended June 30, 2023, save as provided below there have been no material changes from the risk factors previously disclosed by us in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2022 and the updated risk factors set out in our Quarterly Report for the quarter ended March 31, 2023.

The following additional risk factors apply to our business in relation to the proposed strategic combination with TCR2.

Integration of the two companies could negatively impact the ability of Adaptimmune to fund and progress clinical programs.

As a result of the combination of the two companies, Adaptimmune is now required to fund an enhanced clinical pipeline and to integrate clinical programs from TCR2 into its own clinical development plan and processes. Integrating clinical programs may divert management resources away from existing programs of both Adaptimmune and TCR2 and may result in a delay to the development of its assets and products. In addition, existing combined funding will need to fund all ongoing development programs and decisions may need to be taken around prioritization of those programs whilst additional funding or sources of funding are obtained.

Phase 1 trial with TC-510 is currently in dose escalation phase and may not progress beyond dose escalation phase.

Phase 1 trials with TC-510 are current in the dose escalation phase. Should unmanageable toxicities be identified during the dose escalation phase it may not be possible to increase the dose of TC-510 administered to patients in the trial or such toxicities may prevent continuation of the trial. Should dose escalation not be possible in the trial, the efficacy of TC-510 may be impacted. As of April 14, 2023, 3 patients had received at least one dose of TC-510 in the Phase 1 trial.   Adverse events occurring in at least one of the subjects considered by investigators to be at least possibly related to TC-510 include abdominal pain, platelet count decreased, white blood count decreased, ALT increased, AST increased, blood alkaline phosphatase increased, troponin I increased, pleuritic pain, cough, hypoxia, pneumonitis, fatigue, CRS, dysuria, sinus tachycardia.

The Phase 1 trial with TC-510 is in the first dose level of the dose escalation phase. Data from this initial phase is being evaluated and escalation to the next dose level is dependent on this evaluation. In addition, mesothelin is expressed in tissues other than tumor tissue and there is no guarantee that on-target toxicities will not be observed with TC-510 as we continue to develop those cell therapies.

Trials utilising TC-210 (gavo-cel) may not progress further due to observed toxicities or lack of favourable response.

Patients have received gavo-cel in both a Phase 1 and Phase 2 trial. In the Phase 1 trial as of January 10, 2023, 32 patients received at least one dose of transduced cells. Adverse events occurring in >10% of subjects considered by investigators to be at least possibly related to Gavo-Cel include CRS, anaemia, lymphocyte count decreased, neutrophil count decreased, febrile neutropenia, pyrexia, fatigue, nausea, white blood cell count decreased, platelet count decreased, dyspnoea, hypoxia, pneumonitis, hypotension, headache, hypoalbuminaemia.

40

In the Phase 2 trial as of January 10, 2023 8 patients have received at least one dose of gavo-cel. Adverse events occurring in >10% of subjects considered by investigators to be at least possibly related to Gavo-Cel include CRS, anaemia, pyrexia, chill, diarrhoea, constipation, abdominal tenderness, white blood cell count decreased, platelet count decreased, neutrophil count decreased, blood alkaline phosphatase increased, activated partial thromboplastin time prolonged, blood lactate dehydrogenase increased, hypoxia, pneumonitis, pulmonary embolism, hypotension, headache, dizziness, ICANS, hypoalbuminaemia, hypomagnesaemia,hyponatraemia, hypokalaemia, hyperkalaemia, alopecia, rash, sinus tachycardia, cystitis noninfective, hematuria, lacrimation increased, tumor pain.

The toxicities observed and risk:benefit profile for gavo-cel are being evaluated. There is no guarantee that we will not see additional side effects. In addition, mesothelin is expressed in tissues other than tumor tissue and there is no guarantee that on-target toxicities will not be observed with gavo-cel which could prevent or limit further development of gavo-cel.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

41

Item 6. Exhibits.

The following exhibits are either provided with this Quarterly Report on Form 10-Q or are incorporated herein by reference:

Exhibit

Number

    

Description of Exhibit

10.29

Adaptimmune Therapeutics plc 2015 Share Option Scheme, dated March 16, 2015, as amended on April 15, 2015, January 13, 2016, December 18, 2017 and June 29, 2023 (incorporated by reference to Exhibit 10.1 of our Form 8-K, filed with the SEC on June 29, 2023).

10.30

Adaptimmune Therapeutics plc 2016 Employee Share Option Scheme, dated January 14, 2016, as amended on December 18, 2017 and June 29, 2023 (incorporated by reference to Exhibit 10.2 of our Form 8-K, filed with the SEC on June 29, 2023).

10.52

Letter of Appointment dated June 1, 2023 and effective from June 1, 2023 between the Company and Andrew Allen (incorporated by reference to Exhibit 10.2 to our Form 8-K filed with the SEC on June 1, 2023).

10.53

Letter of Appointment dated June 1, 2023 and effective from June 1, 2023 between the Company and Priti Hedge (incorporated by reference to Exhibit 10.3 to our Form 8-K filed with the SEC on June 1, 2023).

10.54

Letter of Appointment dated June 1, 2023 and effective from June 1, 2023 between the Company and Garry Menzel (incorporated by reference to Exhibit 10.4 to our Form 8-K filed with the SEC on June 1, 2023).

31.1**

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2**

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1***

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2***

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101**

The following financial information from Adaptimmune Therapeutics plc’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Unaudited Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022, (ii) Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Profit/Loss for the three and six months ended June 30, 2023 and 2022, (iv) Unaudited Condensed Consolidated Statements of Change in Equity for the three and six months ended June 30, 2023 and 2022, (v) Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 and (vi) Notes to the Unaudited Condensed Consolidated Financial Statements.

104**

Cover Page Interactive data File (formatted in Inline XBRL and contained in Exhibit 101).

**    Filed herewith.

*** Furnished herewith.

42

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ADAPTIMMUNE THERAPEUTICS PLC

Date: August 9, 2023

/s/ Adrian Rawcliffe

Adrian Rawcliffe

Chief Executive Officer

Date: August 9, 2023

/s/ Gavin Wood

Gavin Wood

Chief Financial Officer

43

EX-31.1 2 adap-20230630xex31d1.htm EX-31.1

Exhibit 31.1

Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Adrian Rawcliffe, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of Adaptimmune Therapeutics plc;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:

a.     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023

/s/ Adrian Rawcliffe

Adrian Rawcliffe

Chief Executive Officer


EX-31.2 3 adap-20230630xex31d2.htm EX-31.2

Exhibit 31.2

Certification Required by Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Gavin Wood, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of Adaptimmune Therapeutics plc;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:

a.     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023

/s/ Gavin Wood

Gavin Wood

Chief Financial Officer


EX-32.1 4 adap-20230630xex32d1.htm EX-32.1

Exhibit 32.1

Section 906 Certificate

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), I, Adrian Rawcliffe, Chief Executive Officer of Adaptimmune Therapeutics plc, a public limited company incorporated under English law (the “Company”), hereby certify, to my knowledge, that:

1.        The Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.        The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2023

/s/ Adrian Rawcliffe

Adrian Rawcliffe

Chief Executive Officer


EX-32.2 5 adap-20230630xex32d2.htm EX-32.2

Exhibit 32.2

Section 906 Certificate

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), I, Gavin Wood, Chief Financial Officer of Adaptimmune Therapeutics plc, a public limited company incorporated under English law (the “Company”), hereby certify, to my knowledge, that:

1.        The Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, to which this Certification is attached as Exhibit 32.2 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.        The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2023

/s/ Gavin Wood

Gavin Wood

Chief Financial Officer


EX-101.SCH 6 adap-20230630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Marketable securities - Available-for-sale debt securities (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Operating Leases - Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Share-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Accounts receivable (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue - Revenue from contracts with customers (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Profit / Loss per share - Antidilutive shares (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accumulated other comprehensive loss (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fair value measurements (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Contingencies and commitments - MD Anderson Strategic Alliance (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Share-based compensation - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Share-based compensation - Options (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Stockholders equity - Offerings (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Restructuring - Movements in Provision (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Restructuring - TCR post-acquisition senior leadership severance (Details) link:presentationLink link:calculationLink link:definitionLink 41404 - Disclosure - Restructuring - TCR post-acquisition senior leadership severance - Change in Liability (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Business combinations (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Business combinations - Gain on bargain purchase (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Business combinations - Proforma Information (Details) link:presentationLink link:calculationLink link:definitionLink 41504 - Disclosure - Business combinations - Acquisition-related costs (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Profit / Loss per share link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accumulated other comprehensive loss link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Marketable securities - available-for-sale debt securities link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Other current assets link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Contingencies and commitments link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Share-based compensation link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Business combinations link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Profit / Loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accumulated other comprehensive loss (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Marketable securities - available-for-sale debt securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Other current assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 31401 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Business combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - General (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Profit / Loss per share - Basic and diluted income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 adap-20230630_cal.xml EX-101.CAL EX-101.DEF 8 adap-20230630_def.xml EX-101.DEF EX-101.LAB 9 adap-20230630_lab.xml EX-101.LAB EX-101.PRE 10 adap-20230630_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 07, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Document Quarterly Report true  
Entity File Number 001-37368  
Entity Registrant Name ADAPTIMMUNE THERAPEUTICS PLC  
Entity Incorporation, State or Country Code X0  
Entity Address, Address Line One 60 Jubilee Avenue, Milton Park  
Entity Address, City or Town Abingdon, Oxfordshire  
Entity Address, Country GB  
Entity Address, Postal Zip Code OX14 4RX  
City Area Code 44  
Entity Tax Identification Number 00-0000000  
Title of 12(b) Security American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share  
Local Phone Number 1235 430000  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Trading Symbol ADAP  
Entity Common Stock, Shares Outstanding   1,357,031,946
Entity Central Index Key 0001621227  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 76,969,000 $ 108,033,000
Marketable securities - available-for-sale debt securities 127,738,000 96,572,000
Accounts receivable, net of allowance for expected credit losses of $0 and $0 2,970,000 7,435,000
Other current assets and prepaid expenses 54,094,000 43,330,000
Total current assets 261,771,000 255,370,000
Restricted cash 3,231,000 1,569,000
Operating lease right-of-use assets, net of accumulated amortization of $11,258 and $9,470 22,027,000 18,019,000
Property, plant and equipment, net of accumulated depreciation of $40,635 and $38,588 55,492,000 53,516,000
Intangible assets, net of accumulated amortization of $5,003 and $4,676 463,000 442,000
Total assets 342,984,000 328,916,000
Current liabilities    
Accounts payable 14,713,000 4,753,000
Operating lease liabilities, current 4,752,000 2,728,000
Accrued expenses and other current liabilities 25,242,000 31,215,000
Restructuring provision   2,285,000
Deferred revenue, current 31,418,000 23,520,000
Total current liabilities 76,125,000 64,501,000
Operating lease liabilities, non-current 21,590,000 20,349,000
Deferred revenue, non-current 117,257,000 160,892,000
Other liabilities, non-current 1,361,000 1,296,000
Total liabilities 216,333,000 247,038,000
Stockholders' equity    
Common stock - Ordinary shares par value euro 0.001, 1,702,760,280 authorized and 1,351,828,044 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding) 1,851,000 1,399,000
Additional paid in capital 1,057,547,000 990,656,000
Accumulated other comprehensive loss (3,092,000) (875,000)
Accumulated deficit (929,655,000) (909,302,000)
Total stockholders' equity 126,651,000 81,878,000
Total liabilities and stockholders' equity $ 342,984,000 $ 328,916,000
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
shares
Jun. 30, 2023
£ / shares
Dec. 31, 2022
£ / shares
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS        
Allowance for expected credit losses $ 0 $ 0    
Operating lease right-of-use assets, accumulated amortization 11,258 9,470    
Property, plant and equipment, accumulated depreciation 40,635 38,588    
Intangibles, accumulated amortization $ 5,003 $ 4,676    
Common stock, par value | £ / shares     £ 0.001 £ 0.001
Common stock, shares authorized | shares 1,702,760,280 1,282,773,750    
Common stock, shares issued | shares 1,351,828,044 987,109,890    
Common stock, shares outstanding | shares 1,351,828,044 987,109,890    
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
Revenue $ 5,130 $ 5,538 $ 52,731 $ 9,113
Operating expenses        
Research and development (29,965) (34,740) (55,513) (71,492)
General and administrative (20,073) (14,550) (40,470) (31,354)
Total operating expenses (50,038) (49,290) (95,983) (102,846)
Operating loss (44,908) (43,752) (43,252) (93,733)
Interest income 1,543 357 2,219 695
Gain on bargain purchase 22,155   22,155  
Other income (expense), net 501 (655) (170) (643)
Loss before income tax expense (20,709) (44,050) (19,048) (93,681)
Income tax expense (680) (470) (1,305) (1,104)
Net loss attributable to ordinary shareholders $ (21,389) $ (44,520) $ (20,353) $ (94,785)
Net loss per ordinary share        
Basic (in dollars per share) $ (0.02) $ (0.05) $ (0.02) $ (0.10)
Diluted (in dollars per share) $ (0.02) $ (0.05) $ (0.02) $ (0.10)
Weighted average shares outstanding:        
Basic (in shares) 1,108,166,960 962,794,072 1,050,071,434 951,474,546
Diluted (in shares) 1,108,166,960 962,794,072 1,050,071,434 951,474,546
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS        
Net loss $ (21,389) $ (44,520) $ (20,353) $ (94,785)
Other comprehensive (loss)/income, net of tax        
Foreign currency translation adjustments, net of tax of $0, and $0 (12,281) 47,694 (29,190) 64,486
Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0 10,590 (39,108) 26,116 (52,916)
Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0 385 (316) 857 (1,471)
Total comprehensive loss for the period $ (22,695) $ (36,250) $ (22,570) $ (84,686)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS    
Foreign currency translation adjustments, tax $ 0 $ 0
Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax 0 0
Unrealized holding gains (losses) on available-for-sale debt securities, tax $ 0 $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY - USD ($)
$ in Thousands
Common stock
Additional paid in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total
Balance at the beginning of the period, shares at Dec. 31, 2021 937,547,934        
Balance at the beginning of the period at Dec. 31, 2021 $ 1,337 $ 959,611 $ (11,142) $ (743,846) $ 205,960
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 5 30     35
Issuance of shares upon exercise of stock options (in shares) 3,318,072        
Other comprehensive loss (gain)     1,829   1,829
Share-based compensation expense   5,586     5,586
Net loss       (50,265) (50,265)
Balance at the end of the period at Mar. 31, 2022 $ 1,342 965,227 (9,313) (794,111) 163,145
Balance at the end of the period, shares at Mar. 31, 2022 940,866,006        
Balance at the beginning of the period, shares at Dec. 31, 2021 937,547,934        
Balance at the beginning of the period at Dec. 31, 2021 $ 1,337 959,611 (11,142) (743,846) 205,960
Increase (Decrease) in Stockholders' Equity          
Net loss         (94,785)
Balance at the end of the period at Jun. 30, 2022 $ 1,387 980,204 (1,043) (838,631) 141,917
Balance at the end of the period, shares at Jun. 30, 2022 976,759,524        
Balance at the beginning of the period, shares at Mar. 31, 2022 940,866,006        
Balance at the beginning of the period at Mar. 31, 2022 $ 1,342 965,227 (9,313) (794,111) 163,145
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 1       1
Issuance of shares upon exercise of stock options (in shares) 759,336        
Issuance of shares upon completion of public offering, net of issuance costs $ 44 9,932     9,976
Issuance of shares upon completion of public offering, net of issuance costs (in shares) 35,134,182        
Other comprehensive loss (gain)     8,270   8,270
Share-based compensation expense   5,045     5,045
Net loss       (44,520) (44,520)
Balance at the end of the period at Jun. 30, 2022 $ 1,387 980,204 (1,043) (838,631) $ 141,917
Balance at the end of the period, shares at Jun. 30, 2022 976,759,524        
Balance at the beginning of the period, shares at Dec. 31, 2022 987,109,890       987,109,890
Balance at the beginning of the period at Dec. 31, 2022 $ 1,399 990,656 (875) (909,302) $ 81,878
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 7 1     8
Issuance of shares upon exercise of stock options (in shares) 6,035,574        
Issuance of shares upon completion of public offering, net of issuance costs $ 1 187     188
Issuance of shares upon completion of public offering, net of issuance costs (in shares) 554,496        
Other comprehensive loss (gain)     (910)   (910)
Share-based compensation expense   1,676     1,676
Net loss       1,036 1,036
Balance at the end of the period at Mar. 31, 2023 $ 1,407 992,520 (1,785) (908,266) $ 83,876
Balance at the end of the period, shares at Mar. 31, 2023 993,699,960        
Balance at the beginning of the period, shares at Dec. 31, 2022 987,109,890       987,109,890
Balance at the beginning of the period at Dec. 31, 2022 $ 1,399 990,656 (875) (909,302) $ 81,878
Increase (Decrease) in Stockholders' Equity          
Net loss         (20,353)
Balance at the end of the period at Jun. 30, 2023 $ 1,851 1,057,547 (3,092) (929,655) $ 126,651
Balance at the end of the period, shares at Jun. 30, 2023 1,351,828,044       1,351,828,044
Balance at the beginning of the period, shares at Mar. 31, 2023 993,699,960        
Balance at the beginning of the period at Mar. 31, 2023 $ 1,407 992,520 (1,785) (908,266) $ 83,876
Increase (Decrease) in Stockholders' Equity          
Issuance of shares upon exercise of stock options $ 1 13     14
Issuance of shares upon exercise of stock options (in shares) 698,778        
Issuance of shares upon acquisition of TCR $ 443 60,320     60,763
Issuance of shares upon acquisition of TCR (in shares) 357,429,306        
Other comprehensive loss (gain)     (1,307)   (1,307)
Share-based compensation expense   4,694     4,694
Net loss       (21,389) (21,389)
Balance at the end of the period at Jun. 30, 2023 $ 1,851 $ 1,057,547 $ (3,092) $ (929,655) $ 126,651
Balance at the end of the period, shares at Jun. 30, 2023 1,351,828,044       1,351,828,044
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities    
Net loss $ (20,353) $ (94,785)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 3,824 2,728
Amortization 253 419
Gain on bargain purchase (22,155)  
Share-based compensation expense 5,513 10,631
Unrealized foreign exchange losses/(gains) 377 (108)
(Accretion)/amortization on available-for-sale debt securities (633) 1,636
Other 663 585
Changes in operating assets and liabilities:    
Decrease/(increase) in receivables and other operating assets 1,971 (22,898)
(Decrease)/increase in payables and other current liabilities (8,801) 12,898
Decrease in deferred revenue (41,704) (6,758)
Net cash used in operating activities (81,045) (95,652)
Cash flows from investing activities    
Acquisition of property, plant and equipment (3,565) (16,074)
Acquisition of intangible assets (199)  
Acquired upon acquisition of TCR2 Therapeutics Inc. 45,264  
Maturity or redemption of marketable securities 76,119 97,605
Investment in marketable securities (67,121) (42,197)
Other 537  
Net cash provided by investing activities 51,035 39,334
Cash flows from financing activities    
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs 188 9,976
Proceeds from exercise of stock options 22 36
Net cash provided by financing activities 210 10,012
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash 398 (5,836)
Net decrease in cash, cash equivalents and restricted cash (29,402) (52,142)
Cash, cash equivalents and restricted cash at start of period 109,602 151,666
Cash, cash equivalents and restricted cash at end of period $ 80,200 $ 99,524
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
General
6 Months Ended
Jun. 30, 2023
General  
General

Note 1 General

Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients.

The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of $929,655,000 as of June 30, 2023.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 2 Summary of Significant Accounting Policies

(a)          Basis of presentation

The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.

The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.

(b)          Use of estimates in interim financial statements

The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

(c)          Fair value measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:

Level 1 - Quoted prices in active markets for identical assets or liabilities

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability

The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.

(d)          Significant concentrations of credit risk

The Company held cash and cash equivalents of $76,969,000, marketable securities of $127,738,000 and restricted cash of $3,231,000 as of June 30, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.

The Company had two customers during the three months ended June 30, 2023 which are Genentech and GSK, and three during the six months ended, June 30, 2023, which also includes Astellas. There were accounts receivable of $2,970,000 as of June 30, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no credit losses have been recognized. As of June 30, 2023, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of June 30, 2023 is considered to be remote.

Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.

(e) New accounting pronouncements

Adopted in the current period

Measurement of credit losses on financial instruments

In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.

Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition. There was also no impact from adopting this standard on the acquisition accounting for TCR2 Therapeutics Inc. as no contracts with customers were assumed as a result of the business combination.

(f)          Business combinations

The Company determines whether a transaction or other event is a business combination by determining whether the assets acquired and liabilities assumed constitute a business. Business combinations are accounted for by applying the acquisition method as set out by ASC 805 Business combinations. The acquisition method of accounting requires the acquirer to recognize and measure all identifiable assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values, with certain exceptions for specific items.

For leases acquired in a business combination in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The right-of-use asset shall be measured at the same amount as the lease liability, adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. For leases in which the acquired entity is a lessee, the Company has elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less.

Goodwill is measured as the excess of the consideration transferred in the business combination over the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed. If instead the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed exceeds the consideration transferred, a gain on bargain purchase is recognized in the Consolidated Statement of Operations. The consideration transferred in a business combination is measured as the sum of the fair values of the assets transferred by the acquiring entity, the liabilities incurred by the acquiring entity to former owners of the acquired entity, and the equity interests issued by the acquiring entity.

The results of operations of businesses acquired by the Company are included in the Company’s Consolidated Statement of Operations as of the respective acquisition date.

Where the acquiring entity exchanges its share-based payment awards for awards held by grantees of the acquiree, such exchanges are treated as a modification of share-based payment awards and are referred to as replacement awards. The replacement awards are measured as of the acquisition date and the portion of the fair-value-based measure of the replacement award that is attributable to pre-combination vesting is considered part of the consideration transferred. For awards with service-based vesting conditions only, the amount attributable to pre-combination vesting is the fair-value-based measure of the acquiree award multiplied by the ratio of the employee’s pre-combination service period to the greater of the total service period of the original service period of the acquiree award.

Acquisition-related costs, including advisory, legal and other professional fees and administrative fees are expensed as incurred except for the costs of issuing equity securities, which are recognized as a reduction to the amounts recognized in the Statement of Changes in Equity for the respective equity issuance.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
6 Months Ended
Jun. 30, 2023
Revenue  
Revenue

Note 3 Revenue

The Company had two revenue-generating contracts with customers in the three months, and three in the six months, ended June 30 2023, compared to three in the three and six months ended June 30, 2022: a collaboration agreement with Astellas that was terminated as of March 6, 2023, a strategic collaboration and license agreement with Genentech and a termination and transfer agreement with GSK that was effective on April 6, 2023. The original collaboration and license agreement with GSK was terminated in 2022.

Revenue comprises the following categories (in thousands):

Three months ended

 

Six months ended

 

June 30, 

June 30, 

     

2023

     

2022

2023

     

2022

Development revenue

 

$

5,130

 

$

5,538

$

52,731

 

$

9,113

 

$

5,130

 

$

5,538

$

52,731

 

$

9,113

Deferred revenue decreased by $35,737,000 from $184,412,000 at December 31, 2022 to $148,675,000 at June 30, 2023 primarily due to revenue recognized during the quarter but was partially offset by a $9,613,000 payment from GSK and a $5,890,000 increase caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.21 at December 31, 2022 to £1.00 to $1.26 at June 30, 2023.

As of December 31, 2022, there was deferred revenue of $184,412,000 of which $52,046,000 was recognized as revenue in the six months ended June 30, 2023

The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of June 30, 2023 was $318,107,000.

The Genentech Collaboration and License Agreement

The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Genentech agreement as of June 30, 2023 was $280,250,000. Of this amount $171,816,000 is allocated to the research services and rights granted for the initial ‘off-the-shelf’ collaboration targets, $89,098,000 is allocated to the research services and rights granted for the personalized therapies, $13,052,000 is allocated to the material rights to designate the additional ‘off-the-shelf’ collaboration targets, $5,027,000 is allocated to the material right for the first option to extend the research term and $1,257,000 is allocated to the material right for the option to extend the research term a second time.

The Company expects to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progresses and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expects to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options are exercised and then as development progresses, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expire. The Company expects to satisfy the performance obligations relating to the material rights to extend the research term from the point that the options are exercised and then over the period of the extension, or at the point in time that the rights expire.

The Astellas Collaboration Agreement

The Company and Universal Cells mutually agreed to terminate the Astellas Collaboration Agreement as of March 6, 2023 (the “Termination Date”). In connection with the termination, all licenses and sublicenses granted to either party pursuant to the Collaboration Agreement ceased as of the Termination Date. There were no termination penalties in connection with the termination, however the Company is still entitled to receive reimbursement for research and development work performed up to and including a period of 30 days after the Termination Date.

The Company originally satisfied the performance obligations relating to the three co-development targets as development progresses and recognized revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company originally determined that the performance obligations relating to the two independent Astellas targets would be recognized at a point-in-time, upon commencement of the licenses in the event of nomination of the target, since they were right-to-use licenses.

The termination was accounted for as a contract modification on a cumulative catch-up basis. No performance obligations were identified as a result of the modification as there were no further goods or services to be provided by the Company and the modification resulted in the remaining unsatisfied and partially satisfied performance obligations under the collaboration becoming fully satisfied. The aggregate transaction price of the contract modification was $42,365,000 which included the remaining deferred income that had not been recognized as revenue as of the date of the modification and variable consideration from the remaining reimbursement income to be billed under the collaboration at the end of the 30 day period after the Effective Date. The transaction price of the modification was recognized in full in March 2023 and there is no remaining transaction price allocated to performance obligations that are unsatisfied or partially satisfied under, no remaining deferred income relating to, the agreement as of June 30, 2023 and no revenue was recognized in the three months ended June 30, 2023.

The GSK Collaboration and License Agreement

The GSK Collaboration and License Agreement consisted of multiple performance obligations, including the development of a third target, which was the only performance obligation for which revenue was recognized in 2022.

The collaboration was terminated by GSK in October 2022 (effective December 23, 2022). A further amendment to the collaboration agreement was entered into on December 19, 2022 for the deletion of certain provisions relating to GSK’s post termination manufacturing and supply obligations and payment of £5,000,000 by GSK to Adaptimmune. The aggregate transaction price of the contract modification was $6,500,000, which was recognized as revenue on the date of the modification. No revenue was recognized in relation to the GSK Collaboration and License Agreement in 2023.

The GSK Termination and Transfer Agreement

On April 6, 2023, the Company and GSK entered into a Termination and Transfer Agreement (the “Termination and Transfer Agreement”) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program.

As part of the agreement, sponsorship and responsibility for the ongoing IGNYTE and long-term follow-up (“LTFU”) trials relating to the NY-ESO cell therapy program will transfer to Adaptimmune. In return for this, Adaptimmune received an upfront payment of £7.5 million in June 2023 following the signing of the agreement and further milestone payments totalling £22.5 million will be due in relation to successive stages of transfer of the trials.

The Company determined that GSK is a customer and has accounted for the agreement under ASC 606 Revenue from contracts with customers. The agreement is accounted for as a separate contract from the original GSK Collaboration and License Agreement. The Company has identified the following performance obligations under the agreement: (i) to take over sponsorship for the IGNYTE trial and (ii) to take over sponsorship for the LTFU trial.

The aggregate transaction price at inception of the agreement was $37,335,000 comprising the total £30,000,000 upfront and milestone payments. No value was ascribed to non-cash consideration and there was no variable consideration identified. The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the relative standalone selling price, the Company considered the internal pricing objectives it used in negotiating the contract, together with internal data regarding the expected costs and a standard margin on those costs, for completing the trials. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation.

The Company expects to satisfy the IGNYTE performance obligation as sponsorship of the active trials that make up the IGNYTE trial transfers, based on the number of patients transferring to the Company in each trial. The Company considers that this

depicts the progress of the transfer of sponsorship of the IGNYTE trial to the Company, as each individual trial comprising IGNYTE transferred represents the transfer of a portion of the sponsorship for IGNYTE.

The Company expects to satisfy the LTFU performance obligation as sponsorship of the trials that make up the LTFU trial transfers, including trials for potential future patients transferring to the LTFU trial from the IGNYTE trial, based on the number of active and potential patients transferring in each trial. The Company considers that this depicts the progress of the transfer of sponsorship of the LTFU trial to the Company, as each individual trial comprising LTFU transferred represents the transfer of a portion of sponsorship for the LTFU trial and the sponsorship of patients transferring from IGNYTE in future is part of the promise to take on the overall LTFU trial.

No revenue was recognized for the agreement in the three and six months ended June 30, 2023. The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of June 30, 2023 was $37,857,000, of which $21,200,000 is allocated to the IGNYTE performance obligation and $16,657,000 is allocated to the LTFU performance obligation.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Profit / Loss per share
6 Months Ended
Jun. 30, 2023
Profit / Loss per share  
Profit / Loss per share

Note 4 Loss per share

The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):

Three months ended

Six months ended

June 30, 

June 30, 

     

2023

     

2022

     

2023

     

2022

Numerator for basic and diluted loss per share

Net loss attributable to ordinary shareholders

 

$

(21,389)

 

$

(44,520)

 

$

(20,353)

 

$

(94,785)

Net loss attributable to ordinary shareholders used for basic and diluted loss per share

$

(21,389)

$

(44,520)

$

(20,353)

$

(94,785)

Three months ended

Six months ended

June 30, 

June 30, 

 

2023

    

2022

     

2023

     

2022

Denominator for basic loss per share - Weighted average shares outstanding

 

1,108,166,960

 

962,794,072

 

1,050,071,434

 

951,474,546

The dilutive effect of 201,688,491 and 150,711,054 stock options outstanding as of June 30, 2023 and 2022 respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2023 and 2022 because they would have an antidilutive effect on the loss per share for the period. The stock options outstanding as of June 30, 2023 includes a provisional amount of 35,156,344 replacement awards granted to TCR2 grantholders on June 1, 2023.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Accumulated other comprehensive loss
6 Months Ended
Jun. 30, 2023
Accumulated other comprehensive loss.  
Accumulated other comprehensive loss

Note 5 Accumulated other comprehensive loss

The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.

The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):

Accumulated

Accumulated

Total

foreign

unrealized

accumulated

currency

(losses) gains on

other

    

translation

    

available-for-sale

comprehensive

adjustments

debt securities

(loss) income

Balance at January 1, 2023

 

$

55

$

(930)

$

(875)

Foreign currency translation adjustments

(16,908)

(16,908)

Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0

15,526

15,526

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

472

472

Balance at March 31, 2023

$

(1,327)

$

(458)

(1,785)

Foreign currency translation adjustments

(12,281)

(12,281)

Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0

10,590

10,590

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

385

385

Balance at June 30, 2023

$

(3,019)

$

(73)

$

(3,092)

Accumulated

Accumulated

Total

foreign

unrealized

accumulated

currency

(losses) on

other

    

translation

    

available-for-sale

comprehensive

adjustments

debt securities

(loss) income

Balance at January 1, 2022

 

$

(10,785)

$

(357)

(11,142)

Foreign currency translation adjustments

16,792

16,792

Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0

(13,808)

(13,808)

Unrealized holding losses on available-for-sale debt securities, net of tax of $0

(1,155)

(1,155)

Balance at March 31, 2022

$

(7,801)

$

(1,512)

(9,313)

Foreign currency translation adjustments

47,694

47,694

Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0

(39,108)

(39,108)

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

(316)

(316)

Balance at June 30, 2022

785

$

(1,828)

(1,043)

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Fair value measurements
6 Months Ended
Jun. 30, 2023
Fair value measurements  
Fair value measurements

Note 6 Fair value measurements

Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of June 30, 2023 are as follows (in thousands):

Fair value measurements using

June 30, 

Level 1

Level 2

Level 3

     

2023

    

    

    

Assets classified as cash equivalents:

U.S. Treasury securities

$

29,102

$

$

29,102

$

Assets classified as available-for-sale debt securities:

Corporate debt securities

$

24,928

$

24,928

$

$

U.S. Treasury securities

$

94,917

$

94,917

Agency bonds

 

$

7,893

7,893

 

$

127,738

$

24,928

 

$

102,810

 

$

The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Marketable securities - available-for-sale debt securities
6 Months Ended
Jun. 30, 2023
Marketable securities - available-for-sale debt securities  
Marketable securities - available-for-sale debt securities

Note 7 — Marketable securities – available-for-sale debt securities

As of June 30, 2023, the Company has the following investments in marketable securities (in thousands):

Gross

Gross

Aggregate

Remaining

Amortized

unrealized

unrealized

estimated

    

contractual maturity

    

cost

    

gains

    

losses

    

fair value

Cash equivalents:

 

  

 

  

 

  

 

  

 

  

U.S. Treasury securities

Less than 3 months

29,069

33

29,102

 

  

$

29,069

$

33

$

$

29,102

Available-for-sale debt securities:

 

  

 

  

 

  

 

  

 

  

Corporate debt securities

 

Less than 3 months

$

16,258

$

$

(26)

$

16,232

U.S. Treasury securities

Less than 3 months

41,675

12

(5)

41,682

Agency bonds

Less than 3 months

5,008

(56)

4,952

U.S. Treasury securities

3 months to 1 year

53,225

19

(9)

53,235

Agency bonds

3 months to 1 year

2,949

(8)

2,941

Corporate debt securities

3 months to 1 year

8,726

2

(32)

8,696

 

  

$

127,841

$

33

$

(136)

$

127,738

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of June 30, 2023 and December 31, 2022 are as follows:

June 30, 2023

December 31, 2022

     

Fair market value of investments in an unrealized loss position

Number of investments in an unrealized loss position

Unrealized losses

Fair market value of investments in an unrealized loss position

Number of investments in an unrealized loss position

Unrealized losses

Marketable securities in a continuous loss position for 12 months or longer:

Corporate debt securities

$

15,554

4

$

(50)

$

74,481

16

$

(679)

Agency bond

4,952

1

(56)

4,854

1

(154)

Marketable securities in a continuous loss position for less than 12 months:

Corporate debt securities

 

$

6,424

 

2

$

(8)

 

$

11,283

 

2

 

$

(97)

U.S. Treasury securities

$

31,608

 

11

 

(14)

 

 

 

Agency bond

$

2,941

1

(8)

 

$

61,479

 

19

$

(136)

 

$

90,618

 

19

 

$

(930)

As of June 30, 2023, no allowance for expected credit losses has been recognized in relation to securities in an unrealized loss position. This is because the impairments are not severe, do not represent a significant proportion of the total fair market value of the investments and all securities have an investment-grade credit rating. Furthermore, the Company does not intend to sell the debt securities in an unrealized loss position, believes that it has the ability to hold the debt securities to maturity, and it is currently unlikely that the Company will be required to sell these securities before the recovery of the amortized cost.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Other current assets
6 Months Ended
Jun. 30, 2023
Other current assets  
Other current assets

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):

June 30, 

December 31, 

    

2023

    

2022

Research and development credits receivable

 

$

37,863

$

30,162

Prepayments

 

13,040

9,472

Clinical materials

 

1,334

1,279

VAT receivable

92

490

Other current assets

 

1,765

1,927

$

54,094

$

43,330

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Leases
6 Months Ended
Jun. 30, 2023
Operating leases  
Operating leases

Note 9 — Operating leases

The Company has operating leases in relation to property for office, manufacturing and research facilities.

The following table shows the lease costs for the six months ended June 30, 2023 and 2022 and the weighted-average remaining lease term and the weighted-average discount rate as at June 30, 2023 and 2022:

Six months ended

June 30, 

     

2023

     

2022

Lease cost:

Operating lease cost

 

$

2,353

 

$

2,285

Short-term lease cost

 

319

 

164

 

$

2,672

 

$

2,449

June 30, 

2023

2022

Weighted-average remaining lease term - operating leases

5.8 years

7.3 years

Weighted-average discount rate - operating leases

8.6%

6.8%

The maturities of operating lease liabilities as of June 30, 2023 are as follows (in thousands):

     

Operating leases

2023

 

$

3,402

2024

 

6,530

2025

 

5,142

2026

 

4,142

2027

 

5,559

after 2027

 

7,637

Total lease payments

32,412

Less: Imputed interest

6,070

Present value of lease liability

$

26,342

The Company has operating leases in relation to property for office, manufacturing and research facilities.

On June 1, 2023, as part of the acquisition of TCR2, the Company became the lessee for three office, manufacturing and research facilities in Cambridge, Massachusetts. The Company retained TCR2’s previous classification for two of these leases as operating leases and, upon acquisition, the lease liabilities were measured at the present value of the remaining lease payments, as if the lease were a new lease of the Company at June 1, 2023. The right-of-use assets were initially measured at the same amount as the respective lease liabilities, adjusted to reflect favorable or unfavorable terms of the leases when compared with market terms.

The third lease had a remaining lease term of less than 12 months as of June 1, 2023, and the Company elected not to recognize a lease liability or right-of-use asset as of June 1, 2023. The rent associated with this lease will be recognized on a straight-line basis over the remainder of the lease term.

The maximum lease term without activation of termination options is to 2041.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued expenses and other current liabilities
6 Months Ended
Jun. 30, 2023
Accrued expenses and other current liabilities  
Accrued expenses and other current liabilities

Note 10 Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

June 30, 

December 31, 

    

2023

    

2022

Accrued clinical and development expenditure

$

12,039

$

16,749

Accrued employee expenses

10,020

8,232

Other accrued expenditure

3,028

4,079

Other

 

155

 

2,155

$

25,242

$

31,215

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies and commitments
6 Months Ended
Jun. 30, 2023
Contingencies and commitments  
Contingencies and commitments

Note 11 Contingencies and commitments

Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement

On November 25, 2015, the Company entered into a Research, Collaboration and License Agreement relating to gene editing and Human Leukocyte Antigen (“HLA”) engineering technology with Universal Cells, Inc. (“Universal Cells”). The Company paid an upfront license and start-up fee of $2,500,000 to Universal Cells in November 2015, a milestone payment of $3,000,000 in February 2016 and further milestone payments of $200,000 and $900,000 were made in the years ended December 31, 2018 and 2017, respectively.

The agreement was amended and re-stated as of January 13, 2020, primarily to reflect changes to the development plan agreed between the parties. The agreement was further amended as of July 22, 2022, primarily to make certain changes to development milestones and to agree on the status thereof, as agreed between the parties. Following the amendment, milestone payments of $500,000, $600,000 and $400,000 were made in the year ended December 31, 2022. No remaining milestones have been accrued as of June 30, 2023. The upfront license and start-up fee and milestone payments were expensed to Research and development when incurred.

This Agreement was terminated by notice on January 27, 2023, effective 30 days following receipt of notice of termination. As a result of termination, all licenses between the parties to the Agreement will cease and each party is required to return all confidential information of the other party.

Astellas Collaboration Agreement

Under the Astellas Collaboration Agreement, described further in Note 3, if Adaptimmune had unilaterally developed a product with technology contributed by Astellas, Astellas could have been eligible to receive milestones and royalties relating to future commercialization and sales. As a result of the termination of the collaboration, Astellas no longer has the right to receive these milestones or royalties in future.

MD Anderson Strategic Alliance

On September 26, 2016, the Company announced that it had entered into a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center (“MD Anderson”) designed to expedite the development of T-cell therapies for multiple types of cancer. The Company and MD Anderson are collaborating on a number of studies including clinical and preclinical development of the Company’s SPEAR T-cell therapies and will collaborate on future clinical stage first and second generation SPEAR T-cell therapies across a number of cancers.

Under the terms of the agreement, the Company committed at least $19,644,000 to fund studies. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance and the performance of set milestones by MD Anderson. The Company made an upfront payment of $3,412,000 to MD Anderson in the year ended December 31, 2017 and milestone payments of $2,326,000, $3,549,000, $454,000 and $2,326,000 in the years ended December 31, 2018, 2020, 2021, and 2022, respectively. The Company is obligated to make further payments to MD Anderson as certain milestones are achieved. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance.

The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, amongst other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Share-based compensation
6 Months Ended
Jun. 30, 2023
Share-based compensation  
Share-based compensation

Note 12 Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):

Three months ended

Six months ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

1,285

$

2,033

$

1,401

$

4,556

General and administrative

 

2,552

 

3,012

 

4,112

6,075

$

3,837

$

5,045

$

5,513

$

10,631

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:

Three months ended

Six months ended

June 30, 

June 30, 

2023

    

2022

    

2023

    

2022

Number of options over ordinary shares granted

30,247,398

1,735,488

52,002,726

24,611,952

Weighted average fair value of ordinary shares options

$

0.05

$

0.25

$

0.08

$

0.41

Number of additional options with a nominal exercise price granted

6,148,186

3,361,728

26,015,098

21,050,160

Weighted average fair value of options with a nominal exercise price

$

0.15

$

0.34

$

0.17

$

0.55

The information above includes the impact of 29,654,742 options over ordinary shares and 5,501,602 options with a nominal exercise price granted on June 1, 2023, as replacement awards as part of the acquisition of TCR2 Therapeutics Inc., as explained further in Note 15. The number and fair value of replacement awards of the Company granted to TCR2 grantholders is provisional.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' equity
6 Months Ended
Jun. 30, 2023
Stockholders' equity  
Stockholders' equity

Note 13 Stockholders’ equity

On August 10, 2020 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) (the “Sales Agreement”) under which we may from time to time issue and sell American Depositary Shares (“ADSs”) representing our ordinary shares through Cowen in at-the-market (“ATM”) offerings for an aggregate offering price of up to $200 million. As of June 30, 2023, $197,360,000 remained available for sale under the Sales Agreement.

On April 8, 2022 the Company entered into a new sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the six months ended June 30, 2023, the Company sold 92,416 ADSs under the agreement representing 554,496 ordinary shares resulting in net proceeds to the Company of $173,430 after deducting commissions payable under the 2022 Sales Agreement and estimated issuance costs. As of June 30, 2023, approximately $186,513,100 remained available for sale under the 2022 Sales Agreement.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring
6 Months Ended
Jun. 30, 2023
Restructuring  
Restructuring

Note 14 – Restructuring

2022-23 Restructuring programme

On November 8, 2022, the Company announced that in order to extend the Company’s cash runway from early 2024 into early 2025, it was re-focusing the business on core programs and deprioritizing non-core programs and undertaking a restructuring of the Company including a headcount reduction to be completed in the first quarter of 2023.

The redundancy process was completed in the first quarter of 2023 with a reduction of approximately 25% of global headcount. The redundancy packages to be paid to departing staff comprise a combination of contractual termination benefits, relating to payments that arise from terms of employment contracts and statutory redundancy pay, and one-time employee termination benefits that were provided or enhanced specifically for this redundancy process. Due to the structure of the redundancy scheme and the different employment regulations affecting the Company’s U.K. and U.S. employees, some of the expense associated with the one-time employee termination benefits were recognized over the remaining period of employee service to be rendered. Contractual termination benefits and other one-time employee termination benefits were expensed and recognized in the year ended December 31, 2022. All expenses have been recognized in General and administrative expenses in the Statement of Operations.

The amounts incurred in relation to the redundancy programme are as follows:

One-time

Contractual

employee

Total

termination

termination

restructuring

benefits

benefits

costs

Cumulative amount incurred to December 31, 2022

$

1,171

$

1,114

$

2,285

Amount incurred in the three months ended March 31, 2023 and six months ended June 30, 2023

778

925

1,703

Total amount and cumulative amount incurred to March 31, 2023 and June 30, 2023

$

1,949

$

2,039

$

3,988

The table below is a summary of the changes in the restructuring provision in the Consolidated Balance Sheet in the six months ended June 30, 2023:

One-time

Contractual

employee

Total

termination

termination

restructuring

    

benefits

benefits

provision

Provision at January 1, 2023

$

1,171

$

1,114

$

2,285

Costs incurred and charged to General and administrative expenses

670

947

1,617

Costs paid during the period

(1,955)

(1,953)

(3,908)

Adjustments to the liability

108

(22)

86

Effect of foreign exchange rates

6

2

8

Provision at March 31, 2023

$

$

88

$

88

Costs paid during the period

(88)

(88)

Provision at June 30, 2023

$

$

$

The costs incurred during the period includes the element of one-time employee termination benefits that was recognized over the remaining period of employee service. The costs incurred during the six months to 30 June 2023 also include an addition to the provision for costs incurred relating to termination benefits paid to the former Chief Commercial Officer, who left employment with the Company in the first quarter of 2023.

No impairment losses were recognized as a result of the restructuring.

TCR2 post-acquisition senior leadership severance

Following the acquisition of TCR2 Therapeutics Inc., the Company made most of the former members of TCR2’s senior leadership team, comprising the executive officers and most vice presidents, redundant and paid severance packages. The redundancy packages are considered contractual termination benefits as they arise from terms of employment contracts including change-in-control ‘dual trigger’ provisions, and were comprised of severance and other payments and accelerated vesting of share option awards.

The amounts incurred in relation to these redundancies in the six months to June 30, 2023, are as follows:

Three and six months ending

June 30, 2023

Severance and other cash payments

$

5,655

Accelerated vesting of share-based compensation awards

835

Total and cumulative amount incurred to June 30, 2023

$

6,490

The expense associated with the accelerated vesting of share-based compensation awards recognized in Research and development and General and administrative expenses in the Consolidated Statement of Operations was $0.2 million and $0.6 million, respectively. The table below is a summary of the changes in the liability in the Consolidated Balance Sheet in the three and six months ended June 30, 2023:

Liability

Liability at June 1, 2023

$

805

Costs incurred and charged to Research and development expenses

1,267

Costs incurred and charged to General and administrative expenses

4,388

Costs paid during the period

(4,823)

Liability at June 30, 2023

$

1,637

The amounts included in the liabilities at June 1, and June 30, 2023 and the cash paid during the period, include amounts relating to accrued payments to these employees for services provided prior to the acquisition of TCR2 by the Company.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Business combinations
6 Months Ended
Jun. 30, 2023
Business combinations  
Business combinations

Note 15 – Business combinations

On March 6, 2023 the Company announced entry into a definitive agreement under which it will combine with TCR² Therapeutics Inc. (“TCR²”) in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. TCR2 is a Boston, Massachusetts-based T-cell therapy company focused on treating solid tumours, with clinical franchises undergoing trials and a preclinical pipeline. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms.

The transaction was approved by the Company’s shareholders and TCR2 stockholders on May 30, 2023 and the merger became effective on June 1, 2023. The Company issued 357,429,306 shares to TCRstockholders in return for 100% of TCR2’s stock. As a result, TCR2 and all entities within the TCR2 group, became wholly owned by the Company. Following the completion of the transaction, the former TCR2 stockholders held approximately 25% of the Company, whereas the Company’s pre-existing shareholders held approximately 75%.

The Company was identified as the acquirer, with TCR2 as the acquiree, and June 1, 2023 was determined to be the acquisition date.

The consideration transferred for TCR2 includes the shares issued by the Company to former TCR2 shareholders, plus the fair value of replacement awards of the Company granted to TCR2 grantholders attributable to pre-combination vesting. The table below summarizes the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date:

Consideration transferred:

Fair value of 357,429,306 ordinary shares issued

$

60,763

Fair value of replacement options and RSU-style options granted attributable to pre-combination service:

857

Purchase consideration

$

61,620

Identifiable assets acquired and liabilities assumed:

Assets acquired

Cash and cash equivalents

$

43,610

Restricted cash

1,654

Marketable securities - available-for-sale debt securities

39,532

Other current assets and prepaid expenses

6,029

Property, plant and equipment

2,712

Operating lease right-of-use assets

5,145

Intangible assets

58

Total assets acquired

$

98,740

Liabilities assumed

Accounts payable

(6,210)

Accrued expenses and other current liabilities

(4,537)

Operating lease liabilities, current

(1,974)

Operating lease liabilities, non-current

(2,244)

Total liabilities assumed

$

(14,965)

Net assets acquired and liabilities assumed

$

83,775

The fair value of the 357,429,306 ordinary shares issued to TCR2 stockholders of $60,763,000 was determined on the basis of the closing market price of $1.02 ($0.17 per ordinary share) of the Company’s ADSs as of May 31, 2023.

The number and fair value of replacement awards of the Company granted to TCR2 grantholders attributable to pre-combination and post-combination vesting is provisional as the Company is still evaluating the total number of replacement awards that were required to be granted on June 1, 2023, their respective exercise prices and the total fair value of replacement options granted.

The assets acquired and liabilities assumed were measured based on management’s estimates of the fair value as of the acquisition date, excluding leases.

The lease contracts acquired by the Company relate to the rental of office and manufacturing spaces in which TCR2 was the lessee. The Company retained TCR2’s previous classification of acquired leases as operating leases as there were no lease modifications as a result of the combination, with the exception of leases with a remaining lease term of 12 months or less at the acquisition date, for which no assets or liabilities were recognized at the acquisition date. The lease liabilities were measured at the present value of the remaining lease payments as if the leases were a new lease as of June 1, 2023, discounted using the incremental borrowing rate. The right-of-use assets were measured at the same amount as the lease liabilities, with adjustments to reflect favorable or unfavorable terms compared to market terms. No intangible assets were identified in relation to lease contracts acquired.

The table below summarises the calculation for the gain on bargain purchase, recognized in the Gain on bargain purchase line in the Consolidated Statement of Operations:

Gain on bargain purchase

Purchase consideration

$

(61,620)

Net assets acquired and liabilities assumed

83,775

Gain on bargain purchase

$

22,155

The transaction resulted in a gain on bargain purchase as the purchase consideration included in the agreement on March 6, 2023 comprising Company ADSs was based on a fixed ratio of 1.5117 of the Company’s ADSs to be issued for each TCR2 stock acquired. As the transaction was an all-stock transaction, the value of the consideration was highly sensitive to changes in the Company’s ADS price. The price of a Company ADS fell from a closing price of $1.32 on March 6, 2023 compared to a closing price of $1.02 on May 31, 2023.

The amount of TCR2’s earnings that are included in the Company’s Consolidated Statement of Operations for the six months ended June 30, 2023 was a loss of $11,760,000 which excludes the gain on bargain purchase.

The amount of revenue and earnings of the combined entity for the six months ended June 30, 2023 and 2022, had the acquisition date been January 1, 2022, are as follows:

Six months ended

Six months ended

June 30, 2023

June 30, 2022

Revenue

$

52,731

$

9,113

Net loss

(86,202)

(143,556)

The supplemental pro forma earnings for the six months ended June 30, 2023 were adjusted to exclude the $22.2 million Gain on bargain purchase, the $7.2 million of acquisition-related costs recognized by the Company, as detailed below, and the $7.7 million of acquisition-related costs incurred by TCR2. The pro forma earnings for the six months ended June 30, 2022 were adjusted to include these gains and losses. The supplemental pro forma earnings for both periods were adjusted to include the impact of replacement options issued, as if these had been issued as of January 1, 2022. Accordingly, the share-based compensation expense recognized by TCR2 in the six months ended June 30, 2022, and the five months ended May 31, 2023, prior to the acquisition by the Company, of $6.0 million and $1.0 million, respectively, were excluded from the pro forma earnings.

TCR2 did not generate revenue in the period from January 1, 2022 to June 30, 2023, as it has no contracts with customers, so there was no impact on the revenue included in the Company’s Consolidated Statement of Operations or in the supplemental pro forma revenue and earnings presented above.

The Company incurred the following acquisition-related costs that were recognized as an expense in the six months ended June 30, 2023:

Legal, professional and accounting fees

4,993

Bankers' fees

2,172

Total acquisition-related costs

$

7,165

All acquisition-related costs that were recognized as an expense were recognized in General and administrative expenses in the Consolidated Statement of Operations. No issuance costs were incurred relating to the issuance of shares to TCR2 stockholders.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent events
6 Months Ended
Jun. 30, 2023
Subsequent events  
Subsequent events

Note 16 – Subsequent events

None

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Summary of Significant Accounting Policies  
Basis of presentation

(a)          Basis of presentation

The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.

The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.

Use of estimates in interim financial statements

(b)          Use of estimates in interim financial statements

The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

Fair value measurements

(c)          Fair value measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:

Level 1 - Quoted prices in active markets for identical assets or liabilities

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability

The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.

Significant concentrations of credit risk

(d)          Significant concentrations of credit risk

The Company held cash and cash equivalents of $76,969,000, marketable securities of $127,738,000 and restricted cash of $3,231,000 as of June 30, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.

The Company had two customers during the three months ended June 30, 2023 which are Genentech and GSK, and three during the six months ended, June 30, 2023, which also includes Astellas. There were accounts receivable of $2,970,000 as of June 30, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no credit losses have been recognized. As of June 30, 2023, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of June 30, 2023 is considered to be remote.

Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.

New accounting pronouncements

(e) New accounting pronouncements

Adopted in the current period

Measurement of credit losses on financial instruments

In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.

Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition. There was also no impact from adopting this standard on the acquisition accounting for TCR2 Therapeutics Inc. as no contracts with customers were assumed as a result of the business combination.

Business combinations

(f)          Business combinations

The Company determines whether a transaction or other event is a business combination by determining whether the assets acquired and liabilities assumed constitute a business. Business combinations are accounted for by applying the acquisition method as set out by ASC 805 Business combinations. The acquisition method of accounting requires the acquirer to recognize and measure all identifiable assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values, with certain exceptions for specific items.

For leases acquired in a business combination in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The right-of-use asset shall be measured at the same amount as the lease liability, adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. For leases in which the acquired entity is a lessee, the Company has elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less.

Goodwill is measured as the excess of the consideration transferred in the business combination over the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed. If instead the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed exceeds the consideration transferred, a gain on bargain purchase is recognized in the Consolidated Statement of Operations. The consideration transferred in a business combination is measured as the sum of the fair values of the assets transferred by the acquiring entity, the liabilities incurred by the acquiring entity to former owners of the acquired entity, and the equity interests issued by the acquiring entity.

The results of operations of businesses acquired by the Company are included in the Company’s Consolidated Statement of Operations as of the respective acquisition date.

Where the acquiring entity exchanges its share-based payment awards for awards held by grantees of the acquiree, such exchanges are treated as a modification of share-based payment awards and are referred to as replacement awards. The replacement awards are measured as of the acquisition date and the portion of the fair-value-based measure of the replacement award that is attributable to pre-combination vesting is considered part of the consideration transferred. For awards with service-based vesting conditions only, the amount attributable to pre-combination vesting is the fair-value-based measure of the acquiree award multiplied by the ratio of the employee’s pre-combination service period to the greater of the total service period of the original service period of the acquiree award.

Acquisition-related costs, including advisory, legal and other professional fees and administrative fees are expensed as incurred except for the costs of issuing equity securities, which are recognized as a reduction to the amounts recognized in the Statement of Changes in Equity for the respective equity issuance.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2023
Revenue  
Summary of revenue categories

Revenue comprises the following categories (in thousands):

Three months ended

 

Six months ended

 

June 30, 

June 30, 

     

2023

     

2022

2023

     

2022

Development revenue

 

$

5,130

 

$

5,538

$

52,731

 

$

9,113

 

$

5,130

 

$

5,538

$

52,731

 

$

9,113

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Profit / Loss per share (Tables)
6 Months Ended
Jun. 30, 2023
Profit / Loss per share  
Schedule of numerator and denominator in the basic and diluted loss per share computation

The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):

Three months ended

Six months ended

June 30, 

June 30, 

     

2023

     

2022

     

2023

     

2022

Numerator for basic and diluted loss per share

Net loss attributable to ordinary shareholders

 

$

(21,389)

 

$

(44,520)

 

$

(20,353)

 

$

(94,785)

Net loss attributable to ordinary shareholders used for basic and diluted loss per share

$

(21,389)

$

(44,520)

$

(20,353)

$

(94,785)

Three months ended

Six months ended

June 30, 

June 30, 

 

2023

    

2022

     

2023

     

2022

Denominator for basic loss per share - Weighted average shares outstanding

 

1,108,166,960

 

962,794,072

 

1,050,071,434

 

951,474,546

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Accumulated other comprehensive loss (Tables)
6 Months Ended
Jun. 30, 2023
Accumulated other comprehensive loss.  
Schedule of changes in Accumulated other comprehensive (loss) income

The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):

Accumulated

Accumulated

Total

foreign

unrealized

accumulated

currency

(losses) gains on

other

    

translation

    

available-for-sale

comprehensive

adjustments

debt securities

(loss) income

Balance at January 1, 2023

 

$

55

$

(930)

$

(875)

Foreign currency translation adjustments

(16,908)

(16,908)

Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0

15,526

15,526

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

472

472

Balance at March 31, 2023

$

(1,327)

$

(458)

(1,785)

Foreign currency translation adjustments

(12,281)

(12,281)

Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0

10,590

10,590

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

385

385

Balance at June 30, 2023

$

(3,019)

$

(73)

$

(3,092)

Accumulated

Accumulated

Total

foreign

unrealized

accumulated

currency

(losses) on

other

    

translation

    

available-for-sale

comprehensive

adjustments

debt securities

(loss) income

Balance at January 1, 2022

 

$

(10,785)

$

(357)

(11,142)

Foreign currency translation adjustments

16,792

16,792

Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0

(13,808)

(13,808)

Unrealized holding losses on available-for-sale debt securities, net of tax of $0

(1,155)

(1,155)

Balance at March 31, 2022

$

(7,801)

$

(1,512)

(9,313)

Foreign currency translation adjustments

47,694

47,694

Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0

(39,108)

(39,108)

Unrealized holding gains on available-for-sale debt securities, net of tax of $0

(316)

(316)

Balance at June 30, 2022

785

$

(1,828)

(1,043)

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Fair value measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair value measurements  
Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria

Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of June 30, 2023 are as follows (in thousands):

Fair value measurements using

June 30, 

Level 1

Level 2

Level 3

     

2023

    

    

    

Assets classified as cash equivalents:

U.S. Treasury securities

$

29,102

$

$

29,102

$

Assets classified as available-for-sale debt securities:

Corporate debt securities

$

24,928

$

24,928

$

$

U.S. Treasury securities

$

94,917

$

94,917

Agency bonds

 

$

7,893

7,893

 

$

127,738

$

24,928

 

$

102,810

 

$

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Marketable securities - available-for-sale debt securities (Tables)
6 Months Ended
Jun. 30, 2023
Marketable securities - available-for-sale debt securities  
Schedule of marketable securities

As of June 30, 2023, the Company has the following investments in marketable securities (in thousands):

Gross

Gross

Aggregate

Remaining

Amortized

unrealized

unrealized

estimated

    

contractual maturity

    

cost

    

gains

    

losses

    

fair value

Cash equivalents:

 

  

 

  

 

  

 

  

 

  

U.S. Treasury securities

Less than 3 months

29,069

33

29,102

 

  

$

29,069

$

33

$

$

29,102

Available-for-sale debt securities:

 

  

 

  

 

  

 

  

 

  

Corporate debt securities

 

Less than 3 months

$

16,258

$

$

(26)

$

16,232

U.S. Treasury securities

Less than 3 months

41,675

12

(5)

41,682

Agency bonds

Less than 3 months

5,008

(56)

4,952

U.S. Treasury securities

3 months to 1 year

53,225

19

(9)

53,235

Agency bonds

3 months to 1 year

2,949

(8)

2,941

Corporate debt securities

3 months to 1 year

8,726

2

(32)

8,696

 

  

$

127,841

$

33

$

(136)

$

127,738

Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of June 30, 2023 and December 31, 2022 are as follows:

June 30, 2023

December 31, 2022

     

Fair market value of investments in an unrealized loss position

Number of investments in an unrealized loss position

Unrealized losses

Fair market value of investments in an unrealized loss position

Number of investments in an unrealized loss position

Unrealized losses

Marketable securities in a continuous loss position for 12 months or longer:

Corporate debt securities

$

15,554

4

$

(50)

$

74,481

16

$

(679)

Agency bond

4,952

1

(56)

4,854

1

(154)

Marketable securities in a continuous loss position for less than 12 months:

Corporate debt securities

 

$

6,424

 

2

$

(8)

 

$

11,283

 

2

 

$

(97)

U.S. Treasury securities

$

31,608

 

11

 

(14)

 

 

 

Agency bond

$

2,941

1

(8)

 

$

61,479

 

19

$

(136)

 

$

90,618

 

19

 

$

(930)

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Other current assets (Tables)
6 Months Ended
Jun. 30, 2023
Other current assets  
Summary of other current assets

Other current assets consisted of the following (in thousands):

June 30, 

December 31, 

    

2023

    

2022

Research and development credits receivable

 

$

37,863

$

30,162

Prepayments

 

13,040

9,472

Clinical materials

 

1,334

1,279

VAT receivable

92

490

Other current assets

 

1,765

1,927

$

54,094

$

43,330

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Leases (Tables)
6 Months Ended
Jun. 30, 2023
Operating leases  
Schedule of weighted-average remaining lease term and the weighted-average discount rate

The following table shows the lease costs for the six months ended June 30, 2023 and 2022 and the weighted-average remaining lease term and the weighted-average discount rate as at June 30, 2023 and 2022:

Six months ended

June 30, 

     

2023

     

2022

Lease cost:

Operating lease cost

 

$

2,353

 

$

2,285

Short-term lease cost

 

319

 

164

 

$

2,672

 

$

2,449

June 30, 

2023

2022

Weighted-average remaining lease term - operating leases

5.8 years

7.3 years

Weighted-average discount rate - operating leases

8.6%

6.8%

Schedule of maturities of operating lease liabilities

The maturities of operating lease liabilities as of June 30, 2023 are as follows (in thousands):

     

Operating leases

2023

 

$

3,402

2024

 

6,530

2025

 

5,142

2026

 

4,142

2027

 

5,559

after 2027

 

7,637

Total lease payments

32,412

Less: Imputed interest

6,070

Present value of lease liability

$

26,342

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued expenses and other current liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Accrued expenses and other current liabilities  
Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

June 30, 

December 31, 

    

2023

    

2022

Accrued clinical and development expenditure

$

12,039

$

16,749

Accrued employee expenses

10,020

8,232

Other accrued expenditure

3,028

4,079

Other

 

155

 

2,155

$

25,242

$

31,215

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Share-based compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share-based compensation  
Summary of share-based compensation expense included in the consolidated statements of operations

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):

Three months ended

Six months ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

1,285

$

2,033

$

1,401

$

4,556

General and administrative

 

2,552

 

3,012

 

4,112

6,075

$

3,837

$

5,045

$

5,513

$

10,631

Summary of all stock option activity

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:

Three months ended

Six months ended

June 30, 

June 30, 

2023

    

2022

    

2023

    

2022

Number of options over ordinary shares granted

30,247,398

1,735,488

52,002,726

24,611,952

Weighted average fair value of ordinary shares options

$

0.05

$

0.25

$

0.08

$

0.41

Number of additional options with a nominal exercise price granted

6,148,186

3,361,728

26,015,098

21,050,160

Weighted average fair value of options with a nominal exercise price

$

0.15

$

0.34

$

0.17

$

0.55

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring (Tables)
6 Months Ended
Jun. 30, 2023
Restructuring  
Schedule of amounts incurred in relation to the redundancy programme

The amounts incurred in relation to the redundancy programme are as follows:

One-time

Contractual

employee

Total

termination

termination

restructuring

benefits

benefits

costs

Cumulative amount incurred to December 31, 2022

$

1,171

$

1,114

$

2,285

Amount incurred in the three months ended March 31, 2023 and six months ended June 30, 2023

778

925

1,703

Total amount and cumulative amount incurred to March 31, 2023 and June 30, 2023

$

1,949

$

2,039

$

3,988

Schedule of changes in the restructuring provision

The table below is a summary of the changes in the restructuring provision in the Consolidated Balance Sheet in the six months ended June 30, 2023:

One-time

Contractual

employee

Total

termination

termination

restructuring

    

benefits

benefits

provision

Provision at January 1, 2023

$

1,171

$

1,114

$

2,285

Costs incurred and charged to General and administrative expenses

670

947

1,617

Costs paid during the period

(1,955)

(1,953)

(3,908)

Adjustments to the liability

108

(22)

86

Effect of foreign exchange rates

6

2

8

Provision at March 31, 2023

$

$

88

$

88

Costs paid during the period

(88)

(88)

Provision at June 30, 2023

$

$

$

Schedule of amounts incurred in relation to redundancies

The amounts incurred in relation to these redundancies in the six months to June 30, 2023, are as follows:

Three and six months ending

June 30, 2023

Severance and other cash payments

$

5,655

Accelerated vesting of share-based compensation awards

835

Total and cumulative amount incurred to June 30, 2023

$

6,490

Summary of changes in the liability in the Consolidated Balance Sheet

Liability

Liability at June 1, 2023

$

805

Costs incurred and charged to Research and development expenses

1,267

Costs incurred and charged to General and administrative expenses

4,388

Costs paid during the period

(4,823)

Liability at June 30, 2023

$

1,637

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Business combinations (Tables)
6 Months Ended
Jun. 30, 2023
Business combinations  
Summary of the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date

Consideration transferred:

Fair value of 357,429,306 ordinary shares issued

$

60,763

Fair value of replacement options and RSU-style options granted attributable to pre-combination service:

857

Purchase consideration

$

61,620

Identifiable assets acquired and liabilities assumed:

Assets acquired

Cash and cash equivalents

$

43,610

Restricted cash

1,654

Marketable securities - available-for-sale debt securities

39,532

Other current assets and prepaid expenses

6,029

Property, plant and equipment

2,712

Operating lease right-of-use assets

5,145

Intangible assets

58

Total assets acquired

$

98,740

Liabilities assumed

Accounts payable

(6,210)

Accrued expenses and other current liabilities

(4,537)

Operating lease liabilities, current

(1,974)

Operating lease liabilities, non-current

(2,244)

Total liabilities assumed

$

(14,965)

Net assets acquired and liabilities assumed

$

83,775

Schedule of calculation for the gain on bargain purchase

Gain on bargain purchase

Purchase consideration

$

(61,620)

Net assets acquired and liabilities assumed

83,775

Gain on bargain purchase

$

22,155

Schedule of amount of revenue and earnings of the combined entity

Six months ended

Six months ended

June 30, 2023

June 30, 2022

Revenue

$

52,731

$

9,113

Net loss

(86,202)

(143,556)

Schedule of acquisition-related costs that were recognized as an expense

The Company incurred the following acquisition-related costs that were recognized as an expense in the six months ended June 30, 2023:

Legal, professional and accounting fees

4,993

Bankers' fees

2,172

Total acquisition-related costs

$

7,165

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
General (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
General    
Accumulated deficit $ 929,655 $ 909,302
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Summary of Significant Accounting Policies    
Cash and cash equivalents $ 76,969,000 $ 108,033,000
Marketable securities - available-for-sale debt securities 127,738,000 $ 96,572,000
Restricted cash $ 3,231,000  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Accounts receivable (Details)
Jun. 30, 2023
USD ($)
customer
Dec. 31, 2022
USD ($)
Accounts receivable    
Accounts receivable $ 2,970,000 $ 7,435,000
Customer Concentration Risk    
Accounts receivable    
Number of customers | customer 2  
Accounts receivable $ 2,970,000 $ 7,435,000
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Revenue from contracts with customers (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
contract
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
contract
Jun. 30, 2023
USD ($)
contract
Jun. 30, 2022
USD ($)
contract
Dec. 31, 2022
USD ($)
Revenue            
Revenue $ 5,130,000   $ 5,538,000 $ 52,731,000 $ 9,113,000  
Number of contracts with customers | contract 2   3 3 3  
Deferred revenue decrease           $ 35,737,000
Deferred revenue   $ 148,675,000       $ 184,412,000
Upfront payment by GSK for Termination and Transfer Agreement   9,613,000        
Amount of increase in deferred income caused by the change in the exchange rate   $ 5,890,000        
Exchange rate 1.26     1.26   1.21
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 318,107,000     $ 318,107,000    
Revenue recognized in the period       52,046,000    
Development revenue            
Revenue            
Revenue $ 5,130,000   $ 5,538,000 $ 52,731,000 $ 9,113,000  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)
Jun. 30, 2023
USD ($)
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 318,107,000
Strategic Collaboration and License Agreement  
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements 280,250,000
Strategic Collaboration and License Agreement | Research Service Rights Granted for Initial Off the Shelf Collaboration Targets  
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements 171,816,000
Strategic Collaboration and License Agreement | Research Service Rights Granted for Personalized Therapies  
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements 89,098,000
Strategic Collaboration and License Agreement | Material Right to Designate the Additional Off the Shelf Collaboration Target  
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements 13,052,000
Strategic Collaboration and License Agreement | Material Right for First Option Extend the Research Term  
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements 5,027,000
Strategic Collaboration and License Agreement | Material Right for Second Option Extend the Research Term  
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 1,257,000
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
item
Revenue  
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 318,107,000
Astellas Collaboration Agreement.  
Revenue  
Number Of Co Development Target | item 3
Number of independent targets | item 2
Aggregate transaction price of the contract modification $ 42,365,000
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 0
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details)
Jun. 30, 2023
USD ($)
Dec. 19, 2022
USD ($)
Dec. 19, 2022
GBP (£)
Revenue      
Amount of remaining deferred income under the collaboration that had not been recognized as revenue $ 318,107,000    
GSK Collaboration And License Agreement      
Revenue      
Aggregate transaction price of the contract modification   $ 6,500,000  
Amount of remaining deferred income under the collaboration that had not been recognized as revenue $ 0    
Payment by GSK due to termination of collaboration | £     £ 5,000,000
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2023
GBP (£)
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue          
Revenue recognized in the period     $ 52,046,000    
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   $ 318,107,000 318,107,000    
GSK Termination and Transfer Agreement          
Revenue          
Upfront payment received | £ £ 7,500,000        
Potential milestone payments to be received | £ £ 22,500,000        
Amount of transaction price of the agreement at inception       $ 37,335,000  
Upfront and milestone payment receivable | £         £ 30,000,000
Revenue recognized in the period   0 0    
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   37,857,000 37,857,000    
IGNYTE          
Revenue          
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   21,200,000 21,200,000    
LTFU          
Revenue          
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   $ 16,657,000 $ 16,657,000    
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Profit / Loss per share - Basic and diluted income (loss) per share (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Numerator for basic and diluted profit/(loss) per share            
Net Income (Loss) $ (21,389) $ 1,036 $ (44,520) $ (50,265) $ (20,353) $ (94,785)
Net profit/(loss) attributable to ordinary shareholders used for basic profit/(loss) per share (21,389)   (44,520)   (20,353) (94,785)
Net profit/(loss) attributable to ordinary shareholders used for diluted profit/(loss) per share $ (21,389)   $ (44,520)   $ (20,353) $ (94,785)
Denominator for basic and diluted profit/(loss) per share            
Denominator for basic profit/(loss) per share - Weighted average shares outstanding 1,108,166,960   962,794,072   1,050,071,434 951,474,546
Denominator for diluted profit/(loss) per share 1,108,166,960   962,794,072   1,050,071,434 951,474,546
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Profit / Loss per share - Antidilutive shares (Details) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Share options    
Antidilutive securities    
Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares) 201,688,491 150,711,054
Replacement Awards Granted To TCR2 Grantholders    
Antidilutive securities    
Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares) 35,156,344  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Accumulated other comprehensive loss (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Accumulated other comprehensive loss            
Balance beginning of period   $ (875)     $ (875)  
Foreign currency translation adjustments $ (12,281)   $ 47,694   (29,190) $ 64,486
Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 10,590   (39,108)   26,116 (52,916)
Unrealized holding gain (losses) on available-for-sale debt securities, net of tax of $0 385   (316)   857 (1,471)
Balance end of period (3,092)       (3,092)  
Accumulated other comprehensive loss (paranthetical)            
Foreign currency gain on intercompany loan of a long-term investment nature, tax 0   0   0 0
Unrealized holding gains on available-for-sale debt securities, tax 0   0   0 0
Accumulated foreign currency translation adjustments            
Accumulated other comprehensive loss            
Balance beginning of period (1,327) 55 (7,801) $ (10,785) 55 (10,785)
Foreign currency translation adjustments (12,281) (16,908) 47,694 16,792    
Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 10,590 15,526 (39,108) (13,808)    
Balance end of period (3,019) (1,327) 785 (7,801) (3,019) 785
Accumulated unrealized gains (losses) on available-for-sale debt securities            
Accumulated other comprehensive loss            
Balance beginning of period (458) (930) (1,512) (357) (930) (357)
Unrealized holding gain (losses) on available-for-sale debt securities, net of tax of $0 385 472 (316) (1,155)    
Balance end of period (73) (458) (1,828) (1,512) (73) (1,828)
Accumulated other comprehensive (loss) income            
Accumulated other comprehensive loss            
Balance beginning of period (1,785) (875) (9,313) (11,142) (875) (11,142)
Foreign currency translation adjustments (12,281) (16,908) 47,694 16,792    
Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 10,590 15,526 (39,108) (13,808)    
Unrealized holding gain (losses) on available-for-sale debt securities, net of tax of $0 385 472 (316) (1,155)    
Balance end of period $ (3,092) $ (1,785) $ (1,043) $ (9,313) $ (3,092) $ (1,043)
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Fair value measurements (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total $ 127,738,000 $ 96,572,000
Recurring basis    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 127,738,000  
Recurring basis | Corporate debt securities    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 24,928,000  
Recurring basis | U.S. Treasury securities    
Cash equivalents:    
Total Cash Equivalents 29,102,000  
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 94,917,000  
Recurring basis | Agency bonds    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 7,893,000  
Recurring basis | Level 1    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 24,928,000  
Recurring basis | Level 1 | Corporate debt securities    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 24,928,000  
Recurring basis | Level 2    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 102,810,000  
Recurring basis | Level 2 | U.S. Treasury securities    
Cash equivalents:    
Total Cash Equivalents 29,102,000  
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total 94,917,000  
Recurring basis | Level 2 | Agency bonds    
Marketable securities:    
Available-for-sale securities, Debt Securities, Current, Total $ 7,893,000  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Marketable securities - Available-for-sale debt securities (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Debt Securities  
Marketable securities  
Amortized cost $ 127,841
Gross unrealized gains 33
Gross unrealized losses (136)
Aggregate estimated fair value 127,738
Cash equivalents  
Marketable securities  
Amortized cost 29,069
Gross unrealized gains 33
Aggregate estimated fair value 29,102
Corporate Debt Securities Maturity Period Less Than Three Months | Debt Securities  
Marketable securities  
Amortized cost 16,258
Gross unrealized losses (26)
Aggregate estimated fair value 16,232
U.S. Treasury Securities Maturity Period Less Than Three Months  
Marketable securities  
Amortized cost 41,675
Gross unrealized gains 12
Gross unrealized losses (5)
Aggregate estimated fair value 41,682
U.S. Treasury Securities Maturity Period Less Than Three Months | Cash equivalents  
Marketable securities  
Amortized cost 29,069
Gross unrealized gains 33
Aggregate estimated fair value 29,102
Corporate Debt Securities Maturity Period Three Months To One Year | Debt Securities  
Marketable securities  
Amortized cost 8,726
Gross unrealized gains 2
Gross unrealized losses (32)
Aggregate estimated fair value 8,696
U.S. Treasury Securities Maturity Period Three Months To One Year  
Marketable securities  
Amortized cost 53,225
Gross unrealized gains 19
Gross unrealized losses (9)
Aggregate estimated fair value 53,235
Agency Bond Maturity Period Less Than Three Months  
Marketable securities  
Amortized cost 5,008
Gross unrealized losses (56)
Aggregate estimated fair value 4,952
Agency Bond Maturity Period Three Months To One Year  
Marketable securities  
Amortized cost 2,949
Gross unrealized losses (8)
Aggregate estimated fair value $ 2,941
Minimum | Corporate Debt Securities Maturity Period Three Months To One Year  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Minimum | U.S. Treasury Securities Maturity Period Three Months To One Year  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Minimum | Agency Bond Maturity Period Three Months To One Year  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Maximum | Corporate Debt Securities Maturity Period Less Than Three Months | Debt Securities  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Maximum | U.S. Treasury Securities Maturity Period Less Than Three Months  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Maximum | U.S. Treasury Securities Maturity Period Less Than Three Months | Cash equivalents  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Maximum | Corporate Debt Securities Maturity Period Three Months To One Year  
Marketable securities  
Available For Sale Securities Debt Maturity Period 1 year
Maximum | U.S. Treasury Securities Maturity Period Three Months To One Year  
Marketable securities  
Available For Sale Securities Debt Maturity Period 1 year
Maximum | Agency Bond Maturity Period Less Than Three Months  
Marketable securities  
Available For Sale Securities Debt Maturity Period 3 months
Maximum | Agency Bond Maturity Period Three Months To One Year  
Marketable securities  
Available For Sale Securities Debt Maturity Period 1 year
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
security
Dec. 31, 2022
USD ($)
security
Marketable securities    
Fair market value of investments in an unrealized loss position $ 61,479 $ 90,618
Number of investments in an unrealized loss position | security 19 19
Unrealized losses $ (136) $ (930)
Corporate debt securities    
Marketable securities    
Fair market value of investments in an unrealized loss position, 12 months or longer 15,554 74,481
Fair market value of investments in an unrealized loss position, less than 12 months $ 6,424 $ 11,283
Number of available-for-sale securities in an unrealized loss position, 12 months or longer | security 4 16
Number of available-for-sale securities in an unrealized loss position, less than 12 months | security 2 2
Unrealized losses, 12 months or longer $ (50) $ (679)
Unrealized losses, less than 12 months (8) (97)
U.S. Treasury securities    
Marketable securities    
Fair market value of investments in an unrealized loss position, less than 12 months $ 31,608  
Number of available-for-sale securities in an unrealized loss position, less than 12 months | security 11  
Unrealized losses, less than 12 months $ (14)  
Agency bonds    
Marketable securities    
Fair market value of investments in an unrealized loss position, 12 months or longer 4,952 $ 4,854
Fair market value of investments in an unrealized loss position, less than 12 months $ 2,941  
Number of available-for-sale securities in an unrealized loss position, 12 months or longer | security 1 1
Number of available-for-sale securities in an unrealized loss position, less than 12 months | security 1  
Unrealized losses, 12 months or longer $ (56) $ (154)
Unrealized losses, less than 12 months $ (8)  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Other current assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Other current assets    
Research and development credits receivable $ 37,863 $ 30,162
Prepayments 13,040 9,472
Clinical materials 1,334 1,279
VAT receivable 92 490
Other current assets 1,765 1,927
Total $ 54,094 $ 43,330
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Leases (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 01, 2023
lease
Operating leases      
Operating lease cost $ 2,353 $ 2,285  
Short-term lease cost 319 164  
Total $ 2,672 $ 2,449  
Weighted-average remaining lease term - operating leases 5 years 9 months 18 days 7 years 3 months 18 days  
Weighted-average discount rate - operating leases 8.60% 6.80%  
Number of operating leases that were acquired in a business combination for which the acquirees lease classification was retained | lease     2
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Operating Leases - Maturities (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Maturities of operating lease liabilities  
2023 $ 3,402
2024 6,530
2025 5,142
2026 4,142
2027 5,559
after 2027 7,637
Total lease payments 32,412
Less: Imputed interest 6,070
Present value of lease liability $ 26,342
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued expenses and other current liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accrued expenses and other current liabilities    
Accrued clinical and development expenditure $ 12,039 $ 16,749
Accrued employee expenses 10,020 8,232
Other accrued expenditure 3,028 4,079
Other 155 2,155
Total $ 25,242 $ 31,215
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details) - Collaboration and license agreement - Universal Cells, Inc.
1 Months Ended 12 Months Ended
Feb. 29, 2016
USD ($)
Nov. 30, 2015
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2023
item
Dec. 31, 2022
USD ($)
Contingencies and commitments            
Upfront license and start-up fees   $ 2,500,000        
Milestone payments $ 3,000,000   $ 200,000 $ 900,000    
First milestone payment           $ 500,000
Second milestone payment           600,000
Third milestone payment           $ 400,000
Number of remaining milestones accrued | item         0  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Contingencies and commitments - MD Anderson Strategic Alliance (Details) - MD Anderson Strategic Alliance - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Dec. 31, 2017
Sep. 26, 2016
Contingencies and commitments            
Upfront payment         $ 3,412,000  
Milestone Payments $ 2,326,000 $ 454,000 $ 3,549,000 $ 2,326,000    
Minimum            
Contingencies and commitments            
Potential milestone payments           $ 19,644,000
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Share-based compensation - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total share-based compensation expense included in the consolidated statements of operations        
Total share-based compensation expense $ 3,837 $ 5,045 $ 5,513 $ 10,631
Research and development        
Total share-based compensation expense included in the consolidated statements of operations        
Total share-based compensation expense 1,285 2,033 1,401 4,556
General and administrative        
Total share-based compensation expense included in the consolidated statements of operations        
Total share-based compensation expense $ 2,552 $ 3,012 $ 4,112 $ 6,075
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Share-based compensation - Options (Details) - $ / shares
3 Months Ended 6 Months Ended
Jun. 01, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Number of options over ordinary shares granted (in shares)   30,247,398 1,735,488 52,002,726 24,611,952
Weighted average fair value of ordinary shares options (in dollars per share)   $ 0.05 $ 0.25 $ 0.08 $ 0.41
Number of additional options with a nominal exercise price granted   6,148,186 3,361,728 26,015,098 21,050,160
Weighted average fair value of options with a nominal exercise price   $ 0.15 $ 0.34 $ 0.17 $ 0.55
Replacement Awards Granted To TCR2 Grantholders          
Number of options over ordinary shares granted (in shares) 29,654,742        
Number of additional options with a nominal exercise price granted 5,501,602        
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders equity - Offerings (Details) - USD ($)
3 Months Ended 6 Months Ended
Apr. 08, 2022
Aug. 10, 2020
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Sales Agreement          
Shareholders' equity          
Remaining amount under the Sales Agreement         $ 197,360,000
Sales Agreement | Maximum          
Shareholders' equity          
Aggregate offering price of ADS shares under At The Market sales agreement   $ 200,000,000      
2022 Sales Agreement          
Shareholders' equity          
Remaining amount under the Sales Agreement         $ 186,513,100
Issuance of shares upon completion of public offering, net of issuance costs (in shares)         554,496
Sold shares represented by American Depositary Shares (in shares)         92,416
Net proceeds         $ 173,430
2022 Sales Agreement | Maximum          
Shareholders' equity          
Aggregate offering price of ADS shares under At The Market sales agreement $ 200,000,000        
Common stock          
Shareholders' equity          
Issuance of shares upon completion of public offering, net of issuance costs (in shares)     554,496 35,134,182  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Restructuring    
Restructuring and Related Cost, Cost Incurred to Date $ 1,703 $ 2,285
Total amount expected to be incurred $ 3,988  
Percent of headcount reduction 25.00%  
Contractual termination benefits    
Restructuring    
Restructuring and Related Cost, Cost Incurred to Date $ 778 1,171
Total amount expected to be incurred 1,949  
One-time employee termination benefits    
Restructuring    
Restructuring and Related Cost, Cost Incurred to Date 925 $ 1,114
Total amount expected to be incurred $ 2,039  
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring - Movements in Provision (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2023
Restructuring      
Balance at the beginning $ 88 $ 2,285 $ 2,285
Costs incurred and charged to General and administrative expenses   1,617  
Costs paid during the period (88) (3,908)  
Adjustments to the liability   86  
Effect of foreign exchange rates   8  
Balance at the end   88  
Impairment loss     0
Contractual termination benefits      
Restructuring      
Balance at the beginning   1,171 1,171
Costs incurred and charged to General and administrative expenses   670  
Costs paid during the period   (1,955)  
Adjustments to the liability   108  
Effect of foreign exchange rates   6  
One-time employee termination benefits      
Restructuring      
Balance at the beginning 88 1,114 $ 1,114
Costs incurred and charged to General and administrative expenses   947  
Costs paid during the period $ (88) (1,953)  
Adjustments to the liability   (22)  
Effect of foreign exchange rates   2  
Balance at the end   $ 88  
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring - TCR post-acquisition senior leadership severance (Details) - Employee Severance
6 Months Ended
Jun. 30, 2023
USD ($)
Restructuring  
Severance and other cash payments $ 5,655
Accelerated vesting of share-based compensation awards 835
Total and cumulative amount incurred 6,490
Research and development  
Restructuring  
Accelerated vesting of share-based compensation awards 200,000
General and administrative expenses  
Restructuring  
Accelerated vesting of share-based compensation awards $ 600,000
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring - TCR post-acquisition senior leadership severance - Change in Liability (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Restructuring    
Balance beginning of period $ 805  
Costs incurred and charged   $ 1,617
Costs paid during period (4,823)  
Balance at end of period 1,637  
Research and development    
Restructuring    
Costs incurred and charged 1,267  
General and administrative    
Restructuring    
Costs incurred and charged $ 4,388  
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.2
Business combinations (Details) - USD ($)
Jun. 01, 2023
May 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Assets acquired        
Operating lease right-of-use assets     $ 22,027,000 $ 18,019,000
Liabilities assumed        
Operating lease liabilities, current     (4,752,000) (2,728,000)
Operating lease liabilities, non-current     $ (21,590,000) $ (20,349,000)
TCR2 Therapeutics        
Merger with TCR2 Therapeutics Inc.        
Percentage held following the transaction 25.00%      
Adaptimmune        
Merger with TCR2 Therapeutics Inc.        
Percentage held following the transaction 75.00%      
TCR2 Therapeutics        
Merger with TCR2 Therapeutics Inc.        
Shares issued 357,429,306 357,429,306    
Percentage of ownership 100.00%      
Market price   $ 1.02    
Ordinary share price per share   $ 0.17    
Intangible assets relation to lease contracts acquired $ 0      
Consideration transferred:        
Fair value of shares issued 60,763,000 $ 60,763,000    
Purchase consideration 61,620,000      
Assets acquired        
Cash and cash equivalents 43,610,000      
Restricted cash 1,654,000      
Marketable securities - available-for-sale debt securities 39,532,000      
Other current assets and prepaid expenses 6,029,000      
Property, plant and equipment 2,712,000      
Operating lease right-of-use assets 5,145,000      
Intangible assets 58,000      
Total assets acquired 98,740,000      
Liabilities assumed        
Accounts payable (6,210,000)      
Accrued expenses and other current liabilities (4,537,000)      
Operating lease liabilities, current (1,974,000)      
Operating lease liabilities, non-current (2,244,000)      
Total liabilities assumed (14,965,000)      
Net assets acquired and liabilities assumed 83,775,000      
TCR2 Therapeutics | RSU        
Consideration transferred:        
Fair value of shares issued $ 857,000      
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.2
Business combinations - Gain on bargain purchase (Details)
3 Months Ended 6 Months Ended
Jun. 01, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
May 31, 2023
$ / shares
Mar. 06, 2023
$ / shares
Merger with TCR2 Therapeutics Inc.          
Gain on bargain purchase   $ 22,155,000 $ 22,155,000    
TCR2 Therapeutics          
Merger with TCR2 Therapeutics Inc.          
Purchase consideration $ (61,620,000)        
Net assets acquired and liabilities assumed 83,775,000        
Gain on bargain purchase $ 22,155,000   22,200,000    
Ratio for issuance of Company's ADSs for each TCR2 stock acquired         1.5117
Closing price of Company's ADS | $ / shares       $ 1.02 $ 1.32
Amount of TCR2's earnings included in the Company's Consolidated Statement of Operations     $ 11,760,000    
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.2
Business combinations - Proforma Information (Details) - USD ($)
3 Months Ended 5 Months Ended 6 Months Ended
Jun. 01, 2023
Jun. 30, 2023
Jun. 30, 2022
May 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Merger with TCR2 Therapeutics Inc.            
Gain on bargain purchase   $ 22,155,000     $ 22,155,000  
Share-based compensation expense   $ 3,837,000 $ 5,045,000   5,513,000 $ 10,631,000
TCR2 Therapeutics            
Merger with TCR2 Therapeutics Inc.            
Revenue         52,731 9,113
Net loss         (86,202) (143,556)
Acquisition-related costs incurred by TCR2         7,700,000  
Gain on bargain purchase $ 22,155,000       22,200,000  
Acquisition-related costs         $ 7,165,000  
Share-based compensation expense       $ 1,000,000.0   $ 6,000,000.0
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.2
Business combinations - Acquisition-related costs (Details) - TCR2 Therapeutics
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Merger with TCR2 Therapeutics Inc.  
Legal, professional and accounting fees $ 4,993
Bankers' fees 2,172
Total acquisition-related costs 7,165
Issuance costs incurred relating to the issuance of shares to TCR2 stockholders $ 0
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure            
Net Income (Loss) $ (21,389) $ 1,036 $ (44,520) $ (50,265) $ (20,353) $ (94,785)
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
6 Months Ended
Jun. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 80 adap-20230630x10q_htm.xml IDEA: XBRL DOCUMENT 0001621227 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001621227 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001621227 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001621227 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001621227 us-gaap:RetainedEarningsMember 2023-06-30 0001621227 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001621227 us-gaap:RetainedEarningsMember 2023-03-31 0001621227 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001621227 us-gaap:RetainedEarningsMember 2022-12-31 0001621227 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001621227 us-gaap:RetainedEarningsMember 2022-06-30 0001621227 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001621227 us-gaap:RetainedEarningsMember 2022-03-31 0001621227 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001621227 2022-03-31 0001621227 us-gaap:RetainedEarningsMember 2021-12-31 0001621227 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001621227 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2023-01-01 2023-06-30 0001621227 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2023-01-01 2023-06-30 0001621227 adap:ResearchServiceRightsGrantedForPersonalizedTherapiesMember adap:StrategicCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember adap:StrategicCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember adap:StrategicCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:MaterialRightForSecondOptionExtendResearchTermMember adap:StrategicCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:MaterialRightForFirstOptionExtendResearchTermMember adap:StrategicCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:StrategicCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:LtfuMember 2023-06-30 0001621227 adap:IgnyteMember 2023-06-30 0001621227 adap:GskTerminationAndTransferAgreementMember 2023-06-30 0001621227 adap:GSKCollaborationAndLicenseAgreementMember 2023-06-30 0001621227 adap:DevelopmentRevenueMember 2023-04-01 2023-06-30 0001621227 adap:DevelopmentRevenueMember 2023-01-01 2023-06-30 0001621227 adap:DevelopmentRevenueMember 2022-04-01 2022-06-30 0001621227 adap:DevelopmentRevenueMember 2022-01-01 2022-06-30 0001621227 us-gaap:OneTimeTerminationBenefitsMember 2023-03-31 0001621227 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-06-30 0001621227 us-gaap:ResearchAndDevelopmentExpenseMember 2023-06-02 2023-06-30 0001621227 us-gaap:GeneralAndAdministrativeExpenseMember 2023-06-02 2023-06-30 0001621227 us-gaap:OneTimeTerminationBenefitsMember 2023-06-30 0001621227 us-gaap:ContractTerminationMember 2023-06-30 0001621227 us-gaap:OneTimeTerminationBenefitsMember 2022-12-31 0001621227 us-gaap:ContractTerminationMember 2022-12-31 0001621227 us-gaap:OneTimeTerminationBenefitsMember 2023-04-01 2023-06-30 0001621227 us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-03-31 0001621227 us-gaap:ContractTerminationMember 2023-01-01 2023-03-31 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-01 2023-06-30 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-04-01 2022-06-30 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001621227 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001621227 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001621227 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001621227 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001621227 us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001621227 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001621227 us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001621227 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0001621227 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001621227 adap:GskTerminationAndTransferAgreementMember 2023-04-01 2023-06-30 0001621227 adap:GskTerminationAndTransferAgreementMember 2023-01-01 2023-06-30 0001621227 us-gaap:CommonStockMember 2023-06-30 0001621227 us-gaap:CommonStockMember 2023-03-31 0001621227 us-gaap:CommonStockMember 2022-12-31 0001621227 us-gaap:CommonStockMember 2022-06-30 0001621227 us-gaap:CommonStockMember 2022-03-31 0001621227 us-gaap:CommonStockMember 2021-12-31 0001621227 2022-06-30 0001621227 2021-12-31 0001621227 adap:Tcr2TherapeuticsMember us-gaap:RestrictedStockUnitsRSUMember 2023-06-01 2023-06-01 0001621227 adap:Tcr2TherapeuticsMember 2023-05-31 0001621227 adap:Tcr2TherapeuticsMember 2023-06-01 2023-06-01 0001621227 adap:Tcr2TherapeuticsMember 2023-05-31 2023-05-31 0001621227 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001621227 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001621227 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001621227 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001621227 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-06-30 0001621227 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001621227 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001621227 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001621227 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001621227 us-gaap:DebtSecuritiesMember adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember 2023-06-30 0001621227 adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember 2023-06-30 0001621227 adap:AgencyBondMaturityPeriodLessThanThreeMonthsMember 2023-06-30 0001621227 us-gaap:DebtSecuritiesMember adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember 2023-06-30 0001621227 us-gaap:CashAndCashEquivalentsMember adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember 2023-06-30 0001621227 us-gaap:DebtSecuritiesMember 2023-06-30 0001621227 us-gaap:CashAndCashEquivalentsMember 2023-06-30 0001621227 adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember 2023-06-30 0001621227 adap:TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember 2023-06-30 0001621227 adap:ReplacementAwardsGrantedToTcr2GrantholdersMember 2023-01-01 2023-06-30 0001621227 adap:EmployeeConsultantsAndDirectorsStockOptionsMember 2023-01-01 2023-06-30 0001621227 adap:EmployeeConsultantsAndDirectorsStockOptionsMember 2022-01-01 2022-06-30 0001621227 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001621227 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001621227 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001621227 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001621227 adap:Tcr2TherapeuticsMember 2023-01-01 2023-05-31 0001621227 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001621227 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001621227 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001621227 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001621227 adap:Tcr2TherapeuticsMember 2022-01-01 2022-06-30 0001621227 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001621227 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001621227 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001621227 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001621227 2022-01-01 2022-03-31 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-06-30 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0001621227 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001621227 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001621227 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001621227 us-gaap:CustomerConcentrationRiskMember 2022-12-31 0001621227 2023-08-07 0001621227 2023-03-31 0001621227 adap:MDAndersonStrategicAllianceMember 2017-01-01 2017-12-31 0001621227 us-gaap:CollaborativeArrangementMember 2023-06-30 0001621227 adap:GskTerminationAndTransferAgreementMember 2023-04-06 0001621227 adap:SalesAgreementMember 2023-01-01 2023-06-30 0001621227 adap:SalesAgreement2022Member 2023-01-01 2023-06-30 0001621227 srt:MaximumMember adap:SalesAgreement2022Member 2022-04-08 2022-04-08 0001621227 srt:MaximumMember adap:SalesAgreementMember 2020-08-10 2020-08-10 0001621227 adap:ReplacementAwardsGrantedToTcr2GrantholdersMember 2023-06-01 2023-06-01 0001621227 adap:GSKCollaborationAndLicenseAgreementMember 2022-12-19 0001621227 adap:Tcr2TherapeuticsMember 2023-03-06 0001621227 adap:GskTerminationAndTransferAgreementMember 2023-06-01 2023-06-30 0001621227 2023-06-02 2023-06-30 0001621227 adap:UniversalCellsIncMember adap:CollaborationAndLicenseAgreementMember 2023-06-30 0001621227 us-gaap:CustomerConcentrationRiskMember 2023-06-30 0001621227 2023-04-01 2023-06-30 0001621227 2022-04-01 2022-06-30 0001621227 us-gaap:CollaborativeArrangementMember 2023-01-01 2023-06-30 0001621227 adap:MDAndersonStrategicAllianceMember 2022-01-01 2022-12-31 0001621227 adap:MDAndersonStrategicAllianceMember 2021-01-01 2021-12-31 0001621227 adap:MDAndersonStrategicAllianceMember 2020-01-01 2020-12-31 0001621227 adap:MDAndersonStrategicAllianceMember 2018-01-01 2018-12-31 0001621227 adap:MDAndersonStrategicAllianceMember srt:MinimumMember 2016-09-26 0001621227 adap:UniversalCellsIncMember adap:CollaborationAndLicenseAgreementMember 2015-11-01 2015-11-30 0001621227 adap:UniversalCellsIncMember adap:CollaborationAndLicenseAgreementMember 2018-01-01 2018-12-31 0001621227 adap:UniversalCellsIncMember adap:CollaborationAndLicenseAgreementMember 2017-01-01 2017-12-31 0001621227 adap:UniversalCellsIncMember adap:CollaborationAndLicenseAgreementMember 2016-02-01 2016-02-29 0001621227 adap:UniversalCellsIncMember adap:CollaborationAndLicenseAgreementMember 2022-12-31 0001621227 2023-01-01 2023-03-31 0001621227 2022-01-01 2022-12-31 0001621227 adap:Tcr2TherapeuticsMember 2023-06-01 0001621227 adap:Tcr2TherapeuticsMember 2023-06-01 0001621227 adap:AdaptimmuneMember 2023-06-01 0001621227 adap:Tcr2TherapeuticsMember 2023-01-01 2023-06-30 0001621227 2023-06-01 0001621227 srt:MaximumMember us-gaap:DebtSecuritiesMember adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember 2023-01-01 2023-06-30 0001621227 srt:MaximumMember us-gaap:CashAndCashEquivalentsMember adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember 2023-01-01 2023-06-30 0001621227 srt:MinimumMember adap:TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember 2023-01-01 2023-06-30 0001621227 srt:MinimumMember adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember 2023-01-01 2023-06-30 0001621227 srt:MinimumMember adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember 2023-01-01 2023-06-30 0001621227 srt:MaximumMember adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember 2023-01-01 2023-06-30 0001621227 srt:MaximumMember adap:TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember 2023-01-01 2023-06-30 0001621227 srt:MaximumMember adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember 2023-01-01 2023-06-30 0001621227 srt:MaximumMember adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember 2023-01-01 2023-06-30 0001621227 srt:MaximumMember adap:AgencyBondMaturityPeriodLessThanThreeMonthsMember 2023-01-01 2023-06-30 0001621227 2023-01-01 2023-06-30 0001621227 2022-01-01 2022-06-30 0001621227 2023-06-30 0001621227 2022-12-31 iso4217:GBP shares adap:security iso4217:USD adap:lease pure adap:item adap:contract adap:customer iso4217:GBP iso4217:USD shares shares 1108166960 962794072 1050071434 951474546 0001621227 --12-31 2023 Q2 00-0000000 Non-accelerated Filer 1351828044 987109890 -0.02 -0.05 -0.02 -0.10 -21389000 -44520000 -20353000 -94785000 false 10-Q true 2023-06-30 false 001-37368 ADAPTIMMUNE THERAPEUTICS PLC X0 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX GB 44 1235 430000 American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share ADAP NASDAQ Yes Yes true false false 1357031946 76969000 108033000 127738000 96572000 0 0 2970000 7435000 54094000 43330000 261771000 255370000 3231000 1569000 11258000 9470000 22027000 18019000 40635000 38588000 55492000 53516000 5003000 4676000 463000 442000 342984000 328916000 14713000 4753000 4752000 2728000 25242000 31215000 2285000 31418000 23520000 76125000 64501000 21590000 20349000 117257000 160892000 1361000 1296000 216333000 247038000 0.001 0.001 1702760280 1351828044 1282773750 987109890 1851000 1399000 1057547000 990656000 -3092000 -875000 -929655000 -909302000 126651000 81878000 342984000 328916000 5130000 5538000 52731000 9113000 29965000 34740000 55513000 71492000 20073000 14550000 40470000 31354000 50038000 49290000 95983000 102846000 -44908000 -43752000 -43252000 -93733000 1543000 357000 2219000 695000 22155000 22155000 501000 -655000 -170000 -643000 -20709000 -44050000 -19048000 -93681000 680000 470000 1305000 1104000 -21389000 -44520000 -20353000 -94785000 -0.02 -0.05 -0.02 -0.10 1108166960 962794072 1050071434 951474546 -21389000 -44520000 -20353000 -94785000 0 0 -12281000 47694000 -29190000 64486000 0 0 10590000 -39108000 26116000 -52916000 0 0 385000 -316000 857000 -1471000 -22695000 -36250000 -22570000 -84686000 987109890 1399000 990656000 -875000 -909302000 81878000 1036000 1036000 -910000 -910000 6035574 7000 1000 8000 554496 1000 187000 188000 1676000 1676000 993699960 1407000 992520000 -1785000 -908266000 83876000 -21389000 -21389000 -1307000 -1307000 698778 1000 13000 14000 357429306 443000 60320000 60763000 4694000 4694000 1351828044 1851000 1057547000 -3092000 -929655000 126651000 937547934 1337000 959611000 -11142000 -743846000 205960000 -50265000 -50265000 1829000 1829000 3318072 5000 30000 35000 5586000 5586000 940866006 1342000 965227000 -9313000 -794111000 163145000 -44520000 -44520000 8270000 8270000 759336 1000 1000 35134182 44000 9932000 9976000 5045000 5045000 976759524 1387000 980204000 -1043000 -838631000 141917000 -20353000 -94785000 3824000 2728000 253000 419000 22155000 5513000 10631000 -377000 108000 -633000 1636000 663000 585000 -1971000 22898000 -8801000 12898000 -41704000 -6758000 -81045000 -95652000 3565000 16074000 199000 45264000 76119000 97605000 67121000 42197000 -537000 51035000 39334000 188000 9976000 22000 36000 210000 10012000 398000 -5836000 -29402000 -52142000 109602000 151666000 80200000 99524000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of $929,655,000 as of June 30, 2023.</p> -929655000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Summary of Significant Accounting Policies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)          Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)          Use of estimates in interim financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)          Fair value measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d</b><b style="font-weight:bold;">)          Significant concentrations of credit risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company held cash and cash equivalents of $76,969,000, marketable securities of $127,738,000 and restricted cash of $3,231,000 as of June 30, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had two customers during the three months ended June 30, 2023 which are Genentech and GSK, and three during the six months ended, June 30, 2023, which also includes Astellas. There were accounts receivable of $2,970,000 as of June 30, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no credit losses have been recognized. As of June 30, 2023, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of June 30, 2023 is considered to be remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">(e) New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted in the current period</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Measurement of credit losses on financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="white-space:pre-wrap;">In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition. There was also no impact from adopting this standard on the acquisition accounting for TCR</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Therapeutics Inc. as no contracts with customers were assumed as a result of the business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f</b><b style="font-weight:bold;">)          Business combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company determines whether a transaction or other event is a business combination by determining whether the assets acquired and liabilities assumed constitute a business. Business combinations are accounted for by applying the acquisition method as set out by ASC 805 <i style="font-style:italic;">Business combinations</i>. The acquisition method of accounting requires the acquirer to recognize and measure all identifiable assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values, with certain exceptions for specific items. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For leases acquired in a business combination in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The right-of-use asset shall be measured at the same amount as the lease liability, adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. For leases in which the acquired entity is a lessee, the Company has elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is measured as the excess of the consideration transferred in the business combination over the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed. If instead the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed exceeds the consideration transferred, a gain on bargain purchase is recognized in the Consolidated Statement of Operations. The consideration transferred in a business combination is measured as the sum of the fair values of the assets transferred by the acquiring entity, the liabilities incurred by the acquiring entity to former owners of the acquired entity, and the equity interests issued by the acquiring entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of operations of businesses acquired by the Company are included in the Company’s Consolidated Statement of Operations as of the respective acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Where the acquiring entity exchanges its share-based payment awards for awards held by grantees of the acquiree, such exchanges are treated as a modification of share-based payment awards and are referred to as replacement awards. The replacement awards are measured as of the acquisition date and the portion of the fair-value-based measure of the replacement award that is attributable to pre-combination vesting is considered part of the consideration transferred. For awards with service-based vesting conditions only, the amount attributable to pre-combination vesting is the fair-value-based measure of the acquiree award multiplied by the ratio of the employee’s pre-combination service period to the greater of the total service period of the original service period of the acquiree award.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition-related costs, including advisory, legal and other professional fees and administrative fees are expensed as incurred except for the costs of issuing equity securities, which are recognized as a reduction to the amounts recognized in the Statement of Changes in Equity for the respective equity issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)          Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)          Use of estimates in interim financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)          Fair value measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d</b><b style="font-weight:bold;">)          Significant concentrations of credit risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company held cash and cash equivalents of $76,969,000, marketable securities of $127,738,000 and restricted cash of $3,231,000 as of June 30, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had two customers during the three months ended June 30, 2023 which are Genentech and GSK, and three during the six months ended, June 30, 2023, which also includes Astellas. There were accounts receivable of $2,970,000 as of June 30, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021, Astellas since 2020 and GSK since 2014, during which time no credit losses have been recognized. As of June 30, 2023, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of June 30, 2023 is considered to be remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p> 76969000 127738000 3231000 2 2970000 7435000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">(e) New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adopted in the current period</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Measurement of credit losses on financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="white-space:pre-wrap;">In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition. There was also no impact from adopting this standard on the acquisition accounting for TCR</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Therapeutics Inc. as no contracts with customers were assumed as a result of the business combination.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f</b><b style="font-weight:bold;">)          Business combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company determines whether a transaction or other event is a business combination by determining whether the assets acquired and liabilities assumed constitute a business. Business combinations are accounted for by applying the acquisition method as set out by ASC 805 <i style="font-style:italic;">Business combinations</i>. The acquisition method of accounting requires the acquirer to recognize and measure all identifiable assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values, with certain exceptions for specific items. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For leases acquired in a business combination in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The right-of-use asset shall be measured at the same amount as the lease liability, adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms. For leases in which the acquired entity is a lessee, the Company has elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is measured as the excess of the consideration transferred in the business combination over the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed. If instead the net acquisition date amounts of the identifiable assets acquired and the liabilities assumed exceeds the consideration transferred, a gain on bargain purchase is recognized in the Consolidated Statement of Operations. The consideration transferred in a business combination is measured as the sum of the fair values of the assets transferred by the acquiring entity, the liabilities incurred by the acquiring entity to former owners of the acquired entity, and the equity interests issued by the acquiring entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of operations of businesses acquired by the Company are included in the Company’s Consolidated Statement of Operations as of the respective acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Where the acquiring entity exchanges its share-based payment awards for awards held by grantees of the acquiree, such exchanges are treated as a modification of share-based payment awards and are referred to as replacement awards. The replacement awards are measured as of the acquisition date and the portion of the fair-value-based measure of the replacement award that is attributable to pre-combination vesting is considered part of the consideration transferred. For awards with service-based vesting conditions only, the amount attributable to pre-combination vesting is the fair-value-based measure of the acquiree award multiplied by the ratio of the employee’s pre-combination service period to the greater of the total service period of the original service period of the acquiree award.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition-related costs, including advisory, legal and other professional fees and administrative fees are expensed as incurred except for the costs of issuing equity securities, which are recognized as a reduction to the amounts recognized in the Statement of Changes in Equity for the respective equity issuance.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt 0pt 12pt 0pt;">The Company had two revenue-generating contracts with customers in the three months, and three in the six months, ended June 30 2023, compared to three in the three and six months ended June 30, 2022: a collaboration agreement with Astellas that was terminated as of March 6, 2023, a strategic collaboration and license agreement with Genentech and a termination and transfer agreement with GSK that was effective on April 6, 2023. The original collaboration and license agreement with GSK was terminated in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;">Revenue comprises the following categories (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,113</p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,130</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,538</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 52,731</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,113</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred revenue decreased by $35,737,000 from $184,412,000 at December 31, 2022 to $148,675,000 at June 30, 2023 primarily due to revenue recognized during the quarter but was partially offset by a $9,613,000 payment from GSK and a $5,890,000 increase caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.21 at December 31, 2022 to £1.00 to $1.26 at June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2022, there was deferred revenue of $184,412,000 of which $52,046,000 was recognized as revenue in the six months ended June 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of June 30, 2023 was $318,107,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Genentech Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Genentech agreement as of June 30, 2023 was $280,250,000. Of this amount $171,816,000 is allocated to the research services and rights granted for the initial ‘off-the-shelf’ collaboration targets, $89,098,000 is allocated to the research services and rights granted for the personalized therapies, $13,052,000 is allocated to the material rights to designate the additional ‘off-the-shelf’ collaboration targets, $5,027,000 is allocated to the material right for the first option to extend the research term and $1,257,000 is allocated to the material right for the option to extend the research term a second time. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progresses and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expects to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options are exercised and then as development progresses, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expire. The Company expects to satisfy the performance obligations relating to the material rights to extend the research term from the point that the options are exercised and then over the period of the extension, or at the point in time that the rights expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Astellas Collaboration Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company and Universal Cells mutually agreed to terminate the Astellas Collaboration Agreement as of March 6, 2023 (the “Termination Date”). In connection with the termination, all licenses and sublicenses granted to either party pursuant to the Collaboration Agreement ceased as of the Termination Date. There were no termination penalties in connection with the termination, however the Company is still entitled to receive reimbursement for research and development work performed up to and including a period of 30 days after the Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company originally satisfied the performance obligations relating to the three co-development targets as development progresses and recognized revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company originally determined that the performance obligations relating to the two independent Astellas targets would be recognized at a point-in-time, upon commencement of the licenses in the event of nomination of the target, since they were right-to-use licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The termination was accounted for as a contract modification on a cumulative catch-up basis. No performance obligations were identified as a result of the modification as there were no further goods or services to be provided by the Company and the modification resulted in the remaining unsatisfied and partially satisfied performance obligations under the collaboration becoming fully satisfied. The aggregate transaction price of the contract modification was $42,365,000 which included the remaining deferred income that had not been recognized as revenue as of the date of the modification and variable consideration from the remaining reimbursement income to be billed under the collaboration at the end of the 30 day period after the Effective Date. The transaction price of the modification was recognized in full in March 2023 and there is no remaining transaction price allocated to performance obligations that are unsatisfied or partially satisfied under, no remaining deferred income relating to, the agreement as of June 30, 2023 and no revenue was recognized in the three months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The GSK Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The GSK Collaboration and License Agreement consisted of multiple performance obligations, including the development of a third target, which was the only performance obligation for which revenue was recognized in 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The collaboration was terminated by GSK in October 2022 (effective December 23, 2022). A further amendment to the collaboration agreement was entered into on December 19, 2022 for the deletion of certain provisions relating to GSK’s post termination manufacturing and supply obligations and payment of </span>£5,000,000 by GSK to Adaptimmune. The aggregate transaction price of the contract modification was $6,500,000, which was recognized as revenue on the date of the modification. No revenue was recognized in relation to the GSK Collaboration and License Agreement in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The GSK Termination and Transfer Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 6, 2023, the Company and GSK entered into a Termination and Transfer Agreement (the “Termination and Transfer Agreement”) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the agreement, sponsorship and responsibility for the ongoing IGNYTE and long-term follow-up (“LTFU”) trials relating to the NY-ESO cell therapy program will transfer to Adaptimmune. In return for this, Adaptimmune received an upfront payment of £7.5 million in June 2023 following the signing of the agreement and further milestone payments totalling £22.5 million will be due in relation to successive stages of transfer of the trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that GSK is a customer and has accounted for the agreement under ASC 606 <i style="font-style:italic;">Revenue from contracts with customers</i>. The agreement is accounted for as a separate contract from the original GSK Collaboration and License Agreement. The Company has identified the following performance obligations under the agreement: (i) to take over sponsorship for the IGNYTE trial and (ii) to take over sponsorship for the LTFU trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate transaction price at inception of the agreement was $37,335,000 comprising the total £30,000,000 upfront and milestone payments. No value was ascribed to non-cash consideration and there was no variable consideration identified. The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the relative standalone selling price, the Company considered the internal pricing objectives it used in negotiating the contract, together with internal data regarding the expected costs and a standard margin on those costs, for completing the trials. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company expects to satisfy the IGNYTE performance obligation as sponsorship of the active trials that make up the IGNYTE trial transfers, based on the number of patients transferring to the Company in each trial. The Company considers that this </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">depicts the progress of the transfer of sponsorship of the IGNYTE trial to the Company, as each individual trial comprising IGNYTE transferred represents the transfer of a portion of the sponsorship for IGNYTE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects to satisfy the LTFU performance obligation as sponsorship of the trials that make up the LTFU trial transfers, including trials for potential future patients transferring to the LTFU trial from the IGNYTE trial, based on the number of active and potential patients transferring in each trial. The Company considers that this depicts the progress of the transfer of sponsorship of the LTFU trial to the Company, as each individual trial comprising LTFU transferred represents the transfer of a portion of sponsorship for the LTFU trial and the sponsorship of patients transferring from IGNYTE in future is part of the promise to take on the overall LTFU trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No revenue was recognized for the agreement in the three and six months ended June 30, 2023. The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of June 30, 2023 was $37,857,000, of which $21,200,000 is allocated to the IGNYTE performance obligation and $16,657,000 is allocated to the LTFU performance obligation.</p> 2 3 3 3 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;">Revenue comprises the following categories (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,113</p></td></tr><tr><td style="vertical-align:bottom;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,130</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,538</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 52,731</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,113</b></p></td></tr></table> 5130000 5538000 52731000 9113000 5130000 5538000 52731000 9113000 35737000 184412000 148675000 9613000 5890000 1.21 1.26 184412000 52046000 318107000 280250000 171816000 89098000 13052000 5027000 1257000 3 2 42365000 0 0 5000000 6500000 0 7500000 22500000 37335000 30000000 0 0 37857000 21200000 16657000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 4 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator for basic and diluted loss per share </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to ordinary shareholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,520)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,353)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,785)</p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss attributable to ordinary shareholders used for basic and diluted loss per share </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_10El9uOM5kOeQWxOWxe4uw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (21,389)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_kYwDVJWsx06nhqo70Kv6ng;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (44,520)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_gd-jzOp-rEqRiYtrxqEvQw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (20,353)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pmGzANzkWkSUlln4UYj99A;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (94,785)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator for basic loss per share - Weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,108,166,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 962,794,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,050,071,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 951,474,546</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The dilutive effect of 201,688,491 and 150,711,054 stock options outstanding as of June 30, 2023 and 2022 respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2023 and 2022 because they would have an antidilutive effect on the loss per share for the period. The stock options outstanding as of June 30, 2023 includes a provisional amount of 35,156,344 replacement awards granted to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> grantholders on June 1, 2023.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator for basic and diluted loss per share </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to ordinary shareholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,520)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,353)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,785)</p></td></tr><tr><td style="vertical-align:bottom;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss attributable to ordinary shareholders used for basic and diluted loss per share </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_10El9uOM5kOeQWxOWxe4uw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (21,389)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_kYwDVJWsx06nhqo70Kv6ng;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (44,520)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_gd-jzOp-rEqRiYtrxqEvQw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (20,353)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pmGzANzkWkSUlln4UYj99A;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (94,785)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator for basic loss per share - Weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,108,166,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 962,794,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,050,071,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 951,474,546</p></td></tr></table> -21389000 -44520000 -20353000 -94785000 -21389000 -44520000 -20353000 -94785000 1108166960 962794072 1050071434 951474546 201688491 150711054 35156344 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Accumulated other comprehensive loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">accumulated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(losses) gains on</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">available-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">debt securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss) income</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (930)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (875)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,908)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,908)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,526</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,327)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (458)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,785)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,281)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,281)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,590</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (3,019)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (73)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (3,092)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">accumulated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> (losses) on</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">available-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">debt securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss) income</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (10,785)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (357)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (11,142)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,792</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,808)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,808)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,155)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,801)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,512)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (9,313)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,694</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,108)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (316)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (316)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 785</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,828)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,043)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">accumulated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(losses) gains on</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">available-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">debt securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss) income</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (930)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (875)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,908)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,908)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,526</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,327)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (458)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,785)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,281)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,281)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,590</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (3,019)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (73)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (3,092)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">accumulated</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> (losses) on</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">available-for-sale</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">debt securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss) income</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (10,785)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (357)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (11,142)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,792</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,808)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,808)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,155)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,801)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,512)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (9,313)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency translation adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,694</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,108)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (316)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (316)</p></td></tr><tr><td style="vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 785</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,828)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,043)</b></p></td></tr></table> 55000 -930000 -875000 -16908000 -16908000 0 15526000 15526000 0 472000 472000 -1327000 -458000 -1785000 -12281000 -12281000 0 10590000 10590000 0 385000 385000 -3019000 -73000 -3092000 -10785000 -357000 -11142000 16792000 16792000 0 -13808000 -13808000 0 -1155000 -1155000 -7801000 -1512000 -9313000 47694000 47694000 0 -39108000 -39108000 0 -316000 -316000 785000 -1828000 -1043000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Fair value measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of June 30, 2023 are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurements using</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets classified as cash equivalents:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets classified as available-for-sale debt securities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 127,738</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 24,928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 102,810</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of June 30, 2023 are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurements using</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets classified as cash equivalents:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets classified as available-for-sale debt securities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 127,738</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 24,928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 102,810</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table> 29102000 29102000 24928000 24928000 94917000 94917000 7893000 7893000 127738000 24928000 102810000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 7 — Marketable securities – available-for-sale debt securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company has the following investments in marketable securities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash equivalents:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,102</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,069</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,102</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Available-for-sale debt securities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,232</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,682</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,952</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 months to 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,235</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 months to 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,941</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 months to 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,696</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 127,841</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (136)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 127,738</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of June 30, 2023 and December 31, 2022 are as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair market value of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair market value of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Marketable securities in a continuous loss position for 12 months or longer:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Corporate debt securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (679)</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (154)</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Corporate debt securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97)</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 61,479</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (136)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 90,618</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (930)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, no allowance for expected credit losses has been recognized in relation to securities in an unrealized loss position. This is because the impairments are not severe, do not represent a significant proportion of the total fair market value of the investments and all securities have an investment-grade credit rating. Furthermore, the Company does not intend to sell the debt securities in an unrealized loss position, believes that it has the ability to hold the debt securities to maturity, and it is currently unlikely that the Company will be required to sell these securities before the recovery of the amortized cost.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company has the following investments in marketable securities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual maturity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash equivalents:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,102</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,069</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,102</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Available-for-sale debt securities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,232</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,682</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Less than 3 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,952</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 months to 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,235</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agency bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 months to 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,941</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3 months to 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,696</p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 127,841</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 33</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (136)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 127,738</b></p></td></tr></table> P3M 29069000 33000 29102000 29069000 33000 29102000 P3M 16258000 26000 16232000 P3M 41675000 12000 5000 41682000 P3M 5008000 56000 4952000 P3M P1Y 53225000 19000 9000 53235000 P3M P1Y 2949000 8000 2941000 P3M P1Y 8726000 2000 32000 8696000 127841000 33000 136000 127738000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of June 30, 2023 and December 31, 2022 are as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair market value of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair market value of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of investments in an unrealized loss position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Marketable securities in a continuous loss position for 12 months or longer:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Corporate debt securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (679)</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (154)</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Corporate debt securities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97)</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Agency bond</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 61,479</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (136)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 90,618</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (930)</b></p></td></tr></table> 15554000 4 50000 74481000 16 679000 4952000 1 56000 4854000 1 154000 6424000 2 8000 11283000 2 97000 31608000 11 14000 2941000 1 8000 61479000 19 136000 90618000 19 930000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 8 — Other current assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,162</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,472</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,279</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VAT receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 490</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,927</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 54,094</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,330</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,162</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,472</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,279</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VAT receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 490</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,927</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 54,094</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 43,330</b></p></td></tr></table> 37863000 30162000 13040000 9472000 1334000 1279000 92000 490000 1765000 1927000 54094000 43330000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 9 — Operating leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases in relation to property for office, manufacturing and research facilities<span style="font-size:12pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table shows the lease costs for the six months ended June 30, 2023 and 2022 and the weighted-average remaining lease term and the weighted-average discount rate as at June 30, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,285</p></td></tr><tr><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,672</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,449</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.8 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.3 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times';">8.6%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times';">6.8%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The maturities of operating lease liabilities as of June 30, 2023 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#111111;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,402</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,530</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,142</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,142</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,559</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">after 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,637</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 32,412</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,070</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Present value of lease liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,342</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has operating leases in relation to property for office, manufacturing and research facilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 1, 2023, as part of the acquisition of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>, the Company became the lessee for three office, manufacturing and research facilities in Cambridge, Massachusetts. The Company retained TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>’s previous classification for two of these leases as operating leases and, upon acquisition, the lease liabilities were measured at the present value of the remaining lease payments, as if the lease were a new lease of the Company at June 1, 2023. The right-of-use assets were initially measured at the same amount as the respective lease liabilities, adjusted to reflect favorable or unfavorable terms of the leases when compared with market terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The third lease had a remaining lease term of less than 12 months as of June 1, 2023, and the Company elected not to recognize a lease liability or right-of-use asset as of June 1, 2023. The rent associated with this lease will be recognized on a straight-line basis over the remainder of the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The maximum lease term without activation of termination options is to 2041. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table shows the lease costs for the six months ended June 30, 2023 and 2022 and the weighted-average remaining lease term and the weighted-average discount rate as at June 30, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,285</p></td></tr><tr><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,672</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,449</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.8 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.3 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times';">8.6%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times';">6.8%</span></p></td></tr></table> 2353000 2285000 319000 164000 2672000 2449000 P5Y9M18D P7Y3M18D 0.086 0.068 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The maturities of operating lease liabilities as of June 30, 2023 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#111111;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,402</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,530</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,142</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,142</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,559</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">after 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,637</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 32,412</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,070</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Present value of lease liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,342</b></p></td></tr></table> 3402000 6530000 5142000 4142000 5559000 7637000 32412000 6070000 26342000 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 10 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Accrued expenses and other current liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and development expenditure</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,749</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,232</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenditure</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,079</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,155</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 25,242</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 31,215</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and development expenditure</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,749</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,232</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenditure</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,079</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,155</p></td></tr><tr><td style="vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 25,242</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 31,215</b></p></td></tr></table> 12039000 16749000 10020000 8232000 3028000 4079000 155000 2155000 25242000 31215000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 11 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Contingencies and commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Universal Cells Research, Collaboration and License Agreement and </i><i style="font-style:italic;">Co-development and Co-commercialization agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 25, 2015, the Company entered into a Research, Collaboration and License Agreement relating to gene editing and Human Leukocyte Antigen (“HLA”) engineering technology with Universal Cells, Inc. (“Universal Cells”). The Company paid an upfront license and start-up fee of $2,500,000 to Universal Cells in November 2015, a milestone payment of $3,000,000 in February 2016 and further milestone payments of $200,000 and $900,000 were made in the years ended December 31, 2018 and 2017, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The agreement was amended and re-stated as of January 13, 2020, primarily to reflect changes to the development plan agreed between the parties. The agreement was further amended as of July 22, 2022, primarily to make certain changes to development milestones and to agree on the status thereof, as agreed between the parties. Following the amendment, milestone payments of $500,000, $600,000 and $400,000 were made in the year ended December 31, 2022. No remaining milestones have been accrued as of June 30, 2023. The upfront license and start-up fee and milestone payments were expensed to Research and development when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This Agreement was terminated by notice on January 27, 2023, effective 30 days following receipt of notice of termination. As a result of termination, all licenses between the parties to the Agreement will cease and each party is required to return all confidential information of the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Astellas Collaboration Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the Astellas Collaboration Agreement, described further in Note 3, if Adaptimmune had unilaterally developed a product with technology contributed by Astellas, Astellas could have been eligible to receive milestones and royalties relating to future commercialization and sales. As a result of the termination of the collaboration, Astellas no longer has the right to receive these milestones or royalties in future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MD Anderson Strategic Alliance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2016, the Company announced that it had entered into a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center (“MD Anderson”) designed to expedite the development of T-cell therapies for multiple types of cancer. The Company and MD Anderson are collaborating on a number of studies including clinical and preclinical development of the Company’s SPEAR T-cell therapies and will collaborate on future clinical stage first and second generation SPEAR T-cell therapies across a number of cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the agreement, the Company committed at least $19,644,000 to fund studies. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance and the performance of set milestones by MD Anderson. The Company made an upfront payment of $3,412,000 to MD Anderson in the year ended December 31, 2017 and milestone payments of $2,326,000, $3,549,000, $454,000 and $2,326,000 in the years ended December 31, 2018, 2020, 2021, and 2022, respectively. The Company is obligated to make further payments to MD Anderson as certain milestones are achieved. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, amongst other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</p> 2500000 3000000 200000 900000 500000 600000 400000 0 19644000 3412000 2326000 3549000 454000 2326000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 12 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Share-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,556</p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,075</p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,837</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,045</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,513</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,631</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of options over ordinary shares granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,247,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,735,488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52,002,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,611,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of ordinary shares options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.41</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of additional options with a nominal exercise price granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,148,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,361,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,015,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,050,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of options with a nominal exercise price </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.55</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information above includes the impact of 29,654,742 options over ordinary shares and 5,501,602 options with a nominal exercise price granted on June 1, 2023, as replacement awards as part of the acquisition of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> Therapeutics Inc., as explained further in Note 15. The number and fair value of replacement awards of the Company granted to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> grantholders is provisional.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,556</p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,075</p></td></tr><tr><td style="vertical-align:bottom;width:50.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,837</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,045</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,513</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,631</b></p></td></tr></table> 1285000 2033000 1401000 4556000 2552000 3012000 4112000 6075000 3837000 5045000 5513000 10631000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of options over ordinary shares granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,247,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,735,488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52,002,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,611,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of ordinary shares options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.41</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of additional options with a nominal exercise price granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,148,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,361,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,015,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,050,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average fair value of options with a nominal exercise price </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.55</p></td></tr></table> 30247398 1735488 52002726 24611952 0.05 0.25 0.08 0.41 6148186 3361728 26015098 21050160 0.15 0.34 0.17 0.55 29654742 5501602 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 13 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> Stockholders’ equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2020 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) (the “Sales Agreement”) under which we may from time to time issue and sell American Depositary Shares (“ADSs”) representing our ordinary shares through Cowen in at-the-market (“ATM”) offerings for an aggregate offering price of up to $200 million. As of June 30, 2023, $197,360,000 remained available for sale under the Sales Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On April 8, 2022 the Company entered into a new sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the six months ended June 30, 2023, the Company sold 92,416 ADSs under the agreement representing 554,496 ordinary shares resulting in net proceeds to the Company of $173,430 after deducting commissions payable under the 2022 Sales Agreement and estimated issuance costs. As of June 30, 2023, approximately $186,513,100<span style="white-space:pre-wrap;"> remained available for sale under the 2022 Sales Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 200000000 197360000 200000000 92416 554496 173430 186513100 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 14 – Restructuring</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">2022-23 Restructuring programme</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 8, 2022, the Company announced that in order to extend the Company’s cash runway from early 2024 into early 2025, it was re-focusing the business on core programs and deprioritizing non-core programs and undertaking a restructuring of the Company including a headcount reduction to be completed in the first quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The redundancy process was completed in the first quarter of 2023 with a reduction of approximately 25% of global headcount. The redundancy packages to be paid to departing staff comprise a combination of contractual termination benefits, relating to payments that arise from terms of employment contracts and statutory redundancy pay, and one-time employee termination benefits that were provided or enhanced specifically for this redundancy process. Due to the structure of the redundancy scheme and the different employment regulations affecting the Company’s U.K. and U.S. employees, some of the expense associated with the one-time employee termination benefits were recognized over the remaining period of employee service to be rendered. Contractual termination benefits and other one-time employee termination benefits were expensed and recognized in the year ended December 31, 2022. All expenses have been recognized in General and administrative expenses in the Statement of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amounts incurred in relation to the redundancy programme are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">One-time</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">employee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">restructuring</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">costs</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cumulative amount incurred to December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,285</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amount incurred in the three months ended March 31, 2023 and six months ended June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,703</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total amount and cumulative amount incurred to March 31, 2023 and June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,949</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,039</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,988</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below is a summary of the changes in the restructuring provision in the Consolidated Balance Sheet in the six months ended June 30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">One-time</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">employee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">restructuring</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">provision</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,285</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs incurred and charged to General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,617</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs paid during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,955)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,908)</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to the liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 88</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 88</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs paid during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The costs incurred during the period includes the element of one-time employee termination benefits that was recognized over the remaining period of employee service. The costs incurred during the six months to 30 June 2023 also include an addition to the provision for costs incurred relating to termination benefits paid to the former Chief Commercial Officer, who left employment with the Company in the first quarter of 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">No impairment losses were recognized as a result of the restructuring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">TCR</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">2</sup><i style="font-style:italic;"> post-acquisition senior leadership severance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Following the acquisition of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>Therapeutics Inc., the Company made most of the former members of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>’s senior leadership team, comprising the executive officers and most vice presidents, redundant and paid severance packages. The redundancy packages are considered contractual termination benefits as they arise from terms of employment contracts including change-in-control ‘dual trigger’ provisions, and were comprised of severance and other payments and accelerated vesting of share option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amounts incurred in relation to these redundancies in the six months to June 30, 2023, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three and six months ending</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance and other cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,655</p></td></tr><tr><td style="vertical-align:bottom;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accelerated vesting of share-based compensation awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 835</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total and cumulative amount incurred to June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,490</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The expense associated with the accelerated vesting of share-based compensation awards recognized in Research and development and General and administrative expenses in the Consolidated Statement of Operations was $0.2 million and $0.6 million, respectively. The table below is a summary of the changes in the liability in the Consolidated Balance Sheet in the three and six months ended June 30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liability at June 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 805</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs incurred and charged to Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,267</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs incurred and charged to General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,388</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs paid during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,823)</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liability at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,637</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amounts included in the liabilities at June 1, and June 30, 2023 and the cash paid during the period, include amounts relating to accrued payments to these employees for services provided prior to the acquisition of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p> 0.25 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amounts incurred in relation to the redundancy programme are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">One-time</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">employee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">restructuring</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">costs</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cumulative amount incurred to December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,285</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amount incurred in the three months ended March 31, 2023 and six months ended June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,703</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total amount and cumulative amount incurred to March 31, 2023 and June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,949</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,039</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,988</b></p></td></tr></table> 1171000 1114000 2285000 778000 925000 1703000 1949000 2039000 3988000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below is a summary of the changes in the restructuring provision in the Consolidated Balance Sheet in the six months ended June 30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">One-time</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">employee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">termination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">restructuring</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">benefits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">provision</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,285</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs incurred and charged to General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,617</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs paid during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,955)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,908)</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to the liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 88</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 88</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs paid during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td></tr></table> 1171000 1114000 2285000 670000 947000 1617000 1955000 1953000 3908000 108000 -22000 86000 6000 2000 8000 88000 88000 88000 88000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amounts incurred in relation to these redundancies in the six months to June 30, 2023, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three and six months ending</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance and other cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,655</p></td></tr><tr><td style="vertical-align:bottom;width:82.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accelerated vesting of share-based compensation awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 835</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total and cumulative amount incurred to June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,490</b></p></td></tr></table> 5655 835 6490 200000 600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liability at June 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 805</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs incurred and charged to Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,267</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs incurred and charged to General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,388</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs paid during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,823)</p></td></tr><tr><td style="vertical-align:bottom;width:85.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liability at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,637</b></p></td></tr></table> 805000 1267000 4388000 4823000 1637000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 15 – Business combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 6, 2023 the Company announced entry into a definitive agreement under which it will combine with TCR² Therapeutics Inc. (“TCR²”) in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> is a Boston, Massachusetts-based T-cell therapy company focused on treating solid tumours, with clinical franchises undergoing trials and a preclinical pipeline. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The transaction was approved by the Company’s shareholders and TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> stockholders on May 30, 2023 and the merger became effective on June 1, 2023. The Company issued 357,429,306 shares to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>stockholders in return for 100% of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>’s stock. As a result, TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> and all entities within the TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> group, became wholly owned by the Company. Following the completion of the transaction, the former TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> stockholders held approximately 25% of the Company, whereas the Company’s pre-existing shareholders held approximately 75%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was identified as the acquirer, with TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> as the acquiree, and June 1, 2023 was determined to be the acquisition date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The consideration transferred for TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> includes the shares issued by the Company to former TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> shareholders, plus the fair value of replacement awards of the Company granted to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> grantholders attributable to pre-combination vesting. The table below summarizes the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consideration transferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of 357,429,306 ordinary shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,763</p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of replacement options and RSU-style options granted attributable to pre-combination service:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchase consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 61,620</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Identifiable assets acquired and liabilities assumed:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Assets acquired</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,610</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,654</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,532</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets and prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,029</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,145</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 98,740</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Liabilities assumed</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,210)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,537)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,974)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,244)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (14,965)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net assets acquired and liabilities assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 83,775</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The fair value of the 357,429,306 ordinary shares issued to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> stockholders of $60,763,000 was determined on the basis of the closing market price of $1.02 ($0.17 per ordinary share) of the Company’s ADSs as of May 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The number and fair value of replacement awards of the Company granted to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> grantholders attributable to pre-combination and post-combination vesting is provisional as the Company is still evaluating the total number of replacement awards that were required to be granted on June 1, 2023, their respective exercise prices and the total fair value of replacement options granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The assets acquired and liabilities assumed were measured based on management’s estimates of the fair value as of the acquisition date, excluding leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The lease contracts acquired by the Company relate to the rental of office and manufacturing spaces in which TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> was the lessee. The Company retained TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>’s previous classification of acquired leases as operating leases as there were no lease modifications as a result of the combination, with the exception of leases with a remaining lease term of 12 months or less at the acquisition date, for which no assets or liabilities were recognized at the acquisition date. The lease liabilities were measured at the present value of the remaining lease payments as if the leases were a new lease as of June 1, 2023, discounted using the incremental borrowing rate. The right-of-use assets were measured at the same amount as the lease liabilities, with adjustments to reflect favorable or unfavorable terms compared to market terms. No intangible assets were identified in relation to lease contracts acquired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarises the calculation for the gain on bargain purchase, recognized in the Gain on bargain purchase line in the Consolidated Statement of Operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Gain on bargain purchase</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Purchase consideration </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (61,620)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net assets acquired and liabilities assumed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,775</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Gain on bargain purchase</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 22,155</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The transaction resulted in a gain on bargain purchase as the purchase consideration included in the agreement on March 6, 2023 comprising Company ADSs was based on a fixed ratio of 1.5117 of the Company’s ADSs to be issued for each TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> stock acquired. As the transaction was an all-stock transaction, the value of the consideration was highly sensitive to changes in the Company’s ADS price. The price of a Company ADS fell from a closing price of $1.32 on March 6, 2023 compared to a closing price of $1.02 on May 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The amount of TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>’s earnings that are included in the Company’s Consolidated Statement of Operations for the six months ended June 30, 2023 was a loss of $11,760,000 which excludes the gain on bargain purchase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The amount of revenue and earnings of the combined entity for the six months ended June 30, 2023 and 2022, had the acquisition date been January 1, 2022, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,113</p></td></tr><tr><td style="vertical-align:bottom;width:63.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,202)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (143,556)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The supplemental pro forma earnings for the six months ended June 30, 2023 were adjusted to exclude the $22.2 million Gain on bargain purchase, the $7.2 million of acquisition-related costs recognized by the Company, as detailed below, and the $7.7 million of acquisition-related costs incurred by TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>. The pro forma earnings for the six months ended June 30, 2022 were adjusted to include these gains and losses. The supplemental pro forma earnings for both periods were adjusted to include the impact of replacement options issued, as if these had been issued as of January 1, 2022. Accordingly, the share-based compensation expense recognized by TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in the six months ended June 30, 2022, and the five months ended May 31, 2023, prior to the acquisition by the Company, of $6.0 million and $1.0 million, respectively, were excluded from the pro forma earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> did not generate revenue in the period from January 1, 2022 to June 30, 2023, as it has no contracts with customers, so there was no impact on the revenue included in the Company’s Consolidated Statement of Operations or in the supplemental pro forma revenue and earnings presented above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company incurred the following acquisition-related costs that were recognized as an expense in the six months ended June 30, 2023: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal, professional and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,993</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bankers' fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,172</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total acquisition-related costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,165</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">All acquisition-related costs that were recognized as an expense were recognized in General and administrative expenses in the Consolidated Statement of Operations. No issuance costs were incurred relating to the issuance of shares to TCR<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">​</span></p> 357429306 1 0.25 0.75 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consideration transferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of 357,429,306 ordinary shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,763</p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of replacement options and RSU-style options granted attributable to pre-combination service:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchase consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 61,620</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Identifiable assets acquired and liabilities assumed:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Assets acquired</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,610</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,654</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,532</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets and prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,029</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,145</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 98,740</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Liabilities assumed</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,210)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,537)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,974)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,244)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (14,965)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net assets acquired and liabilities assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 83,775</b></p></td></tr></table> 357429306 60763000 857000 61620000 43610000 1654000 39532000 6029000 2712000 5145000 58000 98740000 6210000 4537000 1974000 2244000 14965000 83775000 357429306 60763000 1.02 0.17 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Gain on bargain purchase</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Purchase consideration </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (61,620)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net assets acquired and liabilities assumed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,775</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Gain on bargain purchase</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 22,155</b></p></td></tr></table> 61620000 83775000 22155000 1.5117 1.32 1.02 11760000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,113</p></td></tr><tr><td style="vertical-align:bottom;width:63.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,202)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (143,556)</p></td></tr></table> 52731 9113 -86202 -143556 22200000 7200000 7700000 6000000.0 1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company incurred the following acquisition-related costs that were recognized as an expense in the six months ended June 30, 2023: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal, professional and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,993</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bankers' fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,172</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total acquisition-related costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,165</b></p></td></tr></table> 4993000 2172000 7165000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 16 – Subsequent events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None</p> false false false false EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 82 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 184 284 1 false 53 0 false 11 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS Statements 5 false false R6.htm 00305 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical) Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY Statements 7 false false R8.htm 00500 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 10101 - Disclosure - General Sheet http://www.adaptimmune.com/role/DisclosureGeneral General Notes 9 false false R10.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10301 - Disclosure - Revenue Sheet http://www.adaptimmune.com/role/DisclosureRevenue Revenue Notes 11 false false R12.htm 10401 - Disclosure - Profit / Loss per share Sheet http://www.adaptimmune.com/role/DisclosureProfitLossPerShare Profit / Loss per share Notes 12 false false R13.htm 10501 - Disclosure - Accumulated other comprehensive loss Sheet http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss Accumulated other comprehensive loss Notes 13 false false R14.htm 10601 - Disclosure - Fair value measurements Sheet http://www.adaptimmune.com/role/DisclosureFairValueMeasurements Fair value measurements Notes 14 false false R15.htm 10701 - Disclosure - Marketable securities - available-for-sale debt securities Sheet http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities Marketable securities - available-for-sale debt securities Notes 15 false false R16.htm 10801 - Disclosure - Other current assets Sheet http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets Other current assets Notes 16 false false R17.htm 10901 - Disclosure - Operating Leases Sheet http://www.adaptimmune.com/role/DisclosureOperatingLeases Operating Leases Notes 17 false false R18.htm 11001 - Disclosure - Accrued expenses and other current liabilities Sheet http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued expenses and other current liabilities Notes 18 false false R19.htm 11101 - Disclosure - Contingencies and commitments Sheet http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitments Contingencies and commitments Notes 19 false false R20.htm 11201 - Disclosure - Share-based compensation Sheet http://www.adaptimmune.com/role/DisclosureShareBasedCompensation Share-based compensation Notes 20 false false R21.htm 11301 - Disclosure - Stockholders' equity Sheet http://www.adaptimmune.com/role/DisclosureStockholdersEquity Stockholders' equity Notes 21 false false R22.htm 11401 - Disclosure - Restructuring Sheet http://www.adaptimmune.com/role/DisclosureRestructuring Restructuring Notes 22 false false R23.htm 11501 - Disclosure - Business combinations Sheet http://www.adaptimmune.com/role/DisclosureBusinessCombinations Business combinations Notes 23 false false R24.htm 11601 - Disclosure - Subsequent events Sheet http://www.adaptimmune.com/role/DisclosureSubsequentEvents Subsequent events Notes 24 false false R25.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 30303 - Disclosure - Revenue (Tables) Sheet http://www.adaptimmune.com/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.adaptimmune.com/role/DisclosureRevenue 26 false false R27.htm 30403 - Disclosure - Profit / Loss per share (Tables) Sheet http://www.adaptimmune.com/role/DisclosureProfitLossPerShareTables Profit / Loss per share (Tables) Tables http://www.adaptimmune.com/role/DisclosureProfitLossPerShare 27 false false R28.htm 30503 - Disclosure - Accumulated other comprehensive loss (Tables) Sheet http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables Accumulated other comprehensive loss (Tables) Tables http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss 28 false false R29.htm 30603 - Disclosure - Fair value measurements (Tables) Sheet http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables Fair value measurements (Tables) Tables http://www.adaptimmune.com/role/DisclosureFairValueMeasurements 29 false false R30.htm 30703 - Disclosure - Marketable securities - available-for-sale debt securities (Tables) Sheet http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables Marketable securities - available-for-sale debt securities (Tables) Tables http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities 30 false false R31.htm 30803 - Disclosure - Other current assets (Tables) Sheet http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables Other current assets (Tables) Tables http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets 31 false false R32.htm 30903 - Disclosure - Operating Leases (Tables) Sheet http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables Operating Leases (Tables) Tables http://www.adaptimmune.com/role/DisclosureOperatingLeases 32 false false R33.htm 31003 - Disclosure - Accrued expenses and other current liabilities (Tables) Sheet http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued expenses and other current liabilities (Tables) Tables http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 33 false false R34.htm 31203 - Disclosure - Share-based compensation (Tables) Sheet http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables Share-based compensation (Tables) Tables http://www.adaptimmune.com/role/DisclosureShareBasedCompensation 34 false false R35.htm 31401 - Disclosure - Restructuring (Tables) Sheet http://www.adaptimmune.com/role/DisclosureRestructuringTables Restructuring (Tables) Tables http://www.adaptimmune.com/role/DisclosureRestructuring 35 false false R36.htm 31503 - Disclosure - Business combinations (Tables) Sheet http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables Business combinations (Tables) Tables http://www.adaptimmune.com/role/DisclosureBusinessCombinations 36 false false R37.htm 40101 - Disclosure - General (Details) Sheet http://www.adaptimmune.com/role/DisclosureGeneralDetails General (Details) Details http://www.adaptimmune.com/role/DisclosureGeneral 37 false false R38.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) Sheet http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) Details 38 false false R39.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Accounts receivable (Details) Sheet http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails Summary of Significant Accounting Policies - Accounts receivable (Details) Details 39 false false R40.htm 40301 - Disclosure - Revenue - Revenue from contracts with customers (Details) Sheet http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails Revenue - Revenue from contracts with customers (Details) Details 40 false false R41.htm 40302 - Disclosure - Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) Sheet http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) Details 41 false false R42.htm 40303 - Disclosure - Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details) Sheet http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details) Details 42 false false R43.htm 40304 - Disclosure - Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details) Sheet http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details) Details 43 false false R44.htm 40305 - Disclosure - Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details) Sheet http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details) Details 44 false false R45.htm 40401 - Disclosure - Profit / Loss per share - Basic and diluted income (loss) per share (Details) Sheet http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails Profit / Loss per share - Basic and diluted income (loss) per share (Details) Details 45 false false R46.htm 40402 - Disclosure - Profit / Loss per share - Antidilutive shares (Details) Sheet http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails Profit / Loss per share - Antidilutive shares (Details) Details 46 false false R47.htm 40501 - Disclosure - Accumulated other comprehensive loss (Details) Sheet http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails Accumulated other comprehensive loss (Details) Details http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables 47 false false R48.htm 40601 - Disclosure - Fair value measurements (Details) Sheet http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails Fair value measurements (Details) Details http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables 48 false false R49.htm 40701 - Disclosure - Marketable securities - Available-for-sale debt securities (Details) Sheet http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails Marketable securities - Available-for-sale debt securities (Details) Details 49 false false R50.htm 40702 - Disclosure - Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details) Sheet http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details) Details 50 false false R51.htm 40801 - Disclosure - Other current assets (Details) Sheet http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails Other current assets (Details) Details http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables 51 false false R52.htm 40901 - Disclosure - Operating Leases (Details) Sheet http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails Operating Leases (Details) Details http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables 52 false false R53.htm 40902 - Disclosure - Operating Leases - Maturities (Details) Sheet http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails Operating Leases - Maturities (Details) Details 53 false false R54.htm 41001 - Disclosure - Accrued expenses and other current liabilities (Details) Sheet http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued expenses and other current liabilities (Details) Details http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 54 false false R55.htm 41101 - Disclosure - Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details) Sheet http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details) Details 55 false false R56.htm 41102 - Disclosure - Contingencies and commitments - MD Anderson Strategic Alliance (Details) Sheet http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails Contingencies and commitments - MD Anderson Strategic Alliance (Details) Details 56 false false R57.htm 41201 - Disclosure - Share-based compensation - Share-based Compensation Expense (Details) Sheet http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails Share-based compensation - Share-based Compensation Expense (Details) Details 57 false false R58.htm 41202 - Disclosure - Share-based compensation - Options (Details) Sheet http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails Share-based compensation - Options (Details) Details 58 false false R59.htm 41301 - Disclosure - Stockholders equity - Offerings (Details) Sheet http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails Stockholders equity - Offerings (Details) Details 59 false false R60.htm 41401 - Disclosure - Restructuring (Details) Sheet http://www.adaptimmune.com/role/DisclosureRestructuringDetails Restructuring (Details) Details http://www.adaptimmune.com/role/DisclosureRestructuringTables 60 false false R61.htm 41402 - Disclosure - Restructuring - Movements in Provision (Details) Sheet http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails Restructuring - Movements in Provision (Details) Details 61 false false R62.htm 41403 - Disclosure - Restructuring - TCR post-acquisition senior leadership severance (Details) Sheet http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails Restructuring - TCR post-acquisition senior leadership severance (Details) Details 62 false false R63.htm 41404 - Disclosure - Restructuring - TCR post-acquisition senior leadership severance - Change in Liability (Details) Sheet http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails Restructuring - TCR post-acquisition senior leadership severance - Change in Liability (Details) Details 63 false false R64.htm 41501 - Disclosure - Business combinations (Details) Sheet http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails Business combinations (Details) Details http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables 64 false false R65.htm 41502 - Disclosure - Business combinations - Gain on bargain purchase (Details) Sheet http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails Business combinations - Gain on bargain purchase (Details) Details 65 false false R66.htm 41503 - Disclosure - Business combinations - Proforma Information (Details) Sheet http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails Business combinations - Proforma Information (Details) Details 66 false false R67.htm 41504 - Disclosure - Business combinations - Acquisition-related costs (Details) Sheet http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails Business combinations - Acquisition-related costs (Details) Details 67 false false R68.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Uncategorized 68 false false R69.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Cover 69 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 15 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityFilerCategory, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - adap-20230630x10q.htm 9 [dq-0712-Presentation-Base-Set-Order] Role '41601 - Disclosure - Subsequent events (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. adap-20230630.xsd 219, https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30 adap-20230630x10q.htm adap-20230630.xsd adap-20230630_cal.xml adap-20230630_def.xml adap-20230630_lab.xml adap-20230630_pre.xml adap-20230630xex31d1.htm adap-20230630xex31d2.htm adap-20230630xex32d1.htm adap-20230630xex32d2.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adap-20230630x10q.htm": { "axisCustom": 0, "axisStandard": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 620, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 184, "dts": { "calculationLink": { "local": [ "adap-20230630_cal.xml" ] }, "definitionLink": { "local": [ "adap-20230630_def.xml" ] }, "inline": { "local": [ "adap-20230630x10q.htm" ] }, "labelLink": { "local": [ "adap-20230630_lab.xml" ] }, "presentationLink": { "local": [ "adap-20230630_pre.xml" ] }, "schema": { "local": [ "adap-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] } }, "elementCount": 531, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 14, "http://xbrl.sec.gov/dei/2023": 7, "total": 21 }, "keyCustom": 55, "keyStandard": 229, "memberCustom": 26, "memberStandard": 25, "nsprefix": "adap", "nsuri": "http://www.adaptimmune.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Revenue", "menuCat": "Notes", "order": "11", "role": "http://www.adaptimmune.com/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Profit / Loss per share", "menuCat": "Notes", "order": "12", "role": "http://www.adaptimmune.com/role/DisclosureProfitLossPerShare", "shortName": "Profit / Loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accumulated other comprehensive loss", "menuCat": "Notes", "order": "13", "role": "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss", "shortName": "Accumulated other comprehensive loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Fair value measurements", "menuCat": "Notes", "order": "14", "role": "http://www.adaptimmune.com/role/DisclosureFairValueMeasurements", "shortName": "Fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Marketable securities - available-for-sale debt securities", "menuCat": "Notes", "order": "15", "role": "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities", "shortName": "Marketable securities - available-for-sale debt securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Other current assets", "menuCat": "Notes", "order": "16", "role": "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets", "shortName": "Other current assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Operating Leases", "menuCat": "Notes", "order": "17", "role": "http://www.adaptimmune.com/role/DisclosureOperatingLeases", "shortName": "Operating Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Accrued expenses and other current liabilities", "menuCat": "Notes", "order": "18", "role": "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued expenses and other current liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Contingencies and commitments", "menuCat": "Notes", "order": "19", "role": "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitments", "shortName": "Contingencies and commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Share-based compensation", "menuCat": "Notes", "order": "20", "role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensation", "shortName": "Share-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Stockholders' equity", "menuCat": "Notes", "order": "21", "role": "http://www.adaptimmune.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Restructuring", "menuCat": "Notes", "order": "22", "role": "http://www.adaptimmune.com/role/DisclosureRestructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Business combinations", "menuCat": "Notes", "order": "23", "role": "http://www.adaptimmune.com/role/DisclosureBusinessCombinations", "shortName": "Business combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Subsequent events", "menuCat": "Notes", "order": "24", "role": "http://www.adaptimmune.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "25", "role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.adaptimmune.com/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Profit / Loss per share (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareTables", "shortName": "Profit / Loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Accumulated other comprehensive loss (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated other comprehensive loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Fair value measurements (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Marketable securities - available-for-sale debt securities (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables", "shortName": "Marketable securities - available-for-sale debt securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Other current assets (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables", "shortName": "Other current assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Operating Leases (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables", "shortName": "Operating Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Accrued expenses and other current liabilities (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued expenses and other current liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Share-based compensation (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables", "shortName": "Share-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "adap:RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31401 - Disclosure - Restructuring (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.adaptimmune.com/role/DisclosureRestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "adap:RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "adap:ScheduleOfAssetsAcquiredAndLiabilitiesAssumedRecognizedIncludingConsiderationAtAcquisitionDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Business combinations (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables", "shortName": "Business combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "adap:ScheduleOfAssetsAcquiredAndLiabilitiesAssumedRecognizedIncludingConsiderationAtAcquisitionDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - General (Details)", "menuCat": "Details", "order": "37", "role": "http://www.adaptimmune.com/role/DisclosureGeneralDetails", "shortName": "General (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)", "menuCat": "Details", "order": "38", "role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Accounts receivable (Details)", "menuCat": "Details", "order": "39", "role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Summary of Significant Accounting Policies - Accounts receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XU5kmq24SEK5ZNKJ80WFtQ", "decimals": "INF", "lang": null, "name": "adap:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_9QTzP2mUbkqqrP6sV9RLRQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Revenue - Revenue from contracts with customers (Details)", "menuCat": "Details", "order": "40", "role": "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails", "shortName": "Revenue - Revenue from contracts with customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "INF", "lang": null, "name": "adap:NumberOfContractsWithCustomer", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_contract_JAaT4A7sDUCt1-O957WIRA", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)", "menuCat": "Details", "order": "41", "role": "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "shortName": "Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_zmhyNVFdeESz6Kwz80PA1w", "decimals": "0", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)", "menuCat": "Details", "order": "42", "role": "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "shortName": "Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cZ90Ehu40kCvm9S3Gcp4yw", "decimals": "INF", "lang": null, "name": "adap:NumberOfCoDevelopmentTarget", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_5-Fm1ODwS0eKv5badmtEbg", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details)", "menuCat": "Details", "order": "43", "role": "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails", "shortName": "Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_12_19_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_tafgYLLkA0yDQldjCOY88g", "decimals": "0", "lang": null, "name": "adap:TransactionPriceContractModification", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details)", "menuCat": "Details", "order": "44", "role": "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "shortName": "Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_6_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_pcN9wlD7L0iOIVVbfMzBsQ", "decimals": "-5", "lang": null, "name": "adap:UpfrontPaymentReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_GBP_tKHN9qt8aE2OivbjVgzCgw", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Profit / Loss per share - Basic and diluted income (loss) per share (Details)", "menuCat": "Details", "order": "45", "role": "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails", "shortName": "Profit / Loss per share - Basic and diluted income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_ijWEOZlHoEWikTRX2lMALw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_gZVjWDau80aP5qDbLfPgRQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Profit / Loss per share - Antidilutive shares (Details)", "menuCat": "Details", "order": "46", "role": "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails", "shortName": "Profit / Loss per share - Antidilutive shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_ijWEOZlHoEWikTRX2lMALw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_gZVjWDau80aP5qDbLfPgRQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_JQRsJ2bQ10ist7Gb5TAykg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accumulated other comprehensive loss (Details)", "menuCat": "Details", "order": "47", "role": "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "shortName": "Accumulated other comprehensive loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Fair value measurements (Details)", "menuCat": "Details", "order": "48", "role": "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair value measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zaW4FT-NBEenIiHxaDBa6g", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_3Rt449gWM0m8Vm__lCqC3w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Marketable securities - Available-for-sale debt securities (Details)", "menuCat": "Details", "order": "49", "role": "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails", "shortName": "Marketable securities - Available-for-sale debt securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_3Rt449gWM0m8Vm__lCqC3w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS", "menuCat": "Statements", "order": "5", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details)", "menuCat": "Details", "order": "50", "role": "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails", "shortName": "Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "adap:TaxCreditReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Other current assets (Details)", "menuCat": "Details", "order": "51", "role": "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails", "shortName": "Other current assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "adap:TaxCreditReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Operating Leases (Details)", "menuCat": "Details", "order": "52", "role": "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails", "shortName": "Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Operating Leases - Maturities (Details)", "menuCat": "Details", "order": "53", "role": "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails", "shortName": "Operating Leases - Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "adap:AccruedLiabilitiesForPurchasesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Accrued expenses and other current liabilities (Details)", "menuCat": "Details", "order": "54", "role": "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued expenses and other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "adap:AccruedLiabilitiesForPurchasesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_11_1_2015_To_11_30_2015_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_v5sy312naUu4nfXhuYeeFg", "decimals": "0", "first": true, "lang": null, "name": "adap:LicenseAgreementUpfrontLicenseAndStartUpFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details)", "menuCat": "Details", "order": "55", "role": "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails", "shortName": "Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_11_1_2015_To_11_30_2015_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_v5sy312naUu4nfXhuYeeFg", "decimals": "0", "first": true, "lang": null, "name": "adap:LicenseAgreementUpfrontLicenseAndStartUpFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_naiv4SjENkeqhOzpXy3tzA", "decimals": "0", "first": true, "lang": null, "name": "adap:UpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Contingencies and commitments - MD Anderson Strategic Alliance (Details)", "menuCat": "Details", "order": "56", "role": "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "shortName": "Contingencies and commitments - MD Anderson Strategic Alliance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_naiv4SjENkeqhOzpXy3tzA", "decimals": "0", "first": true, "lang": null, "name": "adap:UpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Share-based compensation - Share-based Compensation Expense (Details)", "menuCat": "Details", "order": "57", "role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails", "shortName": "Share-based compensation - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kfZgGeZ48Uy42q0jN1Mf2Q", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_gZVjWDau80aP5qDbLfPgRQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Share-based compensation - Options (Details)", "menuCat": "Details", "order": "58", "role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails", "shortName": "Share-based compensation - Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_gZVjWDau80aP5qDbLfPgRQ", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_qMYT8po9LU6SY6zNaM4u7Q", "decimals": "0", "first": true, "lang": null, "name": "adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Stockholders equity - Offerings (Details)", "menuCat": "Details", "order": "59", "role": "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails", "shortName": "Stockholders equity - Offerings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_qMYT8po9LU6SY6zNaM4u7Q", "decimals": "0", "first": true, "lang": null, "name": "adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Restructuring (Details)", "menuCat": "Details", "order": "60", "role": "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "shortName": "Restructuring (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_3_31_2023_U6fSLF2YsUWj2Q_ej6jSbQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Restructuring - Movements in Provision (Details)", "menuCat": "Details", "order": "61", "role": "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "shortName": "Restructuring - Movements in Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "lang": null, "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GGM49k4GlEyTLu4FJtbeKQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Restructuring - TCR post-acquisition senior leadership severance (Details)", "menuCat": "Details", "order": "62", "role": "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails", "shortName": "Restructuring - TCR post-acquisition senior leadership severance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GGM49k4GlEyTLu4FJtbeKQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:ScheduleOfChangesInLiabilityInConsolidatedBalanceSheet", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_1_2023_t95JUnc_9UGN2lWD3v-vvw", "decimals": "-3", "first": true, "lang": null, "name": "adap:RestructuringReserveAccruedPaymentsToEmployeesForServicesProvidedPriorToAcquisition", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41404 - Disclosure - Restructuring - TCR post-acquisition senior leadership severance - Change in Liability (Details)", "menuCat": "Details", "order": "63", "role": "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "shortName": "Restructuring - TCR post-acquisition senior leadership severance - Change in Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:ScheduleOfChangesInLiabilityInConsolidatedBalanceSheet", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_1_2023_t95JUnc_9UGN2lWD3v-vvw", "decimals": "-3", "first": true, "lang": null, "name": "adap:RestructuringReserveAccruedPaymentsToEmployeesForServicesProvidedPriorToAcquisition", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_0TdR4whqsEu1LHM_2apcbA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Business combinations (Details)", "menuCat": "Details", "order": "64", "role": "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "shortName": "Business combinations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_6_1_2023_srt_OwnershipAxis_adap_Tcr2TherapeuticsMember_qu1kwSsJy0i8-TGdT6cEpA", "decimals": "2", "lang": null, "name": "adap:BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_0KOn76gfc0aKxHvhgsSGUw", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Business combinations - Gain on bargain purchase (Details)", "menuCat": "Details", "order": "65", "role": "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "shortName": "Business combinations - Gain on bargain purchase (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_3_6_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_V1_h0xWjK0S_OXNosNbBpA", "decimals": "4", "lang": null, "name": "adap:RatioForIssuanceOfCompanySAmericanDepositorySharesForEachOfAcquireeSStockAcquired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_0KOn76gfc0aKxHvhgsSGUw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Business combinations - Proforma Information (Details)", "menuCat": "Details", "order": "66", "role": "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails", "shortName": "Business combinations - Proforma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_GVsBd4znikSZ_0jome3XfQ", "decimals": "0", "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:DisclosureOfAcquisitionRelatedCostsThatWereRecognizedAsExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_GVsBd4znikSZ_0jome3XfQ", "decimals": "-3", "first": true, "lang": null, "name": "adap:BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41504 - Disclosure - Business combinations - Acquisition-related costs (Details)", "menuCat": "Details", "order": "67", "role": "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "shortName": "Business combinations - Acquisition-related costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "adap:DisclosureOfAcquisitionRelatedCostsThatWereRecognizedAsExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_GVsBd4znikSZ_0jome3XfQ", "decimals": "-3", "first": true, "lang": null, "name": "adap:BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_RYB3aCwdhU6vpOxjv1lxrQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Uncategorized", "order": "68", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Cover", "order": "69", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Mp0cIIvUb0WHM_oskBM_6g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_gZVjWDau80aP5qDbLfPgRQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY", "menuCat": "Statements", "order": "7", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tdATa5-sa068n4N89mXv-w", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "8", "role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Wmu2ZF8q70mbN-1aFGfnJw", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - General", "menuCat": "Notes", "order": "9", "role": "http://www.adaptimmune.com/role/DisclosureGeneral", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "adap-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_wQ6MQgwpa06OPnJ3z1nztg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "adap_AccruedLiabilitiesForPurchasesCurrent": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities For Purchases, Current", "terseLabel": "Accrued clinical and development expenditure" } } }, "localname": "AccruedLiabilitiesForPurchasesCurrent", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "adap_AdaptimmuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Adaptimmune" } } }, "localname": "AdaptimmuneMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "adap_AgencyBondMaturityPeriodLessThanThreeMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to maturity period of agency bond.", "label": "Agency Bond Maturity Period Less Than Three Months" } } }, "localname": "AgencyBondMaturityPeriodLessThanThreeMonthsMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to maturity period of agency bond.", "label": "Agency Bond Maturity Period Three Months To One Year" } } }, "localname": "AgencyBondMaturityPeriodThreeMonthsToOneYearMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adap_AmortizationAccretionOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of Amortization / accretion of marketable securities.", "label": "Amortization / Accretion of Marketable Securities", "terseLabel": "(Accretion)/amortization on available-for-sale debt securities" } } }, "localname": "AmortizationAccretionOfMarketableSecurities", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adap_AvailableForSaleSecuritiesDebtMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertains to maturity period of corporate debt securities", "label": "Available For Sale Securities Debt Maturity Period" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturityPeriod", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "durationItemType" }, "adap_BusinessAcquisitionNumberOfOperatingLeasesRetained": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of operating leases that were acquired in a business combination for which the acquirees lease classification was retained.", "label": "Business Acquisition, Number of Operating Leases Retained", "terseLabel": "Number of operating leases that were acquired in a business combination for which the acquirees lease classification was retained" } } }, "localname": "BusinessAcquisitionNumberOfOperatingLeasesRetained", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "integerItemType" }, "adap_BusinessCombinationAcquisitionRelatedCostsBankersFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of bankers' fees incurred to effect a business combination which costs have been expensed during the period.", "label": "Business Combination, Acquisition Related Costs, Bankers' Fees", "terseLabel": "Bankers' fees" } } }, "localname": "BusinessCombinationAcquisitionRelatedCostsBankersFees", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "adap_BusinessCombinationAcquisitionRelatedCostsIncurredByAcquiree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred by the acquiree.", "label": "Business Combination, Acquisition Related Costs, Incurred By Acquiree", "terseLabel": "Acquisition-related costs incurred by TCR2" } } }, "localname": "BusinessCombinationAcquisitionRelatedCostsIncurredByAcquiree", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "monetaryItemType" }, "adap_BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of legal, professional and accounting fees incurred to effect a business combination which costs have been expensed during the period.", "label": "Business Combination, Acquisition Related Costs, Legal, Professional And Accounting Fees", "terseLabel": "Legal, professional and accounting fees" } } }, "localname": "BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "adap_BusinessCombinationAcquisitionRelatedCostsStockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance costs incurred relating to the issuance of shares to acquiree's stockholders, to effect a business combination which costs have been expensed during the period.", "label": "Business Combination, Acquisition Related Costs, Stock Issuance Costs", "terseLabel": "Issuance costs incurred relating to the issuance of shares to TCR2 stockholders" } } }, "localname": "BusinessCombinationAcquisitionRelatedCostsStockIssuanceCosts", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "adap_BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership following the completion of the business combination.", "label": "Business Combination, Percentage of Ownership Following the Completion of the Transaction", "terseLabel": "Percentage held following the transaction" } } }, "localname": "BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "percentItemType" }, "adap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses and other current liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses and Other Current Liabilities", "negatedLabel": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "adap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsInRelationToLeaseContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets in relation to lease contracts, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets In Relation To Lease Contracts", "terseLabel": "Intangible assets relation to lease contracts acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsInRelationToLeaseContracts", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "adap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "adap_ClinicalMaterialsCurrent": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical materials for use in research and development with alternative future use expected to be consumed within one year or the normal operating cycle.", "label": "Clinical Materials Current", "terseLabel": "Clinical materials" } } }, "localname": "ClinicalMaterialsCurrent", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "adap_CollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to collaboration and license agreement.", "label": "Collaboration and license agreement" } } }, "localname": "CollaborationAndLicenseAgreementMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to maturity period of less than three months.", "label": "Corporate Debt Securities Maturity Period Less Than Three Months" } } }, "localname": "CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to maturity period of corporate debt securities", "label": "Corporate Debt Securities Maturity Period Three Months To One Year" } } }, "localname": "CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adap_DecreaseInContractWithCustomerLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenue decrease" } } }, "localname": "DecreaseInContractWithCustomerLiability", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "adap_DevelopmentRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to development revenue.", "label": "Development revenue" } } }, "localname": "DevelopmentRevenueMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "adap_DisclosureOfAcquisitionRelatedCostsThatWereRecognizedAsExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of acquisition-related costs that were recognized as an expense, pursuant to business combination transaction.", "label": "Disclosure Of Acquisition-Related Costs That Were Recognized As An Expense [Table Text Block]", "terseLabel": "Schedule of acquisition-related costs that were recognized as an expense" } } }, "localname": "DisclosureOfAcquisitionRelatedCostsThatWereRecognizedAsExpenseTableTextBlock", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "adap_DisclosureOfCalculationForGainOnBargainPurchaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for calculation of the gain on bargain purchase.", "label": "Disclosure Of Calculation For The Gain On Bargain Purchase [Table Text Block]", "terseLabel": "Schedule of calculation for the gain on bargain purchase" } } }, "localname": "DisclosureOfCalculationForGainOnBargainPurchaseTableTextBlock", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "adap_EmployeeConsultantsAndDirectorsStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Share options" } } }, "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "adap_GSKCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement with Glaxo Smith Kline.", "label": "GSK Collaboration And License Agreement" } } }, "localname": "GSKCollaborationAndLicenseAgreementMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_GskTerminationAndTransferAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to GSK Termination and Transfer Agreement.", "label": "GSK Termination and Transfer Agreement" } } }, "localname": "GskTerminationAndTransferAgreementMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_IgnyteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to IGNYTE.", "label": "IGNYTE" } } }, "localname": "IgnyteMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_ImpairmentLossOnRestructuring": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restructuring loss on restructuring.", "label": "Impairment Loss on Restructuring", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentLossOnRestructuring", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails" ], "xbrltype": "monetaryItemType" }, "adap_IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable, due to change in exchange rate.", "label": "Increase (Decrease) in Contract with Customer, Change in the Exchange Rate, Liability", "terseLabel": "Amount of increase in deferred income caused by the change in the exchange rate" } } }, "localname": "IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "adap_IncreaseDecreaseInCurrentAssets": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in accounts receivable and other operating assets due within one year (or one business cycle).", "label": "Increase (Decrease) in Current Assets", "negatedLabel": "Decrease/(increase) in receivables and other operating assets" } } }, "localname": "IncreaseDecreaseInCurrentAssets", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "adap_LicenseAgreementMilestonePaymentOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment.", "label": "License Agreement, Milestone Payment One", "terseLabel": "First milestone payment" } } }, "localname": "LicenseAgreementMilestonePaymentOne", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_LicenseAgreementMilestonePaymentThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment three.", "label": "License Agreement, Milestone Payment Three", "terseLabel": "Third milestone payment" } } }, "localname": "LicenseAgreementMilestonePaymentThree", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_LicenseAgreementMilestonePaymentTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment two.", "label": "License Agreement, Milestone Payment Two", "terseLabel": "Second milestone payment" } } }, "localname": "LicenseAgreementMilestonePaymentTwo", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_LicenseAgreementMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payments made by the entity under the license agreement.", "label": "License Agreement Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "LicenseAgreementMilestonePayments", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_LicenseAgreementUpfrontLicenseAndStartUpFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of upfront and start-up fees paid.", "label": "License Agreement Upfront License And Start-Up Fees", "terseLabel": "Upfront license and start-up fees" } } }, "localname": "LicenseAgreementUpfrontLicenseAndStartUpFees", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_LtfuMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to LTFU.", "label": "LTFU" } } }, "localname": "LtfuMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_MDAndersonStrategicAllianceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the MD Anderson strategic alliance.", "label": "MD Anderson Strategic Alliance" } } }, "localname": "MDAndersonStrategicAllianceMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails" ], "xbrltype": "domainItemType" }, "adap_MaterialRightForFirstOptionExtendResearchTermMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to material right for first option extend the research term.", "label": "Material Right for First Option Extend the Research Term" } } }, "localname": "MaterialRightForFirstOptionExtendResearchTermMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_MaterialRightForSecondOptionExtendResearchTermMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to material right for second option extend the research term.", "label": "Material Right for Second Option Extend the Research Term" } } }, "localname": "MaterialRightForSecondOptionExtendResearchTermMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to material right to designate first additional off the shelf collaboration target.", "label": "Material Right to Designate the Additional Off the Shelf Collaboration Target" } } }, "localname": "MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_MilestoneAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of payments that the entity is required to make under the agreement, upon achievement of certain development and product milestones.", "label": "Milestone Amount Payable", "terseLabel": "Potential milestone payments" } } }, "localname": "MilestoneAmountPayable", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails" ], "xbrltype": "monetaryItemType" }, "adap_MilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of payments that the entity is required to make under the agreement, upon achievement of certain development and product milestones.", "label": "Milestone Payments" } } }, "localname": "MilestonePayments", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails" ], "xbrltype": "monetaryItemType" }, "adap_NumberOfCoDevelopmentTarget": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of targets for co-development by the entity and counterparty under the agreement.", "label": "Number Of Co Development Target", "terseLabel": "Number of co-development targets" } } }, "localname": "NumberOfCoDevelopmentTarget", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "adap_NumberOfContractsWithCustomer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the total number of contracts with customers.", "label": "Number of Contracts with Customer", "terseLabel": "Number of contracts with customers" } } }, "localname": "NumberOfContractsWithCustomer", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "integerItemType" }, "adap_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of customers.", "label": "Number of customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails", "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "integerItemType" }, "adap_NumberOfIndependentTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of targets independent to counterparty.", "label": "Number Of Independent Targets", "terseLabel": "Number of independent targets" } } }, "localname": "NumberOfIndependentTargets", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails" ], "xbrltype": "integerItemType" }, "adap_NumberOfRemainingMilestonesAccrued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of remaining milestones accrued.", "label": "Number of Remaining Milestones Accrued", "terseLabel": "Number of remaining milestones accrued" } } }, "localname": "NumberOfRemainingMilestonesAccrued", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "integerItemType" }, "adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of operating lease right-of-use assets.", "label": "Operating Lease, Right of Use Asset Accumulated Amortization", "terseLabel": "Operating lease right-of-use assets, accumulated amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "adap_PaymentsToEmployeesForServicesProvidedPriorToAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made to employees for services provided prior to the acquisition.", "label": "Payments to Employees for Services Provided Prior to the Acquisition", "negatedLabel": "Costs paid during period" } } }, "localname": "PaymentsToEmployeesForServicesProvidedPriorToAcquisition", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "adap_PotentialPaymentForAchievementOfSpecifiedMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the potential payment that may be received upon achievement of specified milestones per agreement.", "label": "Potential Payment For Achievement Of Specified Milestones", "terseLabel": "Potential milestone payments to be received" } } }, "localname": "PotentialPaymentForAchievementOfSpecifiedMilestones", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prepaid expense and other assets current, including accounts receivable.", "label": "Prepaid Expense And Other Assets Current Including Accounts Receivable", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "adap_RatioForIssuanceOfCompanySAmericanDepositorySharesForEachOfAcquireeSStockAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio for issuance of Company's ADSs for each stock of the acquiree, acquired by the company under a business combination transaction.", "label": "Ratio For Issuance Of Company's American Depository Shares For Each Of Acquiree's Stock Acquired", "terseLabel": "Ratio for issuance of Company's ADSs for each TCR2 stock acquired" } } }, "localname": "RatioForIssuanceOfCompanySAmericanDepositorySharesForEachOfAcquireeSStockAcquired", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails" ], "xbrltype": "pureItemType" }, "adap_ReplacementAwardsGrantedToTcr2GrantholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to replacement awards granted to TCR2 grantholders.", "label": "Replacement Awards Granted To TCR2 Grantholders [Member]", "terseLabel": "Replacement Awards Granted To TCR2 Grantholders" } } }, "localname": "ReplacementAwardsGrantedToTcr2GrantholdersMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails", "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails" ], "xbrltype": "domainItemType" }, "adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to research services and rights granted for initial off the shelf collaboration targets.", "label": "Research Service Rights Granted for Initial Off the Shelf Collaboration Targets" } } }, "localname": "ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to research services and rights granted for personalized therapies.", "label": "Research Service Rights Granted for Personalized Therapies" } } }, "localname": "ResearchServiceRightsGrantedForPersonalizedTherapiesMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_RestructureHeadcountReductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of headcount reduction during restructure.", "label": "Restructure Headcount Reduction, Percentage", "terseLabel": "Percent of headcount reduction" } } }, "localname": "RestructureHeadcountReductionPercentage", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails" ], "xbrltype": "percentItemType" }, "adap_RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of expected costs to be incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs Expect to be Incurred [Table Text Block]", "terseLabel": "Schedule of amounts incurred in relation to the redundancy programme" } } }, "localname": "RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTables" ], "xbrltype": "textBlockItemType" }, "adap_RestructuringReserveAccruedPaymentsToEmployeesForServicesProvidedPriorToAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Refers to accrued payments to these employees for services provided prior to the acquisition.", "label": "Restructuring Reserve, Accrued Payments to Employees for Services Provided Prior to the Acquisition", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance beginning of period" } } }, "localname": "RestructuringReserveAccruedPaymentsToEmployeesForServicesProvidedPriorToAcquisition", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "adap_RevenuePerformanceObligationTerminationPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment due to termination of collaboration.", "label": "Revenue, Performance Obligation, Termination Payment", "terseLabel": "Payment by GSK due to termination of collaboration" } } }, "localname": "RevenuePerformanceObligationTerminationPayment", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_SalesAgreement2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "2022 Sales Agreement" } } }, "localname": "SalesAgreement2022Member", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "adap_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Sales Agreement" } } }, "localname": "SalesAgreementMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "adap_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedRecognizedIncludingConsiderationAtAcquisitionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of consideration transferred and the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of the Assets Acquired and Liabilities Assumed Recognized, Including Consideration at the Acquisition Date", "terseLabel": "Summary of the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date" } } }, "localname": "ScheduleOfAssetsAcquiredAndLiabilitiesAssumedRecognizedIncludingConsiderationAtAcquisitionDate", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "adap_ScheduleOfChangesInLiabilityInConsolidatedBalanceSheet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the liability in the Consolidated Balance Sheet.", "label": "Schedule of the Changes in the Liability in the Consolidated Balance Sheet", "terseLabel": "Summary of changes in the liability in the Consolidated Balance Sheet" } } }, "localname": "ScheduleOfChangesInLiabilityInConsolidatedBalanceSheet", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTables" ], "xbrltype": "textBlockItemType" }, "adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, With Nominal Exercise Price", "terseLabel": "Weighted average fair value of options with a nominal exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted with nominal exercise price during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, With Nominal Exercise Price Grants in Period, Gross", "terseLabel": "Number of additional options with a nominal exercise price granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "adap_StockIssuedDuringPeriodValueSalesAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price of ADS shares that may be issued and sold under the At The Market sales agreement.", "label": "Stock Issued During Period, Value, Sales agreement", "terseLabel": "Aggregate offering price of ADS shares under At The Market sales agreement" } } }, "localname": "StockIssuedDuringPeriodValueSalesAgreement", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the remaining amount available under the sales agreement.", "label": "Stock Issued Sales Agreement Remaining Amount Available for Sale", "terseLabel": "Remaining amount under the Sales Agreement" } } }, "localname": "StockIssuedSalesAgreementRemainingAmountAvailableForSale", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "adap_StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of American Depositary Shares representing shares sold during the period.", "label": "Stock Sold During Period Represented By American Depositary Shares New Issues", "terseLabel": "Sold shares represented by American Depositary Shares (in shares)" } } }, "localname": "StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "sharesItemType" }, "adap_StrategicCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Strategic Collaboration and License Agreement.", "label": "Strategic Collaboration and License Agreement" } } }, "localname": "StrategicCollaborationAndLicenseAgreementMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_TaxCreditReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts tax credits receivable that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Tax Credit Receivable, Current", "terseLabel": "Research and development credits receivable" } } }, "localname": "TaxCreditReceivableCurrent", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "adap_Tcr2TherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "TCR2 Therapeutics" } } }, "localname": "Tcr2TherapeuticsMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "domainItemType" }, "adap_TransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the transaction price of the agreement at inception.", "label": "Transaction Price", "terseLabel": "Amount of transaction price of the agreement at inception" } } }, "localname": "TransactionPrice", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_TransactionPriceContractModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount aggregate transaction price of the contract modification.", "label": "Transaction Price, Contract Modification", "terseLabel": "Aggregate transaction price of the contract modification" } } }, "localname": "TransactionPriceContractModification", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "adap_TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to maturity period of treasury bills.", "label": "U.S. Treasury Securities Maturity Period Three Months To One Year" } } }, "localname": "TreasuryBillsMaturityPeriodThreeMonthsToOneYearMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adap_U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertains to maturity period of treasury bills.", "label": "U.S. Treasury Securities Maturity Period Less Than Three Months" } } }, "localname": "U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "adap_UniversalCellsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pertaining to Universal Cells, Inc., a wholly owned subsidiary of Astellas.", "label": "Universal Cells, Inc." } } }, "localname": "UniversalCellsIncMember", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "domainItemType" }, "adap_UpfrontAndMilestonePaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of upfront and milestone payment receivable under the agreement.", "label": "Upfront and Milestone Payment Receivable", "terseLabel": "Upfront and milestone payment receivable" } } }, "localname": "UpfrontAndMilestonePaymentReceivable", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "adap_UpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of up-front payment under terms of the agreement.", "label": "Upfront payment", "terseLabel": "Upfront payment" } } }, "localname": "UpfrontPayment", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails" ], "xbrltype": "monetaryItemType" }, "adap_UpfrontPaymentByGskForTerminationAndTransferAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of upfront payment by GSK for Termination and Transfer Agreement.", "label": "Upfront Payment by GSK for Termination and Transfer Agreement", "terseLabel": "Upfront payment by GSK for Termination and Transfer Agreement" } } }, "localname": "UpfrontPaymentByGskForTerminationAndTransferAgreement", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "adap_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of up-front payment received under terms of the agreement.", "label": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "adap_WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average remaining lease term and the weighted-average discount rate.", "label": "Weighted-Average Remaining Lease Term And Weighted-Average Discount rate [Table Text Block]", "terseLabel": "Schedule of weighted-average remaining lease term and the weighted-average discount rate" } } }, "localname": "WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "nsuri": "http://www.adaptimmune.com/20230630", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r666", "r677", "r687", "r712" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r669", "r680", "r690", "r715" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r673", "r681", "r691", "r708", "r716", "r720", "r728" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r666", "r677", "r687", "r712" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r663", "r674", "r684", "r709" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r670", "r681", "r691", "r716" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r670", "r681", "r691", "r716" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r670", "r681", "r691", "r716" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r670", "r681", "r691", "r716" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r670", "r681", "r691", "r716" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r673", "r681", "r691", "r708", "r716", "r720", "r728" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r662", "r732" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r662", "r732" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r662", "r732" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r670", "r681", "r691", "r708", "r716" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r668", "r679", "r689", "r714" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r671", "r682", "r692", "r717" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r671", "r682", "r692", "r717" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r663", "r674", "r684", "r709" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r664", "r675", "r685", "r710" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r665", "r676", "r686", "r711" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r672", "r683", "r693", "r718" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r667", "r678", "r688", "r713" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r707" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r173", "r174", "r311", "r317", "r450", "r612", "r614" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r353", "r483", "r514", "r540", "r541", "r594", "r595", "r596", "r597", "r598", "r607", "r608", "r618", "r626", "r639", "r646", "r781", "r793", "r794", "r795", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r353", "r483", "r514", "r540", "r541", "r594", "r595", "r596", "r597", "r598", "r607", "r608", "r618", "r626", "r639", "r646", "r781", "r793", "r794", "r795", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r222", "r485", "r508", "r509", "r510", "r511", "r512", "r513", "r609", "r627", "r645", "r739", "r777", "r778", "r782", "r803" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r222", "r485", "r508", "r509", "r510", "r511", "r512", "r513", "r609", "r627", "r645", "r739", "r777", "r778", "r782", "r803" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r298", "r299", "r300", "r301", "r346", "r353", "r379", "r380", "r381", "r459", "r483", "r514", "r540", "r541", "r594", "r595", "r596", "r597", "r598", "r607", "r608", "r618", "r626", "r639", "r646", "r649", "r772", "r781", "r794", "r795", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r346", "r353", "r379", "r380", "r381", "r459", "r483", "r514", "r540", "r541", "r594", "r595", "r596", "r597", "r598", "r607", "r608", "r618", "r626", "r639", "r646", "r649", "r772", "r781", "r794", "r795", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r173", "r174", "r311", "r317", "r450", "r613", "r614" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accrued Expenses and Other Current Liabilities Disclosure [Text Block]", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r21", "r644" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net [Abstract]", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r225", "r226" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net of allowance for expected credit losses of $0 and $0", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r44", "r140", "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment, accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r151", "r152", "r153", "r155", "r162", "r163", "r750" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated unrealized gains (losses) on available-for-sale debt securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r161", "r162", "r431", "r432", "r433", "r434", "r435", "r437" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r28", "r89", "r146", "r495", "r519", "r520" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance end of period", "periodStartLabel": "Balance beginning of period", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r161", "r162", "r431", "r432", "r433", "r434", "r435", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r4", "r15", "r28", "r409", "r412", "r449", "r515", "r516", "r750", "r751", "r752", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r6", "r15", "r28", "r162", "r163", "r432", "r433", "r434", "r435", "r437", "r750" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated foreign currency translation adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r83", "r644", "r806" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid-in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r387", "r388", "r389", "r528", "r759", "r760", "r761", "r784", "r808" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r11", "r42" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r59", "r60", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r383", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "netLabel": "Share-based compensation expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails", "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r147", "r227", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowance for expected credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r111", "r142", "r172", "r210", "r216", "r220", "r262", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r402", "r406", "r428", "r493", "r561", "r644", "r657", "r779", "r780", "r791" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r137", "r150", "r172", "r262", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r402", "r406", "r428", "r644", "r779", "r780", "r791" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r235" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r236" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r232", "r271", "r492" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r233", "r271", "r486", "r764" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Debt Securities", "terseLabel": "Aggregate estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r229", "r271" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available-for-sale Securities, Debt Securities, Current", "netLabel": "Available-for-sale securities, Debt Securities, Current, Total", "terseLabel": "Marketable securities - available-for-sale debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r398", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r63", "r66", "r398", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Shares issued" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Merger with TCR2 Therapeutics Inc." } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of ownership" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of amount of revenue and earnings of the combined entity" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Market price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r396", "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r396", "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related costs", "verboseLabel": "Total acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business combinations" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount": { "auth_ref": [ "r69", "r70", "r71", "r72", "r73", "r74" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.", "label": "Business Combination, Bargain Purchase, Gain Recognized, Amount", "negatedLabel": "Gain on bargain purchase", "terseLabel": "Gain on bargain purchase" } } }, "localname": "BusinessCombinationBargainPurchaseGainRecognizedAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r1", "r2", "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "negatedLabel": "Purchase consideration", "terseLabel": "Purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "terseLabel": "Consideration transferred:" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r1", "r2" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "verboseLabel": "Fair value of shares issued" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r107", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "terseLabel": "Amount of TCR2's earnings included in the Company's Consolidated Statement of Operations" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "terseLabel": "Marketable securities - available-for-sale debt securities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Other current assets and prepaid expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r67", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Net assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Identifiable assets acquired and liabilities assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r67", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r30" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Acquired upon acquisition of TCR2 Therapeutics Inc." } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r31", "r139", "r610" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r31", "r97", "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at start of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r3", "r97" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted CashEquivalentsPeriod Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r747", "r802" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Total Cash Equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r133", "r143", "r144", "r145", "r172", "r192", "r193", "r200", "r202", "r208", "r209", "r262", "r302", "r304", "r305", "r306", "r309", "r310", "r315", "r316", "r319", "r322", "r329", "r428", "r522", "r523", "r524", "r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r549", "r571", "r589", "r599", "r600", "r601", "r602", "r603", "r734", "r757", "r762" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r143", "r144", "r145", "r208", "r315", "r316", "r317", "r319", "r322", "r327", "r329", "r522", "r523", "r524", "r525", "r626", "r734", "r757" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Shareholders' equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Astellas Collaboration Agreement." } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Contingencies and commitments" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingencies and commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r102", "r296", "r297", "r606", "r776" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies and commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r759", "r760", "r784", "r805", "r808" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r82", "r549" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r82", "r549", "r567", "r808", "r809" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding (in shares)", "periodEndLabel": "Balance at the end of the period, shares", "periodStartLabel": "Balance at the beginning of the period, shares", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r82", "r494", "r644" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock - Ordinary shares par value euro 0.001, 1,702,760,280 authorized and 1,351,828,044 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r29", "r158", "r160", "r165", "r488", "r505" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss for the period" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r88", "r164", "r487", "r503" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r33", "r35", "r77", "r78", "r224", "r605", "r736" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r79", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Significant concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r33", "r35", "r77", "r78", "r224", "r605" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractTerminationMember": { "auth_ref": [ "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Contractual termination benefits" } } }, "localname": "ContractTerminationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r331", "r332", "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r331", "r332", "r343" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r331", "r332", "r343" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, non-current" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized in the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r634", "r636", "r804" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r93" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "negatedTotalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r34", "r224" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r120", "r276", "r619" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Fair market value of investments in an unrealized loss position, 12 months or longer" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r120", "r276" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "Unrealized losses, 12 months or longer" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r771" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year", "terseLabel": "Number of available-for-sale securities in an unrealized loss position, 12 months or longer" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r120", "r276", "r619" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Fair market value of investments in an unrealized loss position, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r120", "r276" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Unrealized losses, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r771" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of available-for-sale securities in an unrealized loss position, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r117", "r273", "r619" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Fair market value of investments in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r118", "r274" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Unrealized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r119", "r275" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "totalLabel": "Number of investments in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r39", "r649", "r810" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r11", "r43" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r342", "r627", "r628", "r629", "r630", "r631", "r632", "r633" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenue" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r342", "r627", "r628", "r629", "r630", "r631", "r632", "r633" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r782" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of revenue categories" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r354", "r356", "r384", "r385", "r386", "r640" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Share-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit / Loss per share", "terseLabel": "Net loss per ordinary share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r166", "r180", "r181", "r182", "r183", "r184", "r189", "r192", "r200", "r201", "r202", "r206", "r417", "r418", "r489", "r506", "r615" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator for basic and diluted profit/(loss) per share", "verboseLabel": "Antidilutive securities" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails", "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r166", "r180", "r181", "r182", "r183", "r184", "r192", "r200", "r201", "r202", "r206", "r417", "r418", "r489", "r506", "r615" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Reconciliation [Abstract]", "terseLabel": "Numerator for basic and diluted profit/(loss) per share" } } }, "localname": "EarningsPerShareReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r188", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Profit / Loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r430" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of currency exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]", "terseLabel": "Total share-based compensation expense included in the consolidated statements of operations" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r16", "r135", "r161", "r162", "r163", "r175", "r176", "r177", "r179", "r185", "r187", "r207", "r263", "r264", "r330", "r387", "r388", "r389", "r393", "r394", "r408", "r409", "r410", "r411", "r412", "r413", "r416", "r431", "r432", "r433", "r434", "r435", "r437", "r449", "r515", "r516", "r517", "r528", "r589" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r420", "r421", "r424" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Assets and liabilities measured at fair value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r420", "r421", "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r312", "r347", "r348", "r349", "r350", "r351", "r352", "r421", "r456", "r457", "r458", "r624", "r625", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r420", "r421", "r422", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r312", "r347", "r352", "r421", "r456", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r312", "r347", "r352", "r421", "r457", "r624", "r625", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r312", "r347", "r348", "r349", "r350", "r351", "r352", "r456", "r457", "r458", "r624", "r625", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r419", "r425" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r266", "r267", "r268", "r269", "r270", "r272", "r277", "r278", "r313", "r327", "r414", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r504", "r619", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r766", "r767", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r141", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "verboseLabel": "Intangibles, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign Currency Exchange Rate, Translation", "terseLabel": "Exchange rate" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r99", "r569", "r655", "r786", "r787", "r807" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Unrealized foreign exchange losses/(gains)" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r94", "r573" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r90", "r113", "r210", "r215", "r219", "r221", "r490", "r500", "r617" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Loss before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r282", "r287", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails", "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r287", "r574" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails", "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r130", "r186", "r187", "r213", "r392", "r395", "r507" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r755" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "(Decrease)/increase in payables and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r484", "r755" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Decrease in deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r40", "r41" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net of accumulated amortization of $5,003 and $4,676" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income, amortization of premium and accretion of discount on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale); classified as operating.", "label": "Interest Income, Debt Securities, Available-for-sale, Operating", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeDebtSecuritiesAvailableForSaleOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r110", "r115", "r116", "r134", "r228", "r230", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable securities - available-for-sale debt securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r443", "r643" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r790" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of maturities of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "after 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r448" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Operating leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r22", "r172", "r262", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r403", "r406", "r407", "r428", "r548", "r616", "r657", "r779", "r791", "r792" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r87", "r112", "r497", "r644", "r758", "r770", "r785" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r24", "r138", "r172", "r262", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r403", "r406", "r407", "r428", "r644", "r779", "r791", "r792" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable securities - available-for-sale debt securities", "terseLabel": "Marketable securities:" } } }, "localname": "MarketableSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r123", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "General" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureGeneral" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r169" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r169" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r98", "r99" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r91", "r99", "r114", "r136", "r156", "r159", "r163", "r172", "r178", "r180", "r181", "r182", "r183", "r186", "r187", "r198", "r210", "r215", "r219", "r221", "r262", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r418", "r428", "r502", "r570", "r587", "r588", "r617", "r655", "r779" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss attributable to ordinary shareholders", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r167", "r180", "r181", "r182", "r183", "r189", "r190", "r199", "r202", "r210", "r215", "r219", "r221", "r617" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Net profit/(loss) attributable to ordinary shareholders used for basic profit/(loss) per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r167", "r191", "r194", "r195", "r196", "r197", "r199", "r202" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net profit/(loss) attributable to ordinary shareholders used for diluted profit/(loss) per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time employee termination benefits" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r210", "r215", "r219", "r221", "r617" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r444", "r643" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Maturities of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r442" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r442" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Operating lease liabilities, current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r442" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "negatedLabel": "Operating lease liabilities, non-current", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r441" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets, net of accumulated amortization of $11,258 and $9,470", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r447", "r643" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r446", "r643" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other accrued expenditure" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r149", "r644" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r9", "r14", "r109" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments, net of tax of $0, and $0", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "auth_ref": [ "r9", "r14", "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments, tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r5" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0", "verboseLabel": "Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r5", "r7", "r429", "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "terseLabel": "Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax", "verboseLabel": "Foreign currency gain on intercompany loan of a long-term investment nature, tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss." } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r9", "r14", "r109", "r157", "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss (gain)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss)/income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosures [Abstract]", "terseLabel": "Accumulated other comprehensive loss (paranthetical)" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r151", "r154", "r261" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0", "verboseLabel": "Unrealized holding gain (losses) on available-for-sale debt securities, net of tax of $0" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r7", "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax", "terseLabel": "Unrealized holding gains (losses) on available-for-sale debt securities, tax", "verboseLabel": "Unrealized holding gains on available-for-sale debt securities, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r23", "r644" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities, non-current" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r735", "r753" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r286", "r754" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Costs paid during the period" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquisition of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r765" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Investment in marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r96" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r749" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Other current assets and prepaid expenses" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r148", "r279", "r280", "r611" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepayments" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r8" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of common stock from offerings, net of commissions and issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r8", "r522" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "verboseLabel": "Maturity or redemption of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r8", "r20" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r136", "r156", "r159", "r168", "r172", "r178", "r186", "r187", "r210", "r215", "r219", "r221", "r262", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r401", "r404", "r405", "r418", "r428", "r490", "r501", "r527", "r570", "r587", "r588", "r617", "r641", "r642", "r656", "r752", "r779" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r491", "r499", "r644" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net.", "terseLabel": "Property, plant and equipment, net of accumulated depreciation of $40,635 and $38,588" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r80", "r391", "r799" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails", "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r747", "r756", "r800", "r802" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r31", "r122", "r170" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "RSU" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r283", "r284", "r286", "r289", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r285", "r288", "r292", "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r285", "r288", "r292", "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Total amount expected to be incurred" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r11", "r290", "r292", "r773" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Costs incurred and charged to General and administrative expenses", "verboseLabel": "Costs incurred and charged" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r285", "r286", "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [ "r285", "r286", "r287", "r288", "r292", "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Total and cumulative amount incurred" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r286", "r291" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Restructuring provision" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r286", "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments to the liability" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r774", "r775" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "terseLabel": "Effect of foreign exchange rates" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r84", "r106", "r496", "r518", "r520", "r526", "r550", "r644" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureGeneralDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r135", "r175", "r176", "r177", "r179", "r185", "r187", "r263", "r264", "r387", "r388", "r389", "r393", "r394", "r408", "r410", "r411", "r413", "r416", "r515", "r517", "r528", "r808" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r211", "r212", "r214", "r217", "r218", "r222", "r223", "r224", "r341", "r342", "r485" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r132", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation", "terseLabel": "Amount of remaining deferred income under the collaboration that had not been recognized as revenue", "verboseLabel": "Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r28", "r788", "r789" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of changes in Accumulated other comprehensive (loss) income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Marketable securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of marketable securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r63", "r66", "r398" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails", "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails", "http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r763" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of numerator and denominator in the basic and diluted loss per share computation" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "verboseLabel": "Summary of share-based compensation expense included in the consolidated statements of operations" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Summary of other current assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r285", "r286", "r287", "r288", "r292", "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceChangeInLiabilityDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r45", "r47", "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "verboseLabel": "Schedule of amounts incurred in relation to redundancies" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r46", "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of changes in the restructuring provision" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r18", "r19", "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of all stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r50", "r51", "r52", "r53", "r54", "r55", "r56", "r104", "r105", "r106", "r143", "r144", "r145", "r208", "r315", "r316", "r317", "r319", "r322", "r327", "r329", "r522", "r523", "r524", "r525", "r626", "r734", "r757" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "General and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and other cash payments" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r10" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation.", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-Based Payment Arrangement, Accelerated Cost", "terseLabel": "Accelerated vesting of share-based compensation awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options over ordinary shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of ordinary shares options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "All Award Types", "terseLabel": "All Award Types" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Closing price of Company's ADS" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Ordinary share price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r445", "r643" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r133", "r143", "r144", "r145", "r172", "r192", "r193", "r200", "r202", "r208", "r209", "r262", "r302", "r304", "r305", "r306", "r309", "r310", "r315", "r316", "r319", "r322", "r329", "r428", "r522", "r523", "r524", "r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r549", "r571", "r589", "r599", "r600", "r601", "r602", "r603", "r734", "r757", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r16", "r26", "r135", "r161", "r162", "r163", "r175", "r176", "r177", "r179", "r185", "r187", "r207", "r263", "r264", "r330", "r387", "r388", "r389", "r393", "r394", "r408", "r409", "r410", "r411", "r412", "r413", "r416", "r431", "r432", "r433", "r434", "r435", "r437", "r449", "r515", "r516", "r517", "r528", "r589" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r175", "r176", "r177", "r207", "r485", "r521", "r539", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r563", "r564", "r565", "r566", "r568", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r589", "r650" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails", "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITYY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r175", "r176", "r177", "r207", "r485", "r521", "r539", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r563", "r564", "r565", "r566", "r568", "r572", "r573", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r589", "r650" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails", "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r81", "r82", "r106" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of shares upon acquisition of TCR (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r81", "r82", "r106", "r522", "r589", "r600" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of shares upon completion of public offering, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r81", "r82", "r106", "r365" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "netLabel": "Issuance of shares upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r16", "r26", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of shares upon acquisition of TCR" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r81", "r82", "r106", "r528", "r589", "r600", "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of shares upon completion of public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r16", "r26", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Issuance of shares upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r82", "r85", "r86", "r101", "r551", "r567", "r590", "r591", "r644", "r657", "r758", "r770", "r785", "r808" ], "calculation": { "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r103", "r171", "r314", "r316", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r330", "r415", "r592", "r593", "r604" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r313", "r327", "r414", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r504", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r766", "r767", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskAndTransferAgreementDetails", "http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r285", "r286", "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureRestructuringDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails", "http://www.adaptimmune.com/role/DisclosureRestructuringTcrPostAcquisitionSeniorLeadershipSeveranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r783", "r801" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "Agency bonds" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r801" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "U.S. Treasury securities" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails", "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r36", "r37", "r38", "r124", "r125", "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates in interim financial statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValueAddedTaxReceivableCurrent": { "auth_ref": [ "r748" ], "calculation": { "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Value Added Tax Receivable, Current", "terseLabel": "VAT receivable" } } }, "localname": "ValueAddedTaxReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r191", "r202" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "netLabel": "Denominator for diluted profit/(loss) per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r189", "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "verboseLabel": "Denominator for basic profit/(loss) per share - Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails", "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org//420/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r659": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r661": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r662": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r663": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r664": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r665": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r666": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r667": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r668": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r669": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r671": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r672": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r673": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r674": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r675": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r676": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r677": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r678": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r679": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r681": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r682": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r683": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r684": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r685": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r686": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r687": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r688": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r689": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r691": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r692": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r693": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r694": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r695": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r696": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r697": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r698": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r699": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r701": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r702": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r703": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r704": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r705": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r706": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r707": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r708": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r709": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r711": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r712": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r713": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r714": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r715": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r716": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r717": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r718": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r719": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r721": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r722": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r723": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r724": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r725": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r726": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r727": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r728": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r729": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r731": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r732": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r733": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(f)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org//220/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 88 0001558370-23-014250-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-014250-xbrl.zip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

,N_:\AXK;H%-M .I+L&LFNKVXH2 M\'?@^AZSKC_2B8A'J3W0TQ2=0-RIT!^A7=4"];^ # M1J\!VZI7M<9L)*4I6F/VG*P3)X!.ULU@IAG,-(.99C#3#&8:+?/%%ZL2PG1G MIOG2/,_+8*89S#2#F<:"L]Q@IOG%S#1+?N@(."MJP0!LY5"> ;+4L'(Q<_%4 M&D8F+KHK!I,,D#VR29\HND:X0*HL/$5:? MM)>6@[)&3:(R// _';CCR_SLF M$4.@99I45+8@6JS-.5 $T6Z)\HNV89)L):.Z@E E]2T(&&M3KA*475N<;^8+ M-\#)XQ:$C*%JOM2IT*=43EJT+I? LL6F_.SA!X;(^U<<$-[R$X"4M%O@LK0[ MLV#Q!%A"(NA5?._NR\%QF:GY^>+16=#.]]Q5[P[AW3MAUC_]9DG 8(0>C-"# M$7HP0@]&:"WC[+>3T\.C7\ (O<1IR1-8R[5*:>B4EMXV [04B(U/.6[/2ZJE MN6QJ+5##^ZB]+U+#^ZAZ[X;:MEAU]3ZJ'8O5X_ ^JF#S;OG[J$\@I,U-2]X# M53M8*[9A@;.GLB K0C0]#@?WZZ_D?LVVR1R&S ^Q4 M/O(\$%)44;$F0RB3:"==;;&_MQN&V*-;&WS1GL?M>).C'3]^ F<+/1T7,Z:' M-[1K]R4(*>U571]?6G=][#D)42PJ/R-K<(@8=8ALO9VI&T?(8&<:[$P6R:AH M?SD].3TX_07L3$N67AN$^T1. !PF_KT@/) SMQ/:/<24<4=]=)-Q8,[5K1 M>ITPPU9[Q'"WH/LPV#9'ZG8,QS93,W0XYKJS-IW'A (BY +-7Y:W_2J^@?EU M,UEFVJCCY5K=)KM/"B G)7+^D?ND9_S1;:;?>55 E<+Z(RUMH>6GFMCR\ZT4 MI=$54$05^Q,#H#0M:-2SPP14HHIE$EK#M)NR*II(SJQ*TM"F_(0X.]CD/'OX MZ'E&S\4+$$>!)PX^49:TP(:CK6W9[D0&IO?7=<9O,'$42=[96OO=PD#6ZLN, M )Q)+(I=/)4++#-\A:^[EC_8*/ :7 M4I4K9+T2P-A6 106@*,#N@"<&%_$6A**$)IY*WC LN]R,G]0WI+'IQ]EGFA5 M'0O.+W+MV[""RW'8=M[?, V7'_5O+?!3ZB 1^R=UEZ7M"WH7($N>M+JA-&.J MEB1YH6Z,^+Z4 T2H-]WCR M#Q0%<)JA6QII*FB&5F,6>#I;T 0MJ%W[0 4.L3Q=V;GH&H4A>N/NP?DB!*S< M>,+3%[F>S"?:7ML6^$AU!=XR8;+*EC09:V%L9Q'I$]XLHO M()PXJH#\.YF%0%[>@J1KE3=M -+NT\-U=4Y18D ZNZ6S= M"Y_LF2P$'*!TDL!GU_@8[6Q)F@#VW-'HA7#Z2V;\2BWUJ3"G[:X#E7!NI<"% M!Q:J^^F)I;DBE/=@@0FGP1"IJ3?E;-E*?9)=J:_6A$7&@/XTPJJ[^6VNFO<@ MJKZNM--;GXITUMG:TPXO=E.YED7ZTZ_U#NUIUSLD= MG2/96\LP2DK>N?@GB%C-)^#%F)?K8\HLI\$BS]06SJ#E_/T%E/L!@X4;^,M+ MZ[3\.)H!G/S6MY*K:;'(*[?ERJ[F\VXJ_0-&"X"CCX?0A=%RX[10O!+44]\6 M^22W3ZD5?+5'B<<+;EF#4^Z/>0RFLV@\^4$2?!+E*ZECD8>T'Z4IX8<]PN[2 MM\>9"[\CY+\%+/2P\YE+@P:+W*_;-X-I\'R$[=U-?EV>Y_ ^>AV)(#W;N1[48B2YIV#'SOF*6 MZ/C0KF+R-IG\A7!8/K7T"8[4$K%9L&O_0"/2=FS2+E%TNWAOSPQ?/*-F"=F7 M1&L=]#.*]4*_1]"K(_=\O1TS=S<3?9XQ]DB_(_[T>_C8.1NT M@8V:I4M2RT>Y?F(E=\Z\;4 ?[[6LXOWF/?U.N3^&YRZ>TC\>8NS-Z 1?-1GJ MD5XRU#V']>8@Z+PD_3F+98=#GE1I,\;O=PYY4H<\J292#96HXI G=2-US]>3 MTX-C:[(2M2D_(4H26XK3B775B45F M6*T\)AVPP)Y)H337E*G$4FUF++(NBY1@2GG 3,?F[@VPQ"YQ#I;8P1([6&+-6&(;6WUNP=0-F5.>EN94CZ"_S*D1 MP.DUT,XTT:#]+3+7=H#>'@O@N0M_ DR:"[W0T!;9;YO M,G#PP-(TL%4FOA?:VR$+; MH:1J#?]Q..+TT??_O_4$L#!!0 ( +V M"5>3U__@BV\ ,( !P 5 861A<"TR,#(S,#8S,%]L86(N>&UL[;U[;^0X MDB_Z_P'N=^"9N\!4 ^FN1\^CN\_N'F39KAYC766O[9HY>QL7 UEB.K6ME'(D MI:MR/OUED)1$*?6@)$H,N2XPTV4[R7AEQ(_!5_!?__?774">:9SX4?AOOWO[ M_9O?$1JZD>>'3__VNT.Z.?OQ=__[W_^O__&O__/L[/^\O[LF7N0>=C1,B1M3 M)Z4>^>*G6_(0[?=.2#[2./:#@+R/?>^)$O+VS?<_?/_F^Y_(V=F_O_ M\_'ZWMW2G7/FATGJA"[]'6'M?T[X'Z\CUTFY<93N7Q_C("/PP^N<5V,+^.TL M:W8&?SI[^^[LA[???TV\WTD1'<_9EYC 'U)_MSN$]'LWVF7M@(R&,%GSKR?M MI>YO?_KII]?\T[PI(^2E>5N5[A]?BP]_]^__@Y!_C:. WM$-X;U_3H][^F^_ M2_S=/@"N_&_;F&[JA0SB^#7T?QW2%"SQ$UCB[9_ $O\W^].U\TB#WQ%H\?GN MJE'/GW(:L@/70,LLKTVJ\ 1>>ZH&_W-?5=1."-5YB%(G&*23VK.O8B*8H>\U M^ZFD'_V:TM"C7J8AL&RAS"7B[@Z$@73DEN@%$.E1?&JP) N&A+K?/T7/KSWJ M<^2!'\[@!VXG]LO?SR.&I>O')(T=-\THS!@@-M-9Q67(G=C-> M[,<..\@6K]V((=T^/0OD%\.[;^)H5R^I8!?5?/CWX+'_%YNI4M(CIDETB%W: MZQM5Q6^R="XB:P$#&PW//M_WD/G?.37R:T;O__U7P7="3[J0 ^T#HUBC7N5C MO'Y4IT?F1NIG.+VH5L*A3I01(T!M/@^ZI;$?>9>A=\' N$7':CO\/E6K6=6Y M2HUP>UF]J*/=39 EC"X!PC-B5^R$B0_9\QW=1W'=@-C2%+__->EW@F^5=KB] ML%':\;B74R:"]'RN^)\')TYI'!P[/?&T)7Y';-"NZH>59KC=L$G8T5Z8$Y[- M"2_#U$^/'_R ?CKL'FE$I,5X6Q(%!/) MB@"ON5QZ[7G,BHG\Y]H/Z=M&X]2WQ>Z^+1J6G;:F(697;1-WI(-*FJOL!P+4 MR4TXMU>>LQ]OXH?H2]AEA5++A7CDJ7:U_E@T6X WU@AKRA>!-* D$)_;#P4P M=RJ?-UN*!Y;UJG<_T68)OE>1U)CC";HS^]QME*1.\/_X^];5Z='OK^K?(;3PVHE'+R[ MRSV*49MUNO'@?+WR*/MQXXLC1AV+@\WM\3J9EJ9EE&MHC-,-]40>B76,/"G3 MGVUY\9ZZAYC)\/;=XX.?!G6 5],$KS\VZ9.Y8/5SG%[7*.501^-42+0A;]^] M>OR.9/2G]R\X71G<;J.P>6>DI@E>_VK2)_.OZN'.&:#M=A<]L,G M6-,^)(W)0V-SO"ZHHVF=))ZB0G3P3]^7;O4@H'6?UG>N&D MCA2G92NHH3EV'VW7L[I15]<6LX]V2#QZ:RZG#N<&GV2M5J<'9_(FF/VO7E #QV=BDE&=R]GN=TX0O#\D?DB3YK&ZV@J[L]5J M57:V4A/,SE8OZ$AGXT1)1G4N9[O[?9.V(QP3:VQ.U^K MEF4GK&V*V1G;!1[IE!EQ(J@327XV*-S2(.ARRDHC[+Y8IU,%!Y46F#VO5LZQ M* @TYW.SA]B!^^7WQ]UC5*=H]7.\SE6K2>97I0]QNE2]B(-7D04U(LC-MMP2 M[79P/C%R?[O?.LPZ-X<4KO&#*,VS^_9.>#U.7^?* DQ+#YR^V4/NL8LQG ?A M3%9$L"$*G]D\F4VN8R>X"CWZ]3]H\]A[V@Z]O]9K5G'1?>&EHA],+.Z4=?!)&KDL+ MR@1(6[@W7.CU@?VE;CFFN25>5^S0KGI9L](,IR-V"3OZLJ;JB)STW%XH+L_K M^6&Y[5(\L4;#>E]4&B[!&^O$->6/LJ3"3!ZY9JP]KEC@U,UIJI_C];Q:33)O M*WV(T\/J11SJ53DU N3&^M'&21XYET-R]N0X>^%,-$B3["^%5\D__)W?MP,) M;C8?_- )79_%321J-#24L>K9%:/$CZH<[]^=/Z\\75P^4% M.;_Y=''YZ5[\=']S?76QAC^_7U^O/YU?DON_7%X^W-OP_G62T#3I\/.31K@] MNEXGU7?++?!Z:8.<@\&6DVNNX69$GY3&";V>6ZDI-'FF\6-D09>?[0&!G/QJ MX<%IVR7 0H.&I^A0:8@=))K$'>>*J_R8'@K0,*UDIIQ3AR&SA-VYDVS7H0?_ M7/[CX#\[ 9,G6:?G3AP?_?#IKTYPJ*Y$]NV+.RQ[64 -4ZV.>,.VG_B#/9R1 M)T[H$?Z#PFA%G)1DO AG9B6P9S:#"S_0@I&5H?;9\1G7@'Z(XGLFACRK[]/D M@CZFQ6_U1Y*'4\&- P.M4AJX^Y' BPU#%1D\V&?\SC91?)8PCJ1@LB+ M/2' M^F/0X\QR6L\>J642#T1 Z:.U(,Q0!(G!?458?2G MP4'M,)]%Y5A1F4$S7)!V@B#Z F_$$!;7A'[=4Q?>K7%CZODI"2(VETJ@W;^\ MX1G7O[RQM38SLX%LH-EM3/>.[UVR+R%,*,NC;](MC4N3Y0;KZ/7$C6T]M%*3HDI8V8B@.YJDL0]I2_WRTR?FLJWAU8L M[MCK;PLU,/5[XXW: 3H,#8""%6E9F2T86AE@[=@#5F9M8,'-GD+I[?#IFC*1 M[ORG;7JS^V@%O7.N)/3A%S*@33GY%.(.S:'/& M6(A$V4KTSJ5U .1)G"E]@'F"3%BRA0+7/>P. 7_5UME!D9=_BM)]L#CP]NWJ MW1]_%"L$/ZW^\&=;JP36S65GV2!B@J7'6Z96R@ >P'T/I^$^-4)>1Q?C M;WF%H+D]7KS3DGKXFH @OB*TFK +$KOI]CC2Z^/1 &]JQ"M'183Z1J7(II;+R*:3=\<4$BC MN2,QH;J9AD'!PN;AO5OG""=N]([MG33&'9;M.M8=U2NWQ!N.'?*./HHEZ>(X MEC>5DGM!U_Y.688VQ_8H[.R$.QKU=&[>+*OVP!N=FG(;VR[+.4Q\G> )EE[T M=X F5%QL 05JYF!SFQ^?WG/E$/&!><1)LM0,Z(WM<6-7IZ:59**^,5[$ZA9Y MQ&@+E$E=EF]GD6TR52>[IZ1W0G_B+S [ILL7&:+2H5[+4QE^\NG@IH>8023[ MA<;/3?>\&YKB!I\V_4X.$%;:X86<5FE''8++B!))=8J0W/.2;9=A:SHTB8KO MG8#?&')2PH*0T-";3K_[U(E;[Y#.H>$C??+#\+1R\CRIW0QNNH^C9S_QH]!* MU8PHY.M:?_/3[?DA2:,=C37GHYI=<8-K'_U+)3,T^N$%WU[2#U[IE$S(%Q_> M'9%L)I^N:I?+F,,&%W1#&26/Q/29A@=J=;ZF/5%;X Q-;VJVI#G9!+D\FDG8 M5+,O+%.2A@6ASLM0.OUPQZ&VYAH+O4NX\:0O^A3+O1-=;QJ]XCN)^C6+GV$4 MGB%<^+6OOOVY0R?6Z??&C7@]K: ]B5@"^O558,*IA.6;GG-9XG1"81D$>'T' M)9_KSG':.N .]6Y=2UE-8VN\ :TA\[A"(*4IB.68G5Q93(.UHF?WI Q])-9H MTS#/QQMK=4(:F-G;GM ;FLE;GL'WOK:PX(L*_:XF+/$RPH3G[^]+Y^WEY8-U MFL;^XT&4\DPCO.'/Q"?6TN<[BE>*R:O6(B]^YFU??.[UV%Y\[>9YE%PQ?6W!HW,G1H63J86-\4+TYT M"3SX3%M.EP#A,S\DDK2=BP[3J\DK;3(UW5HUYSHMG%W?Y[-C!FC[F&YIF/C/ M]"ITHQV]CA(H*G"S>7"^-MFJ-Q7DX3O,*I7SQGU(( [W@8J,.-J:%Y00"S8E MCD2P)*^ Z7>B%D>T(8RSM1.%^2Y%")2HMW/D.W7\D'J73@S?2J+(>4$WONLW5YO5Z(A[Q-#7O7PXO*L7 MWG&AA^S#3^0*%B3C05ZIOB_9F"V[I'_*8@8#K$N5USA-2^>M$:AJ:859>]D. M/48UZ]:^DHP7@UIDG6'EV%K".8':IQ=8(*F"'ZVGE]-K6THDI]6Y<\]N FW% MUAW"$D2U-9BZ]S*;NN%&7UV]^Q0YM]&EU/]MY1U11;9^^E M?8CBB^CPF&X.P>G;9!U%"'K2P!WJ@RQ26CSL0P O" Q38_ ,HO1N7\:/U+YN M:+6"DD6KU+]F. U'$]"P9L__?"&PP'\I?VU 66*MU8J!5?,-(8.3E@8;1F MAL%$[,*#%S&AF!\;_:;'!\4.HJVK?'74_;C%)&\"U$&J/5O5OP,#]LG?@2'J MXHW*?%9\Q6"BED=CFCS-\J[OA?*@ _LYH/ #2V-5 S6^0=&](3*6/$Y$G\J. M#1O(HV@C3@]-:VAB[5F59$5R6?B,2Y5F12HOQJS*3\;8WHFT:]&.AV6:7I2Q M@84?_-!/Z;7_3+WJ4QIZ">LH0KCQ;;AM5"3K3P4O9HW096@L"99GG">I>8UF MSN1+XXRM!0L5?)#E63]SHT4/[AA/S M3=WPXD,?X,%>&\+-VZGLT&B;!!?L[>66M?V2:5;0Y*'6;5.ZDUJ@JXS>UE@6SR[-Z?^ M#:?XIK1"?_R>( 3*(*[<[[7S$#=<=^$SOEWWZX+-K7'C=X>6Y1>V:YOB1>TN M@8=ZZ^=/Z\\75P^7%^3\YM/%Y:=[\=/]S?75Q1K^?/_ _OEX^>GAGMQ\(#>W MEW?KARO6P,XU *G^ YS%:;#422/<3ENO4_GHO]H"KXLVR#G\R+\D1W[E!*MU M8.;UN&L_I%?LQZ:"8+4-%^)Y)[K5>E_>:@$>>"JK 2\$HH13M562:#KM[%Q, MY54Y/S"GK*L(>OG5#0Z0,,$N%?N?UUSH8!@EW-$YPCKENZR]R>"-[S'*#+_M MRGD2^'9(4VW=G#/)6$]5^D#C4J@U&]E9HTI2N-]Q*9]I;7 MI>K;X@WL3HF'3\8987$$+'N3SW)APJ0C^+6VO5)&93VBOHVPC< M7VC(\". LZC>S@]]0*74?Z;MH=O="W?P:FJMAF]'%[P!K"OX4&^6],69[!(' MRT$\I^).B0.&C%@S#T$?JDUZM66^>(.Q45)SF>Z$T?;0=?G>N'KBLGV$(L?- M,^VBBER#&>I;XHZS%NUJWZ$KFN&-MC9AQ\^W2K4OK=2ZF%8_6Y4+KT(VFZ9) M*I2ZH(_I/74/L2CI\>SX 6P+?8CB>R>@N;2-^Z?#:.&.U5$6*N^'#R"$-][' MJ3/BP@OG*@$![BD^IJ3@O"(Y[[--%)\E#A2]R/E;68ZR;"F?L[4!+N\/B1_2 M)#F/=H]^R.\BO7?B)\A)V.&% MK3F4'CY+4M:5B@-(0D!22$@>N8@9('(AX4R2(J8XMRA>$2XD)9FH5A:M,)L> MI,K,*M$W=;YFJ\[VH)=900XM[VE(-XUO=S2W7@+D-6IY"EE545ORV5-UI&I5MQ%;VEDU6DJ;C/&]+<]P1UZ6G&GQ-;?$. M=9T2CZA@R,81\IKP!(TEBB+ZK$S])U,RAQS0KPPS&$+RO9/XKJ9-LK;+"L:2 MAFV1R!LN)PS+X@Z_X,^H\#H.'IMU.;$2AU;>KJYJ>>$'A[2Q<%!SZV7Y:$7+ M-B^539?CIU6!AWJJI(/(5_]&H0@Y]=8LJ7.>Z*?#[I'&-YN3*A0=:<\ ,KB] M>ZA=5+?O2P-O/ S69&B@9 R)Y$@$2RC9(FOA*5Q7)(LKRU>I[)G)D68ZK>[R M,V94:K2]H&.W@3$<4\]><'KD5 M]GRF^OI5P#=O\JR#G!$-%$$$(A+K=0L ]J>R2"#ILHH&E#216!R8="IB(GV? M E#R_8S68GFS:UV!$T]:H0%0K%9%NMF(9>=UZ)U'NWU,MS1,_&>Y9=LQB>E/ M!3=4#+1*;;$E/1)XH6*H(C.5L3N_^7A[=_D7UN[JKY?DZA/[_?+U]PHL94:B^>/X0B??..Z+,''73QANM MIA4<=]JQ)$CYR_1 &L M]L/]:O@:;D*E;$;L)^RC"_9K^'3+7[L9.$ :8+?,(=*4G74&R;&\EC=,&M-X MPH&RD)%((451"WD9$MX8RT4E4E8BA"6W\H4II&.F=?,KMMU*VYY"MW-2JHAX M4,XH4E51S M+V?&Q;SNVJ73V4.4,2UOQO"K/G#2HW@=$5/.6S?#J,XI)M]SZG':<:%7V% MMS^JM&]6<*1>YICW?X:"?^'/=)/K+^M,O<(6(7/[GYZN'__HOJS$A; % M$X6PAK'^ZC<5*.SJLY 8:-.XUO?K.BS YUO%'NKK@B@IJ))?@6[UOLP\59S* M"EY$.S88-5BEJ2UNGVW5L%2_J:XA7A]M%]>4;Y)?!6$KSLFDV$4A'W4^4KC_ MW;QU>-(.MU,V:E;9UBXWPNN,S:*.V,)F%$D")&WXWMKS?%C1NPG-G M[Z=.T.J'77UP^Z26QJI_MG; ZZMZ8@_UVX(ZV3/RQ ^)*QA8\6+7/>P. 10. M;YH,MWMTC_[(O;NO)4J>KML9L=?W5F%P!!2<2-1X"]KB&X1W-&49#?6R^I>M M$=#8&+>[M^NH^G9]2[R.W"&O":_UZ,9W?5M//<64"71!Q;]7X>FBRUT4!!^B M^(L3-U7;[4\%MS7!FNRM#0X52)8%G=B>5L5R*,B.1,.S0! ZSZ!93C+/MD?W@,?)?]M*$Q?\U"WJKUL]YNE-@IRM2* MI0.!XK3S(I&BP0;:JC'71S#;7OXB"D68,),PZ5'R84,6^,)AQQ"B:\S,'Y'2)D$& Z'!IJ M^R\2&YHMH9U=+!H=6E28,L? B@\3F$,?(&RG$2-KUC=8>CQ5W,!BR&H&GYS M"T*F%$/QQ 2J*WKS6K"FA-$KN#YF!;:*R][)0]1PJI+C.E]15Q?>[ZB 8'I/ MXV??I6(,N*-N]!1R*CQ=;/@F9F"+&_CFLGOYK.^T//%"YVR:#S]QG L(&*D< M0+Z5!Y"EE"O2M!&V(KFL1 HK,T>BB&L%=]&;7[6IJVXNTJ_PL^V7 L^=9/LA MB+XD^I=TZ[K@1D0=?1NNY)ZTQXM$6E+/=0%W??\7\N'ZYF]6WNYC"1=8X#:. MGGV/>N^/GUGT784W>QJSV N?UF[J/XM;_.U>/X@0[E@8;ALU0OI3P1LW(W09 M&DTPF0&>)&,*QTM> 5\V'G]'$G8H4[Z*>T;^.J M@"$^>(%H4FT-S?YSL<@)UL''"\M)EF#Q.+=X*!$5_@H_NV#L@[!O;6[SLPWL MO:![)K+/UR@:S%YI@AOKZO11,4K]'"^VU$HYU$-58E;B=BYM9DY6/D3Q>@=9 MXC_;HJ>M/>Y0ZM2T?NRO-,8;9-TB#QX3%&*61\H959MG+1O6U]]7%_>;EDB; M&N,.O'8=2RO7M2WQAER'O*9O='UOYTS3]$IBV5EJ?O@TJZ%;%+AML%9/$K@C M=X@]U'CNTQ]OE _28NRK +6/.2LEO]62X--Y!X@PZQ+P 9K,OA)ORTESBXZA/S4H,J9 MO"9.QAP^V^7LE4+JDR0*=1 YNV$JIEBKIB@8DH+CK"G3[.9XE3/X[K6CFD:K MWKZUT^ U"YC9F8_\&$C#H-.G/TY('6R)D[/<.IWQIE7]51AWNKAN"V E]@R M'G'3(K\/)2]/)0]<1D47CJ/Z1Z28/:;>/,<_)M-EV B ME-O6?^?P 7%Q4;S[Q?N] R1<_W?*W&"DY4B1M04C(A@LO,2TVS*)[1??TJ\RZN>.$N28N_X$BDUM+';YTC"+P. MO7(^>5W N?;8TX\F3A0V:K'V#*P'P24E94/4,HQ F0A$RK""-7&OND%D*T6; MTT"%75[G R$ST%ZP5F'*E:BMY'$XD.H<#ANS#/9O;(@]/R1IM*-Q9J*CMM&[ MJ"P-C;2LTHX_K226A#AZBIC.VSP9'[")1S>4H8C' M,J%G&AZL[,CKW]MI,& O KAAH[\MAMUYPPL6 W28\8[;) E)E#I!&T#,;)+. M4]^(0.(J?*:)B0NS[806"1H:MM$ CQ8JBP,1'5TF I.<-:++*1:L5+TPZ^=F ML7QA5A3+APH=4%PMILPH#/G2XRU3-&43/G@ 9]^R9]V+ &XXZ6^+TH5<[=YX MX6. #D,#(F/%"]\(9B3CMB*4M]-X/I^=0-]KOHW+J5> NK?.WS'YJ.3PI'8H];9 M_C%T<,?[8,M4BN[T(X(7&X:K,GC$EQP%6 !/GM%F7&<]Y:ZQ.S&_@0I+Q(1! M#=WM6R]"H)@!],$4S;[(<:2/!5IG PO#BU[BFYP53 \*(V8&DUA!+$3R1RS] M$%_P?XAB%1SYD9":M=,.$^I3608@]+1*'31HDL /$GT5&0T7&S9DOBHE&-\1 M<3.F;O_!,GC,91UKEV'T]U=&;]"@AX?^MABV-XD7% ;H,.->)*:##5.9A!]L MV"LFP;+[V&"'#W[HA*Z!PPWMA!8)'!JVT0"0%BJ+ Q(=728"E)PU_L,-4UJI M>KAADYO%>C7P/,O*WI2[V9Q'NUT4\M?L-)9^FOKA!@]MS9M6-VL[X84&?='- MK%ZJ+Q0*+H2S0;!6.8?ZOJ*^*]1/^!.6XC$ ^?1SDK_]#&U8'W@"!()B3G M8NO1@5EUIY(N?[B5VR':USU8BVQR,3J30A_T_6TQ;!*!%P8&Z##CI '3*L14 M)CE9A< R3;AD^8J;WFPN9E-R&8!OX/QSN?G0 6;N\HFS#Y;DH]?M0D M],I_4%HV6'P:3KBA9T+KJA@U 1N\8#:ELD-#7,@$(W\F%0&QH%H?L)+5R!2. M\'1I)HSX$*8&U;\I':RD4+A-[6:5=/-ZL3'8W)45D)CM76Y[CKVT$(&;.BY, M#9_;.G,ZV([B6=C36\3R63#U&Q,6:_B*9Q<"-V#;^4ZJAVWGDP OS%NRPZAE MX"IHGP#Z^A3D3Z0F>26#_,Y^\=I?>7@1LEO)GQ?V]4 .[BDE$%[PR##%%_:R M<=LX#+]05#4"DDAS85%6\#)L/<2$P7HZF$6,NKQDQ/*8N_G49A$@>^)BO.A=\M$SNITWFSD4I43Y!6DNPZ*F**- M>R@P:L%2:783A/$.#6;5&QJPO]"0QDY@9<\$KJ#0FXTLL<-,T+1V7-<0=U T MZU;:ZSAIA===6V0=/$G@) '_"Z+DUP?Z-27OFSY3ZH@_^T.D5;OA!JH[4>(5#D'5%9CM&'SU>^.&GYY64)%&LRM> M4.FKP- XN+-73+A#Q:Z1MT?W1;MYZXBJVW>QCFX.\24C<>RSOL"X_3%Q;FM8 M.;SFQ"&2E DC33AM^[$Y MG;:W<;3Q4_*:P"O=L(U!$F!@[4'8\VBWC^F6AHG_#!O\#'I LD\TO=D\.%_K M#P)T;6.8((P[W,W9[N1MV5%4\0*(0=V&E\ES#[M# )4PLL=Z5'GX:_96"N/5 MF.53E':.EAK=<$>1KMZE!D?UR=W 0Z M(6XCPC\X?OQ7)SC0"S]QF1"'N'-?I:,+[LC6T5>-ZK;V>"-:2^JAK@S$R3-0 M)SLV##+:NYJS5=:\MVMPZNJS//]M'99:.RS+@\VA,7=A3IXH].T/0S-HC2-P MZPI =@P['5UPAZV.OFK4MK7'&[1:4@^O\UM3T).<$>?9\0/X\]DFBL\2*)#L MT<>TN>KG/*$\ORU^MO.<:U9T-;D*+YC=><'G3#HXD)L>%0.$WCF-4\ MN"S-WVTHT*YK\)Z0'6X F=K.Y9=DI^&%%[@FUWA\3>,$+A^!:++\>PX 0CJE MR#-Y!2VDA$2**)^&^4[)=^RG.VC-;FRLF:DJ$]T[OG?Y=4_#)']N7%CG7+SZ MW9%;]:. &RD'6*-OR]AYB$NOX4CDN15P]99UV3_I!'N:*S720W <@N\ M,=<@YV"GR]\##SAA.P['?)WFD@@-N\:&SD[8'5)'Y[*#MO7 [+!:<@]U8$%^ M10I'%ASLCQ43*XXA)F[!'VU@:!P# M[D?D!81&UQ'A'A06'AQ&CP]G['ALE*,%TP \NV&0P4:A)']'!X9]?J?^CO*3 MS^?P;@V_MP3R>]G+GAT#[&BBN&'%C,U4F!E'$2_L&-)K<+D&('W&:?/#^QE[ MU('V7C5%UX ]GNH+";5VJPV*M7J2+R#8.A0;&FW*L"Y>B\LE(%($PF58$34N M\Z>MK:<"MNV'":W$2:Z.8?ZD$6XLJ=>I=)F^U )OI#?(.=CQX 6S;11X+$)^ MSVOGID<;3J?*(52$&WWZL]<^_7&[:F]+J%ZLW1FO@_=7P8SORY.Y_(8KIEFJ M+7O8PP)>)OS@I@=X8)67#>>#L/9#Z7WZX\:"WI8H5WK2[(P7"_JK,+RZD<() MI=/KCX4#22T\%#1'R"%T%AP@4XP3):;R$0\QQROXHAI"[5O)2NWB0^*'-$G8 M?/;1#[-JJ?R@\MIE@WOB\S^UCZ6]B>!&D6$V*54D[D4!+W(,U&-PU6')#E8W M,GYV*GJ?ZJT_LFIW7EP4:(Z>>CT7Y?538'_N[0H?5"/BW':P'?7WA\>$36AI MF%X^:VQBMC3''=E=>I;6BAK:XHW>3HF'UW;/"!/Z;&L[OJI=YY)G2_ME>6G[ MDF93X^7XJS$I7YRHO"MQ%/_5?.FENS/N:.UG M@YK76SIZXHWCGO*/?I&E8+02CXDQ\B!S^4$T47?-/K2C" 4*_)#)H6_ M(YOLT4]X)3=%4"ST8U'\L,_@VZ<_[K#M;8G:@J)=G?$&>W\5#!0:57BA0X.9 M#8*C!NDY! J\;\./Y?G);^_( OI*6VAOE;HJGQXHNT*J\2,DY7'N.D794X11R'[T14HTV>T M'T &-P ,M4OIF>^>-/!"Q6!-AL8,8UAZV;/$$AUZ6#&/4YAG7V*)9%=7JJZ_ M 59TP T-W;IV[-C*UGC#74-FDSNS";9XGD-_VSNR%W[B/#W%](F+<+.1STL^ M0"D,C9MO6GUQQW$O"U1NL75WQ!O=_<0?<2--X0*9;O:QX2U?W<=>A=^<$BIIX4$PZGAQH:15BKM MGP\CA1<_QBHT.)0D7[Y5<^MYTGI!Z6E;?BWV8&]#L#"B\CA@VVND/?%K*-6EX-@HJ]7C MV2"22\"U<8J9"%?U 4Q93:_E55!T.&??@.Z6T1 [JUV/B;X*N!%]+I9=:,MW MED0Y>S8R*+4'Y6Z3=Q/>P0,J<*V%']?H"71F>"P%]@Q:M!X$#3!8 B2:5--$ M?!=;Q:OL/0K(7=1:HYE4A!=!D7(1<<()'6*BL&\Q5]T4&\_L-Z!-1"JKXT<,/2((N4CMOV(8 7<(:I,?CP:LZ- +ML M#LK@0WU^$PF4S&L:%3>RO06J)D*0086'W2.;@[(FRF.96QIXY/'(5^)@LNR$ M1YBZ.B$Y%.86"W*1N!EN-W^J>7JM7Z:D00 W^/2W17WVT]4;+^P,T,%$8#6\ M18@";N8T23%9B\R\5>AX,N;?_.F'-SSNX2]__QOUG[90K>69QLX3O:,[AJ39 M$UH/--ZQN6JE#5QEA[-)=PS^6G%A$@8X<6,Z6P*NF*=N%W>\R#WLLOMGDSO- MZ&!DY Z!$Q.O5(87!O,O4H8S1PA!XDQ2\5(<89BRXWE!;6M/RDQB)O3W4V!: M'<(CM'#&Z4RR(KD\XHE! A(1)A(Y:7FAVM#V2('0M.K@:M)=L;Q>FBVD'C\Z M4 PL/6JEJL,HX1Q[#%BGZ_'3#C)XL]@QR@R-N(9G4E?Y]L5Q13+6M@'+IIW* MZW!I-EF&E+?\WJKME]%*.]^55^3ZGT/I(H ;9/K;HO%T26MOO) R0 =#9T;X M X+J'B@2\+!D$0?]DXK*T<#=/HB.E-[3^-EW:?'8A?H#.!PIIM&+D_%1>A$KV4>($65SZ M4)D.CK%ZOH0[GZ5:-#?7BA=Q>XKE+WPC%IHX?BSJ6/$WAQGPP,4$Y\GQPR0E M-+O)!KXH5M7AA.R9%WT)B[.W\V[]6/V.FU\W$1FW$$!^RYD,M@<8^V8KK7OL M8!,F*6* 9=,Q" .###,<>!G[\R'TG- ]0OD0YK0[VY=?2N9CO[#I"WU_?&"\ MX4W0)-7/G/M0PCDD&;!.?6ZL368)R7!_94Q$5QF@)%LXO >,Q?.[#-?19;QV MC*70S3)[?)\YIA.SH-\^A"XW,!:%=AOOE]%9XKJY3O':8DK+I26GW=9APEG+AA MP#KYK'D8&>3SY9%*F9TI5T;C;//SF/U!%8=(>0@7:-X)J"6CJ3C#S5$VU[6^ MN>:??-HR6;&<.=RYIL!I>8\:GE)D0T+Y/C7[C 6M5^Q[764K0B"C[\F-I;7Z M$N,%$[O=[A-Q7 3N3VGMFO%A"G:+&4*,R)6GLA,F&\JPM.T* M<\W:+V>ZB8(@^L(L]C-YY7Q7T&024O\9,O#D?Y%7C]^!)E+ M(HJ76%DRY03N0W+(O>@L7-CIW3<<21)P"&+%5/L*/ MHH9\ #>CF\'Q&093MQ DBT@0 F[S/PIYR%X*-._08]=:RE/1-QNB\"=, /+ MK,1+']R$1,I!,D%LK_LC,%YI^5\Q'?A;FX/9?+= &19OXX@9:N=7 MZ=@$Z$\%)Z*/M$K=LP>:)/!N @Q59/0# 0K#%3R 0CA/HC"UC36V3'2Z':"6 M5X<,,C]4DZ>E\-@"W 1A4S:3Y^M4I%74+VV#;)WT;VPV5^3F:WX:).R;.1J@ MCQ-V)K-D;5XYEOB"TDQCJII=%5)F;F>QW.&41_>89.0+$ZVR'N3D-P16D"XD M!WA+#4Z U;RF(F:=<&0O"NWEK-9-7TYA%7'.RIO*(!$!D=0K+FLV_(1$"F9[ MF,%GV_(=P^'.;"/CY3OV/AR7/7>2;<.(?M((Y\#1KI.:CI9;X,TV&^0<=:*$ MDR- STIV.)U*[JE*=I["%:MOJOT7S!?EOC=#&_5?0M^/! MAR2-=O"N2$7OCQ2*JS99J;,7U=$'NTIN"#O5K2)Z?N;<.AY?/! M4-9<'C+X1-/U(TMUV$2VP41=?7 [LY;&JBNW=L#KR'IB#W7CC#HIR*\(8\"R M"\G"SI+P3%H79W+,+>E^XO6Y;S890E1S^L9&...M7:=\A?2D!?)ESF9YAT\L M]TQ27ET$M@R*,NUNQF+>U43S&GXZ56G^A3P;:EE_4+L!)3NZX 24/OKJOIJ- M=_C6DGK$&GWK&]GFYE9)G"H^S'XK_)?]\O?;./(.;GH3RYI1-4M9+(:]'&J&:+$^=H/Z55*=TU[:AK=< 9F7[TUDNB\ M#[YQHK?D$R33P(1P+G96PR;7_6YP]'8M@L&E-(<-\7_STVTV96^=UC=TP!F* M^KJ>+I35M48^6NK);F@!+8U2)U"7T3*FY OC:GU5;1(3%$M1YV5M,PX6U]LF M5KCIZS69K;LQ//;!JQEP7JHJ>;&#^A1*MRMBG.JIOY+::_5#CEU]M1B\MY1? M*/ D1[B#'3T&_E-1/U'>:R5/4>21*":)G**RSS+'Y]>=OFQ]=UNY%+MU$O)( M:2@WKR@GX*M[67-/+^8Q;,:'7(4Y.I*_J>!8%%BQ<+YX-BO(^]#9=97,RRP= M!-/&4=T^. &TE\:5XV!8(;/C0-B$3IR';RFW65F*WWETK@:NN;SF\Y[Y:)C> M.D<8 -\??TE^^Q#%\ RDO-&R#KT'.>*LV2R2%YRNP["AA'"&['C;Y!G0("K( M\Z%Q.HW/C@Z"/]D+ :#^[2_W_\&S'D4(OH"?B4%R.>;-<.R82G(EMT,,-'\" M9-=(@[S(' 1?A2():\\"16&]J_#RJRAU!V_QMDX[S9!%#,\&[9:#M0&:R*'; MI(;C@=R7TI!7V53DN]EGO"OB'00MKBKPIU)M"R^?8_A^KO)OY4+]5IHR[_/< M;K#TFHE$0"9;:3D:4]:X.K.3E^7S[(],!N(Z!WC.B@U O&!$R9XE7[0Q46=MP\1(OS?.H6:@%=1IO&97O!/ZO@H,#1;)AV2, MJEBB,+,RR9_+#I>V0UYNZ=Y1.//DAT^W-.:E=%B4W.1#%BA? M]M?HB#?4^XD_\LC BN1\B,*(%)PL%0V8PP9KI7A49H1J7G (61XKBT@%3,HH MJVT*U3VVCL=+"&?9K5+EHWZ9T(CU-%[HF,E^\E +5?BZW&R90$K MMS]:%Y_S;R-SD"$KV'5$< /X,)MH[[Z<4, +Z0/UF&Q_9I6?C2NXXMNS,6^8 M3&L%JN44;\]?/I]J4^=.+GQT+[PJ+7$&MX9V#?LN63/DJW,=0IO8.3DK+WKG MRV)R,*/QKJB/CF'+Q)@1JLO]F>8V1FSQ\N$ZCF&:!]*TU&]J:HLS1+4T5(?9 MVH9X1]-V<8' ;ZU,4.L5? M'HIT/&DMD-.?"NX &&B54M61?B3P!LU016R&D_$+?_=0YX<^^>ZY.I?G3ZFX M4) SWUINO@?8GP3.&!ECC^)%KG[]D6=^0[4Q<&'"5ZJZLZE(*A>CTHCP+#"7 MC)1$DR\<<>%L':Z9VVB]3&$..>#!;!956WD9^E MJ9O-YGY+@TU)M I@I)2JMEP\9;&"V!IGK/WZ7 D;*>V7.S3L)(NVK606C:^ MZ2B&!]'VBK1 4XB+"KRF-6@W7*G\22Z .63ZR-+$F.$A9_T07=#$?PK9WS[X M<9*N/8\_V= *WLTX99 V8M0R;<$C26!%X]-9H;IR"=$/ 4<0$)Y1)R(GG*!MNJ%@%I M)A-6L [(L:T:9N:-) MZ MP:OW,&TIC%([&YGVD.ATC(SJ=$".6 MMLXY;G7V0(Y>^O(;REJ*:Q>[C%5VMC)AB8M'*UA60%<@M\HM0=CTECHY"T!R M'EE)#@NOGTRO]\<31[!Q'O$VCEQ*O>0#@X.K!-[K=NE-?.\$]&9S^8]#>,\6]I!]Q(, G 4!6Y.,"=P* S: @(*1E5LL,^@/;[KM M)1MS:8ER[O,6[NG5059-&YSQUZI1GF-4&R!/*1K%'7\/I?ZF9O7>"8&+F]SF MK,V\28)QW16"A%.>>#2PJ7K'YTIZR_V1+#JV/@=:VQNFK"B> M-D4^?FH(;G8]T2\8\8)FRLJAG57""30O%@D5X@UG2V=<(IQ.4UX[3/E>32\/ M5K."[%K\Q\CS-[ZKG1TV]$.,07TT;\SAZSHAQZ5>*HS,#9V\3$MCBIB]WD%V M"G^[V?XD%CF9 :R*DHHJ(_L3@VD<8J GF$.ZVRB%M6@GD N>'Z)X[6Y]^LQ3 MN)O-_9ZZ/E3VR=M(*7I]HY M1_)(E=(=>[B#6,@&X91DTA6[,PD<+K&UZ6+#FCG/O XZXTH4MI!%YHR+/1H+ M::1=\]1LX+'I@^)BYC#XE_O_&'[_O4]GQ'C;VP8YRFKW1(ZM_?486X[LP-Q< M*3HAJI/]$CA?(W*_@Y__@_69N=;W?%: =PTJ*U=37UGGQT_59[XB"I7B.:^*SFK1?+BN_4E M=U>EQT\DT_D3HIF-4GDH1\-'#*9$R6\=3]VT9$3Z?1'C8U\+%/F09D?DF-A; MC>&QSXCRY!Z\'-M;6;.904]Y@T\\/87'E#9'<>5SQ)%:ITGQ>I+R(?*(JQ5U M?%1=_?+IOQXN9WXQR*0J0@ \_3S:'9[TN?(O;Z4RV*8^/Y1\@]OD;0\?Y^ M_?#A\\R'M\VI <(;+[K-1JWJN>J[_*FQ.H4T^R&.CCZ:5\MSMW9"'E&]5#!1 MNEO4KX9DY63!5GG/SOX=L5D,\UDQQ\GM"E(PLO::Z7SJMWF#C9.6ETX,%Y@3 M-GF_WSHQ?T0A=/W %WG]8\)79"NFZ]T9)R(.LX%Z E.O)]Z3F#WE'QH &1M8 MQB*<$2ES(K]FO*I%G*?%@)GM\(D-4C$$,;]-S/[FNQP4/#\X0+FS?1QM_/3U MJR!*DN_X#G "TMC A4\TO>(/6UTS6=;/CA\ 0CU$Y]%N%X7W:>3^MHT"-G@E M[T&-!KOVIX(;*09:186,GB3P8L=01<;<;!(,R:MK'B Y4YC>"+9$Y;LBG+.E MI]5LV*<,($Z:QO[C('SKQ4:"*9$[X<[8%'BT2@RX$@([^)@HZ+P6' M*I89AD22R$O HJHJ\"*(GMKD)D,Q->/HO(VXE7[BY\!.7^?J!J8AM7F36*AIS_6&)XT2ZAYB/QU6Z'HTS-V[6^H=H"J!*M1]+M/E5S-2#.@9L M -D?Q,+KS:9JH8>:E?3)F. &TFELJB*O60YXH7HB/8?&;28.K/N78KB0B&0B MB:HDBE"\(,GIZMBO7#0[+P2.L^G[8SV!ED12MR5&XJG>W>%4]%E:3-1(;MBQ5P1X3/!B MY^5N'T1'"M=ADT.0.N+UT@L_IBXCD? %#E%KN.59J2%$<'KU.)OD)S]Z4T!^ M#&2X/L/CH'R5B4WPZ2,4"R94RK*"J]12FA44JMO1O%;(EI+WD1-[\$LN)?$3 M4:CHNSB'_%#WF%S2 ^POI <'O^;=8 6SS1)H4HY3*TCOL; K)O&OGC( M=T4.*M\J_L.\]>X;K(7IPXW?\%[E,VO8V7F\:B#%LJ$64"UG]""!'L,'J M&+CFKKY]$-/ 23/\R44B#IGNB]G@DB$2Z3G8TL[!9=(-:)T^[3V#NG_:)1KFQ!@Q G"+]8?*NH9QG< M5D3(8VE3&H%G)]H^CF,J1/X_Z3>50BK\2#6 M+XX?0LSJAH4NF<4$2"^[-(2*%HU%!$T_34R$SR%G1YX8EX3PY(LE6@3")SLC M?L:B["R!QY,\^IA:/IFH.?!VKL/U)[.8J.IEEP&IV1+6SX9J,E.*9GTUS*9] MQ :T6[(/X(X-.&E/WK_>1C'/891[*P_1+9N+AFG'I0\CA'%#CCG;J2 TGBI> M6#*HV]! [ 2G%6&2K(B4A:PK5[:$."OY[Y:FONL$F&ZL(+"Q#MB15WN';W4* M"UI9VOK@^/%?G>! URSIXR=FKGWGT0]X1.O!]>C?A'21\L1\^L0:?(I8R MRE_A]DOKNI=)^KBAT+@E540T1APO,)I7<6CL@B2$B[(B.3M^;DYE:'.1+;?5 M^Z.T#'^#(*;_., 22,L]"[V>"XFT;NUK8ZBYVP*B0T/XH7ZO$"8Y98NW$'*= MZS1NO8B@UW,A7MZM?:V7-W=;@)=K"&_8RX=?1IC$SY-\X&E=&=;LNCQ/;]*_ MR]6K_9;EZXW2#S]MF64K<*_>RO**,G+E/_[%IS%SD.WQFCXS/]-*5]H[+\3# MM6S0D+2T]%R E^O)/SYE)SEUD;&O_XHL@TE.[= [EVFCL9!(Z&.13M!O(K" MN.BEQC3A@2'UN0KWAS3A@/!6+^.I[;$0YV_6MM;53YLOP+%;A!Y< !Z(D;=8 M'/5=;T=]MV!'?=?/4=\MT5&K0H]SU'=6'-4/G=#UG> J/W';EE\WMD;NH.U: MEIRSOBEBQ^P0>' 2D-$E!6&+N7'V?A.L]-_3^-EWV33U9E.C??+ Q$CJ/VI- MG0VSP!T24]A3C2.3]/$&WR1:FHS8Q&J^?A[%>WA/D5[0Q[2X:=*:"'7UP1U6 M6AJK<=+: :_CZXD]U)-SZAC.CWZ^?XCYK/OXW@\"32_N[(3;C?5T5OVXO0=> M1]:4>_ [/M_??T\R#M8=^9?HF<8AC OW^RA,HIAZEV%*XWWL)S3I =(#26%W M^N'V*8="?SJ8 V2$-H//PSWQ;=;'*/3L[D*-.%UTW7&AP#0/W,$UB45-GWF[ MQG]/81HU39Q]$P+Q?0)%))+)!!>$6H['<<'L7W/ 95[%I(%BTEUF4B^M+ C7.#+%*:$/8A M@!>GAJDQ>,+(V/ PX3\H#%<0(QE/N:=I^;J!!WA[2U.)Y0[8497OX0V(N).XY[:*\<8WO!'=1_CA+SD]IJ4J[^O3Z@&F[\PD<:HX//NM<';VR]_O MH.9VS?9W]3.<#ENK ;ADZ0-\3EEFC:Y'=2^.EX M2V,_\JYIDCQLG?"!D:(?HS#=MCPT,9HB3E\T:*W\$8IQY) _26%(.0,/5$ ] M6?61BCV-4U[8+(W(3HH#?V3R0"W?@,G$^CCP=@V3BNRX6/.^3V'9>,7AG,H4 MCF02$"$" 1D("$&X%$2(80Z?/G^??)^=K3 "3V,)(D8G([;*P6D4->389$:W M^:$IS4X9/?I!,#,DV;59^9"514#20F9%_X?H)J3_19UX9,;42A(Q*!FR5[^< MJ9D>>AV%3T,)(4:E M4;;)L6@0%>0(-$ZG;RLELF,K[51H>H@19WC?1Z$W8D8VA AB:!ELDQQ6>E- M#BG#]9D?3ISB5/J\6#*_D>0!?& Y^RRJ2=M^B0 M.)G(SBU7UHSQ6D"43J6QD2"W6#&CQQWL1=ZQUKU#O:P[TI/<@:XL$N.YWM=> MOJ6]"V[OU-&W^ZX>=F_5DMK4?3,;;GOO;JEW".C-IGIUH0BGZX[;^7UIX';L M0191/;T7 ;RN/TR-P>?&)3>8_=?<;E%6YZW?>Y_7,!^=^#?;6T@Q&S6B=G1A@W.7SESA*DN+M M=GBQ_3UEWRE]<+X.,ZZDV*3\I;MUP84DA#0)P5 M>>0"P;/"=MXZ1V%+89M#89LG2"27A&KP@/)4J%:E_3)1K=:")E"M1/CEH5J] M>M90#<29#-5^$F8,Z1,PGP+7S%KS!-?@<7,[^QOM$]_B-TU[MG1?%CQUV:$- M@9KZ+@=D.C4PB",JA+1O^-E)?::SQ=-3S!&+T"3U=QPW[=8R+1:E"S7;BINU MM<<=[IV:JO'=V!AO0'>+;&#C0MV],5RF;*33=FUM=O59GO.V;EVV=EB6$T^R M X=I&W(VI>V^Q-%>7_$\"E,_/$2'2@I^&R4^;"J]?2<.3]_$UU'XI'D^S 3 MW+@PC4WU2WKVY8 7>2;2<\)"H2M22%6==Y-,L!5Y^RZ[=A#%1$AG!>60&9@_ MXK#CV"BR;]B9]L-GEIB+)^3\D#AA=<9.]JI==[E=@SJ[+@!5L[MTF7DG^>YJ MF+QD5&VRJ3E4K7)XJ:C:J*=]5+W.2Z+E^+I 5#5NX-&H&JAVW0V]8SLQJM8; M<] WU$AJR0C9;A]]'*RGLU2TZ]!F4DQK C(K1V2LF&DD,N$#H;X9\Z<#7'6X MV62?3Y/KZ7!=,K09L_IT<^P3EDL%3'.*F]N[6JDKAPPRFH"5X?!_'M@'<#K[ MF9(+/W$9GAQB1D"("?"C-/Z%D6')GDA]V(3R\A^L-YR?;B@4L(3LE26*^5!SBG6+*;'Q6UJ]4,[I0K-9YBNG M/)<,DH8L/MVZ187A4D'5E-KV4]B:DP/E(__0WM*I?MS?P>+QF5-2T^W>+"-X+*NFK;1^7:A847@,G9.#[ZX5-QF,W910?^ M0H?SE;B<:T+BG"]DN\?W+ID7ATD#,':UQ0F+6AJJ>49M0[R91KNX0]U54B62K)V8G$%%CL0F MGVUF37S7"3["N4/?"9*6'*.E+$&YH2'R[*)3[,&YA20,Q7L%9<(F MY.20P--?)&X:'R!+($[ NH3BU.OFP%(+ROM5D@[VU25,.:\NLX"4(H1:PD$U MLY@WFYC>O#EE>WG$C#YD(UD0S^YX'O58PM0UG=+NA!/S^NFLYA'M/? F%)IR M#W5A3IYP^E"_SGKB/Y?:ZP?+*;ZR9-,>J;4-<4=GLVX-*XCHH[!%5A/KAW9C M;3+EIEH\+,] UJ%WJL%5Z 8'CV55:]?E2T8%AM2E"*,IX@Q(@];*)Q+CR"&? M;AA2;D2=>T81%CKWP2_5 XUU7E-4V MQ!UES;J5GC@\:84WREID'>J(G.09"X&=]3";5CN[<=857LN)JM9@6D ,F7.N MJ>.EZ\B=.4V0)'E_H_[3-J7>^IG]]8G>47B//?L0@.&MU@"M109WD VU2W/Z MV$T#;\@.UL18ZIGQ))(IR;F*%@3X(LA-9[!-QN+,D::(F MM>^(#Z*"$S!&6B7?%NA/ OE6P B%!B?I<"HH+WU1#0)QNOD+C2EQ0*:8H0F4 MQ""/4E(V]=T]^J%XGQP.,WW9^NZ6GS62'1@1.4D.G"3Q-[XK&G]Q8-- :#'O MEH$%*V1\4:G^C7].$+#9YIZSLD(\CA!I6Q=BJO M0@^CA1=L1FLT _ D GE !")DL/DLB#6+ 0)@!AHHI?WP)1IIMH+*RX"5BE6& MH(DDL7P0J2HR'W8 9X8=$6K$,&4>%L%_0 \4C&?30\A#Z+P@L% M,Q@N@,@+ M 8R2*G-#!C#'#QI&3,3B^8_88>,#,[0!@TDR+P*%J,C=>,-[X\<*$@5@@ M_QDS7JPWS&:&0*-*ZV4@1ZV%AL!'B=#R,:1>G?F Q '^"X$3L[82FF-'EI$F M>S'X,08REH\2\P.#I[$C:GA-BP*?P^R0(?4NO[IPJ(9?MAYB MO!9:"\:'+@MI@T43H84B1Z9V2.Z&&B0\ONDUY'O*'>);"Q$_\Y:43'L\:K>0N5$<.TJ,A'\'7ZH7\U'T_'0P5 M%G?XL4(XI_SH,(HN)H>25=SS6/(X.3UMQ*IJW MA!H]+/_EE_Q_GJ];B?"1+%&>W%$G7XX<;ZWYFK6U=D);_ZE M+_I07\\XG&68J_"P6VAQ>MVS.*>24SZFV"MQ>H)O.N5.6SKA#F<]G4_+H#;U MP!O(FG*/+(]Z.G)/&L+/-'Z,=*JE3JRWD\6QW6&9"],O=)<:LSV"=7%1.IF; MHAE9)U732M4^=TN]0T!O-N=1P-A',7]N8AW'3!'*MUC6H?>).7?#QP_LI\1Q M^>SSH:;L\:2,<,?[=+8M51TTS@4ORDRHZ^ E'I4345CQJ:_ZNX R_D!RN=.O M7)+J]=KY!M[S:+?S4V&]KW[3?=&&IKA#L$V_D_&VT@YO&+1*.VZD5:B27X$N M"K>\B* PF*8U\L;+16 ',4LJ'DVG=Y MK?2GF'(0_TBA:DG=^JIV3YQ>.4#[XLDWK6[(-X1Z*C'4B>_H7NQLP@[/!C9) M^";+GL:I+'T(.S>J+#R/"(0TQ,G$F?GYMGF,<]ZMM['1*(E3921BOQ6C$/N% M:0S'2^*]$Z?'3\Z.UB1&+UL@\USMCCC=N;_X!GW<>"[U.623VSAQ@G,:!,E5 MZ#8G3\U-<3JICGYY>M30#GD^U"7UX(-=I4PGYT(XFQ4\F?3]BCCDRY;E D<2 M?0FI1Y+#8^)[OA,?X33*.DE96R>9-P6:RAZU%K QYS:PHG;MA_0JI;NF)23# M+'!BPY3V5%<%3-+'-QQ.JJ7QM=Z$3U:8/&=NXW*P*A+Y%80B7"H[9161V36$ M,X(T=.'$')C2+59YS"4DU5GKYSV+V##-_AQZ]RG+AS[O/U!:1; A_7'"TV!+ MY/E,G\[(DYQ!JAA8^N&EBO,W. ^"*W?\!!B>'?9D T6,X;G&>=.<62TBJ9*< M&Y'L2/X),PGG>/9Y3X#G_ =G9[5(IG^^[E5UB>G0\*,?T"2-0BJO;-Z$U:W\ M'MT6A'TM>C="7DV?A2%=FP9CGA4H4&V7<S"6-D M'[2FT/Z#'R?IZ=<\'T*=UI[MT6W!"%6I+JO;9^$(9:)0:@="D?1+A NEC!3/ MU4&IN4OESJ;]/67AYEF%J9K*M[TZ+AFJJK5M]7LM':Z,E&CM!"S@@@RRS)3O MU0*MV8OUSOK5^_&DN)6]\)0_[9GKD;^FV1WC>9%JQE4+UXR*Y[R+;AD5\OFAZE956_[QLU!UL>+=>@Q MI:/P/H4G/)]\=QT$/I12:#Y9",B<$PSB!"U.VZ%;5,:G5N:HDY8%NU*Z*TMAGV MT&P7VOC66%;F452_@<_8;WYZ)#Z4NI&/@[)8W3F_47( WQ4$BEG#80]'B=VM M3Y_%%A.CZHHX+Q4FX45UXL@[N,J:YLQGC":R;C%Q$G2))#Q_2C*1@K=1"F[A M!*?3)8,;9G)O3D[RZM0[:8$8I>JU*0XMECY&CDH-P@XN;J+LS)^)_=ALO45" M#(UW>2DO2U$](3ZONX&U7 M8'X&/WOY=HURCGA%+D7!.(^CVKFS]U,G $E6V23%8E6,J]"-=O2>#2]FAK9J>+4TQQLD.D(/=75!F^3$24;=8@&-!GU;ZVAT]5FD%S=7 MU6CML#A/-G0OM,67A]\/'>W-=RSQ9JZP78?>19$/RQ&D=N.G7T_]6_ M-;KA]?(^P@^?T0D>U1K5-CS\%QK2V F8NFMOYX<^WVORGZF.C^OVQ>WEO2R@ M^KE61[R>WD_\H;XNN7!7=TI\;%9A'S=1N>ZX;6R>"^X(FLBJ=?7@#;' &Y53 M*6IB.JV*4+IA_'@DM=/N+T[,IM6E;B">_4O(WX*5\>+KTU-,GUB>?^$G;A E M!_85KQ]A6'"[7L$80_.DCFIC7^$@4@32%,0KDLM!%$'( MKYDHF#%P2@N*9U43Q6RN"F+R90]XD"HX>/Q=1/%.5!0F4>![_.F3)%LPX-OB M\M4GUL &^LD!@WKUMI2)="^ S*LX.E,NNN!II6=[/H1I,A@WQ^+)C)[Y,1HZ^(64228D.@9?H\]/X2:CQQE$_($K)F97S%#BC]]MWQ\_1OU MG[9,JS73V'FB_,,+-GQ]AO[+NW.Q"VPQSD,V/H>\@/R M,_)&?O3>AB4&;XL#%:5N 4>& C@<([]R04,K*IOA"2[$%* MXAUB?G]X2P%KF*3SGL]?DO5-CKL@-Y&"DTQRPD5',?]:W)=33,H [9FG-)EYBJ_4G&@O>& V_/T9&[0-R?7"!W335AI3HNA+ M=0;!L>H,-C&KDPD)==F8KXSK,=U',12LER,\<1+B.H%["/B&$!NQG/T^.&;- M/;%GRSX1-#E*\DHY--U&;&(2/1V7E21@^48Q3-Q;4X_EI1A8OMJNJ;Y.(F+W M'NE]&KF_O3^>!TZB>1NTK@?.4;V'MO4W,T^:(U[-U!!Z,(!)VN#2G#J@%:=O M\_KC??[?#RVGK>&=\4.G"B187NJ6*$??Y.-TY*;1<3*Z<:-L1+T7!1,5,C M]B+CQJ >0(J,#Z#1^1.?;,@A];KK^=:&MCCC3$O#TH.J=0WQYD+MX@[U2S'Y M+/*?:]OOE$ZB)5\"VT8!U#K^/8$B;>G1X/ %PEXER8%Z9?S(*[&+$D?K9\%,RR-6*@8'@<2PCY\CE7+4)7#HJJ_K'?H9 R52H8)'\4L ME4&U9BF!CX)S=2!7'H*0QTY5\:+"=Z:;0A3*7O"=.[&A MP3.:NJ?)XX4._]<;UC?W.=\(+NH\1/8?N!R_F) M?N%FJS_&;(0L=C V8["$1A0H#H(4<9THLA!WA_;S,N$$<."C7.[&$P(QDLJKB9.F[58S?9=R?SL MQ!U-TOC@IMR ZY!9CQ^6ZU$K78<"3O0?88WZTS.=W?&N6@Y1PL3IFA(WGFY+ M?KQ(E]7C-B710!INC(3&S[3ET$UW+]S!H*EUI:)M6Q>\3J\K^(A*MHIS/S = M+)[( ?:5Z&X]B-/6'K<+=VJJ.F]C8[QNVRWRX*/XX*(GJ&RSQ/AY%/)J:@\T MAJ/$,!MI+;KJC-W]<'KT]J2#W5MQN L91P(S1W_-9/D:_^&67M*;29MY26PQ,>1\[)]]F=\(U@.\O X M_[\*W4,<4^\A@HMG;W5,I4-D04&O;9/&\.^DL! @T-?##"14EXE6 B0RIO"J M)[!%%C50XM25/P^(EVKWQ49*K1TT8Z34=Y'14:_!5'&1<:M[\L#"8#FE*43E M7WF2B69Z,RAXY#72.3*8VVPOU*)_H8[G M<["D\ L\3\EC(KAJGS5'MT5+\K MSA ?HG^^,:[9#_GF=U\MAOIT00I6Y;89*Q)GO+)-[+@0:-Y=[+DLH? A.2.2 M+0MJXU3,7\"!HX%>VTA.9FF(BSW MCE]SN-%Z=I =K'#=^. $:^^_#TD*9M!:"FGKC#MH^]F@,:=H[(DWH'O*;R;O MD'Q61'(B!2O[NH_A>0<6LX=/E+")RLGT9,32Z-6.92 Q" UVO0G;/7V+9GGEG7(KB -X!8'%:^NN\*YS3*EY0)]=2U^FF M*%J+F;/I&YS6^I_Y%6XH8Y)+B.O36I05%^5)J^SG2OC1P^_(@BY2N:/4A@-?OAZDQ^!&> MWFO:,X6'C$V^VM6T>G3:"KN+UVI5=N)2$\QN6B_HX/N"&3UQ)]#.DWR3Z03A M%:5;&A/72;9D+Q>'%_6$ZMIU:4!C<;"GZ FV:K+G-*R0!_F$]C7RXFD+'\1P M,Z6VXYY >5]^VJ00B:]/9\SM'M?!=FMS&T;/OL5:Q'\4/T=K]Q\%/_.YSFR;9X SD MJ>U:8#%KH/G7B=)$V>J1/?AC*%'GP2:^&4=GDT/LRQU=C M@^@+'2FMQ4>QH5Q:52,[QZ, OLL8"JV9#]V UGVZUJ[!3H_>VCMV6]3R>W]( M_) FB:)I\OZH_*97XE&;#$ZD'FN7^F*/>C3P+H<,UL1$V<>,I8H7R8H732W^ M8+/X8XU-6HH^-K?&'1$=6JJ.W] 4KW]W"3PX\ZYQ78ME'>O4A!]C2EO+.^KT M6Y[SUFK>Y<:E3LMRZ'K13;KVBF1,)GAT]<&-WSUL:>SLZ2'UW?HS3>TMI^QQG\#1J B%S\B$^P&X6<7 9R(R:Z41#UY]J4XGZ%@OPJ=/T MH.9CY'YE:,A7/,OXZ+YF_TG]W>X0UA^Q;VR$TX7:=G/E/6AKZP^J M9JT+#K4-<;MGLVY-[Y-C31TT9#7EB18?B^ ;]3[4?>2R? []-+F[_]QZ4ZJK M#VX/U=+XY,!F4P>\?JLG]N#3/?>?D2S=7G>4SN_H@MM9=?3M6*N]QE\B7TOJ MH9[ZD<9/-"9?_'1+3E:9H !V]7R"+4>^9#^EQZLPI7!U/Q&O\M[$\"_LZ8F7 M.]E Q-] %)_JVW,8\<4%QP@;=H31 ,J+"K@Q^IG=/!&2D$R4[ 7M*":9,"M2 M/&,K!+)RA0")%>7[J.+Y=2185E3PO=G\-8+[2+E-Y-Y8#^S2([8XK.IAHPYL MTJ"T*"SJHX]9["E7#Q>\FS<"6]KACM%/3 MD^(S=8WQQF:WR".7,P3IE0A%&+]%:-JK^3*)LC>QQT;V^"A*M8C A&M0XO=) MYUAWU(V>0O^?U+ORV.#N;WQ8H5HG"2TFC^O0NY8UT7V:L,]8'NVQ*293UL\; M7X7\@3JX]!)=4Z96]KAX=4?&KB0X\0+!M],VVYM!C.7-#>Y26>D\[\7-Y"OX#Z>6@A.5%%)T*< M?'V1%Q%2Q"=2_A4I-,CZ7(4D4X(\1(2K07(]4,Q:E_!]79V$24N,Y"%B<\*K M&)B9(?$]* 'IH'Y^(9"M:GU8\(%[IAL]*.$+;-/=[&&AQ># SI6G,@ M/'61?Q&PI:WD3'!V^)-)8>9)W5)+=,@:V<@!4LL.>),^EM"Q<' M3^H_T;3_O-00M\6AK4DK=P"S"5:+PG"C"B-;)V0B(IQ2H[!XR:!RK<]1#1HH M!G4$?RPS\L$&E$WFP]T3AM\.]-;;>BKT+7/[-@"X06=D&"P;OB 8-FSW=1E\ MEXZQYTZR91_ FLFS$T!-W1F^DEJFWP[6-MM\*KP]Y?AM8&Z+WLAP%R3EGRJR M+AYZ)S!_;B=>[YTV&@O)N;.BH $(/O71@Q-N.#%U)BM/ 2]2'Q'FBWPN0]$,W.'@4RH@?4N(G)(Q2-OW= M^= YC5:$/UH6ND<2A63+H&)%/+H#R/#H/DI\!L>\KL*C$_Z6 /$-,TWH^HR3 M'R:IGQ[ 3G"D+'^QU7%=D%9V?)(/)KM;!S)*&OL)+\O =*DP6NZA,\/?]D2# M9B$E=XUEGQLS;'+%-NZI;98W3^%!G8J6XDH(]+RG+-IYNSG2&0T9<(ZX5K^1 MR28U70)\(W,<;3,@0V\IN.RP(H7LI!!^^7.@R;\>Q6Y)3I6<$>?9\0/X\]DF MBL\2-DUBB.K^!J8:#1L;?!OQWJX\,[C.! MV4\@\BK?*N%2+Q[*<"W ?#Z9D &]"=WQ5X3#//&LRWM,"">_7DA:R)&#+R0Y0Z0?54_=+A4OW+?"?HZ[E^.T#: M8O6I4+6&Y;_4#>:#LUCGVJSTR MJ0S?#DQK?R,3;TK;]J'S(LNKLF*@4'D^9 \1?4&ZT?:W1 MD)SCK[5#?*#9%FR2[<&>-ISZW.@XT7!B/C(CY4,!)KF^H;L')JPT_J*"(WCF MQQ^4"P+980GU%KYWH/R^@!^2**3D2)T8;AO(/T&-VC"*=W"_8<^+I(1/Q#VZ M\%")5EP"^OJJW-KW3FG( [S:7J-&)'HZ;]S!G#B_I6U[W"<^ES MRN8$8WIN.'.&F:P\PS+>MS'W6P"BVT-F[ 876R8U18>6CJN?Z$P%WKXI'%6L M.F%!MV\#-U5%D>$E$VWQ>QHFS N%["K;R4U%VLPM=]V!WA\B\6XWB^Z;#3/' MW@F/]^L=C7W7"2_$M?0H/HK'H5CC2\?=WFRD0>C]?1JYOV7FJ9LL3,$$)PQ. M:]-\,'T(/Z$;6/W:J/D,Z[D(/U2V!<2"83N2E]"5(N4@A& MY*-[T ED@PZ9=*P'E\_.X^>H;:SKZ _G=^^DM]L\$M7Y+.Z"WL!M?_!V":_; M&GS6=>)':S6>E#"HS'G (CE\DF]A5J,*R9SX-@8\VCE7X0;^@3]=.G'(Y$YN MXNLH213D\9DSKXO-A@LG9;^F!Z='!FZ*'>Z8GMK.'=-E([SPXLWD&IN=0#/9 M"!>.*-*M2"8?;/^!A 0F8PD 2'5][P)B D;1R HENDT#JL7>[&0G3!PI9EE M95$XC\BMU0)_X:6+*/!AM]1C22'[!^8G0.-F+Q^GL+H9I%@JR:Q\1Y]I>.@Z M%MC>:7H5LZD\! M*@>8I]I_N<%=:PG=$"]U7F:@UZLP5;C#0K1@1UX!P^_0!;Y9>X"^;"HV;3%H M10W^LC/USB-X9S#DQTR\]\Q$(&X( -DUER(;&4[6_.V?O1P/J/53_;4*9L4 M@' )H(B!M-G[8S[10U&<>#Z;K;4<"J9Q2%;'&DRC/T5N)H 3M(?;HF--JJ$W M_GRMAPXS00F6Y9^IS-&($GA>F9Y*=5ET0-, LV2PU_3)"5ABOF&MV4=.L X] M>3W+#Y\^4.V[3&/HXP3+R2PY(./M)OYB,N >JHY?4PZ V8KL%7;\U):3,R0; M2I4$)HT(W6RHFS8=\/BR]=VM3'NVSC,ECY2&V04%CWB'&(A"5KVGL1]Y6'/J M&;Z&WCGVM?BV5*D($XL4IT&@_]CX+J[[]5@#=IU=Y(_CXS/G:\-FHEU>-LP"\_6Y@= M3JQ;ZC!![T6 <;.E!F#R*;$7 \TMJHU'Z/S(:F41D4^:.B1AW M>5\Z3I\)>:MVC&UY;-7IF?M209.0Q"F*5(.4JMR__@)<)&[82( $*<59RI*P M9>:'!)"92/S]WW\N7&,-8.#XWF^?CGXY_&0 S_)MQYO]]FD53@\N/_W[/_[7 MO_S]?Q\<_-?UZZ-A^]9J ;S0L" P0V ;/YQP;DS\Y=+TC"< H>.ZQC5T[!DP MC*/#7TY^.?SERC@X^$?4Q+49H"J^9T1M'?]RE/YPD[3F>[\:EY^O/A\?'I\8 MI[\>7OQZ.>C,0?5[PZ\_ ^>W3/ R7OW[^ M_./'CU]^G/SBPQFJ?GCT^;^>'M^L.5B8!XX7A*9G@4\&*O]K$'WYZ%MF&#$G M4_WG.W33!DX^;_HBEL"?#M)B!_BK@Z/C@Y.C7WX&]J=DB*9M+G.=X"]"9[%8 M>> 7RU^DY7 S'(-)B_\LE4]H/[JZNOH<_;HIBAIR*$UOV/./?S&,OT/?!:]@ M:D1-_!I^+,%OGP)GL71QU]%WGQQB@O_/;8*A]-^19]]Y MH1-^/'A3'RXB=G\RT@ M6-_XG@V\(/HC\%W'QEB_-EW,S+A+ M.\9LB@7CZ7@)8(1?!0 A]:,U0V[\Q1*".2KCK,$#6J@6X-$/%'.'V&D?6:5X MJHF/0&\FSDUOAL9^]^<*+2B*V57H2V_&F,'\WO5_J)YZVV[:8\>M$UBN'ZP@ M^ (\I!A%IDE%W2X&_K9:+$SX,9Z^.3,/;9DM$^V++,M?H8V1-WM!K+8<("([ M\::[(/L5K(&W K7HVM3M8N OT)\Z8:0= 7R;(PU9BX:J9KH@!^%AM5BY>#:/ MD::'N95 <,$6:K4+8N]-!_[3=%?@"9CXAV^F"V[!>[C]M1;%=;KI@ATQWE80[UQ&02!V8J,WTPDY M\7[?FSTBH-447:F-CA0-7 '[[N<2;R,"=/3/LOC1,=\=MSXZ!5KO@GBT:<+\ M!QY><-'@D#Y<.&%]]4-MKY-=#%[!(ILA5O5(!L*F(693G9 5^M;WN>_: ;" M!PMZ,]ULNH(0KJP0*6AO5G/KE6NA"R*N5X'C@2! Z'AW/&&;"ZNA;LX [P'X M/XY##:BOWYD>1Z,&I),;T^"8U(2NZI:T/C(U4U9B?>ASNFA -;W! MSK?FC;8-%>WHLDUO0!>MN0[]#;=(^SMN/9**3>B[7<>^'?P_?'9=HR4-+?%( M4410&$@E'HR\SDF^ 56 #1\8YW"*I91^FSP]-1\L\]]!?8H 5- M*PS^<,+YS2H(_06 01/&"/?1(2-N?!?M&/TXL&,T@R#:1F/]X(7 FN=_]NQ' MQ\*+]::@!#;)&H%V3!P%(4#?!]6_*N,<9[?:L>M+\+T[M GTK2/CT'@GT/2" M*8"M,(O:GQ[V(K3%=BPTSEO'7:$5.A-9E!1HPI\FW>G!GA%:I&T\5F<='TD: MK7A"[6MI=&M"/7_CVIC=FI!+;[ ?AKI!8+K.7\".9K0?.%C_ MM\LRQACTL&$V80FE-0VLF(TH(S2E 5E/9BA! ; ;U=IDVW"I$^Q$LYB7KYZ# M+[*9[@TZ) 6O( F9!\RHS9NT:;8]9>;S[A5 "T'JREY9SMMQJZ9X)YL]!E1 M[WMO(:(5S-!VVW4=?&5'$;MY>M3')5'];3)1&YGY&G2G#WO&R\AN+Y\1Q8;U MB!4;3]'1'.&Z&<$NT$#7??_(UW3OK$ M@FBO'XXL!+=XR_\&/,>':*>%43AWEF]H)8--M7[C/OO$J/3*6+H[^^B"<^1! MZ.(A;L(5:GNZ$/C%=+RQ=VW"&?KC986VCF:SG8%X)[JP MLK\:W_S.5_V8R@ M=:$+&S(3]Q5$]LL;-)VESP16-SK$/3=SA!/:4D48;C! +4:M!<#Z9>:O/P/+ MCC*=X#\BJB.*'[S 0;IX DV8B.FDMB!*XA.C0ZH41+![1 M;PE5N!\.AO.E\,CP#OP, 3K"V9MOG1!W='AX>'5H'!AI0]D_3<\VXE:->IE! M,)V(4M>W2\FN"6JP82?;G;^GAV?G:"I>7!X=;<>6!<0(YL=I0BMM M&OU9PDB>_TF)S\LH;\"!-7?<7D*TZ4&0^>W323ML?T&G,!^AW[Y%VI3"_URYW@F"/?I$(L?=2R1RAR=+ MW-*'5=.35+1W,:?R.6TNRD3 M+Z_WC@N>5XMW "L$4BS2&TEP#3P1P5G7(G@%,P>3X87/YJ)J&:DJUC-1< P^ M$<+(B?+;W.#(6?AQX]MDZ5!K]4Q8XK0DLKOH>BJ-;!MQ M,TC^04<;<$246$79GLF)EX)$.I>:2.<&>S#@Q/_AL62S+9FGZ^CB\O"X!Y)A MC#^1RY4N2H0R^/1<>:B)/+!-WW3_G[.D+CQ5A?LI&S8)J80Z M//KC*3V"P"3()/MS;Z3 ''3*]PX/^#%2)N;/!QN1&5USPF-@'%T(Y7LC&7$J M4E'1#ORG:D651(]^'!V_3["EMT(ZQ2*]$0C7P%,9='BXQYG0W9>Y[Y$/]\4B MO9$!U\!3&=!.]RW-@[N?5N1U)YSNJXKU1A;<@T_E03O>M[*$)#&RL6G.\6;X M?+L*B"M(=?'>R$>8B%1.G1_E'[P08(J<-;@U0S,A@6)_J2K>,SD)$)'*J?-# M/3:RPAL%Z;II[ =1&+E2>8*.$4$7 M.@N#/?;4&4D[QK>(96E>R8?;=""+G?>\-_]JA3UG=X5D_V MA_YB@3T]OO4]OB0^7H7X^2@[3O%*V!E3*O5&2#5)225'.^&W(SF ,]JX#YX- M?OX'(&NP0KF^R8=C]*E(.CSP)_OU>R>P3/>_@0G)D6&DHKT1C! !J6PZ//RG ML3G; =^C;ZKVR(22O9&,R/A3P71XVL\/-XXUY!--IFQ/A<.B(!5/AX?\$1JM M'8W8-:OV KG?\T2<("+.]!0#>]0IZWF<\W__7 RH;QYE7_/ER Q/B5'W1X/H^>;.>/O][F[R M]JF%,/RI&;Q'[:V"@YEI+I,[%6X8I-]L<9I\\6U#TGAZ[WB(+PZ:8DG*$D*\ MOEC5^A.M#CEQ.A+&P/.%=)F =22"YZ8 591; & *T.;$?HPY120CHB$$, !1 MR6[$FZ:>X9%RH:QNPN80&DG2/)0I$+BDDT$=Z>-4M3C/12&;;7AC0OB!CIU1 M9B\"&KCJZHD.'D&705*?X&&!IIBK*YO:+)NUJ]I95K.5(0%)!NF4RT[-(=7H M+DXM2)7R0C^#D($?2I5!@4643LI=JQXJFQ<(EJ:3YAA+4XSE&$H "$?-//]. M+RZ/NG$!R\!)77(I5\!Z"!<>8 P6 MS"KK)."PG;#TVW>V'GGUPH;\V>?<^B M(H&_ 3UA(HB/AN0.:\N1S]OYZLSFX7CZ%6E.S%D"7JAU!@$1<0J'MMWP$0?" MCQ?7C'.*H-D1)HOOMIN2OL MEO_B^_8/QRV&BXA4'01$:A,J:T.B!U0V#[23MYV#$#>%%,K]^1[N,#,YK)'B M*Z= 91C,>:OK!HJZ#I-&]"K87G8&%CY_"KF";H!H)%@J3G@('YCY/#'HO9@? MV)K'9^7,%]88'CSR)!LY.<@<%ACRYZU-/EPZ*.B5!@>.&N0J-55TH3'P.QME M1I*51G7YP4%#C%))IHHU@.]^!2[..[%_INFW\0L@<$URUE<5S?/H#/'HL-]H MX"92J8'BJ/4@CN0]V>QSLIPK"4_5P<&D-M%*C15=GFWI(&%IUP% @I/$81DW M"/LJIM>,64]C>,@XO=:C?UA;4JH.92*(L_; <=2$"\/RND6A*AGNLE40L<+ M,2-(^+"">S)TL[UYX^3LX7 @2+FM'JX>"R-R@I]Y<*!33 M#1*",JS:67 0*,F03K*&M6\EM6TG)N'%=.P'[\9<.J%)"LT@E,YSZOSB\O"\ MWU 0H7-81Y219:T6J^B%L?A9:G^!Z)@#+W#6 ">77P#\FOPS",?3B?F3;$L7 M:65X^)% _[ .*Z_X03GG^>I,E@,L&BDO//;" @=6MTVQ8+Q-#DU MHE\Y+6['XHENWR;HGZ>[Y\F;,;XWQB]WKZ/) RJ@JZTM]@-N2&28UXBEV_;C MK8&W O=HEE1%8F[R%^!],_JO3?81UVA)-^W D&#>IR>'VJ[-:A(6C"#$KHDD MY1HK1S*I>(^A($12[ZUD^$898B-.G'6+YH#K1T:8A':B:J#4T4WR0N*L4@RB MM#95 5:F3Y,#+2;CUG'$"2"&,Z\UF]B]F_-TPA'I=JM-5CD,BC5T$88;LPNDY> MF+WQ%^^.%\GKVH0ST_%>5FBCA<[Y7]#?K\#R9QXVR8X6.*R!@*-ZC?482!() M[KUS(XK=?O8]/Z^!Z1M3>J4>(Z,&8;UW;&R7W-1RXW@K1/K6GGD-ICY,8OHG MYD\0W/U$'$2$H\D#/QX06Z/KIMCFX[MNQ+584U/M?$IZ[#'VVN:*@HC8+H"+ M&)%,SVMT@)P2+UD02O<>,'P4-?6]5!Z4VQ7W,PB9IZ)[O/*))[;0:.Q2GMJ*QNHA:2'UO\9!HI MUO#44G7<,/*\6[P". MIZ7H#H:J%FU&-Q0(J' II*;3N[\.;UXVT%2^4!MY/EYU?@=)"@[JPXO,$QV7 M#@)5B;;D#;$3;&6W$2/$%8&E29/0.T+N"7U[O?4;F'?]X9 M#\_H\]WGQ_&;MF%YF9#/F%OXR; M#EP8C/0S+_A&$Y)<&$+G?15B3^'$C^^K,U NJ?4!@DLE9WH?$TABSKT/T1+M MQ=?*K8\)-+T ,2&^W!E]\U 7Y7ST(3!>'H_SNN]'SF:;C86Z. MO4P8%'0"]--M]-#)"T!4V#6QW[2[/?I;XZK2+(I7'=RV+'*- 6%*C=U&H2AC M9(5%5L92G_7"9%0G<]J)>.8T3OM1#U.J#=>>)++%+^Y?E!_?Q#K,S?[30S3[ MM;F"+ML8H8A9O;^C*KH_K^"9I--41=K8$_G[Z/D+WD(:=__Y]6'RWSW8,-9XP8>K;MNI MW)-!3?#6@37RJ)#&NH,MDWSJ=B99.H:A;(8=4XA5GN_AR3OZZ9#\Q=0ZV@J4 M+!>*,+DIU%&V-]O<5$\ A\"034?Y2J.*N+CQ$V0I02K32MWP!)$_LK;] M!)"N?U25':(8^0DE)@[H:!.,SL0@ND',VOEN"FHKOUK;73I9FBR?2,E#_"3% M+8C_??#*)[57WW7O??C#A*3+6(*MY!ERU+D/E5-D95G+H%MIE%67S^)*SVRL M 5)D")QZG.+C@"3,+"-S*D(_#+M/5";KZ<+!HH23;DGN&QHVNGG6,DX(GW4$ M1"]%1+^-(RJ#NY\ 6DY O#0LW,X.(:LQ6R2Y7TA/N%QH KI80TM ':6AG8:= M*%^:QIAM$M&4%5WKH;JTF?@,?D2_D,]3''5W&EDZNBH;/6=1A4?-Q0\@J0?KI*'P&H#JUQ_IY'% MR0X%SRIU"*V&-R1JQ*2*7K@<+ Q5,$E6FL)*<)ZU'YR0AN,&$Y_@A(]F+8ZH MBP(O$1\C8+R">!:#-P#7C@7B&9ZDF,8%HF6$&-^@MMO=@'"/9VUJ_IBG- 3!43'#2G0)#C@?@SBL_8C0LK^)0 MX2+,@10X32WX9."D;-;E1H49S.]=_P=O6K>SQI/XS_ZD,=MPQW^ MVQ,555K?3> QO$!_[2 )7G]\1>)_\#9O]XRLT%G']XKH1(DWI)M2X9%D8<7V-%#)@Z(64WNBV@F\@EB;",#0;)PPIARIWJ\)',LQP7Y#;D$U^.EE'1 MU1'WV;1*>!+M/H>6W)8IC06L/7H MTBBZHX*CJ;EQ8X&DA=#PU-_#3Q+/E,8,MGY +;O--HQ)@B\8YC?^!G1#H#*C M6D.6*$T<+;J#(RR;91+CC4(X"@(05BZ5C"JZH:.A$ N+7AWBFUK"&!LH#50- M6O[Q@3AX,3_PPC_R[+QJ?G3,=\>MVGQ):7.PD%/'':76M-:CI2IFI>]%#/[# M">\U&L=2Z(8O9=NLABQ1^JR" M+@![\-8@D!&T0VE(-\!)"MH1I;CW*;_1GB -P\>7FR! '$%S*?QX<4VT4?5L M'$2YI-@B^!O0#3*2(% 1]-.,)8J/ *V;\TOL>$!R]F8.WHI6'1RYZ^6Y=XJ6 MC,L= 107)YKJ)MUPA'F;T&_?(\9G;F.20MG)-78&.Z(\4&J(:MTCC?AI 6 ' MF/(W,SK[/IDA]C1\S,_B2PQE)^W)M4B"5-+8(UGCJ[@Z^:G-#L2^Z M]3Q_*2?N?9B==)$MKX+/#'1QMK)S.&O"EZ9>:MWBN?B9W=BNL#,X:\@268YH MK0U8]XYG>I8$ Q:E(=T )\F )4JQJJ>_.MGAX[P]B'H0/2F;7N'EV-%7UM,- M()($3M_!\W-"TI4-THZ]?2M5]APCD*.466\G<<3/":7.Y=;WZ/S,;;R0Y;EY M=G%Y=#1,7#5DB:P53H\=T]UT"BRT1[C[:46O6KZB7P5X'BG08E#6--+Y*4'_G8(ZW( M[-V&VI$T6UTQ*YBR1&"W3F"Y?K""X OP ,0CS0J*D-WKZ!#]QS@PMK71AVT# M6B;K&L.9Z277T;8YSC X/?LEP\+Q-#EEF.XV_1G#%"FI[9;/K=AE"\;3)(Z2 MG"Z\7#"/_?/.,]9*E6WN',I'NJH\7FIG_-MJL3#AQWCZYLP\9^I8.%(MOC> MDZ C)EH9HP5#(1R7%4+2ON%/C4P/QK8+(].'ECJCS U6CBI*A983B)B!$XRG M6?2CR4"5] 0)]]HEF\^;-*F;QF!+-I?_0S;E_508KV -O&V:=(9&."EKA&T# M6D[W9'C8F%UUDX4Q][EKM_WB-W58K$G/6UVW"2XHR_QCX U([N?,WN:L? $P M2D+#.THX8Y:3B[?L%"B,@S6/B>5U MF[@L>>2,\T)$]7-JHJW%:K%R<718^868;.9=QDP]*\_43-.&C]LVK&SCAANW MKN6TY7HMI])$S3K+2VBX]83_Q<$^^R%3(["JZ:88Y$F\D/A?G M*>M*)6 M[DT'1N_F/"$.H<^+K)68H4K.RZH$-V>L<7O&(M^@EMIC0_V6"-;1GEZEY6QY M%6-A37=JG3S*+Q#*SSJ=ZSSRR26Q$R:NGYN!JHL0H[7IN/BK>Q_BVSBWX#TL M7SAA3.F+\I3>]F4$F^;0]V;:W\'4AP90KK.^DKNT6<]O4K;64QP MO'BD5Q\\+.7HWE4ZOOCEF\PH/?L&P-!TO DTL4<^OC:Z%3%+8:CJ3C==PX.* M?-J3%OG22I9TM3HKWK=590UCZ*3+LDX:QZ>4N#'#3%O34MN\0+ T'?ON)\[C MN\G %',@90==^0BUT,4[L5FALM0)I89N&J&&Y,H/N?)3.H#3Q#:O&#YO\4[P MJXH)GC9D;%K2S\28!J*63G8@UZ M!K#DXG3+*Y JL"#58(E.JLBV2)^H1X>5MD/B;U MT[Z!_:U(30//2HY._F+AA *VR:.*P,1LG+-:JF9,I1'?,B0D-'S=)TD MV$;[SQ0S!\?APQ!H1#=M4DO&Q5>+&Y+?3SU!?W6(H2*J0A5Q>P=XED?*(=NB MEMHA<_*:9CGP"B)O[HT?A$%$4T12FN>$H2Z:-MKRTXR\H[W.CI:E4!JVJIN& MD8.3W+N."AC44QU4>G:>4_]4!$9FV_J_!DA;TU+WQ+2RPJ0*A5I^E*XD&NS3 MY]]6<-?/P_FJ\QB):MGD7IAK1%H_9VITAVMEX0R%WHQSDE8$-A:;T7)VY@89 MW5^+]#)W5B6!^FW',3,&QC^]ZS2EVTP7EG,^PED2 Y3:2H]:40[7Y;==>6T- M%2&5:6OX%)%M3DM=44$ZMFAAEU4F93!#88@VTOD[ROQZ@J^R;IJAGE09SQWO MD$)X6[T': >.6KI;"Q@>*X(BMRT9(&U*2T50))DQY[Z:RT(UE!*;#X_HWEHV_I7_]JZZ3NO^7EPL#^HC_G_.: M,J-R;G:<':+9<:R#9U'L0G(=&E5I@-; \34 X^E=@-0%.K.0)WZ^\3T+X!O9D;- MF@-[Y>*S;V%$V/IAC3S[UG%7(;"YYG[-UO*SX^CB\K#;!XQ%LN/()+F?=F-F M[APAE7!65@D\&72TUP_[5#H5.H<*G2T9@KJG5JNZZ2 UB7A4,&D 5_DJ\_0( MJ:WSLMHB9.O17E/U/&W/%N*;4<7WP]%2G+GIE4C:'GNO.(T$CM&*_#V"ND9" M'[II'M&T0.J9T<]]D7@:(2&-52BS[A80L!T;FA:^9Z'9 M$@%/=,]3J]G\;#ON_ E%T2Q!2NAOQ2S3GB/?0YM"U_D+V%],Q\-;NK&72:[$ M!3.A-OJ.J>;$*GUYLQV[7D5V'9&UZ;*\-E4EE=)^U1ET=JFM\B1(FW_U836@ MFTYHF'NJ(>'#2T4EI!RN*I1#(2&5]HI!?68J+("HW\/SD\.H;_S-MS^ ,YOC M6T1KQ+$9> 4+M$BE:_Q()'5>R^] MWE/3F75$NW#VEM6 MY?U*3_P?3_A5+_0OUU)2HZ7^8$LVD4KWE^VL']RYTT16EJ/#2M^10 8U[=>= MG4JEEG-6%(8F[A*B-I"?9R<7ET MI+W*V&1&PTBBN2Q_YF%K4.QLC2@3"(.1VY]N M:DI^YJ-V62=)P:&CP+O?4:3UEF'5'(I2T8PCPH(D]03?EKQYP[N$5JD\4G71 MK,4$0$+++2L-D/9K;&OY@+Z)GO$)9B1"A]$4P("N[ M1EAA*M9$%ZF5W4"6$/62;D'G=];U<458!K>4WLQ-;P:"!V]CD'WP;M"NS7<= M&Y-\;;JFAT\A !07\08M#00XLCG0RC7J]A/>">V)*^Y!5*:]TWYOW$'^.UF[ MY(SY- YHQ5TA].4#6]%OJP6PM^8'M+US5_@5.@QZQP9Q^H!1=J2W:![0U8B* M'O.3[;3S6Y?B4B7JG-;8I=6&G(#;G*'#="U\S0.-\MZ'.*1M[%V;<(;^>%E! M:XX]V\SC7:,&!X%/\3.60X\X)RMC(DE,ED M@8)T1$KU58;6W&EC;H9_ &QD3)7X*$BB!\345]/VAX2S=I@S@-W\%^"A38)[ M"T+3'%8]D)>T8?TM:TG;3/D8K&!)TQ+?MT2W&UDN&I^/I/0*=9SFF M^X:^ 3R^8TEMMYT8'[\N#>STDG_F^NPMF#J60S;MLRKJIE&DRCZ?$+\6*YKN MN*_BV>SA#"U)68WRZ=Z8P1S_#S\3LC9=$+\R%AEB' LK8/2;F-ZI>GF+/^7N M@8%[_#?#0O\?O9&3#"H*G(.;8<6_:Z_'>IR>%XL!OS=7P$9X8T+X@<877;0E M4,%5-S_9SCJ_=RR8FK$VB;W/S4N^ZYB_3IP$")*0+M9*O]$B@]AA'=+S*PPM M+F%3J-\0X*!%Z5GY6*--1QI>C YT *G.=YR(0&R+T22K_T'Z;8 V%.D ]GL) MI4_U)?OSZ+A. M]QGP7I:LK*.M#.GBJ#@D"U/92B:+AL[%YQ76'^-IJF"*D[.ZD&Y"%9=-P2%8P5V-O*&Q456?^#;-K_0,PJ_$63GGKL@4$*KDI\WYQ>71T>=Z@E%CUM4DMF: M526 84:TZ--6K.C#MQ?HVRLK',/D^G"%"8543#?Q"UE;"=/&('9GY=SRBE@S5N_2[ MG\G]%QPFC/YK3\R?]7;L52T-# JR.:%4!UQ)U@%5IV*J/JBJ,#! U"18:7#) MJ:S]6_R$4'1?MP3QS77>ZNT<5]4A8J$)Z<-Z,5H$-5QU!@:7^C0K>!%:^C6N MKTO$+"],$F==?WP)OM_[$.=-WEY,FD#3"]" 1XB)D9.J2I?4:BC/MHO.\P'+ MT"SR&-'*P](-\5-\R*Y:G\;9)1X\M.&*_L*9MZDKDX1FAX@M56Q)D':A!=(: MKVAHN@%GYL4>,>LCRX9HXL57OX\(:QMG[8'!2P;U"8HNAX&BC;\Q>5#@!<#H M^K9G@?&[Z\1\II_ Z74'BJ#ZM"?XN=(D_Y3:G?6&3>GU[#I;[5(C \64!":D M)K]#+;03UVX\CN\H(8-2#?\7OH@9?D*8+@7WOPP?/"1W3 M'4^G;W/@3G,Z;&+"&0BK]PA2V]80)ISR+JP%2AG2.VR] !C@$6(+W60.H+ET M0'TT45K;%?R(LJ##-8> F">T58)H"D243?Q;$#@S#WUW[\ @'-FV$X^0,D/( M^)'5]F#0I)0AD@+E5&$+S9:(S/A9M[O(&)K.+AR9P0DCOF:&B9@&M$N*EU,( MCC=@^9[='!T\[0P6'K6)EQ0GUXEMK97+-[T^%S1:YG?AAR%J!4[ME#NG1+QEG'!4'H>R!]4+A*T,Q* M0Y1Y/:*U>M!$0NXPW_K^$ 0K8-]&K^[%;Y='STD'S^!']!,YGQA/Y3P7K]": MVFOH2"!^6)=NT,;; L .<-P")CJ*CHRR7(^G.#4Z\>8-N^) H5.3<*WNX/0M M)GDPX*E/NZ0[.(K?Q,WXJE\@6J&KMBO%,@,3-3^-K5QVZ3!2=!2$ 'T?5/\J M&AY:>M&6-SPT'0:QV#XB-,GY=W%\>GEX@3!Z>'%T>G5QJ(D-2TZ(:/>*I8D@ MN,U89,IUS%DO.1:T>QD+2Z4L6'XZ.20JFMMA"#&>W:. 7X1E\2MNJ.[%+D'-UR)9:?XG27F Y'HHM)4U M75 U/!3\B[KLY/9RG8?GA^A(?-)[D8F22YF:=;?7#+D]H)/R$A^7TW%1LRV6 M2P]9:IS4*O4'29JF15M2>G9\\NWHH;P*4RMWO2%"H#;=6GEV"&!X\4/$0L=T MDZ7DWHR-/[12*=1H9HA0D<6&O7.GOH.C_U!J3ON. M.'?Z+VI^&H?NW/D2?)>= .2T=@*0M__8I_X0\B^<7AV>'U^<'YU>'A\=GYQI M8B62XNC10,DT$40#1T]!]0S8T7.N;3)?LE3J.'K.^9\)V$%'S_E%YZ_H\8M0 MKJ,G)5WI@SQH6:V?D8.[LFXBE2&6PH:Q&2^TR\*AF3M( \Q(6 QJD=P'=U![ MYDMM<4 78F/SI5P]L9M&J-YCISGM2I6))!-40ETE49F7#1)S;I5:$6MA8""1 MQ8%6KE%U:]RJ>AQ#U*!UUL2@A4U8Z0CV-BRVZ>1;ZTN44BM6][JFF2B:V+'8 M&YJAV+&ZE[*P5&K9L?@ENK=C:6K'(HI??SM6\)WQZA7%C,595S>!JK!B-6&% M?ED"'V;>1TAY8CS[>YZDR\YR2#>70T&F3"+UD]MC.%V1I;;]=; R8Y"H749? MW %*Y>KKP8:O#@,7LMC0!\MO\^## M8Q'! PG(?D"@A]YQ?G9Y?'5T>GQX=GQV='%VUKESL3 MXLFQP0!6K9Z%E&T\X^F4\57.S[&KSO.\"LJCK%D:D*T@&JI=O#R#<*LX"+#( ME=%-^@V$5T8"FU*EX6^M:XLB]+5SWT44!Y'"Y\$' MNY7=05!-7D@RE)#V*U?ZHBS9RC3&6=+.'FE,;BBUX9QWO?N)M\ABFYY<'=T0 M)'VOPZ96@=FV75#\ ?"+/< >(85HSD":NR7.PCY>A4&(SC&()[0E3J@-W4 C M+O,R;IHS0-+.25;V 56P2I1MB3%BP"*ULD/0$F)!4R5U%8/+ R%Q4]ZV>6>$ MU'QD7''6(&:"J#WGF-^>D^TL_C+0WW)3!)_@0K\MWO)[*M8CMVMA#O)"]=$TKOC+TPX1V\ 4BU )[XD\L M>!Q]2&R=Y*DOVH9N>! 39&'*2R&^]\[.ALOJ(^."@*SF=4->'W>[=&8J#45N M?5.LUNNA 0"58J&)CT2R9B39MD53O'>M*$<+[*12HR7CMG5#J#ADI&L\"F,4 MP[,="_G(LE:+E6NB7$G)JJBE'%#P]U-PG@P03G8[BM[4Q3;X7934@V[NI=73#0F.I53A6 MA.G7T:)<&#S5C%Q95C=)BXNE8@?,3:@F5L ,O*.KBV[,T7,U,U 0U*>=:$G1 M;J?'BP-Z_3P3CA 3CH< @!I$$R.'M9,\AC#3=BO8C&XX4+"_D\(2K9+!M 6V M]'#5#&MI*SV%&AT7M>%&Y8HD0]5^%\;61ETCN@J8?)6/8$;QWSU/%]\Q:O_U# MDTY]KM:PAM;O;,>QKX!YDBZX:7.9DL2Z[?GM=]_%]R32P]O8RP0 0B= /]VB MCU$"#;3*U81YT^YV'.A*V"/I&5FBO?;=YZM[VX[ M/CS3ME@-O*=\#>^XRFS(*$E)H#0Q1(ANH(I;)GG[VHJ6=0.J(D0UW];R\DYQ M_$[K#S/+WA6UMWW=HUL]+ULR2ZB-5KLW'?A/TUV!)V#BS]$3&6(1:N?E"#7< MJK'&S1J+3+OZ!Z5MV+$EAY5FCU8%)SLY/46=G%P='9Z>GQ]>M)[^83.\41" MZ )5FM44H3T1NCWV7O$,P)B/GT>!Z4<<($H-/)/6?GZ.':,YUFTZ4&&YEC61 M6M[H&*6TH?CZ(Z-0[B'X(UB8:JW&ULY@I9CN@\> M.EJO&&]($TIK*]^VEGX!ME#B3+I[1CQY_A-SZ@W M6,A+HRG%60%^&GFH/HG MZE9 9A?:P4U _&7P*.>,)BO*C0^7/C1#< O>PZW!G[JF4.OH!@/E@BQC1YP_ MFH#AZ]L$1GKXX]IQ74XTT"OMX5"'09IL0[Z^??'7 'J8YK>E[P4^6J'OO!! MM"P&.*4QM\ZHTU2>-2>(-8>[AQU);-/DOI>,/> CXS*8U#YTPV!G]C-ES%3Z M]&CKF_8;,Y@C'N!_\.7.M>E&E_?#&Q/"#\20F)=TW[E0&T,$*!TP%1NNQ@Q3 M^C!8Z_&%=$904$>NI!O,FHN\&D:"'!@6;I(IRWA ,U=(-UQTH7XX.#*TRWI/ M)OP.HG#$3) @'3>T*KJAB$.B91@($ZA4>;0>%KQYQ.[>AV]FE@GY0TH<0TW4 M+F*MZ 8<80Q4:!,)'&B*+,J#2ND],K4!N)5\+# FSPZQZ-R+=OO$2UVF;\7')J^U %4> M 54:=PN_ZB(D-FLKQ$ A0:5WAL'[)\=S%JL%D?NYW[7C/V58>0FPR>A2!N9/ MN@RRO_=8!DPR-/%**0B.&<*"4H=@'4-<>QWVTCV01,3?9MB+5#U.>&B*%'AA MAOBOC_CBZB,(@LG<]":H*?#D>^&<\NQ4LQ9UPX9RZ6X!I8I[2O'S]9?@ES16 M0PI\&C6XZ^B1SSQ)5GA7WM-X7#,D0]S$'WO@OX$)&ZHLW6 )%&YDUQ$EAV&2RAY/4CA&S,#6V97IR$E_XYH![9DG8GG=8"'1 "1$LHXWGPI!/!5A.U&< MSE?/?P_0#,*\B>[WH9]]-%%<)Q),'8:3'.4-N62+K]30_-%T-+H?0 M6;)-)_\%^D&P32N,\PE?@ZD/ >65!QEM[W'9A%&27MK1Y29333[AQ->JP)IK M>P_6)HQJNNG;W&^8X>XU>"N'\\Y'PTLSNP@Z(5Y(\IK0E:!N-V?R$^_%#QP\ M!-'[-,<2[],<&-LQ&:C!P%@FH]JYJS;?6D^-7S4:VA4;8OG\##M',ZQ;#PN+ MS65=(D::E@G%Y<=*ZRE(LE@J_!@"9'((]60?(2W@I.X>/B+B+X-'.6=T<7VH M30S8/0R4"[+"X2','TW H#PQX$["H0:#.HQ@'E8VP1T%G"2V23(6=@+#JMTC MRUM+K:,;L)INC\6)E>7HT,-V3/=NW_A>Z'@K?T6PFQP=QS&58_CH>S/.8*&F MG?0!@G0(L6*%E'!(:0*FUG-R-6-8&EZ>,DX);HN=['%;BT-*]:UFN*UF4RUT M5C>U>Q@4X(,LKW!E"$/KUE"Y2\KS"N^/Q]/T=S4JD]GK[N%7#;E=H'D=K;C4*_',J5N[M8=EG46.SF YFQ[]V#;A#'$BX8RMARM^^KD MKF29F"ER0'FI'*OD:)3;;SG.)P#F.2"CZ]QBD5N7I8SH4=- M&E;H?>/D"P=)T[+N?2^ %8.39$1DQ2U+^T.,PA5IH5_%D1L(@HJ*D M;HJAAJ2R.H&70@7>'2GYNLR?-ZAO!]^B!DYTJ?JF\DD,1FG=I,HKEJU ZQ"H MU&77^GXB/Q.J84 MVW\0B).GE?>+E-<1%7$LTWU"VP/HF"[AU1MJV?[+5IP\ MI;<06S?^Q+DU;+3M0EJ.I>[Y*N6Y=GEQ>7S4,U TH%.IBZ9UOW=YU\/>T@T. M!9RT*?582-+Y'-O:!\]R5S9^=M"R_)47!EO<5ZT,S5KL/TA4,4&IBZ&E8_\2 M0-2&-WL$9B#Z^ME5Q9D_;<^(&]3_O!^/DW$:+A9J6S'V;^S"< +A@2;AZ&//: MZ0_@S.8AL$=K].T,O )\B2;]$2/\B$M1LYOI'RBD4#BL6#HJ2_ N"N\Y7\T0 MO !H48YQ@LT,##N\%+:2@Z7A4>]Z%3@>"(*1]>?*R0H-O]6CVM)EDKA9ZNORFEV2@-45)U@)'(FMT$(7[U9?+#;XB]I)4]Y+@X,C0#B0!'\)M# M,K"&V]FCC9,GPTKM*\*3>W]%2L @VLP>;7PL&9;I1X@ESEJ&;L/-[,'&QQ*M M;$6M@6TT10.6A+A<6WO8"?!%J55*6^PUA-L>8716-+T7J)?3C 2 M???3PF;B!?Y4!V&DMG8=;D)\:7I9CZK06G]2@< 1(0/MQP[@1X3RIK?F-'@> M8619< 72:,(@#2=, @DS'!5RS!P=EB/JDIX,D'1EF)YM^+FK=>ZV._T]-6EL M)8(:#JQ$G$LHS#"-[YY=K9:DO,-7ZN;>AR\K:,VQBX-R18.KHF[*HH' MH_M MU2:\Z]MWC?%^MUBZ_@< KR"^2EQB&@'=S'HY=ET>=GZOIR%.FM&MP!;>Q2T. M$L.H-SI(E08*D!I$2[)G> -<-7E%W2 +S&]]% ML,!OAF!Y>H@[5G0+:@8!B!ZNP6W<@C5P_>7F,VX50/Q0@/-77#$M+G:H.2H? M:G($1"<::TM"]&Y;0H41D6&D=/R;D:,DJIG08FQ&%WU[XQ_86WK2KZPB28:Y MJ:7]R2DCY4@^&19F#J;T,Y-0&]]:SZR[?VU.?D>ZJ5-A29=5:4M,TO'!N]B:DV$A^;6[JJ*Z@:$E21*V9CS, MZ0,(J$_=51?6#0C<\F"+DD*@G.?&2#E1&'N9RA>?!&KJ+C(*WPM6MP;T2C*[ MN=).2 $,,U,6?=I.5_0!D;J*WI\R8?CQ;"Y A;XF%=--WJWK:B'&4 QM FPR]B[X MYG:1'=3&K3&U#R[XC<$K3BV1W *JW)55EM0-355@FJ4@2;R '_0) M(BHC(E-D,5P&31OMRH>09IUX W#M6 2PC=QH&.@O[*BS_)GG_(6( &@FQ)3Q MN1$D]J6;XI.#J6K7@FJVZ7@#[0&M%0OPAF08+1"/"6V4VXB4&KJ!I3W1EF$E MRJ8>@8-Z2Y%:)T_Y2>?.*5$A<8N90JXFIIPTX0':,&;2,B1[BTJ#FT#-GLB9 M(J6RI.N2K8F\OP /0-/%24_LA>,Y>$'$IP,>B7/5':+,ZQ-./ IWDQNNV;K' MLME*[D4W)'6YC6B#M4K--J)OUK<$^=D,@AE2#=OS!.O@V;A=W6#=!K3J EJ4 MC<-Z$RMA.K"IQB<"3ODJ]Q.,HK HPZ\!=UK!6!-RQ#/%F)ET ML;=9]L%FF6Z9J<;&7"'=M(D"*R&;7ATM.*,?)K0GJ .*02]71C=)S7US3(X8+J^Q*-^2P05 QR]OBB])(Y%>P M=$T+;,86?$'C1VIOXD\L>!Q]F/LN#KXE!R:+MJ&;]%N39,%1+H5OO7^28&MU M8UB.R@6U U*=!8B3K&$97IA3CC3CDL-!-#F"!R\V+GR!?D!$C?R>\O(Y1?(Y MT@-VHO:5MGBC58B?9MC] SBS.5+ZHS6 Y@Q$/]XB>=Z;#ORGZ1(?)VQY%'O, M2^2;5F^E$S:&3?GTAQ/.G_V%@^BZ^XFSW ?@!3H68&ONMKOO/;2U8%@?,A2U M//=)+%6!=TE#V\\%U38L] Z%O?DY/IW9\KU/-XBH;N>#-!O\!)19!S MIFT#1(UCET#:OOY.@9@A+/]PKM"W]K>PFRB%B-_7'S>N&7 &#)=JZ*8SRLRM MV 4*DJ-=!OHZ!I:8,5@E^AZ@/R-"K:.;P$6%2;'!<)/;9T 4B*1:_RO+:@< M8?%5Q)IP$ZI)D";.DX038B#$4P,R2^5TDQX_Y\M2XR-.$XF]K=X#QW9,^/%F M;K0530F3RNLF00D*6(A4[=*"B(!@2Q_V%HVGF7N6=#\LLZ)VL! 2:@4HZE'< MX=),LCL@0@*.)Z&JRFDGU'I"*9[0>2G579CH]V->@6[+YDD]0Z2>#TZH#&JU MT^'R4WII(-?:"S.;++D7^+7-S=6=$-DBJ! 7>\9UDIO+_$G/S97]73O^4X:5 MEP";#$U.(I$:2)0"*^RFLJPN,I)W N$G4X$%7\J^!(_\(0A6P,XOQ)LL[G$N MIM':=%S,F'L?XH*5^Y::;>D&"WZA%KMSF.$@8I$""/&8+^I3W.3(B1S&F,Z(Z '!-NQ3+J*4;/IH*N R9.@SH,TSPC;\"]ZBN6V)Y MW:!11Y!E.(B1VV<@X-?)L":= (C#?_'(&;$XA/*Z 4%,A%5Q.2*$]AD"8P], MG 7($'H-/#!UPNH+T[S5A@:(6O1JYR.6LY5@>5QXJNJ&CU8W%70N*#";=@B= M/ ?Q_QX\:X6IF/CX%LJ1V.F,T(AN<*HM? :.ZC%"[OK4H4&,P@N?!>H+]V AQ(*&A?+>4,S-M7#XQ-)X;C&9MN]H;7K8'O9(<, MKQ=H)IWJHTA8$TH[_,IN@7#:_?X:"K@AH;7 &U>VC4$61MP^L M@*#(\-H]$,1$6-OP.@ (M&)X[3\@:M&[-[QRG@2[QT>KFPHZ%X9E>$U(YH%* M4E0W:-06) ,3-'(EK2C+.$@Z-&'8?1AAGH]S$\Z(\>U517<%%C1RM;)\-H\K M31X!N/=AC@.D:%)"\0$#0XCDIL;/JQ@<7O3X]UMW_QV M3;>W6T?=N93][9U77JU$8^4);MR'Q=)T8/R8:1",/=H^A5UA@!JB)M&)_"^& MXJB=6/ %\\_Z<^4$#F[Y#7AH/(_ Q"E8Y\[R#>"\MYX%1/VW)RS_[>3FU5BB MS@_,;>]&$'5ON)O^T3?) /:>W:T'L?5W)COT[%[J%2+"DHM$S^YE_^.C6_#L M=H^/I@)NZ-D= $P4>7:[AT8=0=;V[ X "-O'?9-5G^K-(Y36#01BXBN+7X3, M/@O_P4/[5;!]]"%Y3IRR4%!JZ 8"^8N$*/%]=NL2:*4N$M0ZNL%#5)C<'K$D% ;0P1.>%I-9ZH>\"T>I2E,Q;;8-:S0IY($N->^8,!@XB1V:+<\!9R'-W,\KQY0U^:[XZ(!BWH3 M3Z5[$P^,>%#X]NAF6'L?X]:7=;9#/D;-U!%++A)]C'G=U,M3OD*SX:"K8 M!F;CX4)#EMFX>WB("K.1V7@ @&C1;*PM."BBE6 V'@!(&*9.*DRXZ@X1*/4) MWYN'.0^@W0-%_FZD-A>ZOF[*3*!5N+^R,2,%$S\-Z, 7I-Y0"<<"093!"!U^ M7_"1?N)G3M55\=H*NM$-:[61L059JZS:WWUE7 8=!*2$R96DI]8 OOOJ\O[) MU$U29M75X1#0(I\?FMV6'?8J." 0ML4J29=PV3?DU#HZKE]-E^5$$VQ1E!**T;,J1(M0P6$>J'A@G\)P2 ZHU@ MUM,-)R("Y8,#F]P.@4'8 $\L>#R9 V@NP2ITK.H08TK)/DB5+9?"'E2 5.VF M>@##S#1'G[93''WX-O[AQ1$F%8J^]+MNPI6LVOGHU<[JSROA2G5=44(7*?.) M@R"^75>ZW01?\XJ@KG[M]EH/07JC[8F<++A2(2UG&;_(^.C13E>*'*Q3KW+V MC6K*<8A8/L^9HXO+PZLAK9KUZ)<44]Q-%O<,@=0S4+F@=E@0$EI9Z)P4:KPQQ/]B+CZO\%Q!DP_?V4I^Y0=3 MC<9U@YTP/K@@)HLQP[K56<&H[?M^X^D__=#Q9ANF)68R 3AR-+8;\*O+"*WN M7!).NQ6.MBRYFZ/DO>^Z_H_(][]8N@"7&T^C',:F10J+D-7V@%"FGB^MW.[L M4L=%6OX%;51)OF]JG0%AJ3Z]P\I0GUWV(YK19(J^(UEV2.4'B TQ6K7*-,^_ M8+T"RY]YSE_ ?K 12YVI@W>%4;#(9H$>>79ZNQI?8D4,6:#B2)[>S-D4?O"B MZP/X3.0_ C, Z3MVQ1-AAR,9$$AUXZ*DK/J:J,4*QB+R \?&64,P2_!&(B9+ M/&:.U=* 4"J;"ZWD[M<1996G>#2/TV-\<_2Q>LC+X_CB\NA8"U0VA50CL-9B MFB1+BJS;)&W"F)1 3:2)/1"YN:*5$44%SFKO=IY!*+YPR^A-5_3*7=R5<2I! M].4>T47.)47: W6^0UUQW08HU4X)#CX/TS]OC7969CH//^UT_45.L($9* M7/+)A-]!B&N^ 6L%HW)M+ ZL,>SGCLJUHA;WA^D7EL[/%PB6IF,GV<)0^7$X M!S#^K>V911O+?H:U-<.$I3 L[[I,OKY ?PE@^/'BFEZ8;'>7E+?C6^E[/Y,4 MSB0QKFL5?]!XYHR7D8W;FT6NYU=G-@_'TZ]!S#8"XJEU\CP[N;@\[O9-ELZ1 M*LXM22Y^G?U6TJ(GHG5N,C>]+[YO_W!&MVZ]GB9O;?H,JP-V1\LRU]Y8?!B M?H@%QJD;PY G$"^$6S$Z"8J@J4>PG3R\ROF$\\>F+P"G)KIR0=4.Q 9#V\\O MI2Y'V9)INII)GG:2;56;=P@3;G 9JXJ5]HAFFZRX>*99JG556'OV/:L.W+;U M\MP['90E7SKB&&QKZL32#72*9-'N:78/\!9/L[1I4=M#->1I\4ST:DGN93\- M6KC"0(._VANR[;^H\<5TO+%W;<(9^N-E!:TY6BE%G]DXYGMFX\# O1F^9[S' M_1G+I,/]"QQ53SN<[.0+'%HJ-8:8RBI)"@\&EF2PZ0L# )E>_=.)RD\&?H=V??E)ERZ5@VA4@=6!3_5%:CMGNH=#> M0D!G09_3TE=LL]I+/-$]A(1ES77N%2-?,Q?JWJ8S7&!*Y]#@HVH*1AEL.]DR M<;3 \1'\ .5H;#=P6)<16ETB)+WYC"F\]^/LX)Z%=B+!C#1Q^_ZK*9&PZ:4QEFWZ*M MY\@*5Z; )1TIW0T0B*VR:J >-<2P:8%AHOZT$UY_6MJ7D>EL[TNK&%*G6]*4-%!,*?&GG%Y='EUIH$!Z!-O:E)>0. MW9>FIU39HGK[TKJ'0GL+ 9T%0_"E93F7GMQ>P1IX*X$GHXHU=0., ML&2YP,%%M5992)6BYAF$#QXZ;@)\QJ^!G5S]'4,0FW:MG%?\-UQ$5Z,UG/.Z*7=[ P*0&EYHY9X:GC>TUXA3P(AA>9_X9Z. ,;*Z M@=V E0CQP\I\.'*C=H$=^?2NT9RRL?<7>$'L.HGOW!-@Q%=Y@!!J0'A3+](F MA"W4R(=$F#^B?J137C]2IK\#&'>(BJ >]\ZD*B_%Z4XZD_31-/QBDNU,&J8U ML:DSZ:)S9$B1:DUGTL4P,:' F=0]3D0$VMB9U#TP6G$FZ2E5MEQJ.).ZEZC> MSJ3NH=#>0D!G08?.I,;FW$X!=S;!VNWKABIA M\=-]6[P'X%>=BTJB1M&H4FN6=C)CDOW^.$9=\]X__#U!+ P04 M" "]@ E7*>V4@C9! @#6=AP %0 &%D87 M,C R,S V,S!X,3!Q+FAT;>R] M:7/J.O8O_/Y6/=_!-WW_M\^I"MFVL8W)/F??,F#F&F3_]( M-B20$$("!)/0U=T[@"Q+:_BM04O2/_]O9NC8!-B.9IG__I>XP_^+ 5.Q5,WL M__M?H9F.L/_]?W_^%P;_X_\?AOWSOR,13.LDZD5,M13/ *:+*3:07*!B4\T= MW&--:S223*P$;%O3=2QA:VH?+!\A\+OH'7X7QR*1/^L=)B0'/F^9]ZMV=\3+ M)LGE2U C]E?\%XF348RZQV/W!(M52R^;!_T4-=F6[/EJAO>P8_R.I4GVCJ2) M.+W]H0:P)YH"L+PE8[G4/<80<36NJ+T(H0(Y0DF]6$12527"T@I08PR+R_'U M"<%__AFXD*R0M*9S[SF1OB2-_KT9N.[H_M>OGN3(=Y;=_[7\P9_(S;*QKIG# MIY;3Z?1N)MNZWYK$\>@O]+,,2;5J+JEK':/FZ M7,PS/!'>*9?A]XTP47SV MNE/=IT?6>Z=_!3^NFFHS-^( 9:-[^/FN;TU^:28<"4#$^N7:DNGT+-N07$A@ MV!%!1W V$B56_3BV^WKN\,N->6NSMV9-1-?>MFIN@]Z;5&)^P5_7YZOM(*AF M.JYD*D\$58&V29S5C.$/FP-V+(HD8KNZ#EHL']AH.(WZS8AX//YKAD1EU2M0 MU.VOAS]LO'[V2E V^D2_/C7=^FXX1.)7IU1L* -@2)&7=(#,WSZU]SA/1DAF M0]BTK<+&!,*FW?SY9P D]<\_!G E3+%,%^+)OS??US-U<&??WZM_@WZDBUU_ND2_-[TS(!:J#-[E%OP [^U%05F/Z?L$':EA0T9\PS M-;>.9%& ?X@-2$)5LE71&4@V<,3^0^NQG9(\%I>J]#@E%WO5?KUV$TQS%CR8 M\FR??"(E$B+BL-BT1$:,XL&'>C<1E9)3=2 PDU%E]C@A])D-NU"!HAF2#ED+ M5=N4##B!)9S2M,]^&W#'UK%#V4 [=<^;$ _G28B4MJ3G M3!7,"F >C+>IB.28KW .0YC##.^,"['RI)*,U412)&[^X- J,"1!DK'5@)<# M/.EXDYYMP\&F-4>1]"Z0;-Y44]#7>QJR-A:$8I$K]X1,-4I5< M;ZQ5^ )+W1RM*Y)6JV1229Y,*;J0+ V,KE(3:33:&OF58PWDMBG-_.?KQYW6=& GH=CV+7N^ M,5K2, %;:N9&P[$Q&N2J*2HRQB%@EBTS(BD*@,_YD8W?PQL#/R)T,(2HL@ MEQW!$II\>Y[+CL7H_+'6ADZ0H_7-?V\B1_8QR9>4X"7;A)-V()[XE%@:R0TB ME.NQ',V6K+:@96?=X6S""@4/^I+X'?Y1G^G(\_^P0_FY^7=D/K6HN7$\P]7B MCS)EF3FF[\^?/M/\/^L^?FK^//$X)O-D ^"12E[+>C8_*4VF9^7_9WW%3\U? M[75SDWJ';^-&:R)%DEV-I48.1#FAW'<$,N1P@IG>F9^9.I M?B3Z/ TF'@[&RC"H'S>MRKE.AA!=3: MLTI[!B@/2@5)1"$NXN>CS(=!X=B4&7:GJ5:^[F##0KORA*)K$ MST*9S\+%L2G35R./B\HH8O/CNM9U[=F8G]20S.!1.GI.RGP82(Y-F9&167#E MQ; ]; BZ;E)"]S$>1\D)*L;2.RAS$C>8@W&&ZL<:NK3TA\J2;8OIF@R&\Z+: M&GKN--ZUI M)+^V37OD![%/HW8EVT79 A1:DQ&<@/]]ZN?IMR?ZJ6M-HW[>8/.7U>?52WYM MB, ^$A%=EXCHP1(AF],.$5,*%&Y,Q-BE2:IVE8@])2*ZOT1$CRX1VUV+ M0R7"T>8/L\FLY@Z9UE1VV+3A&?I5(CZ $=3^&,%$HOCQ)>*%;3U4(A(U(U^6 MHX4);X!199@&*2KRV+]*Q/X8L:]$1(\E$2^3NO>P?:['%(9@\=O=PM_5+U_-7TY5-807DEZ5-#5G M)J61YDKZDLV+C+W "ZFFCA<: \J=5>MNS^4NG,T[IWP9W/ZLT_>&-I?[Y,-0 MD*J/@C$?%,TYWM4]Z]+M_%=K\[I'=R[^[M9F?%ZI3XC'JLIG2CR>Y6>%;&YZ MZ6P^DS8?D]MKJT5'4>W ?E$M'[2]59W*UU']F!N_6 MY]R@*9O#FN7@H!=OQ6D@C*G8I3MAY]#G([/[LP'X&^IL5\F<$QGE\GA$U!,/ MQ3PIF/*EQUQ?K,XG\;6/J\T/C1YMI^J.+4B%N!WO)!Y-M7#IJ'T>;3Z)KWTD M;>Y'P3!"%^<9W!C.!6M /8[2SJ4[85^MS:?PM8^KS5:ZWL@->M.N4''Q8E3E M0+,8OW30/I,VGX;;# L2N9KR&,7'GABI]3*6;HQ/CK=GG?R3'TH<"AG&> "6Q)YTR54PW-U!P7O6$" M^-D($ABL5/X9$6 #3W$]&SZ;M!P7/@B_ _8$;/3.&R/=F@/0 &BS@ZF 93\3 M1W6+1G]X_I'0X\C^L-%H1D(?S( MRYZ'ZP.BH60K TC.%*28;HU\+ FX=V0MB&1KM.F.8$1?6/2)!Z5:CRT2EZT% M>Y#O*OLG7>!U;%>LVI8*Z5.QESO,?6E$96I/XKW\H8ZVHCD92!L7J&G+K@+; M03916P"U.8 T&VFOL+\Y'X%*C[/A0WU?$IY[;R"P WU-25JZ+LE6H)60.T7X M+B@ 7-\&_B.KI$>$?]!2Y:8E@'I9>HA3F5G="9UG 2EZOXVB-W_0I.\_3]+# M-6$K+Y;C^B S+F/I\TARGC.A\R?IE5ZO,0!Z;X-"3$4A^M);5ZDL$[ M?*9=9$E[+)FY\/G3ATG]W@2^ZL#)=* $IVY#)OB\:5HI@&K-X7=IS88F\RG^ MV<&CT^E KE(B$K5%NB(P+D>25K5#%NG0N3[OZ,"Q"'S5@:_1 8A+#0#[4BLC M1 )^YH+ <41 U@2V<3IYI_)Y+N[%^CC?SA6+?(VN1>3ZI6'^9XAYE>TODVT? M=KY>M)E$)=D1K%Y5B#06@&[T1_%Z]J*A?#]:7B7["&6J1Y3#A3&8EUMI%?"- M!5.8+EB\RA&A@]@K[_?A?='M>4NV%ENEB0-BC(9[)"YJ9C\5X5*A+8S8Q=;G M27U#CN7ZYMQ=)3:E^,.,,D4'3 MS!7"-/VS]H#]$EP'3KXX6:@M9^@YU::[Z(LX4$*[UKN+H_M.^3MRNU'8TY8V M\'3Z@9'[M#"?9G"/9:4QY5ZD+=U[SF'G]SM;^W:'"FMK,77XI^FMD+K8C[<[ M(R8N\6VU7HN-9[I%-T*'U.\X[V_-[I3K/%^^D>^=-)S&IG8L385.T4/(__.M<6_?[/U)_KN1!3GJB"E/:$N)D41G"XPYN?+_'?Z? M=6OW]C-A/LG_1VZ:\>1LMRD8O,O*(SZ5QS.ABZY"R/\/'/]QS'7^UUL#]RU" MJ9B@"2FZYOLF@ EZVM-*YZ*C-MK68.X-,]V"Q^6FXQ)MA@X*/EP#\MZ\3^?W M':=V=\_:ID-KD3*9$A4?4AF=GS>+'I7.NS(HA,X1O%8 [9(01B2_H/JM*[2L M8AY(C6%D1K*M13+;:%BA,QE?5K5V!(EA(NBDRLN4F'?J79RI6)'7/"-[B(Z!"W"I?-7 M#^3#']SPI?! MZ2WG%1Q-Q7-*WHAPTWYFV&Z.[)([>:3,\N5S_$PJ?OJ#*@[7<3[3G#6=.CGA M&2H)K(5I(MA?RM#+O5V./E\__ MK]3X<*X]G# 590R2N*%+Y!@GTY-%:=)PJ'[OZ@A>YN&TQY&9MPT,_FB[4PD' M#;X2B3$EC9^V->[R >9+#$QXI.08!]9RBN(9GH[N."H#5S!M$&R[RID32'7T M>$;23'0 _FH#9IY]I+O%5F\XK]7QUDS5AG0OM&F)?7>V?Y */]%2G4B>ZE$= MMSME02MIXA1I;[ $\G0!O$G1D;WL7 M^I#1.LY6RNWH,$,T6]4')Y'6'[Y1S'8F] EK?NC8Z%.:=LL]LI]7<*;*N<-L M,FZ6Z"OZ7+0$'3DVVX4^Y01>L0I)Q>G8FG]&T5DYT"?,%R4=2S9 M>0=]S-%,]MQA/C6<3W&F!,A<8AC>7/7%H,]WBN1WH4]CR*>Q9.<=]"EG7;Y=BN/3LW=?+QI?[&V_M 4AKIF0JFJ3G3%37 MA":T(09"HVD#R?'L>4+3]090/%MSG\^4QM.#YJQK+&+#^2AN9MMI2FZ$]^K1 M-R;[+ B[9WM,@?C*?1[O\SAC38!MHA\:4$$4A:=DC=-H.V,KX^'RBQ',#I<@W M,MYX6F@4&H^1T'J.[S)^YV0O@\-;MGV<1.5G)DM4ZR!+"^,$Z.&1[&"NS"Z7 M\R%2^=/O SI,YQ5.G0J*I9J"5Z238T>-214CM%Y?*'7^J_?_'./00&/@@GIL M]$#@))YT6NUBSLWJH65[V X-#&<>Z3224GK($>JDGL_R#5:+\D[:K,RJH34- M89>4L]]!]+%4 ?S:L,R&:RG#E:=02=./6FV0&I)BO<(2X_2L4PXM<.R9)7@U MS"- M2J'-SX2.JZ&X@_XU5SU&&M #F<$%LB7PDEB41\7P'?<87JZ&XCKNUVPMC7 E MEYL(,M[.ED3+&29*(G/UE_9CZY$OX7Z&8*JF$$6R6Q?X2#_).I%\9U&OGMS? M.2M2KLU6%Y?%,J2#@C]V65HR';/;'OY";V0B57SC."<_13. XG (% MW]&>SM+S8^6F8I/!_:# A,>/@Y,+VF\<5+D MVT0^94S/?"2FQX^VXDN_BOX^(\064[+%,<4+N&:5S7?4Q36%?T=4:!/6],C:79+TCV0F#_]F86D1B:[C-R!?>"]K79;\ AG?S*9M,/: J796=G#F<&=I#Y9N&LG"DO43A_'*ZR2PR-,1ZKPB4K7*X=48N(G*_$WJ)OY'N^ MJ+_*^Y8C)*'+2]QYU1]\$3A./!T>#V9DO5,PHD+3),I&Y-T MJUP);P7QFX1\EJ,/^8.'^Z/^,O1A/+A8J=XEEEP?J7C",M5-*JS-OFE53- % MDKT4Q0EO*YUTLZT(C/C ]KNX4DR&]]21W1+Q\>G_*"EX&X_<7%=1&&+2P MT MQ=$CU3$]ZH0W/?0I(?A^2'!N^[8#5=)DOM9KEDT7+\1&$2&?CU&Y2GA1Y8(- MW#?$MG?E.BDYZ#YZ] _:)S&1=.2V?D2^A3OG;K4J\7'W31G%QG%%G$K#RI#. M1X9BU^K1E^R^[2+HJ:7\(%9\7QG?BMW1NDM1\7Z[A!MLRQ!%/3E.1L-KIX\, MJQ?/TYVXU6C%'XNVTX_P4LNAXU1'54;J):2^C@HJ8>?QZ8Q*KE]P(Z[>B T! MV7]H"AEO-,V&E_]73/^0;*R70.SO1FNY"J%WLRT<-])*9%+L=Q:M\!YJOULF M/D6!L,O"GN< <7!8JJ9[KC8!S_K SQ3=4X&:MBT#[?3U7+^O2F]U6"JD3F,@ MV0ACMW;P+%YU,-(E)3AP9RK9JI.QX82 VK309@W_P\#256"OT"93*2E:=M V M>1+/1:.=3"/?&X?6A3TA_9;2^5$"'E,PSWY&45BDF#=&NC4'(&F9CJ="S%M_6ALUZA]1+7#&T#O'IQ?C#%/S6 MXAE./T)!VCP0TN3SOS MBY8B/>U%7;6I P>@<@1$/51N8(U04WXV@CQ=W7TS[#WT,^"!8H4Y18[QQS)1 MZI&A]3)WS'KC+(+WIGU*Y OK?;7[2$P&F,"6=$@Y3C4T4X.NO(3T=%-FN&FI MFJ4?9DE^3-.R5&A'*O@LM/[C7C*SU\2_I]3L]ON.A3-]OMP:Y8O3(@[2;$.2 M:%FNAS=M?@DXK$VXYH"(/ ,P2[<"XWAR.!,:6A%XQ61HY2-LYVI\0!*.4 MS)CFCDO37#Z\IZR'WN*$^#;BXUF%8!K%Q+<%VE/%E1T/GM3BA MN:_M=#@SC3^TTDV]W\,C\UA#, M[###/0J=WH,\[1"7+3-GQYFP2LUG/%N:,;0!J3&.D'3$NIUH@^ZX%MIH.52> M;8ASMOL=8\VIJD]"2:]*FIHSD])(..B+(NFVPJM M5[OGD=8[I_S]LVZ?O4IDMZ30_:&G%]S8&,^DH@-K@9?:/2&TOFS8)>6R;Z3> M+2FXKB0?8O6"RFOEPD"G.E7#"6_4$VI)"4V\\]F[,79+2F.X* %::K?Y!M&K MJD6QW5('H?5;PRXI7WY;]3N2$J\.'^-56Z?XMB67Y4BZG]1:)^?N)1#NL(O< M.$7Q#$^74$D9NO5.#\(G]=%S7/3P4KGJ]>)T)M%&E4]VLT5G8"1JY/CBE6NO MN1]3R[ZR[/?#_*^X,!)"S6PP0!2=@""X7E5C1!;-4J,YF/#C-,2@,A[I#B_? M9]MW^C]&"LK %4P;2+JV -#@3$"@"QE),XN6LTH"5(LL71L_/K+XN,E6*_,A ME6##N[SU<6'8BPJ7(1.?CN#VLPRUG!*KQ%O>8#CO]MVQ]YAC"WIHTT$78AF. M>6?9$?C_CF5@!VZAQM(S1C"$MA45:"5;P;\1&)S+,H1,"O:S#)Q2>- J$Q 3 MI*P;3](,Z2S:W\A3/+-E",6%LGN:ADEF%%6G#Y7*$.1S#VR+B"R&L:MI.$ MCGSU[#$$X!W;T&[FRGBS7\R,U[O%)O,#J M5-Q+4[/8Y:_SA<4RA.)J^STMPYRR>G:L7QP- >',YK%%+_KH?2./\2R6X12I MA--9AN98&+A2N]H>M@N 3#*+81Z0W\@Y.)=E")D4[)E06CB)'&%&!T.-R,6& M?*G/S%-7RQ!&F7@*)(G3F :/>BP6B4%>$C*]1E'(]^==E;V:A@,$@#A1)N$ M 7@OH=33%R4]UA5Q;58V%%YLE":CJVWX=F*PGW&(&Y-,'5=R-3[2ZN>;F>A# M?.I]HQCRG,;A5$+Q[#$D+5.!@PD*O^J:,TS,F_,1V#R;$L(@%'_[5=M52A'O M5V=Y0+BX,>_@*975$U1XMSCMF/': 96[IWP9^4-6C 7KC4#S'K*+:2\GM&N/ MQJPU:-7P>A@J]S87UM@('CO6W)\76P4&.BIILNL([4>R)H)'YK$AG]QY/=.J MXHL23B*&2CA7:@\_.;8+5=[S[QZ4;'=>E@SPO-VHE.),=(Z=93:0R(.^IG"Z MKDE0!Y:J;DK:A&H\\N4A& \JBU%G'G47H3/]<);WVV:YW'+T[C2/J=[KQ:E$ M;._B5-AT PN.7YR*0*_2XVSH\/:#PPTWKU/4=4FV@DUZ:XV6(6N="D@S4)K]+=.=?WJPEUS/5TAP3$S@A3D\![L]=4\XPR;P#8T,PAS MS"#HZ0&;Z]M@G4/2(5'\0_&>!0!]Z;QD]KC4;;(C*UX4F$:7692E$N7%PIOD M>6N&2X9OF^*I8#T\!^<<* G(!5T5%%9[";ZJ)'/#!C\B.2KI1NE.Z S]YZ3A M>9K?4R(HZ/FOMN\\_8T\OSI"1I_YZ%-)FFF&9ZP2>P<*S&,':!:3*)6%AE@8 M5^/$\)%IATY@D&?X1(6;/^CC!AG>%(C+%<5@SR&[CRB^:'H$461%P@3".-JY4K7NL5FT5@(H*55R5;12.>LT#DM81/$$PLACJ)[ M]'"%\T/8(0 M,AL6\D4-MG^D^U/*ZW,GY@]J3'6>7 R[PWDV7A*SR;A3".]BZ<:,0WC&/?,1 MPXD?+4(F2)&(;R9'=\50C<):V.B'%$5-04?9O,0C5^KUN\7BD,/GJ9JN/B8K M798-'1[M%43M.^=3ID>)^/%2A"]"YL\%ZF/(\:$C,[ Z%CY$-&2CD^U5.Q(JY5G85@HV$(X\DL)]S*%O'L503"U"704 M)#T)=-W)FUK40CH'.('C*\,*/XA8&;I0R75#9U'? M681X@TJ'^_W;R/MT:^P9K??)]]D?8RF[(]!#8TQ2#;Y /Y0+>19OI]W0(GR( ME[*/?XW:]L/SZMU$5$I.U8' 3$:5V>.$T&=V&$'[[/=^O#@AK ;J;*)%&#A? M*=OZ9))7-?ZJ?(0Q_F!1^'#Y,2(-Z(9943-0ULR$YKU MT_#DV->/R%HKJSJTOL(F4Q6@.'59&-<'E0=;X_-,(71R$=;ZBH\=_G6D^HJ7 M(D%LB 1QL$A4E52'3FA6'B_PBTK#'%0DT[XT;_=\(D'L+Q+$J40"WQ )_&"1 M2.M57!^P49%O=(1R1YPU[?;\*A(?6(S85R3P$XD$P6X4YK$'BX3+1\Q,M%B* M"*01K<:(V&B 5Z\BL6]A'KM_81Y[W,*\N$BB-#3!'"P"6Q95-7-M4?6AE,W- MFOEJ%3>F>+Q0-1J%9BMTL>W)1&2O-[]=3:L"7&T#[& M$$'D C^=.6TWH9UYE"!-2? HL]<9>%T TI<&43\C;;>!C72$V!<;_:8GB+,^ M:"Y/+LJ9\B-NZ_)) 4$ MSS5BHXB4[X)IZ!:PKZ+\4I3/L97D293)0)09),JD2,;W<6!/+LG:4(\\3!^* M@&]K"[LV]$@S$KZ-J%=)?BG):#E[3TGVFY+QPR7YU7[8,\LN[Z7:=*O8EG'& M>XRG[?PH%<+U@*OL;H1NQ]NO^\Z]3Y7.H!LG"<7DF9I-E :#6F5R^I/Z3KL> M<\(K2];46B?:4[:DE6C>8^*63#;B:BQQA':*-WV3?VB.&TX>3G MN,9&FAFUR2A\^$I8D>W9F-,/8!@'_\_5#,,S5SE>/C?$N[D.:/%,)*:[9:5J M1LU0YG"W\>K5?,+.ICU+03X#FIF6DU"IA:D-&P\B_F@9(-KIA8Z380'-LQ=^ MO%!8-T[G!5,1XT*F3.KM5'02F4S"4#UU!BW8=S-?6M+LEJ1[(#'G' >X25UR M-L^>2@'9;0#%LZ& >?EXYHIF8HFZ3DX$=O;+.%/6O8(!0'@11>2B_Z:5_VY M%J$ -P>2V1S X* $)SA8O:/8GHWKB[VVL:C([QX.W.?@KQ#N/NM<.C+=#$I.0,83Z-_T%%I$TE'D?='=%*X<^Z: M-I IY"Y6G5HU#V+R#]?,C>J, MO51J1>F$INLOB+Q&W*95,4$72/:R:SH]=G*&37)PIJW(5(U&I[GPG>7QZ?*+ M(TGRIVA[E> /2O!>IGR'+#_VQ51,+3.C"IG/+\H%4ODKU M!Z6:ZP-3F2_NG M<].%GMR1QSC7$L:@3U&V5>ADPIF0/+&;?O620R/1G_.2%^PH&6':2HXOQ+)X MH3FHMHJ%JR1?O>0S2/"A7G+'4Q1WDDO;.#,8$WVJF2[F[9^8/+EZR2&2ZD]X MR8NFTD@:>:L"!7D>X^Q<+2G@5T&^>LEAD=VW/>.D*+0>9GUBCA>TX6*J5BO# MU./5G]A3=*_>,/PPK3&E6G\ZDG"F4C7ST05A+MS05:^%@7 O#C=QTY8E-]C. M O>%.M4]/!V.$]HI@MB:0T4N0PE):>[N2H MM?+0?*WNY$FY1N":X\8R,MWDYL,P*-BQBHP]4PNF+L _Q)0V@>,0,XFJZ PD M&SCB+%%VNP0;C0U)AAVV^HG$0(L\LU_U'UCOK P!'*J>]61J##\>!'\TQZ)( M(G8/.U^-9?73ZO/6Y]&7*6!:_EF$K[M=JH8_VEW];G3Q:W/T:\VVTZ4!*:I* MMBHZ01 P%W,33U :DC@7,G9,R=)&PBVM71JT&H%OPE8/[1K>.^\5&BFQ;7CD M0YH=QW!#+D<(*9WIF?GIJU>NZ P?.>"%.GP$B+%HJE&L"T(=EQJ>2M&9--GO MO#%+_XD#WCB"[46\4#%C3+^GX%)AEIT,^DXC([R>XU*RX9\'O%!S@2'2D;1! M5%+3!@X*$UJ65,/EUVXPV9@A>N" ]R'-LR7%%?.]=GN\FQFO-194T!'DX'MM5QFG%Z\7Z&]QQ&*N(5L.3YV M68DG*]I$?FSU%\G^VS+[#C;L!"VD(DO0,GE>=@1+:/+M>2X[%J/SQUI[>@AH MO:-,(0>M@"K]A]9C.R5Y+"Y5Z7%*+O:J_2WLWW=L\(,VNX>-+,]6@!-\' !) M]2T8'.6??^#_88X[UZ$A-*199*JI[N">P/'_^3V25%4S^Q$=]-Q[^HYEG[^R MM?[@Z3LK*"6%K]']P\-^W[SHU>YK9L2U1O<$=4>-W-^06I$!\+L@B3L&?K/V M5OCP:/5H#RI6I"<9FCZ__V\31B4.5@93K&X9DOG?V^ ;^*\#K6?OO[_]UHZV M + C]!;_O??P3PS]CPG^1?U+&(Q'>O_>_*=92<*/SD@R-][H_WUO6K8AZ4&O MTV"TRZ]N_C0E60>8U<.2R%*;+F0"Z@725(+_&VVAK0*AU[Z7+7?P^R697]%O MC3[T78P.!GT2GU_L/#'=9$BHH3*Q$@1 M4!0K4BQ.BC).Q\5XC*)4H+!1Z'/>!&)TG&F\YM[FQ.0MM&>W$?_FCU#.-?D4 MUFAR3;[QSR_YF-0^XC ;?%*HYYHYOH%QY13&=Y)9KISAL62E5,HU&KE*^0O' M[D,/]0P]F_/8''B;:V1SY4RS4K[%4G?).XS$:2I^Q,&R^PR6V6^PZ4J]]'__ M0S#X;W^ T*R8ENF;6$W!EO%+'8'LY[(CF"FAT$P%VGW*4OQ\$SJ_\L;7HK)D MV^*8%Z YUY**P'3Z=%NK)H= GKXS:@*/U *";@PX(+#K@_KRX26&*6AGZL@! M]ZL_UNF)+-<22Q&F*X$M6!(T,)N2YUJK+P*CZ7^S85KQ-= -VN"O3*)KKP:V M!M[H>W7U_038KJ9(^I*Y$'R775!W!/T_Z^JT?-=*M=:,U%K?%NROIUO3%:BM M/D>F-O0\91M(P\@4TNA=\__TNR1#,^"YX#>R"Z]G^'6H3>R/VH$97_Z_J^Y% M[SATBZ@KP8]$\%^NC:3_*)+^)3->==N&+T8O=S8Z( _P:XXF@(?3@5R#+!_# MGFV+9J(DV7W$_V:35IM&HH><:???&PT^Y %DL+294G7+5>V9C>GL2$U3[*A MS=/G=3"R;'?-G'")14:O&]: K]AX+C^U2G/>+QR1MQ*K ?H6P(0:(_-__0*^.^;W5WKPI-J\Z1OT$9C:0A,\_NA.K M"O6&P)6;6+."08^J"=TFC(ABE3I&T'^I?V.5--;,\MB:L_7D:''))OJ9B$>I M)^'1V7[3^Z.PNFZN7R<>/A4LO/'?+QMP!P,8K+,2" MU0<,0.16L2WN_!I2WZN2"PRTDJM*\SF0;&">"*J#%60^6"-; ^J(58CE$Y1N M"O,*;YJ>A<]$V!1_!9#@W@S /@&XKRIQM_ T_@(:ATTW6_ ]\OG M]"&X5JE_7V_CF[#WARKR1J04NR.WBL)&\!0TND::EQMI^E=O_SD M;DC#J'/;SNE <)5"MZO T,O#MZ[IN],XT&N,]&F)!CF$!1:M&B- M=,[I&E68;;\_D <7A7J%0 M%VJ9<99/OD;!3>S@4ERUF2N5A#*/@*#.57FAF4LVL&HQ^698]^62^!<_DQ37 M)P6J$7@F 28YF#,""BHA5#'-Q#37P92!'X?__9W7H&C\CHE=UT2^;A&*BM]% MR2O!S[ (]:ZHARFFV.TG [4OV2/;FBCHN&A[?O1<7V B38HV=K MCJHIOF,+S;2V+H9^,[LOF=K"__SW!4K 7QM(B#0ZHLTB ?#=9_U_1"51G!I- M4I%QC2C64C/)+/32_9WIAH^.!'V7I" M:/^?N[^O$=Z7._.8R6N!F+DSG/*3R6QA9.O+>S-RT(R M3WL35>E*&>\]GE/4AUWBO[?5!AQU@D4+>E/5@66^3J(]3.I*-CZ3FWPE5:.ZAUQ& M3((K[1[KNTU>=>=G!>X8^*J@8Y*^@ST'B2_$*O!$1\Q/6MUL1N=' M9-XR\_GRV"VST5@0^ <>;;CH?2>:V&PA>^O$N1?\M\(N% & MG5/<^_5=('B/B/4D7!%[:HP1J2A01)DDHF(\)E$]EJ%4)DXN=X$$3S05LMNQT MJ!S%":4JGIS46K5&07A\Z*"6J[=_83KR9:YQOT"+OF.C;P5:&'VWY%SPU]<$ M7MCJ?[XDO0-03S/6/ \)WIVU+?G(%JP>?GC" MT=A=G+FL&9>72P$^F\%,&:##6C ($].!!K]YQI(#2EC"IPIOA\Y?49P03KW8 M3H_H%] CI&IS(H)6=%"YK>DZ1E5CK$+VW[<[$#Y,.@\5 H M.A59%\;QH5.=CXU")MU'=RY#7PB&!V7)4:4QEM$M6=)A!*'#& (K2?80N._4 MJ1\WZ;TC#@I;%GRO:&UCQ&\4.>5,%2TQ $R>8\H *$,,=C>$?AGP%XE0]&8_ MUV_\1?R-#20'ZVDZC/LD74L -]G)DC,WW[A8'_!_J!\8XX'T=89 M6*B(9%6@Y0XD]^78I]+F*-$0@X>7<_C[UE_T_(L,YBA#+8&_RX](&F%[ORE\ M"(UBV8]_CZ\_"'^0DN-B<1Q3I;ESAV';:P'?XOKVJD8V'H\'58U[L/+YE2=/ M;2<]VX9S#TH[$?"ZDNLY:^FJ85&QJC9)\SBHSTIBU)JQB43MYD\7K2=OJG10 MFX8M2]3VJ?*%4WVW1/,5?8,B43*ZM;KS38JN+;M]"P5&@@UEVM! MX ]-!3W-]%/2_B(3\EE(_/=; _1_)GZOFKUJL/H=6=%EFS='N*7M&Z-=M=3, M %Y@F!8A5S[$NN-PAUU ">F^946Q+R@K>B>6*&X7 ^P0C?Y@%1%Y_BHB[C3S M_V"560C$88]J*M(P 5MJYD;#L3$:Y*HI*C+&N7-44Y6W0>9F!=6>=FQVN:+; M>-,\[-C@CC:' 6BK; ^QP"9]"KF4)JJ1KQ>4:JZ/MUS MW]\ZFXZQL3V$&G?D;'@X))3?;O+/N'\Q$-+5N#+^L)+!J-:K,6HXRWGY: >V.KM\(!1?X,R0+3L$H0..WJ7/T!C1%Y?PM639#C\$,L9 %U_LG9_ M01;ZD4ZPZ6QW%+&>%S@W##70-%ZCSX#L#IO&4)@,O5*F-^8,M><,^KO0I]3 M,I8[T)0]<&>OH+L+G,VDP(=\JG,D7DZ1)KBT]0$4SOB!/N?U/^ M$@25=^A7RW-]$$)H9*W6+8/#MM];MEQI5'U#(9>*E/;S41"\T-'H,M>W'^O)1XC9.,2ME6U'BSUUX3VP^VX';F\=K;SM!>^V ;>* [8_ M2@A5L$_=4;&7!^PO MO]O_@/VO.TX_BE_.>?HW3X6W3"^FR!0%1(J66)$BHZP8!S%<5*-QDE$4AJ:) MZ&:1K#^CXQW'_LJ2OUL$A$[ 61*ZR26*/#KD)%DI-_ERLW$!^=[5P/8\,B MO96^W>'G/#1@"<#X>N'ZTW;VK]W&?O23 C;I3-S%SWE8P(\A-(%?J7P(E==3 MF!#94,M_;\B;O60\?A>/?_%.]5?A2&0+79Z,9Y6K-W.?,Y_HT2 .S:W..V)) M@OR-I7-EKIS,<44,NO:5>HEK^M=?O+"MQQ+@HZ=,?;.R22]J>T+[NTC#Z<_T M#!D_/YWC?W\YXT.^Q&D/JMAU!LL3 .1<8!#/%QB+_GD5Z";>SX$"ZFYYC-[= M 2K_KG-P"F-Q*IH\=82M.G*=^^^(AQ>M$4=?]CN_0)]V2N<7P^\%X]]>')_P M-<$5H8/(-[(\WVQ\#E,%4_)4_P")I(64V@G^\E.2?NU)0M(AZ *L,0# == 9 MB%8/VSB1WZ^"2P$%/)_8&27\G\@K.%_E/*Q3.K^ 76'WHL3Q"7;].S1+*(5; M25>J?-V/RT^%O\^N+@+>R@@$:_//&W=<."K@8["CS58;#H+*CEDP\NZ\*,W7A%RS^S7 '%3&:B;&CSU( MP,_C\3=QG6-7+;B"\A64P\B[,[O.7".;+E;:7Y/'2$K. $OKUO390_XQV8OX M5>:O$'R%X##R[KP0_%3O]9Q@_AP8ERT7CL>U?%Q]%YFWE55<-, 2^%6DKPA[ M1=@OJWLC2Y(I]0/D2&F.XOD7>4*/C3,E?>YHCLC$#RV#(R^[#.YT)'KN^.E" M@N<7^!F.U2N0X_T,]L@:!+N^49LZ<#S]Y1KC15L!,NSYYVMQW=56_#Q;$:VA MPR TU]_D I$'?M27GQ!LZ9;CV8?:BNAEVXK3D6B]8Q_VU[K&GOJ&\^!DRUN= M8HS5-6=XT:8@&O:4R]447$W!SS,%E(@VC-N6[H@0B\2J;2E 1?!S*/Y3EXW_ M1Z;+JC,?\)\[NR)ZV)3CBN@7)X='0?3OLOUU^K?D (OB/!IZ8?U'$9;MB;P%92$7Y MZF1=G(3]'&3E1)1K$].2XEKVX2='.L<<@!^H!6_9PQ=GO DI7G+WB[ &+ M\8+Y?&GS3R],.)P6ZSU@#4D'?AG!0R9:XIU/E/GD[0@/.1W,N/D*-GO^3Z M,]= GEFU=]X$B#I_NCD3O>04%UN]>6_4_^$KR"^^GC!-W.//&_93^ M59+8\Y^(&M?[*?<%G*^ZGU+&Y:@L]R019VA"I&2*%=DH$Q<)F8TIH"?149:\ M^;-V/Z68U8 "6Q)Q[3UF%H^)G[LN-WY MY4AS)N8.- ?M4+6AKNASK Y&ENUBEHFEX?"6)6YXI(;]A8"&Q'^_;.I_3?S^ M^Q9;-N!4:>1JAN&9X';YHW]$SO+G#%3ET;8?EI>8/_VT_'H*7G[C.:LO4*W# M\DO+LU??0D%&=[Y;V-I(L.8 4GT$/&CK'&RD*_ZST/%&MT$_G]+C>+*CJ9ID M:\"YQZO#D:LU!69*HYZ%;YL:=!(WN''9&!KZ1FG:.[16\M M4X,NV);0U=Q]Q,HI_#-2M*PA^KQ^!-'11KW"O=6US2]W8[V^:'P#9IYA_OX_ M/?\_"%20<"Z!Y$GPWG]L)<6(7Y(6'./O$T!?$L!Y/B?/'4@N5,:)I4\@.S5G M&)30>*8"'2/XL.N+@N1@4Z#KZ%_)<3QC%%P/@!Z^Q33_0O,Y9@+H3&&0^I ^ MT/8M(!S:V,BV)NAL5,6R;:# UHKEZ= 9E3Q4I./94(2"0T&@P*I:K[?6 ]2Q MGFT9L',+M@6S$6R*#I:"O6K&2-?@G_(;XWUZUM0E\=+WTJ C_Z:]D#\DAQBDN:D_$X[1/ M55]QL!Y0?0ATGA_5I2D<*0 4) MHKV%:.CF^5U4@E#H6 ;4<Q\4X2@8=$!DFBHM5!R;=@:FVA@"K%!?-429VXWWFFAGP=(/)=H:&$R6 >@ )+03'THDA#I M@DGLU=];H!6(S"Y]3&^?T.9D=H#FBD&!?"^O*LU[ROU J%K2[T@O*AP^]]H4)M7U1W\C,E.' ;>DR&%IQ ]=>:(]7@DRNG M#+V[)-D0E9C@A->ML_3!'A()=>1J+GKWCCDN:8@D$\+XDD1+&F&0/$L:O.52 M8KXWN2+#.&BUI$0PU"49X%A?TH%/!A.:0Y=G[5JTDT\)(K@UO<,R$._,I>B^ M\ ^0N7 &OF4W+1TA-="W3#W$/L^<#GA$9DZ5KZZ@+-XRUT0 +? M X(O1!-97]E:J />"/FO2,=L,$%^Z7LO\AF E!D&RHYEWOI0A1P9$\+N6F@" MIPZ!' G>1-)T'\V7U U0X.Z<./Y6PB9Z1W]USN;#8V]N6)B-F4P'F@LB\!L% MW$/T]&\Q7W-J)=VQGCW;E7N <-BV'@.17S<,Z\R$3T&I-9$H(!6%X_4E(.<75^GD!E )Q,%LK*4=J1E(/"0 J5!?4'9DZ @K:(-].AJ6.CD M_\7224!*NNSR^1VP%^1B+LCI,#^K)^IKTTH>' MCICD6QISG2JP%8 ^G;M)H-OE2) A 3[JP#DZ&F0^A&4#P,&JR%]!D*LALS'P M;:".O&WY<6GD7YOBI7%Z-ON*9BN> =4.-G5\*_:&M5H^@CK9?&;I-E!RNV/[-\28UGL?%YZ@_-]L4.MGDB ME>/9$S"'WS@N%(#EW%?$\Q^$8X#.W\K4:S;D+)1T+1";U=M7;$5/]Y=9D9$' M<4V1ECSJP]#)-A%@!=VNO\>!,JL$@??9E?DS2=HOS/5 0&3IUP-=)AW]U"5^ M37*?-LD=O2:YKTGN_9/<)"VI.$.*\1BCBA09HT19B;$B2G'349*D"'\;V7.2 MVS\,)@SI;300+(>MCI-Y.FU]\TB99;X[&/NN"^S//I\@!+C;>G[[W2D2]]OP M9(]Q^7@X;"\;]A:3_D+S\Y2^I6)X#?97G)01G@-*/R(?Y M^P4S1 KT&, 2C-A355RD&)8160*/BBS9B_=HH( X'M]0]:8B=J2%-YO2*1L? MQT27+7ILTQ)J(B&2+UL2 LMV!BX$$ZD^DLM];ZS-YJ@E_;+EF/1Z BNEU&&A M*/*4V*6>:TZG(O'Y[JYHGK)Q03_,9H=OI M9N5$%H":&'O=TJ"+E2%/5.7A>)I6'7'8Z=. $]G7+4E0:@]C,SS'C[4D-R;D M:DRJUL3XZY8])S7H4PP8XR"2-OI1J]_J9"'?B==-396TM7&+:.%DCZ$B\P(0 MBO94),@M%'73M4R1D_LXPP[&\T6MH"3KG$AL82@S%B:"V.%D7$O@(]WHIV4B M#9MNX:@EE>.-*1?)0AFM1N,Q:<8X(SC6+2R%5-(8C_42O$;P/4ID])[5\YN^ MXJDIET?4>MFC1/U6-SN3=%35\Q=:H5TR:ND2D<=".>+/<2O-[OB\06 M7I7,1]#NE;J.T"C.RY4*/?'T(1S %F:9F=ZH'>D)>3ZCU6RR1.NM!)K6%FX5 M:]UY=U(;SX0&E*Y4EEBT'N<<:OIJ6AVMU<+S(M7&([%V*DTE!#Q"^[V^UKYV M*BH_5N>6D+'Z>H^9#2;4E!-)_/4 "J5!VTHRI0D^ITBY$I4ZM2F$"7*+N/3S M5LRJ,EI2#IMN$9>6U^]3'GG8]*C.;96"O6R2KE!1! M[='.98=M8E3B$]U>>1*!O6Y1UVA]T3*2^?8,K_2DMC["16($IB*Y1098-_60 MY5BE/C3R9J+9B]*YQ0/L=8L,3!4.+]1Y(/!,EF6' IC2DPELND4&$JGV(L;W M\='0&--\K\<7)[46Q,HM+!ADBC&CV"C30@.T)"4MM#H,U-CH%A;(;:.J)8H, MP#./"VX49U6N3W!B= M=%W6.9?#:H,PG:2U!53J=>JP&FVZAZ\,PSC:TKM$; M%J M$H4!G[)<.-8M&DL,F$=/+=<6/"@-XJY4:1?*(SC6+2SH+A)J [CSA#!O MFZ*>Z0]9UJR)T2UT+7>*/1:4S,&0&67YEMOKB*KA-WVE,+5I1])R73O'SV.E M/J>DZA70GZ*F*X7Q*\J> C$_:$)!F"Z-''"_^F/=84"ARS(80SZ]$L0"O]?C M:JKKT:V/*%1.""[%>_Q\3O8CMK4=<"E;7^ M4=:EIUO35?R]^NQG(N^#L!.M]KT;\2T#=;"]<_ M4C9)WN$["T>O5#\RU=<2YJ;EI\N7T[PCV2LCPL (XB[&7#GQ]4 4NP+1EU/] MBCIGH3IQAU-7LA^/[!__Q=5.]YA=^:/OOOO7K3A8B^H]\'TR]^8 8;7:6]/!\+OPW^>$KV'M%H M?QUZQ,/!>/(N>EI@.93QJP*^)?.)KH&7H@"P6>#U!R3>V56OMPR!"%Y MJ CQ-?,.\F[?=^)K"!ZJ27Y!/!E"F?Z*60=IGN\S[4N("W99I^1RGY5TH)6Z M4/8=)R7\':;XWA+/-YAC*%(S5TD]C@FYT#E>8(#SM!6"\?M/2LX@V.F$_D"[ M'/T]7\O#*"X[O/E!TCX9,>Q8UAT8^<.]H\V@Z,VT[84["?V3,VMHWTD M OP#[58P5)-M4Y-!V.']XABMB22TDB1N1M,!8IF2+KS[TTD>H,%>_[^O=%F[KWI M&:KE+G^_P4S)@-3PG$A?DD;W2+LX4T7_\,^JQ;E)R;;GD(PM2?? #>9 )L&G M8,^KLDIVDA,2:<[EDP\5D7P8-(2XUQ=I5*L98V[C3/R?7YN$^ YQVE5?/ZJO M9XJ^SJVO!(E*<5&^4E&L$KCEN+"/336X^['^YPM99\Z%%>RK+@UJ[ M/GNPZ/JB5X,*R]S\(7#V%H]&=VALV,/.%SY#R=^?'!3J/I^&$7D^EB "Z1UQ M((D@&V1WK=&E1:/?SZ7_RDSG=X>AD[D-W$J1TI:-;A=\/G,F!?7I^=,RW;,% MCQJU5%)K+>HD7FF7*] LF,,8X-"((1Z1L=M8E#V2!_%-1/E'*>=71-SG5L[3 M^0B':V=J-IXQ1C=IXP6W$!N8R=DCS2/MA-Y"G+FE8^1!SH(!94<'XIZ_(4'^BPAL24X;.IT@!FNYW%J4^#F@Y$R6KE%J;BXJ=S3D.?$RK5P01J&[&T4&D_U/DYGZ^6)[E.1I*GVPAT36U=Q@KF-U^5 M/[>%/!W8O=+;,G#?MH:\/ 0%=2H7AP7:Z?(UUAIW"E,QAGQ5\C8>.X8"?^]< MUT]7X&L:[-C6^&,:'(U/(O+XT>:ZGH"I/,5M(8$G6+,^:EP;J@ZF:]1#=2.#[2.,U5? M08,JW;+]DJ-FL@BEX.F;O$X=?:K7:NXS;=6X@.3(3CVX,&_F/9C3V0K#626]*12,)&7T\S6!F:(S M!U&JA"%N8S%B"\Y]=MOS#U* J]I?6DKE#&I_PGS+.WI?*99UBXH-X[A1)4FS M9:=FA>(4ZCUT;TB:OHUN39)>\H[W[W?DQ[5+9'^''7J/5RTRO/ZO;]LKXLF4J;WJM$7U4DCJ9 M&B=$"/HQZ[2 H\K^N?DM%MP>K%!ZI7??Y)8>BE19H'*;13S3M=*EKL M\VV*2CQV&= M3^4?>(,L1>:I@:ASY2D4$^*6I%]O/CA)T>I+NI&(;FNZI1/M*5O22C3O,7%+ M)AMQ-98X-^$\^ -#)MKQX7R8-Y/E2,K-9KB;/_%;ZBBE<-R\?P\36FDA;W$R=JT0^;&J>-T_=8@+ M^E%=C+'R0[)$:14^PX_'Q3;;[FIJ'PT0>9WL+4X+V2U@9XA>!).=EW'M+CC*- OXK";YDM%_"2OJ=DOK'Q^0WG+VZUH M!(PYN\!:PCBK=II\L=1/Z%-T72BJ>:9OJ?BN3KGNJTN/^?%OE:;%ZNU9@WI,/2$Z>@M33"7G8#-F9!#?0V=+'3&=.N)@3NM MP5&!HC8!ZO-\@PJPC^0))6^2:RSR_RT3VZ4P/SNC>NXM+N->R=$P9<* M#2T>/U-T#Y$P8UGJ5-/U+29P%)VE$U.M.\(;#7'6:LX?!FZFCZZRAVXLQ>PZ M9>]G9V7/+JP M@[#"F-G=8]O>=;O>Z4[YW02 * 0 U?)0O'$6'#SML=UGGVNH=_.<>!/?MET\ M-NT*OE/?%AR0LE.G.9Z4*X(TR9>J)M&VF],^P@'H\T1)]C:^-8]WW<[W$](NWV1& MX2UDNV[GNXIF2 N[?MYVOIT&OZA)_NS1[1)H^<)Q+64X@+\!VT%D(&*__7HH M=WZ-E2]X]?IZM,V7VZ8?Q/^KU(>^B./KS5YX;-SJQE[]V=9=K^T-I0]Z5C-U MH=IY&?'257BO$=6G3,O%7+0SDN;H$/=O$")=[PB]_"CGL@N75DI5#71JQ[TF MNE@;9.;E/F]XQ00SFN-N-U(3"?^T3H*ZC1''JE8ZMZ1>-?2;16077HNTMXJV M8HQ)9WJ+B "4Q_DC\=!-C_4^4E%4?70;HP^[M7>;?W V9^#EX29K$>?MZJ3P M2PL[OQ!KOOLDSQYG7K97L+FI?;5R,=]Q!8F< 7J\)-2%"E7QO+2:GNA1#H[- M+V2&T'.L[7C?77!_B'9>SYPXWID3>ZAG54Q0E=J@/,(CK6EST63'67KJJRV!YYO,_/77ZV-N\\V,M;7O,(EK#G]W(75RW8NEMJX5@_Q M-G"QS3:;S1/%)"]ITU(G"(AL;<" M%[2!Q/7T>G_8KE?5S& D%3NTK\"H.IBX)8G#KE,-55+"/X[64US/1HF)D6TA M$;?,'YV'^%%AS8F3#NS'8,6O*B1__^A ^T>)WS6J/O@P\15ZPP_ GH M%FW& MI;WQM):-X,E>=)@?U*M.W8*Q-!G$TB1[?(,6IE@Z!7H &GL5L\$$F!XX,-O^ M?3W2CVS9^XD'&.RUS??GG6EPLK ["5^%1MK6W$'2[$*X\T_:@PX\11SCL,R?'(&?6^+/#P5[;?7]>5!P.E?GLUB0 M4RLSIV,]\',6$,5&K@ZX> UA 7)]HK?R+R<-3W+YY"_FUQ#WL4==/+7$_ M_RD$)_-A]DHYBS^H6HQYI8@MT5HGSV7Y+O* M]\]6X7!E4K[502)[Z7"N;WI.5*G"5\CT3TX>?)-)7M3R_2&4N( @>&=I/32XD6MY?4C< MXY\9T%Y8S/I&L>[.JXE=;M&:EBWA@9=:ZER/EA+)?ANZOXQ?]D;8/\8PN)CB]M/CS,_J8G]:+(_[_9^]+>Q17DK6_O]+]#ZCFSM4Y$O1X7WIF M6C)@=C";V;Y8QC;&> ,O&/CUKVVJJJO+=&W-8B!'HSHTE95V9$8\&?ED9$2# M[.B(5YQ7=&:=P^IJ9(\1\0UE4>SVBC8F#_K_>.V_M$C 2;^?C>=U.PUO'M"] M"55(R^3%EAYT>1,JYGG;5PC#"5T',KZG#Y-9!#]6L>?;U?1[-^?T[;FOW.GX MNCW3WK-4I?7P#?$%_$ RP J'H$" M9I=C*2(C?'$T]R8FC8ITV>S85 522E9))TL-B^Z$VR$J]C&R*''H< ZP$\", M0>&RD[,;G[%CT6/L:^KH/#_L*"6G#>3&([#CR+;((??P"O!=WI]^/\#M* M9-_%Y00YJ0'W<=L1@ < ;5HI;HG>H&"SVYE*\CUY)+!4N%FB]^,#*)Q-):ZM&WM,+O<+"&;46HJRHD95'IS$8F870 M0W>2_CPZ\$;4_*9YDAN1*+W1&.>*Z+OUB3R+MEYJ'M,;O7#^X+V+^TMO>08] M4(7L%MWBB]Y]2Y>??)<1Z$#K016R,Y>*N5A&FH)MFG8D:+B297(9S@F?+3K; MC#L7'26J%N-DUJ+A*YG_^P=,A.*^N14N:FM-5H1ROBWL_U[8Y%O>&*904D<( M2A^H^?QJ=NBPSGA=MU3Y$$D4UMQ>M%K/N^2H?TNN24Z MCM BYL/"NCMN\EHCUUIQ4TURIVHX(2<;@4\Q N<8@KK9U8D KB]9KLVP)0-; M+*L6\_ #^@8=O$'XZHOL1XF3QY%2)X/%L"CZ%"2V\55QVIBUU6[G3W6EVBI] M;:CB<7$9WYO;3FA'\L$A:@S]"E56)U-VBV%;;5TD6+S5B6EB^:ILSZ "ALA^==5'EGTU/A:E0K,@T2R)7\XLSCE0;]@%26R&:MTV M<=ZG^SS<7HSS:S?$#IHBLS!$9ZD#]U0^8@KU&M:;>@5SQM:K$\[/0WF;1R]B M"GL3_M4*(C\"^G><0_ZGH?P-"%A P-Y.A,H)(]N?X25VWPZ<[Y0&+CFP<^:( M)Y0=JO1[B(>,.@**[,/+*!R$E]VO\8'+;W\6A_ZN]>'YXKC6HTP4_+:X>&5[4*>[,[ %%=M36:FI.VU7Z406'#H9- UE"?SXL>>7 M\RDDR3=](Z*LG\K.V>;24>:*Y6IK)6/8[A>KSMV(D=[5#N;R\5N9OZ[,,_AI M/_']EL)+ZZE:H3$IC="$6HK'S?KB)L2;4/#P&0> QQSDQW6L6">A MKC 9=HO,'N 7$BQ1.DE%TYGFBP*D2M.I$11_P*G*7(TUR;3]4^Y P& MGD(:YI+WP2Z]ZT@A$EXE47-^,TH=B0',*%5F=)4TQ_&&[C88@!?I]N(K,^X) M,A+AMRCN1\C"5_:$\" M;QM-'36;'$2P\Y%$+5M8=1H(:)Q*&,60+$TE+U8"8@$ P5<2#0,@N$ "OX\B MP7(EH0U:Z1BL:8W7O9VW8-IY)D("(D0"A,K2\*&0T 0]\2]/#"_NMR.^^9\?ALK:^L=_PA]/?R<9BNA$ #!_[/S9O*.' M/)H_!/WS)$;\Z^@CV(LPGKV(V(N7CG_^S_][^?(_MRLYR39LY_L3$+V0:KXW M?23&)%7)31U%U'/B+'SP=]$(Q*W[*"4=@MRSM_/]&OK/=.,S[NZ,8HJ>ME:CO7WJ-9\6S ME]\1^!MQHDEY%4B%OD!2,3-W(I3[1Y\K'%J&X\]O7OON1QB2L6>9J'!+9!+/ M&BE^1"M_'=5#PR7&L"?0F$2(^$P6*!''!$R:S0115$+(F\DP3L P1,#0P_ZI M9P&2-Q;;*O?XTI< M.VS:KW*M7FHDX5L,7ZSVV6*FP+6*;*NW_]3C&M4B$WW]\_TS7"GS4X)G,4\O M0ZS5,/(Q_^"OJI7QYK;OAGZ F\TH&TD)_S!.*Q%OJI>*\_BO$/7%OU_-EH!. M(40A<%(@9W2HA@H!"5,%4@02@^ I+:,P*2F/DR<^K==,3ZNU=_Q:Y%?4>I:# ML%ENB@<"(B"O6\[6M:VZ'JH4VRO.-_G:H%IGVDS8DGK=4D3M-0675 KJF>N< M-RD/"A(7^@#)/@,,$C0C(#KZ4&896IAP;EWLA"T3??+6:#I:YS9%=F6@96^\ MJBRJ#B-@R3Y'5JY+B[BU8<4VJZ"SQHYKL5%+_'7+HB9Q"ZKL]-GAB)B:O:!+ MP+(:MDP\G1*$NMGWM"X[K$.PAQ<(L6)$+6'X==/RE-WE>F4'UT6AM_&K_34M M%CL"+D"O6Q)%@K!*SU*K?6ZCS2F\U&*%>=@"9%8=*7Q#-(D65_!AQ/=0?7>F!'( M9$L3[SC;]@"ILYPS@/LH-.JM2D$XT(F6]5(G*#GD;,KV+ WV\I2-C?5 H),M M)XB'N.;";$'#5GY8$TE?7(T[ @PEFZZZ=&5KRFJ7S]6=@=XKSNK#7!#*GFPJ M\Q459]QM$:J7RMT>WYNLVELU\KH331NFMAH,G%P'RO%+6USD*FA>CIL2KYN. MS4O;IH0*T]1 M^(:8X1 O5N#N7)TJU';*1$T3:EW>S5L[R806?+G9E[0),I%[_;C7A%Y71EC! MH/4*#0WK=F[8W5FKMAGWFE3L^K!%Z-AV4(+JP^D6W1)4"0[A!SZ@A<&T[BX# MM3?2$3+HHWIKJ&\:X1P<4,,"(3#]NMRQ>+^W69?]OJN[955 #BB,9.[(2LY" M*I#/CARFDF/E2C5L^G-FXVW0L]NYWP>'+JGP0O%_:/D;A M8.0W\N(4SKYA^,M3'/V0^(W*]SN:!OI&W>J4OL5,73[^!Z@Q4.,_$ID^2TAF MJD0&BGT/(M\R/@/-OF?-OD/(AF*"_!I%_F1P3WKV1M2-.Y6GD2\]<'2B^4O/ MJ@H4%"AH4K[T+(Y'ER_]7M\71)9L(_KROP_(P]<=??J\MPH/GE/^?D0N%3)V MQ5IQ[7N!LXE\'KC[;"3\N:?]')N#LXS!->X63GV/)@4P]@*5(BV* 'TC$A+]<=C%!^)<:2(N4_XLI8DABKXC M1OU$-Q3W.6+Z]HN$,=UQ'A4+@3SGB?62VRS6L+%Q.G^003NVUI)CF]%%ZTB& MH>;-"[X;SIKBL!O)\*.A9UQ7"?\O[PN()/):$G:%G&U&;=;<=-:>VG7G*Y(1 MXI3Z>!9&DS7( 3P >/CX*3E A]^A _(2'1"AHW2I_ V(99K.<9Z79,UQ@HN MC ZC"I97;;96A!2[N"[W=K,6(D07FXD('7#TO9RW?[B%N+B= , _D0*$ ,^ MZ$\$':+948.E"!%7]2D>,8B.&@\QEL,R3):EQIM<6&&D:848(# M.D0,)$NB?YSJ'D &@ S@8WP,,5[Y&%[)MJ<]:K2#_!%1K/&Y2M\T=,V,=B!12@XZ"\/HJ1!C3T^E2WN."B%7<)#YEG5P2R52 M9TO-*)MEE'[/_?K>\U87@?3$8%\DB?D9KD5]PEA!E!90WFN]0W"S02-G%_+2 M"@W %R@P4& P*DXD3^FU%=YXMY57$5TI'F<2E8.=\R&O8P2A=_ $=JI?,'; M%?*JJ.]_GZ"L]+F/R/>VQUAR\:?EL7LRX0 5Q1-ZL#-LO0$19L-F9[D26;94 M@8P.PQ$Z2Q-'*"\/[/@&A+PF/OH<9GSJL^S/F;%2:PV(=KU$\]M.85Q6**?- MDIW0C*-B*%B6Q))!+9\QXRLZ@+JC\Z:GD%ZP%J?U>/ES1FQV3 RSI8H-K40& MZ]3K;6>N14GMHX-D/(L?.!8"1@R,^%X7XC,=^'YR(>ZV#73>A48Z@?1Y;UKA MC!D>V7!TM$O"68Q&3F+$UW"P>UOGN&7%4AS1B$D.438U2W,])R[8=&TG7B?; M#*6V!/59&8[T7(RZ/;KCT0A#=&9^,<'? W2]FAO#*K)J0+V249KI_7[15:)Z M0!'A 64A\L^<+�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

/^S!M,)_H085@)GCQN)>VMHNX;S$='QZ M4>9=9#E-=?G3)Z76<[M^L]>?K]E5*42?%I0;Z_RY"L[O)-]WC"*_A'*%7(]A M&[4%60@BO(GR3*-9B$9.5FX>H,W].C6IWRM=&=S\IBA?C6S-!H6E,M2'8D!X MU:[8P"I?3WC_26S!9Z+7QT19]PN3AF(V=[1FQ;Y,5)F/1N@L@>,G0Y=41:D# M<#GOCHE,@0]W)3LFJ"]WL6"^F)=SD;@;$UQ5CR>L[G&3.< M&QBQ]\@095I!B! 9WN-2XE.=?\59R$]OS1\TUYMZC1?Z*X7KC>+\^F(]1S#."7<5C6UC_^$_YXZD@R%-&)@&C^^+1GG(F>^G3Z!/WS)!?\?IT. M!'MQ;V(O,_GBI>.?__/_7K[\S[/SG&0;MO/]"1%?2/68W0>)P5%58+F;F3H2W_^ASA8.^0?0YQ+<05XU?_(/'KQY^]"-LBXY]"Q%\AS;RK)'B M1[3RUU$]-%QIM;:SX->;BRY39-K]:K/)M]A,O\)VF3;+]ZN%7J;=*#PO0Y=_ M3;[%\,5JGRUF"ERKR+9Z^T\]KE$M,M'7O7[XGR;;ZOM3X&&\JQHZ9 M ,_@V8R08(&B,4S :$H1:)28"2@JHP2E0+!,$@][^!&?7+E\1Y"\5CXOLF;X MMWU\G<=YL2,@ @R];LI"6U(831I5B'/J(XE22,6%& $5R-;,Z@/K, ML%$,>DS8,B'^-#_'B[OJ#N)S_G(]'FDE84ITPI9)\<7F/,>B>9;30RT8C*<5 M:=$WXZ8)\9G.O*J7*'+$YXHN6],*LQU%1S(EQ5]#\IC#VVU5+Q!!=>'/&GV$ M"L*-4.+Y]5&^%M25C<"N2@VZ)VLNW>FH8E]@9'%@L%CYZ>%%]0A&X)M6IU5MMU-KY'3^ME+7I\ M4GQWTEE)*XM?L%N3;;.CX:H\D^.F"?'EKHS4'4&J0=R(L1&B*+H[.!"HI/C+ MG5] .L4FS_>&]JJCU"=D78A:)O2D7&/J+CW>^;SO[K@"/:E*.2=JB;]NB5=E MIE%H5ON0B&-"8(JEA=E3A?A2R:OWW+*V:TPG$E]O-7T6\IQJ'6;"EA$?_6O3 M"FH6FUT)IMD50E4JBT9I[G"!0"=%LA#&[+AM4=-[+65$3(KVMM=4!3HI4D'3 M.PI,+0VVW&Y#2YO/E>U*U&=")*VZX/"J(U*\/](E5\40)!AU!#HIDN 'BTHU MZ% ZHGFC C]4ED,E>CJ<4*CAM!_,;*(TTI5QF^U7+*[0*(8;8R@I4VLQ]YUY MK5J%ZKWJM*Q5!+BE!U'3Y$C1=G-AKV:*IZ^:JB)B<\4EH4[<-O$*'C,Q2:19 MK4!;NKAM+Z4FM43"5X"3KU!J5 A/'[M3?=A!=6;(S8=!/6Z:&-=PB5.VQ>6: MYK6N;*#X&N6KN[AI8F"W9J$HL 5SRN=:U*R$M'FN,E:CIDG!AB0QQVI=>Q:B MY'9!]DUN*?"=N&U"L-V$93?>SA9TL3Y=<1:/+5PO;(LD!>O HRU256N0GMOJ MC4[X5[2K!E'31*]-K%Q U-7(U;?]1;-:R'&YV4*-FB8P@'6Z7LD+@0(2*0]; MK7O->DF+>TV"0''E#39U%,)UA [7%K%!6;E9_+))%) '' [/YUQ7+_-=0@X':W9G'J? 0A: \;&E29 M;PB=J&EB=KO=6;=D\94=1+06[@2I-+=K,FZ:F-V6;/EL468L7?/J*Y,;JY,M M$D1-$W:3*TU9_9JSVO+]F&(2Y= MY?O3AY<;IXCO>62P(B)$VA,HOW)++WC_1V8I2=UYSM-3G[)=[S==[QY-/%TF MP-Y,HO."NGG1OQWV.3/LX&G+]O3O7'3$\7U/Q 7A(+S+@3U2DO&#GYJ*4]/-0%DP#L(=[FPCHS;278"+.-!'D M-PQ81!HF(H0F8!'IF @ 3:F8B/>2K8.) -!T;Q,!MM5IF(?WDK:#B0#(=&\3 M 9RF5$Q$N)_#P42D8"+>N8&/1@6P M,6#7#=@8H!=@P0!L#-A) &.X.S8&&,,MDB_4!W3BS81"/],!'R][[@VI ,!# MP*P 9@78PFTS*X!( 1MF0*0 O0#K R!2P-XQ-7M''$WWWO&Y2A78.MXG>V!' M%83 Y(.U$/ &@#L')*XU!(D(E"/H^ZKKE@]_C)LU_T[\Z^,*H+-]TGW75>L M)+(RTR3- WNRT^W)KE@[E+CL_3&V:3\+=7__AR0IRFQV:KE_D3(O&J(E*1G1 MC:I0UT3+%YUM!LYF$ A!CN9X7UC(/=%ZK!W5V65YH:AQ$:L7S\N@OQ2%S_Q' MVX1O;)4<48K"B3*^I7G=J$0Y'WX0>IYHR:(C"W'195=0)X/%L"CZ%"2V\55Q MVIBUU6[G(1/7TMKL_Y!Q!6X6%1I$82'4"5CPW9PJBLNH,T\Q0\-A8ULHV.;2 MMJ(2YLQ&I&WWE3,J>((S24D5:MK?@H-*TW!=O5\4R#4AXRL2)HI M&NY_'ZJMTD-F%I5(]_[[H&V\[Y9ORK;WV. A8XEF.**/3_C^X@F]6"S.]]Q( MT' :0GP*)S=L##T\E2*3^C6UJ11IB>6$77^H8%U[U^\(1%00CD;)+(Z161K% M_O.O7T?R>)O0\^K/IQ:&,P;F7!@1_O=HD::W =\KR@,31^9E*@5"9G35@X6 M2^6950LNC@4Y]!-0T'O!I.[?Y!D T&< Z,BR,5PKA25?F(JB,D11I+","CKC M#S_@+(J2)S+]LRL],/V3F?[^@C(P_0^;_L_XYK:HR56KL&=H'F& K='-BM@V M%$CI,LW-''*WM2FY9?VIWW";*#]<^U&U=BKT W Z2\ P (+3 M <'E=S['<0'HBP#:&S@0V?Y?*3/^GT?<7!3E7G@9]U"U)-M4'H%@.#-V38,< M"Y"V:9D2*_2:ZR5S7" (!RWLY@ BM"8M7B@B4P+*]37/8L8]$=E$.X.HJ#,, M9V$,22#"WP 2@&]P*.@>8,+;F-!5/%&S%)D5'2L<"?<1 %22;#FKP1QF"[MV MF1@.)NAB<^0-P6\! %]:EE.5ACFVWI848423FPT;N011I7820[,41IP$ 6)V M& # C0# /D-!J@#@W)N#R79+.K)$L5"Y6>>AQ7B@->C.:1WZJAYT4'=*0I X M'QH&E5/RS6ZTKX?)AQ\(A&=I GK#H[_N(*L[C*FZA1LD*13X#N !E#L:\XJ\*\PV*?)=Z?7> ?9X4%:D2.56Q@$"O MKSE-Y2E$?I\(\>SEKRS()4F[)UHK0\3=MQ0O$X5W7VFXUAV'+L97'Y&CB KB M["[$IZ=O%*X@2.^HB@^F'"C^M82H <6_^JBJ] U""D.R@-X#P#\7DY(JQ3]% MW%'1=\2H'P$6XF #1.C; OH8>8 <)PII/1KB])]E&,CW)B^%8"TEN BP6.-"B1N,5?F9HK;5E2!B@.0<"B+$#B(/P(H MZMY1A&[K"[KM&!@[M*>M::ZD%K3!UR\D?!@ RM71HBWW<$??;K269C9FZX48 M P#Y$0#X G5W*9XN#@3/_)(![S$= PAA25V8TH69O/N:ROL[*SEY--*%]V=W M-9EWJ+\G#SH"^@MBBZXXMNBREQ..2AA\_"ICJ^*Q0X[2A>'O-^+^!T7?N6^<$P$^6D! G_MT! :Q M[SO^0@BI (&00 O;KW]KD4"8I6TW&+ U,=.#15&JRLH]LS+%544WT$;CEF4H M?=L2^RIHZ!71@+LX8FO4ZRL[61_HJ68BE!K'ZLWLM,T.>S%RW3$096/7N__\ MK>CK&TK$JV=UW4PB^LE;WV#+5T_>NFN)>&'GU^4E5[<]C)NC32TLB+F$6+89 MOFN,L.2*_%YR/79Z6]8T;5RO3Q]0I(@;94,]A0(K8$B*29ZCVY*4/D,;]_/@ M'BX/[O(E_"ZJ 1\6\;+D>$,,!TV1YJ-:J!2-33N+X/+C!?WPW C1@0Q7#D^B M B&JRZ2X'_ZR3'!;<)!>/E+F3U]'U*;&)*/-]/,(<-5R4QE$ECV&1G7^N #' M1 -TY+">QX.2R_V)4#^:]B#9A_=L;7^$U[R_L, AJVF)J@W.1: M'^]],?LUDFNO[./^[B?NX_V=IH-^*>?X)51"<\X7RYVU*D\2>8F9L)*Z!BIV M=2%_.'?.!'V@A%'L_@OV10@#G#8*-!.?$P56Z#-XA&S#*WNU[Z:=DI\@>GW! M=+O#OC^0.&[6[XG_WRTX[^/_*2?@P^"_[Q%TU+^X/+9-"ZW);.@GWHP5'ZSW M)#QJ3PUU(#0A/M2!L5 D0/3&&I#TH89GP2KD$6T1+%/QS<9.24U[)6928Y6F M6\_Q'L,@!V(X$(X>ECCW^=3''88^FSKP'CX,F_+%M"^FK^!$_(;X_UVS9GWT M/_0E/@SZ/[1C\0::976 MX?NMM8NB(8TH;MM9N_^HN8;O X+KX;S,=H_'I?99"@=9BJS;?17<'T\Y"ZJK M->^^7/J=S8NC\*C/TTVVU13$7J$_*Z3CG]:[.P-'%":SF20$@57E(PLVUQK& M4>,AU+P[1 >B/!^@Z6-LYF')[5UR_ "K;ALJO35AOIU-_>="&'(RX??6H/AD M'O6^SF&?R: NWWB,+[9'[=Z$W0@B.\_SL1@]"]>'B"N1CN)'VH9>CA_==XZ" MSX]NS(].I@??&A1?DA^=CQWHJ5H].QHLN\VR11YL>\*;1)L[9 MDWYODL[K\(-Z$VYWPXP+(1GSM],GFB)OH2R=R":^-2C. M%R,\SY"NTV?Y^O5*&O/FR!+;E?:DG0=L@M], Y-@N+!. MT]/)NJF/0N-9RKQP'^F33,EX:?"R48E/A$1Y4"FLU\U&E,=V'>X''PL%&(:Y M&ENZ]R1\GRO=W+0[D9I_:U \B&G'1\%SMBJ-.7IN]X+505I7I_,KNXJ:"6E2 MB>5#^4G]A9ETXJMB+A?'#FQ*&?_XLW8'C8W_VY([I%R M[Z]X)-^OIIE?9-G'PWO 0[]8\EWBH5_TV$?#.T##;\<.;UTI]QJNH&VF8\B3 MZ0I"/70_XZFVT[M@#_6F= MM>ZZ_,FE_3G?_L#]NC^/4;C6+_3F(_ZWK*?J([Y?V?,[5O:\9R_%V_/LM-FJ M;UN37'*R7M)\$;#9YTG\XRDME^^NPF;56KC?:\TG=34=;QN]O"%6ASTFA'/Q MH@$VXE<9]H6P7VW5K[;JX[U?;?6AG(J7%Y8-+<^'[/A\WF0W@Y*4BZ5?5LDE M%I:1WPO+!TKENEWCL<>,>=Q5SM<56XI=0GD^O,9K*NN7U6)5M29\:]DWHZFI M/56K-VXI5ACT-\RH6J?I=B-;*K33.W'B\6 M^)M[$;?7;N\J$^^>[>J/L(9/+\ NR7*6EL,I?1(LE@4VPX]JH!I'C $5 'C( M"&]J0Q;';G; M%*0J8D!A="'B2R7OW#>%^8SG47-L[YGQG*\R2JM2XB52R\N"4LJ/U%"G,C7G MG\^$.F&0'T5#RXR0+C!3NSF?)9ISK 6APJ.!&';.W=<2?4P)SJV&GVNWV:3K/R]V5*:L#M39$ M2B!ROD,M,/)G'<'N)CL6>P6#N)4:OHSO]E)S'>>/D@5XO638QVG[YQ=(]-M7 MGG&7?D\\?NR*8CX>'WK?'@:/?5?<[5JZKEZ$;%"/)U?-_)I5*L_AJBX-H (7 M05Z\<( ^6JSZ>_,;UF/GH#JH_&AJ^QAT/BA M_68WT-CJY51P5+8R@L#3F_8JETMMPANLL2&7V^]4MM^[W%S\NI>T5S3EN2XR MSZ**TV!%$Z6UYFP-$.["T0'R 9W[ [<'?Q\T7,YZF>T>C[]\L_9#[\B )1V( M+I=OMFE4TR],1>D*^>)ZG,BQP)X5XQ]/>?6\@:2YEFW+1/N$1W0DT74DCKII MKLOE)FM#&+9>V$5'0TT;HRC1-1;A ^A.?)@]EG#VL.3FMTC[##9UP<:-QS'D MUJ"XZQ9IG\F@+M]B+6VWRLHJVLM.H'XEC.R.$%VTAX@KH>Q)N>OS)N&H>>9/<^VY\UT MP9X*]?AAI-@H'6#I:VI+/G=Z>VKLK2GR%LK2B7386X/B_KI<7[]* M<"_/Y0O%2K N3#>%>M+H=9MF=?A)C:\3\;Y6*\_"DE!?])A&;U!?I4;8L$,5 M@)D '>*NUO;:9U.^$O7!).=;@^+K\*D3/=>,"ILU@[-LC@[VU.>70HYM:OW/ M8DJMMJCTJK(JTN)+=)F*M.V7:+**F5+HQZ\H%PWPW&$YATNQI7M/-O>YTLU- MNQ,IZ+<&Q8.8=J&JQ!38;JTI!(>)J!G,=3:URA]>6_R=.<;+E;BTGLAZ,UB= MF=6178V:(^PJPK5A0DP@QOS.6X0C9O_@,M'7I_DW$O676H8'?R4HJ(#Q.@N? MV6%P'0!*E% "OJBM(2%1FF[!EUDZQ%;1EB'IHO1\348I^?@3CGHC=9P:*)JH M28JHPD4[(M)\NB=H_B,KBU__!_]Q?R>I0#007QHYDV]Y#'J)PZ!I^G^O@G(JKH =@#AL. MJF!@_22_1ODJ>J>!N$\^O&K@?@:"IPG$.N&)+'%2/$M6+D/ MU6/@$C$O[K%L=!#B6+['QGBF%XJ ?B_&TV(/0"8LT5),"M/,#_+6ZW.5WXG" M>#)>:62+Q69)H!H9H1:O",U&-E&G*H7$5CB0C27B]4RJ4&[7[V;QS5*\F20JE./M7+A6PRCA[7&_#_BD*I4:?**0IM@,([V.[LL]@Z^S;%Y*^L M1EDCW3:A F+^_0K^/2X49B%;P;D^88A8?;'7C_)R+R3U(S03XD!DP#IG(VY3 M:*)LO!$:&T-A"IB-9"I22DTF:;V9[TWA(RD;C/?9P MY%IO#!9A:UR8L,GVE N"5KG<7?:XPY%MN:,,GE-A=1(L; :%YHM1SBS1R/#K MDC7(POAT"B24J(M(?\"8DI5FA7"<&3X M<&1G*;;5ZD"="^G!2^W%FM0[+[-J+WRXSM0P+%OA EMH*AE6G6QX$._*PU[X M<)V)Q8LN,Z-(4E"D[O,T5&@R"KV$NM_!VU.M./6J%=G&^-4=-B+ M'(Y<;7*:T>66T\E46H];]LMSU(P,>]'#D5UK/=++TY74+"^J53:4&K++\K(7 M.QP9[DR%CBIRTB0A)9C"TE"DR'@(1_('\&PO:[K)5DN"G3-64:F>LIM6O,?0 MAY-6V)Y8RNN#L;#NY7)Y-68ONCF(3,SAT"%O!HT(FU0$GLN:JRFW6EA17R M@Z&1;D$'K]8&G0Z JGT MR!$HC<2RI*^M2+-NUH:5F@%ZC2F<]<@1I.GZT)BO-CK-B@*?[5928C]=14,/ MT 7HZ6I)ZO0,&F3&FEQOKV03P 4<.2WSI3CA\F:F-E'$,!>=6[2=8)9HZ,&L MH_C,2,@I>BG,L\7I4F7"T1H+AQXY6&[:!72N*"B3? O,,ZTUK16R< %'#G;U M(AJ;9E4NT$%]/6Y$VG%0D^&L1PXV_<)'U+E8,NB@P$4%G2W$YU(5#3U8:SXO M"C'+KKB7;"LEPZ%'< #$LNMJ*Y17FW,E/K4SX[P08^ 1'"'8-3F&7LA-V7DTS3%_-3PO5'G?D"'*&7IRJ:: (B?" +SVO8NM@$ X]1EOITDPR MB[)**R5N-M"&L=JR !=P!*Y28Q,,\:-J?U)OB>*>"A!ZP]HC0B,2F= M92:)1FH]TIIM( M5--3E[=C>W>KRQ,,!]7A5G)G@I_O!*_*1]NOH\T@ME(@Z MZ1HN6-$6;4MW'Q U&S_94\8]3A)GS*&M8QGNPIP7,D2)>%M*:X1[BIXM).W1 M=3WSZW#.@:HO71/._3N(7$0_B>6RA'#ZK='@V'#XQ>Y0L0_M5-L"5[8?3GL8 MF7=DI^\LOC=ZU/">V"?V["4#'^K7@#KSQ)UM.^%#_1I0CSU%?:C['.9;0-WG M,+?A,,S98C@^U-\']7=>B_JM#ODIN[Y:-/A-[/3>MPB-%/3P__T(__A@Q)?E MGF*?VP_JW<[>NK*BIO#QR*2 )@.9.A*[]-':1^LC:'WK2]-_@O9';GGZB/\! M3+@!+?S^\NKAOP<9/%LB8#]*! SSQ#XX$; TRUTHM^D[(P)]ZZIOET $]A+L M[^;9C^LLJ7ZP.ES.1YLL5+<=M M&&UC??PJ4,70!XI5@%1P[@I0?%465O- 12HH*<+]D)+W14_190H:HC:Z7*-I1*_0G!-U7T,F_A0K^*=SX M$>S.;V%F^BA].92^?[OR*YF1K]H1)<$,2B@%ZQ7?6@&^E;9[*R%R0_+ZK,+- MGV*/>@GHB'X\T.VLT0MMV$FB.'_FYAP3ZHWBO0@R1+E ]&C)4Y\*OP45WMA" M_60JO*ZQ^ALJ%/.6/C;%,GP"(_JJEQ^;H!-E6;[!4TO MKB.;QB#>BV*7]1%_M4_)/B7?M17]I12,]U!R9\KQ[7ZDNJ;31BL::K0*Y5FE M"BD9:ALA)G9Q7>-FBD5:1)YKC>K# >CCS#:DD?BN'L:^"7/_.[I;1\+C1[.? M;5/1@&DF]&E?T?"+GPDQ51Q:0C3F-'/: !ER'ENSCA6HR](TW9JS46"% M/G]0(GY=/?:;*^N^V7U5J8JI\?EUH\0C4C.OQOAV&D*D-4 MG8M#'1##C&]V^Y3LF]VW,[O?3,F]46Y8#IMB==*F6\OG3D2?, RNLP>-;H8^ M6O']8>WNIF8 N*P-*D:L&P"N#^H9T%K0A@!GF 'SG[^0#6'Z*OYW4?']D/[E MU(<4H:F$;1A D]8-0X1\!^\#&>,H(W9'@.=R8_/-1#26&2EA6IG(DK8&D5IE M$4<%/5'P/W*L7KQ/K=^"6OWD]#_4"]Y)HJ\I,S3HS\L+-K>=NM&\ ^0;0';LR'C8#-/Z: MM%-21I5J"R (\VE^5"PM,TQT,$2DC;27 ,_Q7\?5@9N?^G;1-[&+?"_&Y;P8 MF'+*[K72^/96*:I_E%+UY;:_YQ$.LPS:*SFH;X*3=5_*#4;583#6CJ.F(4AY MX"\5%?DB^/R=*/3.4@D>4@6X!(6NY!:;?>E-(Q-[GND&U9SV$NQA"H4Z0/C( MK?N'=F#\^[M+]PD<_#!?W:0W36"9%,0!2E5$3!Q?Z%;](1B^A?5SY6T_F*/C M^]V\]]'^<]'^_MP ?X+V#V;])H%D -$$__RE:.33WTC$&4 "R@+Y"8ATTY$B M<2#X?)W\F^CDOM5\(==[UB$RE^RR3H#1BF.".N=N[R0[TVE:6@0G"6:27S77 MX'=A]?<_KMZ U(:9N'ZM,T@$E%[[^ O8"-_"(OC. M9N^#QO==Q]\A2XM+$KK89U8(B<8U>=\Y6-C1YSDM9%BQQNIJR9NT* GU;+UE MQ*LZ[K4-M9!H($H?:B%^V-^G]_NV][^4S_]/2?\UQ4=R/6Z4JJF 9NNR_3*( M\;T!&"**1[D QW6=AW>'(&5&!@, =1>9,L ":+9?<\#E63?N/W1S!A:] R!\ M,^TE =>"MM)6K%'"-B',@>&RK?4Y?26Y2#?7_2H3G*QI<52*=Y.+-N)>N#QB MB E$Z,/ZB/Z=)I_2/:K*]Z;TSU96/DSIDW)N+M9"88TNI_+!EQ@8;%*C):)T MJ*?P@4CXJ[EDT)SGVM"5WM(!P.]#]\ &VW5W_6 >F[.T\. *$21EE+)5,?2% M(@/Y>=V$))W5CF1VG>.0_6X%)'M&.$FOQ^5N<1P5V&DCWF-P <@H$Z!#1TLX M^0S"9Q /[^*Y.8.XKAYU&0:1$F>=(!V/IIJLE:D7Z%YKWC&KB$&@7DOA !]F M?\<@[MW?\UD9;5]I1]\DB'[[4I,^9OJ8>9_I'9^<#GES)>H][=T5;0%,WZSV MM>:O:59_S_Q_'^F_M:GX3;+_X]+G"7;45J( M(V:\'J]82URO)K9>-U2M->MWU&&/)77] F'>K[7_?4GS]M;@@SM+_X@TC4UI MTY#,99:V6VM=GG'QU$:)(])$Z7!\@(Z<32AY0'OXO,Z@:/"PATI?!7]T*?"N M=.%OH?!_9Z/VJ^D6V2T1GKRR--,;8XYCQT%!S!4VX7C,?)X*U1Z+J_4QL<.> M87[:OD_(]VVH7ZGKSVTE*THXMV>H3NZ^G&TD:BS5& %X),"&6S"IK"8]^4K_ M-U'Z_1OXEQ.?*(#CTEK*T*<>C?:(X!Q4-I%&LDP7Z'I!S;56W173F2Q[+*Y4 M%PH'6/Y0X??)\IN0Y9T5J_N"?>^*HH7JU*XIW: @O8+IS)6(TVTM6[]VO*^T M/HKU^:4D:<70(4!E$TG1NHBOEKKT^N9:T]/9_TUS2[[\^EX6053"1JF M(21?(WR .=O/VJ=RG\H?P#1];'_Y!:AR:N)C1(.@>H243E* M+8X$>/KR!65OIK-D<488-L5RP983M5Q.C)LBK&Z%DO$HRR[@.P/ MU\\+0N+)); M7@>['[H\7SWAH<7[B>()QR7[@9M!J:Q+W09XII6"E.VDHLG::+7LL;C 7)@) MT-PQQZ9/Z#ZAWXLOXIX(_2954MY&Z,4(]YQME?DP#4;=UJ;(-MEIF-C7XUG?0Q?Q,=/'S/L4GG^RZP?T9?]./WA=&V6@:*(F M^;51ODQ&SRV-X?M*\?DLF?2-CM]'^GO/:_M\<7>S.*T;Z7&*?)FF#2490(GG MDCZ=Z@@$NC0AW^J# 9Q<&YH!2@.6.P;^!AJ!I!G:]O>2;OJ-4[^-=GI?/MS' M=M-Z0Z]9AYS*@P0FQCJBQ6--4U?LK%YE6XEF\-D,@P307DJ).%HANO4Y MR*?,+["CN[4;OVR"^%LILU7(SZ6HDUK%V %#$DQL79!U H=7W/SK[/YV1]^GMA#:BB8[Y4)%0L.>OL\1?([PK?+!OHQF]%:.T&HT![1= M>I:$\KRQB5?3F;0U&2*.@ +-EU>+[B=Z<#13[K(AA*_J1+P+T\W/E+MY LU- M,N52+HF>3:"I=Z;ITGA=7-'K:*FX5F:Q:=6&F@ZN0,Y(:)R5!^7#M#,,9O&3Y.[)R;V]7C6]U!$ M?,ST,?,^A>P7!@,@D;0 VS" )JTIL))&HC8$%!3L@"*?30IJ"LC^ M#1 K&'5=64#QJEDDA\ IF4HD@7M8O2][PGT/8%^;.!13&?" \H#P2'\&J3[ MLH;T;/0_84?JM2V5XSJUFKS_P#/RB/;]G#% 7 5EC\/% M]+C8I?(=?";R39G(XX43_GWX2CO7X1PG*U1$TT8P&LN6&3JQ'#87Y<@\'68P M"X$&?#@0/1*!^./Z/)]*-RC* $%M -$$J#[?M36N+\(4OI.U='L[_L&+]OT1 M=ZI >.ER5B,DFG1(%?ZMVN@8O'R0\,9S[&PYM/E1+AGD)F*QMC#58>FE6X?L M#)M_U\V\]W('VW$B).G899CI/@.3+JCH1QRN/UFO(X8L104Z7J4 MGZ[V-C;AL,\]GL!!GB#K-NJ2<1MF>0XK_O/.L_V-$G7KC=]IEAMAE3N?%-V0 M:Z'E:&X*-E/(%'NL.)/Z\;OAE&HF'(]&F,QH8M>+H^)FTF['+<@I<>7'*!U@ M:3^EU><1']6A;KWQA^ 1;"]4E9@"VZTUA> P$36#N5;I M3.RFK&J+I5ZNMS"/0+><8X$P^]6*1GY" OQW9HA?WH"\?>C-1VHI__\BY^ MYY0,2KJJ&S]=1=JSJQ$A#!83ZA $^P80)T%Q %_\4U27XMITZ9IYHK?6R<^M M,H[@0(6>0I'_I78?$30.0#D55T$/P!RV$%3!P/I)?N4^PA3M/M--!:F(/PV@ MBI:R &CNO5GQJ5CZ["?+//%7.I176,9YL$RD1@;2TO^G44X@Y'B6[!R'ZK'P"5BU;P7#DD#,1RA>]$0 MS_1"7$3N]7F&Z_5#(J!#@U $L.(/\M;KLYC?&5'Q9+S2R!:+S9) -3)"+5X1 MFHULHDY5"HFMM4 VELJ6XJ5$-EZH-^(-H2B4&O5/V\9K3GG^KG^Y(=2I1IEJ MEN+-9+8A)*E$N9042G7RJ5XN9)-Q]'B[)6JWI^VNB>U4LJ=PM=(E$IY>785$ M?8Y!>5"> 3*;Z9AV_9Z1R+#59/FY*I1G9K,GK%<2UXK_H T F=P"LNPP;5H M[LU AJ*)8B@,K7/CMCV7?C..2@,- D+=@O^"2*4@D6G]Y/BSVXW+XLQ2IE-; M U1C!-9K*V5 L0O$>7P#-!@&JJ*B6KE$5T9@$J'@?LF-9UP)4>36 C-\< M*08<4^XP(2I4ZP0HY-" ,^;QL.D3=7:IN"8H7(II]TU%5D1#@1#["THF%:#; MM4!=XT98+/VO9QK\A/F7T@W*&@%W0(*H(LZ7?Z.]B)2D*AI65*&F,0147]%G M(Q'R6 FO 6H@C@)#S0P%0AL>&S70)1NI+'#'I/X&46[@6B@)J"IZ)=R#0G2= M&=!GD%$O%6M$2:C>F_%$M:%B9,#_49 C0[F(#@ M4P9P"GV&VV%#QMX(OIH- M M.)!EKV5#?@&4%H49Y=,9%_3;0DN%1@B09<,V3GR*5# 0V)"Q-"$JU)00BD M#-;.@B@X=@@L,X#T+H(#SE*\^\&C9:R@F:3""-S!4%0T$\XYTDW@3H,G@*N0 M;8@OUNX\O;]'6Q'E*02]:1%^@6$%/V%5C[H-S7C B9 #HMP874>#*Q,IS9[V M(:C@N1B*.8%?*G YHH&^U-$F3V(..CGG@*'\A>A#$ W=<7-0;^_@%3>I*T#U M;0OIS)0*7X4(QM(#>!H-X#\HO6]!\$,X@KF-+L'GW=%+>OQ65F9@C]T=O@CQ&-[N-K M , #K4@KKI[Q*0"S\X"TDB#ZN40OU#1(/D0L;'_3M.6)&": UN%@$.E@E$U M("A5-P!CV7"W(&1J@)GEEAX^MASOQ"Z"BY#'J0K6I7;3PRDU>P!QW$:UBA$X MT"+V)WB]F/4![8]$"TZTIOK @10R;""DM@ ,N)1B >+RQ6>SH]XMC-:0&P_P MVUWLE'7X!H0;9P&T/@4)R :6"GP$EV9CSH!V-,0B"^(1H5T+0@:S=X0:HC12 MX%_HJX$"#5ML%.WQ'VHD(M:!CL&>VBHVXV0 98:"F=E_'BL$5@,(UX$LB(:& MRE7'=[M*DDT=9EC21.,IB8;1L\-5M9DM+#("F,_-?*46LM1%%=I>;"S A\,! M^DC(BQ)-!*DV0F+__[*EQ5]?JGD53,5$4V';& M5K*C*CE.!>*7'+?.C.NA8.\[W&=HX>]7M-%#HM[LYE0TPD81%R?:"K$AK!$$3]46#6@P0&%4 S/= ML+"BN_/WH?E&(A0D?0"0]@QFHF.!($^A(6/QC75E(HV05"."'?UX1PY01L+% MS-2=;N48%74+ZY=HLY@P1.HO1_MO/M6?J'0\7MGJ_]C@,8![GF0=>)@,S0L1 M*=AQ*"1-#T4JR))W+0)G/01*4(W53,+)3;@[:XDVZ!791^&[@P5 6IZ&CP\5 M-]@>)YSODI[/=R+8ASRU^P ]CA;F2+=5&2D@!K2!\.U"71O;&E$., 98!,%_ M\RY\B(=>YGW$/+22XIIFPXF2OWE,2OWIG*1B^A&?5'%&&V. -)0,5XF@020*>'(>&8GXUEJ*2)%V5"P MJHCJ77N@_QLXO&_#R+38ZI#.3RE(;92LF)*JF]!20-;_W%8,4EQR2SW'C4XO MC7C)U)5:B,QD* L,I4^6Z(A0J'82V_%3W?_O((($,+#5XV5Z".4&NFXA3-L# M&''.JNN]PSA%(2 MC< ;!N\A@RB/;=/"SP/XA!32B5O75*RKD/U"/$'56K!%Z/W!]2<3I0C>O3QH1__5_R.%K$GZ M 74A2FT].X?5M=C9"\Z!KZYQ8:<.0A8CG0SG[-%A#_05+) $-DDA*OB<.L M30]E(>R>BA/@@1"6EJ9I3TEU9>*D$$G5)4)L2#P@76M*5!NX4CC>]>HA3PDR M_;$38)<3Q\)S "VV)R-[ /@C1 MRATU&O-C&;C>4Z1^.F^%R^W;IJ)!WH=<0GVD5A(DP1 CL'#0D)R"9&"80_CW M=@'6PP,8)^\ M3MRA*PMC*19*'AQ%KG$L2!P!:J/0DG.6CA?N]?P>(:%O(U!P\TC'! KQST*# M8J!8>(UX%<@O)T.Q:*(8 J$!K.L$L.?,M*'P0!9%=H^'D+;NI4<)GGN.\Y198N(4L.3#B784X MI%'S5YMR? A(^X<[=#=/5'9C[W1=NQ5OU+M/J,PXZH\,$5^RD-UN8%N8_'5+ M(' 0"$W-LPL'A?$&H2A47:-DJ^QQ,:CJZ4MM7X/OZ[;E[G[[U D*0XL+HH " M?PXG7F)UT";%S!"470(\!-L-7?JB86 _IL?B.:;QDINUFGQP!3?P^OYM8.>H MAH<.% QLS\.9N,;@=SRI4 QYS"H9(\C @HBK[3$: MXFR"B[$=1U3CP-PAYX3?;R(WDF-;;GU'KB!YS701I_8XGOHX-J,@[ZDE8O^M MZV/D ]0)L703WPY4S9 Z3F:J*>8D ?>F6.C35E-8!O4<\YQ.QNAT2*A#]6BI ME=%5K;O2%.3?1C7_2)7PAD$E+\PP04@8:#@3YSZ4BQ%0Y=,D>1\)$/0[K_?% MM=?W]N)6PN%.6/4]FOF0C538<3\'&DWEQ90BLP@W'R2J/WY%^$",CQU-? @< MYP*/![7X O(>M(N4;M0A9.K;O21!W]K]E<#%S:VC\!,BHU&;382L)LAKPA34 MEDE]/80V.AL)1+CHBK68!A1(F=^R5G=JJA>+04 )I$R<2[.$+4UTCZ6\X MF.EP+>),VZKB^)?[N5134=%0V,D1\TX8$2NZ8(5B&MA3Z"@(<)CM1.G06U( M.055*@FP#0_U3/@UCBXE= ,:&JX>?R1J[JZ^^91_HM+Z A@:-F-26_=L'>IJ M6#M%*X4: IFL+HV@2'TUYS:]]UB\4-$6@ 2*2(QP39(R,D9\LH^MBWO,R%N%"W&7\S*%F- $J8)UI_LXX.3!JNK> MMMU3$"'\4::H\Y.Y+2+-U%6YD,DX@*#3;Y@=X$W]>R.KD6S3TB'0>[%J8U-A MI\W^9#XW*KS9BM4*M>IY?N-PBMZ!$O6\;L 3B*\4='!V"*.OO*8TE=7>A(']&;>ZN&KJKDUJ M4G'3 JHJ$K8%7[9$_QPQ,SY#"GTN5KQ+'W 4MO" W4,.R/\^^2!U"AAY55#C 6/5UWZ*0<59]# MO>6G'0 K:8Y'T\:-)OFV+$NK?K5.CR 2"#$GTB[!+U]Q(0"+D438K4@EZJ.ZOK@"1F.7;H$)EENA=J/5:<,X$( MK3F27(+3Y'8\Q/3@^([1*>8V DH74%@A M[Z&C,NYDRBZQTP J6)#1J\77!?VZIS9A'(DR*I84-66\"5*?;9-8P5;C3P==D9IR'B1C:SE=ZR*UU;2\C?&MR M71@H[^"_68U(""@.>9(DDHK7GXE%)E/Q>A-_$V10V&%GT&9W2X?/$]X]NIJO M 1RKT,F5L7&2#1I#*5"F*P:&T!1 :U[&M[4PYSX*'9S7Y2 13N7"@E_<^[$W M_&&>DK;$,>%D?.UG B'/ -4W='RSU,#Y*SAI2C1U;>OG-^T9,B"=L,LN (HN MA^(_O>_;Y>;LJS*B0QT(+D-;(2FL#JD,%*1=X1Q*R*_AD>%H9T[4;)3GR1 A M3J;;_G0*I1/)RB'SVE@?@-#1961(RT$#6(:.[&IR^12%)D3'OA$1 ]E^A74K MA:1HN:.\PA,=T&N' 'KFF#H:$8U!%)4+6F"*7 APU9[31A;O*TT*_@VG(#FK M &<3H96@;+>MD22B%&'D3("XCA #SB=9NZ0IO&]/7M86,/KQE.[$VW*FCR4K M[>=*/%JZ$N.G*_GI2M=(5V+?E:[$G7['647M.C6A;J,D>*XH(@:*CA)9QM"J MW*;0;)\5/+DTF.FYWYA$#FZ=9U?3K&Y:.^N,@N==DZR84-]8_U0T!/Y@'QD* M>WK0C@5SI&NNNU3O+":* B?MO["=DDF>/:_V+]1!@;)UP?&=&LB*X:C1B#QCRX-0N4%#7J5 M1[[917Z<5QE$K8*6J29OM4Y\"P\=+MPFLM')@_VM]=>.AD3,?)1F!,UL"&NX MU+_O1BOU,FHV&WO5/:_"X?3YW#D+A3!,9[FW2L1\!TFOMBPKT8[BKJC M$).U[R?2'R[(R:4_N1[O#8!CNSLX4)RY6J\^@0"[ MFY=0-585G'"VU9Q5? ?KZ.T!2I?<;!N$W)#TD+)T1-W=N63<]Z,2/_NJ+2H! M8CJ.9ZQ,0[W848<_JNQ2]LR]!Z%L?5B.UHV#%[M7D*N5>$D8TU&M%W0I#/DRYMZ.FHEU%*2K(=[]JC0F? P9,PMGM&>_ M]J]E9S7IB2)&PTFV1B(O[KT0$V=%H;L0+J2/G>7.+OC4G&E7CGC%"/&(;1UA M;+\UE7$R]\\/N_E"& G MM.B]/X_ON.+'2-19I$[7*U'[X% M:1L[/N41A3N] +'VX\(;IR"0HF"D%M);;J&1>#(Z4,@T,'^"NA"Y+H=*QIF6 M*[.<68!S U QO.L/RONII4CKPQS.R?Q ;GXGDH#KGY&L"HF"ZNWT9H7"4BA7 M&%^&>Z->XX3EO,# 6*W"L0 $]H_)'*'S<,\&?87?Y548/*^2G2%$AF"A3![H@_T5.>\[KK9@MT50'P110C!)I28[ MZ.]K0CC9 H$)U:#EG-D;X'=W3^,KB0-?" NH/V)_04&96N[/XG*[*S7V 4!#%. M.VM!6FO@U, B=Z*!\>+DZ[A_AG6S>+ ,YJW*IB0UG49UQ:#T-N=ONE<^/2& M[,Y>8#VENE H*\U1(:U#<+Y*FC_'T[:AR".L#5]Q17Y[5)ODVB_#8 &R>1XH M$#-(N3LD]B#TT<>9;4@CW)Q]+_B^K0#BT9CKKIZ,5KLKTNHD0)X[B5-,[?!X MX6Y<6'CX^9:9$(AX9]^S6Q%*$\(+'$!J&W4Y\0M<.$(WIJA XU)#:K$^.$;2 M@>TY(/F(37PBJDS7_W'B!;>L2'G\;C/\RST7KQ1RUK\U)0WPV\HP;\$3C^T* ME[.-P+R6!W>@H9YP?+6Q+7@4=X#3/=DDY9E&$&9!DEWA^F7$);0,G61-\A$G M $-8#R$V6P"\QC?@Y*;NID8'81D PQA;:22H)6UC=F?>Z]:I,K9E!70TAQ.7 M](QTY/'!\U=.B9-NB"UUX/H).VL=47,04[.S0%XLEH[J-KP:ZGRG0]U,T4Y^O;_#Z6"7=M/8*<8CR0C%U M QZB"H;H8NI<0O MQRGG4#)@=D%$QO%K:A[QZSAA4 E5)Z3N35 ZE--[+#?ALB*-$LC[W/5X^*XK MO.#"D&_P>)CW\B?(1I^X\-EXBN?'R-'UQO89#Q^/9OUXM!^/OD8\FCM:VL+I MS!$)1Z1HOQ_K#20IU@OU0TPO!NA0+\S$!F(T1$L/6%:2HQS\E][[14/JU4O#2=CJ:E%A/71XH2^0% M?CVRU9RH.6E>K]'MH#D>B19@E4U:87#\.1Q[,.6>"DT%D9(FT&.PO,L9H4AFDJSWN M<,[PM&[VQM98;:X3W7BG$^H6ZP"-#+\>V>B-K-5ZV7H6E!!(3?1&30C!'7&' M;V^7%VRH,9AU:'NS2K?GC#Z0"W$XDF%>#TUU.^(L+;140:S6%J%.2YQKPW@O MW#L _3#="-?[>B,Q6<^&PR2T[8=V&XT\V%)FV%MEEG1)HQ-RJQ@5<]E!44%V$ML-*33\=:L^)QH)JO9(1QYL*7)*@4*?K(W8?+K,C5-JO)LUR% M(P\6VI]%&NM5.:0*=C=NL[U5I]HM#N'(@X4..HOGY#@K]R8VX-7Y0$F%[3EZ M^W:A5XYKU$A$-F7H4S>4W8;ZJ!O'/DSWC4#2+%:$85A(MSN-H-*K]>/C(Y7\ MCH^[OW1?IR(V=\&*V Y,KQGVX)XBX=\:WQ^YXN;@0"\7%QNA>,1,-A,6$RS' MPI%VMA;_<1P!0T<1L-9]YL3$4AXU^<6LO!HO&'5E_/DM-3>8Z$73XQ>2Z%!W M*+12Z8FR%!G-SB["=75XXL::DYD0=!H)>./FQ[(Q7M]G(\Z9JP+Y?53^64"N M1$6#KBQR[8D8YC9B'_#B)AN'0$; .02S [K=O;W _DU Y]K>U@,.#9#/P%S6 M"U2V5P6UZ'.+F=)"N62HBT5.5N+:\O. .HIEF%XUEZ]/P""W7*SB(S537?X. MJ)^!?:\ 9:5TO5^/=C:TW>%31G[46VB%3R3Q2:M<,+.#RG+2'DKLK-YN:,'Y M\"2@O7[%^%%;I4.?E?/[U:V2W*! MOXK/#$5U5T7<;EM?R]N7!:=_M6>(AOC*X&=T>$@JICB$*QKBJ3D/17-MF^TWA29A.H'N;C$=)"$5T MTBL,D[9NF_ DS+\O6;GL/7FE.Q_ S_\9P/] Z_^H,\0I@N(X#DAO>XQ0,Q/\ M=#]X%X),;<=Y@&Q0B=BNKIL$6_6B;>GN V+3XR=[EC\]LU[9_8>>%(^H:WQ76V9>0K=ODGW)V^9??INIQQZ MXK_;EGW$_@Y;YK[=CK^AC(H]?3=%A'NB(]]LR]^17]-/$>XQ]_R/92 #XP&- MB2C\\L"#_$21J'Y=NV$8[[ MUEO^=.?$*7BPV3\_=#;R1-_WH==?>TOWH>!SOCOD?-$#$-P$N1V.YO@!G9PG M9K:B<,(NY>81W3'R'XD,/ C'.Y\&]@#BT.&,7QEY?-[Y17CGJ7]/\U3VHV3! M<$\\\]!D@6)\%V*B5_?C^LAP?61@?8GZ+HGZ<6R!ZAC[Z-AR*=9Q=9?BO;,. M]HEY;/7JD'4\MC[U-=2G^]OR_7C2/V_+GQ+Y]! OSKFY+QC<3XS?QW0?T[]% MT-^78@\>]+]W/+^7+ "?HS]\%L"GH/K'#!)OLK4D 3 8?"X&)%%_8WTV]91K MO1C/OO7>7'OZ0I1Y9#LWM*@/M_N?BZE8=[C3,R1,<7LE#MYZ,>JM/<1^<^W1 M-*Q>Q=!1"8VRX?2\G'L@3O.PPC#6[LSXF"BTY5HU,E^I>KB^ M=Y4JR+VK(>G9>[W"RBE+@HI804W[*S32]K-MO@\ M$\.9/*\MEC?F%7P9U""(F&ASVEI-(NT67\LN41T''O&*,!>]!J_@3F#<[93F M3S2![Y#2+LY3L.5[AQN] Y9R_/[L!UG*8EQ6JFP_*@KE]6B\C"R-2"IT:Y82 MMJJ+>' 2$>GI.F/(T0@4R=P2LI089"EL(,(QU^$IR--P:Z;BZQ\?=1[+'G]53_NEV=X]\;BS"0W_N5!JBV.$/0S#.U]*ZW-= M-[^O6'4#MO:<'^<2@X+Y(JRM<&\>ZJYM)HE*Q)WQP3Q&?J5/_3[UWY+ZWUWU MZP;4OZZ,$]V@7)T+8K'>&FURBP%;1=1_QJOR. FU=Z'?W)I:/I]+$*>*SR0^ MX%[Y?;W%&S")A%MBK=2CX/<^7]P_;Y?G]", MX54[C=_+_K=6(/R,I2;=3C9N,V-XM ; '57Z:^H_GX&.#-OCG+]4IKV,%I5B M6+#YF-YGZS$Y\KPGC^@WH",NOYIT]I'5CJ&BV_EZ?;00ZSC+*_ER>!%IIEO5 M8%9[[KV,&\L?O[@PE#Z1 .0GA]58<2?;2\,K;O;* R^ #E?CIH9<%T&Y >4; /2]?"@ M%[EL&VXOU+DM&JA14=\F%7116R=%5.'/]<$ M8E$S5/OX!3>3-W-&:0WS:J0 M]ES/Z[0Y2>E&8U=-.*[)#:>6<-RM]7OT9!:Y4$L>)(RDP'(+,[V)#/E@8HD$ M#<]PQ\_%;0J&21Z5#B:UC*_-++'NOH-FN3/JQEA&T@2^:C#%T:A:7B3>'[7 MX,QJA%F>9YJD(U)6$YQ>:C71 N?1/EK()T4M,FU-1#X=JNXBR%DD3;W+7K(F]TBX.[W=Q0%R] ]8&U!$"C9DBD0ID)#-S\UFVAUGRJ M/U$R*MAKD"-#=,3]RSS1]'MXS\PV0(_.E[4(/QQ(M)A?91:CH5E/-_^<:;/O M8#X0SZ'*J"50JRQ-6GL/ V.\BI&&.7H>C7$Y63"U07NT@VY%EJ.YJ9@,X5,L<>*,ZD?OP4@A[.2SN4GHQ8M+C+= M_M!4NL]*' .2?P\C_ZQNEH^EE,9QO?DSN(=;!QH RS+YM08+?_KE];!!I5TP M11V4FZ+]7"I6N_ILI0U_HX=!P) V>9\BJ=[C9;H8L!P+M+;5@HY"SYC:T<4P MTY6%=7VZ*L2LK)34J]B[1(?XX\!;BN:KUH(NOAUT 3G;BH'S"?X-G7;==@C; M%N5NBTW$F!VDA3JP!';]3555ET2G6?D,&!B?-#A [ZO*T.F=BP>C)I$VG,52 MS %J"*H;'GUX]Q@"QNEOO6T6X3;?/:65(QRY#NMYCPQ\#S%MZ<5I95[9 :Z\ MA=M1&E+6'6Z0!'I8F-:M;IYY[D16"\B!."8:8.CC1O*M>C?_G[)__PE]_JE8 MHJI(9!H(':=+R*N^D*^_A8HE^(DQ WTZ^)K,C#V/#B+O&IXD#IJ1%)QF)%L# M!0+LEC1W>TKSM(?9-FBY/@/(@;!E(3T=IVN65UMQ7.WBE#(]0Y MX^T1.REGF^EH76JE9"#4-WQ^N8G2E3BS_'PJ[B;C9JABI^% M2X (5QX,ZB.@#O;.IP'I 5BF4WJ3NMC#&RWC35I[HPC'J;3@EW> M]DE6".@IW&J0_U9*O!V;"VA$@4 MC07H6/1*.#3SP!H;?1C8MT:0(FK[#E$;8T9#3P)3&:*V82G%,*VX3+KQ1%H9Z<7E<%8?-#AD MHG(!.GS"0CV&+E,'UBZ&P,>R"V^BGF_A_7B<9@^1(&O!"%2>H84(*PO:D2XK M0J[MZ^$,_UQ.=)KZH-(,UC<@7!_.8K7,#7 F%&+"BUY1&PMB*#.NMX1R9;:\9(" 2^DS@@ Z!3"$]WD2Z@"(^=%]X44=VAB:_/F($C/N]H8\A%. ;2>=.%"]RI\-1(]VT4(=CR<8>8N>I^RNX5/'5*[#E MJUL0, 2^0"9SD,:B%X+]68GV)]*,A+?P4G0% A\;X3L$-[%!#E9PQPH"DG.2 MVNDS"R#G)O)TD#:I?ZC40VISUD.6AQRGD#1VRW3@ <&K&.#:(#])ZA\$HKX M6Y55T647F_!K3/C#=^__V_G*MCV(]UUE=^(>!IFQ"?$G#%)C6U M+1L[M;#;BH@;MY4P/MG?;>U8BV7J+_1+1%,L_:\GM8%*PEGQ8^;?OY^HK(;T M# T0+65+IY[.R@$D"-W6QX0/FW9_^[=K08@I[.0X%#>L(^1O@0NF;GG >4\E!IP M@W MBJ62C4 Y U"#: ,HTS[J[ M[('87E]E\JO]SLK.,]W$(OFQ4?BZ7/?K+,$W^E4WG%?3A/QK!( MC0QD0_Q/HYPX6M -LU(-"4)UKSB[\P@R,-S,&J(MBIZB2-8VPB?^\ASP*;3< MA^HQ<$$L1]:.HMF$ )Q>Y9$HQQ:,]J5A@V@L'4U.FG%S6:9!?A/NB/+6$_O!= M0??SQJ#[K8>G+X!GD&/^22\Q6AC9(7J26$QC=2XMS4+K/?,O6TKM&8!!:"8A M(Q!R4]D$VEZ6&>2!<-+R(*%[KN(3=]A1HV_3RE:8%,NN)W-1:B\+3+UH&?$? MORS4N^W0X)/TH)>?;^V5MQDD\B,;)![D]+QYJU?Z*/I>%,U"_C #F$DX0:*C M&%JH)E5A-BZT)],>G^\J.O\\+"XAAB[U8YF-VSEW^J"+I4O=5B&N["7PH@@J M,16"2/Q KA: :HF.]*0IA(!$E!H'2;;JG)LBN7"^U/2M5N+B$WYG@#(5#8=U MP9JH9E@F0C$7M,W=?#BAKLLF,OFV40Y(9'U,ZPM%WB6V>LV*@]G)BX'L'JKA>L[VPNKHI\?B MZJ?VN(NW[QOJ?8AZ4S3YP-Z;B/":74K.86J YGCIW'[$/T;64DZ_R+,)ZE(C&&ZEQ MN3S\\2O$!CC^Q#T!DM1'S!0@OT*4;7HD_%YWG0TC48:X:L$3!]J)K+:=.2=[ MY-\^[D.\6XB&@G5+>#HFQ&L'E;8^E-U"]DTQ=S68)OK0?-O+ ]G'2T>*(6^- MLPQB?+G6V,X$$P8#9#]"DM_:G:>Q]0!)/8" ](:( /T_L[0*.(0YJ5O MZMT%1I\0C1?(,^ER$2XA:PJ_/>V7P_GRJZGG3WF8=O7"21,2:B?DAT4+NS%&A^G6(# 8_C#HLQ MCQ$(?RZB%#9#WBK#1(@NB3X'-4AU?6)BK'R2T:>1$5T2N%FVJ]<_Y+TW/S- M$-^<)U#?%[)XYZ[/&FNGZ%3@5LJ2I4-V@;=$_05V$M:YGD&Q'"8N]N\GBHIO M]5_(&S29&.+Z,9F^/53T8NR%Q)"#@Y'[U)V;B9&YMZ%:&>P,;@D8%N0U1*4V M#RQ:N'XG(&5"*\JT]NP)"'-[ )D*N2-)7.*S&;H0Z1$D1+%>NRCC^,S(I:TDTRTV6"V< MC>%;@9#E'5=Q'72$IQJ'BX"F\!2R];NU2Q[@&#]LH P$/EN++ R^*1:3H=(H MK8)%&!HH?"!\XO"\O/6XK>&XP4X9&D^W5:?>>4AU.I5ZX?O#<'.]3--V-"K. M0]:9E)FKJ54=>A 2Z]7:A 93PWX1[8%5R2]__"J]2ZTB')5DQUCOD-5$"'Y3 MC6.H&A7H9Z@70GCL,LH"2('*EH$91!>*")1- "]SV5I9U9W*U4Q;NZM<*N4!2AS M!A4@W3!'RLR)D^ GSAW"7>:< XALNM1MD$-0X;,@2:2!H-67R._ZEX,7A4:J MN3UY!U2O@Q!GP$2.S7*1Z;4VD-5<_"'+4Z -X!G@)@4@AREEDP(27O7N*GK= M-@3"?R $0B2/.?E-70M'\,RD4FRI)B,%6BEG6ZW^H+AY-O>+G(0_5E^CY@!N M*V9XKYB);0RNMQRFFOR0*:J9G#$.F5 AB#R%#^4,Q&@5AX7$!&+N&$(RA6+KZ.JV#;& 2CG!CK& MSM%!D&H?@XF#.UY/4#S-4^=TE!^_'+V/>-)= \8D>5'N2TVD1;A6T%;Q.AHH M,P%D]$B_WMI"6Q>]&SQ^JVJW'WI&>_;$RW">_9:>?Q^!VJ[[)_67\C>6 >($ MD&1*KPQR@>D(&HP8>'E_*6_Y&1(\Y$=W3L_L@I?D82.[#6X@;JG=0#$V.+BK9G J*>[+FF M3LR(E5E7Z+@XVH=P.LA(^NV;]NT[%QX.JU:0F8=X/QJ*U]\?$_\NY.I08)G$ M":"!H0Z5",M=B2M$X-SZ$&"-# NF[72R:(FO3+O]_"6G9IKI$!-%."A.2ORK@!E4!I>K?JU>4"FNP,;\P03QZ;+NUCX*=Z],X*\ MG-L3)=_Z+B','+AA8_!.0*D1-)+/-]KK$@EFWF"DO(%19)L">\FD=\Q?]Q@#_A#(S;SB!@C6P M'?@76L6%"2*\0MLLW8,@2P;CR1L4%YU5:X5AF>@?#+PXB4OTQ_F?>QS#7.(8? MT$Q/#L687D@68[V^V&=[ \!&!K%!*,;W^S^(NT9T.U#E1B4KJFK/,Z&]FM:7 MA?9XQ;2K2*-]/?)ER77$6,$$]'K8:?'%ADA/5TLX,GHPSMF,ETNEU'*R:H),,E=:UL?3;B\.1Q[,J2W:4:D57F9IGJXN M1M%0HQ_JQWON>:+9H:MSSO"V@Y' M5Y5%RZSS:.3!VZ?)6#G(KY\'D[*0U[NL"%J;]!".9)C70Y/=<%WMXFKS<+R3@T$NC7(^MQ2QTFRBM6R%NS];*O M@V(RI8MCK2*A!ND'F\];BF5W]&B3KK?:TGB\$"L#"/KPX>9!DIGD7E;=\:2^ M6D6TEQ4SKW30G >;;W>'5BB:#Y>$?*S8?\[3R0)OH'4>;C[.SKALL:ZLFFLZ ML^@EDZ56);>$,GI_2SV1Y7@F-.CWH@P=[86 R/=BK#3HT?* BP$FQ SH TR= M\B G6MW,:L+KY<$J)_3R@AX_AJGZC)N+T_QXTVR'V=XB6@RV^V&$T_SKD8R8 MK/>*MCZC\[UG;19,9A+"('X,4Y?B")1'=?&EJ9B1X<#>E.(5$^'TP9Q3NE1O M6F+)FB1 -V%U7_),BEL>P]10XD69%&:<+"BA:"752:P!R"/\"QW023M!V^9: M82;U1$)6:R*OUWDTY\';XTI83>2R[:1@1ZQVM+%L*[IZ%*=GF6S<"!93<8%] MGK[P(TL;3I6E!U'WJKE$Z?O/" M1A;GLU&GR:?Z]L9N-LP4!^!S0Y7F)?$FV3:E[QX*=H+9%;)N_\(]TVX3CS;]_WDO3BZ.: M @;'-NY&&HGBM."9"7ZZ'[S+0&]U8F\HA".1T,]^5(S>=1IU8F*'44?+<-_J MS,:0/?RV&2J>)1S]3;M:3]#),S]R[PX@(K@@Z MBX. G(GU#^)R!_&/92#GW\4B!\ZX3M'96!F*PK79J+^0HT8/ M0' ^.08=ZZE_#SC#EBS8CY)%[(F)/#15H-2>!^&8/BI<'158'Q4N@0K1)_;1 M,<%G"A?"A ?7F@Z9PL?4I%UICI__(TD # :?K#F=S;W=IG&BJZ._S=F\&&D@ MW>GF@+D_E1)%,&X EM^1R;T!BF1E^(!ZFPSRZQ> 45R>7Q M^73FT]F5Z8S]3H!Z +]^"5C$R!0MRU#Z-KE=A_IZH5JPHK$FEN<(;AV5;'L$ MQ_WA)ETGRZ4H_79.E<.]_>=R>N:-M^4A4GP%C?^"V&7"&;3D=[L>V5(&A&?/:(CBB MZ_WG<*D77*(DO42)=NK@EKTN<5, M::%<,M3%(B"5Y""FV=*+T5U"HN1__ J% F'VL,*5 M3Y1?D2@CMTY;NBE1OJ\\Q[6)4JS9F4BW/Q $N\WW$O1S1F5M1)0Q%#P*<&'. M)\KO0I2WC7K? U&^DI162M?[]6AG0]L=/F7D1[V%5O@$]35"QU;K=:^;:,YG M0.H4E=!\;N)*6^R/7[%0(!(];$#V]]<.\;[/PL9-7/Q@\#VY\?8Y"P559! Y6<&_U^/H04U9I>+X4D95-NK<9_OE3:%W)JQ!>BHN+2:GI"GTYUK6[ITL1A M:[@$VSFY,4OWU[-2+SVFQ;$X '4]G'E>Q-'2S[D]+I>-O2.*.DPB]+YO1Z#B/"M.7P@$1 1! M&9Q^_'E)6/K"/_N#_\NZ#_Z M,_RKXQA1$@J>AV]2&\W"^T*QTX'X]ZZ'">$?PK\C^*>KV'1;GV.NL&@9 ]]= M+X1E\\KUOU_&:$2^.['$O\N[ZOX,_Q:;K.\(K/?\=C9R+?G3CCWP6]HG^&?Z:Q M5/W95%T+F_5HC@V[\F:\A6T'WO>;'J3'_#=T+Z+JW?-]]6XN]<@1IZC?C3\R M!"JK]#I"+I+Z5O@CC2KOQ6$C".*10=598[$3C_2[)8701EQJ(_!'$NU$+';B MD478%(N-0%(B+CN!CD1,-@))B=/NQ.^UDR]U#UMI'9M1UT>"Y8 KUY9*$ MU",5[[J<9RW1^JYDN$->2)V7(#&KT8H $0'B+P#QBDM(G;5&*P+,0\"\95Y! MD!I#2/U*$;Y30<#.KW'%+'_28HOO.Z C7^NG*R_^D45_W>_WSK M;QL-WH9B),C'Y%-C^$M#PQUR0]S@X(^YX0]+L>Z4H:B#[+*:[V-0R6).L:[LOO(03^!X,2 *3/)EN%#5)3I=;_ 2 D19W.F!SZ@V; M)SX9;[;;<4D?=J>]K!RPN-Q(+K*CRKBAMYHG3KG"?R/B;,^:_(XS:\%LI+GU M<3N<;OTG?^[CS79A9OASF!E;9JKXW\[R>:2'$\/MAB?&?!3DRP0N6:%WF"XO0)3 MI[_]X!CR(<71#WB*/ ^_L]$@(D+X\_#[5Y,J+LGOF4Y?6?#ZM"FT\_5ZVIE, M]2FM WYG(,+C21QP._% 4S3B>(3PG^7XWPZCOR3'YX@.VTCG5Z=B;:KBF(LM00X MCYKB)YSQY:'_B84EWO:-_7S:FA*XAF]HGK!6K$#5U)SKS#+.;![XX;/J8T%V M;<#07D-S0RY/;XX_@%\;GB2KX 7";&XY&TW+.+876& AOL?;:M9PPIS^'2OJL'S(QG3GE ?6@5'Z!EFI]4GK2I?^;(6]H<+Y&< /?VW9[UI08@Q6E/#WD')8: FL0PFL<+6AVP@.]<-8'/@*[VTDQH?S&6F*''CP&=HF ML7("2]W-"D"M_(+TS\!FAV]\,ZG]1, GAJ,^)B D?H92"3"I1#@?PP[7[R7D MQ-QU(+H[MFPEY'#[;AM.6]K< MK>#$@7?@76X.5=0'E-[3@=Q27#?SPE[CT= ML'R]JAB%2<\62+Q(4?U\NS1>\"\/6+&6B\41:U>VA)-2QGUA-BN7JR6-&W$$ M.&)4\H%(,@\4?>2$N3_)D9!#>B3T'4%@G;).IO7_O."U6 \%=0HJHO]8AJUA M^RA5J._-03+]1ML''T)4,5(5@_F/W_'W-,\!;(6L2.\Y\W&EF5Z*'O9KF M*>S&UYP"^<#5)IKM 5;999O6'%_K@)>D+7#XR6! M% +J ."^H&T+L\SW'V?GM+2T@@L/=ENT- M/)&.ZWL04, 2[ 1 "%>SE4W"!^?&>Y)%LCH-/!^>6B\4+E <[/\ "+>);.M: M0I<-.P%D!5P;Q'H7<#40"$]"Q=66LA7L'@<0WX"7QLK3'"Q'MD.Q(8-?;1T# M7\W B*6V>R?@4S\ @FAE^!/PBOH1>OX%7_HW%#2 :Q\3HNUJ NV@/IP5KM) M/\T++F>?0(V!16 >0#8 KR,_X3WC8P(*/H"VSA-]P(,^^W8@O'P#"+=7]$@8 M7F(_I8>$["=6$T.9).8.H,-..L,7 K7+DCW/&!L[/-R]ZR]M/0$C8 MF@]^#\D*-#<5?JG"W\([OY#G@,CT=R@+J%J?:SMX\([CW2Z\_474OF)IL@M] M%I,G)GK.^8?\A^?_W_[S*.7AVHL!\;\?]OK\$ M?;&L)RE"AEX57<-V*0WR&+SYNVRMY(VW3^HF'O'G^]7OSQ>ID! )^I%._2?Q M\U=(C@-:PE3R%Q1[E4V^^ZO7^>1/GWV05_&T+5 DL0C8,@U(M+7#D! MU%(@>?[5J6>.AH/!WX_5K'CZ"(!0F)\/V#/CA(GVWK.HDU_F7OR*+5]3]1BY MY%!>29JJ,4Q2IB65)3B)5JF1-!IQBD2,4MR8P4DFB:O?=F^5]XZ>26>A;B=8 M>FUN9#Y3YVH%00MX*%O?CIP5AE)[E!RPPH(HFK[5[GHD#TPL[[#K55\'(P_>7IYTEVS3L'EQ1HR:N:U#MPRY"48>O'W"%+=8CZ72 MYJ*7;/NIE.G(0UVB#M_.-"MKK$C/-O@B3=K3GM?C'6D%1AZ\/37-#KGV,%?% M#;K=\Y=] 3-233#RX.T9B4J2.8]P\5EKM)@W>WY%$%:[:\/7(S=-U6P'R7'6 MW/1]TND,R4FY"=W/!V]?RH-!>5A)BB*F4?XR<-NJA<&1!V_/SGL]RL1H5C"F MY+*S7B^(A0-K"A_NN]C,9;W.##/;>=KH%MX<]^B4..+G32DEX6]'\DVEG5MO6Z20 MSRGR:DN:I1ZQ B,/YDD%;8VNR%Q%,"J.2?FFSO3[/!AY,,^&.Q@)\PPYQS=\ MD;$GF-QU9?AV]NU(+""Z"CVU)T*FV<2Q_+"=(@NZQ![.<^T0F64P(G5SENW0K2TK<"1S\,R26,].&TL+[VDIGIL9G>+6U"7N\)F-85V:%7L49LJNW^V6 MR$%RAL&1!\^D[6[>;KC&"E\D9UFE4+=]N0C.)G[X4*]NU)@BB1MFC["9H!XH MR2:W@D.IMT/-K19HS+ ABTR)J_.X/ 2BL2D1Q.%31]-LER_7.!MGA&Q^;?;S M4ZH;#CW8ISR%#?!2B6V;FEXCA#&1&N6&/!QZL%'YWDKN>$Z0P;%T"6,:,Z3Y'B27,&A M!UL@K5J#K:#P*0%;9?F!+ZP(KQ4./3@L5,8RQX-2KX-OC%P7F:3E\ZL$$&EE:)=+.:BTRZ6)7R)L+*RT "AR1*&E, M:K;21G8I8/JVVV,%S!H0<3T+'T M,).9L@UAHS(B2#J9X412F 4/AQ[,M:/E&%)@X:VTR4A] M2I SD[E>:<*A!^@BKOV 83;CB4DNC'[):&_8<1\,/2(UN)&C*VZ3WH@S+&5A M*9:M3*&F=$1L. 6[YQ4ZL@PV+UYEBVK1) M!DWA@MEV%NE^T0]''I ++TH6%7?F?""W&";YDK?X/DR M6-81L;%:<>X0KWL8WNZU?,%VDUM]I<.A!T\U4OW"W#.L--Z;Y?U]E=>&UEHJF! MI=7'+QQ0H1?AB',/EI(+C;!##U\S)\ES:9?':_Z;@: M.Y;EK*!G*;Q&]Q+>Q%F%OI"='\J#KI&/_&^O/39_A?KC"WM^[_K+X<0SVRJ+Y<+*IS/+(DVHA8; 3^;JLM MM!$7VHC4^RW/T#Y<:!_(1_;=_M!H(RZ&3$A"Q&$?N$<:[4,,]H%X3*$#$8^- M0"I3+#:">R20J#[A1GP^X?A7._*A@7UN0NS#'I(,I1"'!5E"AXNJ*<[.XX3! MN+KO@:UJ+OSMX.O=57X86W*I]B#OF\7G)M]7:QJ17ZUIQ#ZR7*QKFKQPIYVH M;L%'!L:9PXK>18^3%KKZ,E,0^&.\"]VM/ZIE$KD>@:3]74K[I\CNJY+T2*Z?;/N#Y^!Y)-:O7JS'FP:Q%^+RKW1< M),J1*+\"4;[/YD*R_#YE^5^[I+>_G]+@G%,I=4BD(Y%^I2(]# =$PCR.POS7 MM7+O2VJ_3+V^%LE]FMK(!ZN] QE]F(V.A/3="&DDDT,SY65P/I+-<93-ASP< MJ>6UD^'Q*7O_^ZC_LZ3*M8CXJS3.KYA%WM2D05K!W6@%49KN5WQ@7F7U(34B M]FK$79SLBRSR@[RIFUACU/K-A;CU]D_D![DT-['&RVA9D2_R#J#U[,Z3$R[R M:UI.U%TTTK(EVXH&RV*69#N0W5!_#XFL4\;K._W.U5F$1 M@',.:[4X-O0,A77$GVN5_XQ%ZOR\(.*?_4A/!<27^3FEKH;UNJF5BD.V2V!; M,_6J@#A&_4[]\,\5DJEI?GWI29)SK=QM!+YZSAUU6F7Z'>TQG//!WQ<$8[HO'V\?GM,;+AN.$7ON\:HR"L M6MEQ&C)XC/\>?%II06YT-Z4ROBDD_54IQ_:4>E-BH5%&, \HQ-WS+F$>]XV$=S.MH6NRVZ9YF9 MB5U84$U27J]7WWX<>KUNYCKL7GU<$=F!\7*(G?F6[8:MQ%\AS><$XA%AUZN8 MDH[G^A73:"OXU#3*%:'+2UQH!28?DB2#KN=N['HN(E,QWA!T:NLQ7JM% O?B M-F:\&.!*)6X\+-"3"UUADYIFG4I^8@8V9DWYZL!.AT*7^X30O;*[JQ>-N">. M!5_\TY[\N OW?=B//VE4V)%H'[51M]O/I.!WW=3!C,'/!M@$1_V5/4D:=7N1 M2[UZ MZTCU$HXM"'8T7&S'C->$^,1]A$]7>)_Y.J&L*KO*)$'=6C[9O?KS;C3Q[)\/ M"EN<*8#\S+=BS:*2JG/=8&)N!KJ_"*9%MFQ=,A/MET$>?G?8<4OU>D[L\=V. MSI0JC:*_D@@BO/AZH,C4L2"/$U9IBOH+U)]8$^R$[_<9)-K1IR)/8<2DTJA MCL=I>E)29=$8 M*Q*EM+9X.G,#*7:=M HVI]GKF7G)ES.BY/;GW I*1NXSDO$*[Z1N(K6),>&*VP"8KMRNNO&5#AO3&2L M_$GWZD=#.7;G#<&X/3OQY.'^!77":7U3G0J++E\_JHNI*16X\;-"32]WZNLF[)M?9X-A&9Y/I9*?/ MSWDH=;E/2-TKN[^ZDBR[2"W(4V?9,5XFE?6WHBG4:=/!*I.)NFXU498="NY' M67;HW@IEV:$LNPLK2B)H&#A)'8E)0A>52!"C++NXP50\[,TSX%.GR/:9'8;DO>[H%MI:@\'T&WHF"V=$5VZMU1PU4 ME\^J^=6M6]24B%\L^YDOYEJMRFHM)V<-(3,H5+S)+-TD%['(M6&ILNILY+$N M,O6%O+7U85^=ZQ*1A%=OU -.<"C-+ZK[N*B/:7S2 *.FQ$T"UB<;XE789',Q MG;+XHL,VZAN33K.96.3@^'XFF]=FK938LPO:P,;(I)AM0N@"UFZ*0EF"\GPHQC O5+^ZP\LR7\PA_Q:H7OYJ-R"R\F_O!&U]D#+(* M+[_H^[GZN_$U1IVR%M'&WN\ET[^="+5Z$86B52CVUCC932AR!=Y!]"*%)_8+A^!K6HN_.W@Z_"AW\,T MA$OEB5R52@6H#3_\WV_DMR\NF'UDN;,NF)V_NN-7-%@D^S=2.UZD-)PTN_." M<0U'U_QRUU]3ZT\SI/Z<*0C\D;DSIKAXL,LU,@49;Z[H.+YL7554^]*@%W5<@5;^ *GI/=D31#TNR)*>1?Z3A(IB&9=@4R;=\?"0FU^Q1J MB;\LQ_,T[^^$F^1ZV4#\6J07 M>\"Q[ZWPUSL]NCLY==AC TDK)*WV2NS+ DI(:L51:IVTNMRII%N$M=3^& ^? M2\1ZUR+\KM)TNV(6>=.#"LG+R\K+*^:7KS\C3.@6F_C007 MI\.EZPG&E RQT!^BJ;V.-O_2I7=B2H:8*D=(-$1V+"X1UGPQ.EQG$Z67?9)D M.Y#=38((.R61M],EZ6,W\LG,OUBT0X^R^]$%CW-,*NP3I$2%'>J(\[0W"NAI MI4),2K*8'[&W"J(18.B23$0 M&BE!7N,:2S2SHXDX'P@K"#ZP'6\RA3H4Q:=#T;UA\B_[$R&H.D,#HM[8VE:M MU$#"C75MI@A2N[J<\W' J&Q&J3EUDYZ+]1;1L>VBD:4&.L0H#BA(Q -!G[ # M4317"OL.T DF?'YNEP62V$?.)EX&(KVZEKWZ>X4;\A5%O,BH>PY=JI,YL>MD M3L).YM03+)+G,1K;II S1NU!R'3<<\\G?9P1CNB M\?;Q^>UAL^&XX1>^[QJCP(?!:QVG(8/'^$> U*:VPKHOI44<:RE%::DZ@)0 M2-G0TF0>4D=:N=W K!R3'OA^Y$; MD8L?F NU@B_TZJDU)VHMWLYO!6T\'7[=7(A:-*:E4C^O5[M#LZRJ^F3-_XT*SLM;O-;=VLRJ_*(3LJBE<6!K.-" M,Y!Z8''VF#_M%B\;[^AN,1IK,5X0=&X#,EZK10+WXF9F[!C@:B1N/,S-\PE= M9Q!DFW-AS N9GI Q)QUJ.9[H4.ARGQ&Z5W:!]3,F(C%Q+/CB%P;E89YUXDT> MV7T8D#^)5-C1:!\U4K?;SZ3@78!>M@YF#'XVP"XXZJ\,R@&1I=GNQM'Q>HEL M!Y1G=NJYYED-RAL']2=A%EV671R(L#,E(Z9!)$K=_5Q<1;V]D2MO=/0TN!%% M[G,1D6I+:'CC6G-K!MJD)1=;9KJ2C(^(_8Q&-]MFQ!'.;YJB7,O(S5:KE^YD M=*A$,$"C>R"21\.VT54EDL1_:&,BG+H=@_.< #4:)]?BL+',B@MB;DF+_&8F M.3P$*.X3 '6%=YJO$_&JLJM,$M3-Y>'=JTL/Y>-=,N+\S)=H&]H9NRF],C2XW?7^)TO%0.M[-8-4'YF=G(4Y\N=?HF;VR1F:8K5G2 MR%ADXTW4?ML?X/.MF+>9:EW=Z@%+AR %K$KN@2(HE(R'+M7N/>O@7I+QZ*,7 MZ&H<;_(T:F<=;T9!RZ!>>T>Y8[,>IJHM!A.6364E421 MT,ZD4P\,1Z-D/)2,AY+QHC<\D%A$R7C1RL4/K 5[O@8"QRQES(O M_&)@%)XO+R#G:GVA%6!KL===SH+I*MOJ)H&LHZ 92'$/!$K&N\&K192,AY+Q MD,"]MZNJJY&X\3 WSR=TZ[/B4I]9AHFW-\7II-]AY.U@!84N]QFA>V476$>2 M\739L..6BQ>I_7CJ7+Q@X6_'Z]:R)]2)8"55)DY#S.@H%P]E *!)?2XSP5$;K:I_B)'3+JX46># :4*ZQ9Q7:DN0V:$$Y:F-@2L[PXG,NUJ M)8N7*#IL8T P5YR)%SDD(;%[YXEW-VEWE1T&X+YOC!;:6H/!]2MZ)0M?1;=JK=;_&*0K@E.H$P,2/ 5I' M$[G^J_NWR GU>4OJ_2CWLP2YG_GF;IW"M/%DI)DX!F-"MA2[&&'^%K6Q MC$4EJ[.B;&[:TZ)/^TH-@SID,DS\.]*$#V7]7>9J+O)C&I^TP,A)$;]Y0,C@9=:BN2!'KU.+6.0-MFC%3Q,#PA7J0V\]SDJ+PKRS@L@5Y@VR MY-';#)0WB-2S6%#JE[>UD5/J)M'N _M;*E/E2K6!M879MM+.NM) ])JQZ%4Z MRQAE?L'J+7&6%>V<:BYZV4((.2G+X M*OYWBOGXM.W^$GSYV:,&9@W9PK #>:>%7@04?G>::%)H4FA2:%)H4FA2:%)H M4FA2-SBI_ZK&\L?_ S_V3U$L37:AO3=Y>M6S[09?^607X_A_SF*A*1K,C=NO MD:1?Q$'N%@POWIYG'?[\O__GY>Q_6J"8XEB.^WUO9KY8UF1GY)&AQ:EKV,C5 M9!.3Q^#-WV5K)6^\O5$+[']F?V?\_=E4A81(T(]TZC^)G[]"[)O,4L;^]]W?[7_*#1-]Y\YG@'-@N^N!OWN2PT^^]53PVWQG?EWDGADSK0K M;T)1J1?W&')BXD)S]E^=>N8H#\+?@5T&S$OKGY=V]=-'WWYTH/D&(U$ST#H. M"Z\\L:3\&;9\3=5CY))#@U-*CC6:Y48C:31F*8EFDXK$C1A24N0DJ<@$3B9Q MY=ONK?+>1#4Z4MT;5D0+GZUIJM&I-3.#9%,BI.3;D85):B@T,[2&E\51@4'_M!1O;2P$ B7DNGMMJ/I8.3!,P?+Z7C3+!J^F!FI3LL9 M&RO6XL%(]NU(MNWGU4!T>+/75U/;!57%9 4^DR#>#JUM%DUEDW;RY@S7>D$> M7^FDOW:W4JD(@+Z5%6] R.-:4: E_.])N8K->=FD8(FGE!^MR MVA2SX/7)PY&E3BF?93)Y3,"(LE/NL?W)H !''KQ]6^5Z9H!/YN9L,A(6(B_W MA_4F&'E IA0E;#)*A9)Q+(.9:RNK\,GR2@J]I:]'-MHCO50LZ5UQ8V:#XIRM M;PQD&;:?GS E74H=TDF9-K;9(@H<.P(_7)/;F3;S M#:SDB7EMHY7T2J6.;59PZ,%3-1]WR@UAH>/YS0QOU9GQJE4)GWJPJM4XRWG= M.IL2\P*N+Y)IE:BF>#CT<++SIFJ9C++$A#)=YK+\J&S5QSK8T\,9;%)V6JZ5 ML2&.!=6\KR=K"C7)AT,/"#O,NG9*[&:V MHM&QA\T<6UO*U7 "AWQ5Q-=!H.?RBA!TZJ[(^R[9:8:/?5[8*Q_BNW7+J9?A M4Y2T:C+5IKZ:RSA3;]@E:DO86U]_ZSW-R8;;E:U RQJ>8CE>X&I>![PA;3F* M^>08'4FEKK!8K8;\6&@KQG TG\^;RJCY+:%YBCP'3_/=0#N7;"?(S\4HU!Q? M2S")T!_[WKCGB/$/QB4@:1)+2)O$3),A99ZJL#TY?,^\,VUEHJF!I=7'SWO$ M>Y[F>[RM5@PYU)X-S:ONIJ;6[1:,*H-Q9&G9,[Q0B3G<22ME<&QY2I3%LL-+ MVPPSHCH;_4P[^8ZK^NW6[I:6D&TU8?U?B$?PL?N_D&]?,R+;4THK@%4;$-.R!Y4_6 >]GW_RTM20U1V6N?>P GU<3GPG?T'.VT\_.25SO[BDNIIS*%- MY+O[B3V]D-@=K,_% B:9#TH(O5")7SS? <\< W+M3;W]OS%X1?=]9^"L )T^ MM"V>;+WPQ?NA\LASK,#7SFQFG-"0C@TY$'#:">,311L1A(]@/4O/11ESL1#!(1L1C(Q TQ6(C4H\DVH@X; 2" MIMAL!(*F6&P$\\A1:"-.MQ&_F?3[H:/O\[V.["QK<.P$^\BR= M.<@HIE3YR,US79RA.!;\\'^_L=^^2@_ND:(BK=_!?H*+WKOMA'>,NVNN\&IL M]^O+:\_=)P&L5O%'S;:0:+DYT?)\?LBOGA\"/W?;CC\]'T?N@T^6G7^36/IE M7N#.76OR3UDA#"38L0!QLB3G]QT ]\8#["-Y-3QPNBI#B =>>R>Y\_8?.R$/ M4$@EBKU*Q!Z0X/TH0;BOO_IY<.1/I@)=L0D!X^.N12\D\42_8\8VS C!/P+]F;)+1%8"QE"_K OY^NIAT7 WK$[4Q%4V;Z MVF31[D82$>J31B0Z9<>E.R++40,3':O/Z<*(?]"Q^@U[$QTK=*S0L3JY^7DW MQ^H*;M3$Q_9CHN.&(5.;%^U-K^%N[ HX_M(Q,O^^QN#1C[IEGK5B./5<"_RY M8$EZ4_T90IASM44 >RR_JAO^//;%2.^YE,E3R?#GP88MVXHA6T7;\]T CGWU M,+&]/X!IP[)^MMEZ>DR+-3S!2=%+DR%)?KPP2F:!_GI'F(SL382?WB'>S\BN MNP&S#M=SI+YX+CNCZT6NQ@CYM$FH5"ON_D+ I-'F.YKU1!YA=4$^X M.H3X*#OXBOOI1AW/A-CNZYF?=R"8GG\M&)HKN\ID$\9S'9=-17L>^%XX@'PK MDF(JZ_B*-*Z.G&H;#T:#XJK:[C,W41OQH+Q8QA& MAAC_QN,K$>,CQK_XNN,0 7E*QK^"NZ>,X\X=5_8/;)7$#=PCWWG^UZ_ M/0.6 B9Z)-##F*98>HZY#9%,:XP\RJP*:P^VT81!C?0#1[(HJ/%ZW)TW&=1X M/=%E1%RBR]X'(7J%=[F%4M+%LBNM6X(XS&:X*$&(3Y8QK3NODW@P5.FT&V0# MVX<->IES@E#45S((A&)TB8@BJQ';W6Z08]0.AK-GUT6]P+N\(3N=?1HO1U#T M"FBL-9G@MQ Y02MMNS,\UZZP,YXB8,V*P?412)U/ILUZC.' M7-3W?"EY;JWT_G8Y'MQ].I,IWOQZ/:Z<.TT4_'/AG!_42RLQ<#DQ+U:*Y*+4 MJS::32"2U)9)$3D#!VW5GNY)8^"G:/P^7]25T& MAVMYS<@48&35"0#^1G2)TI9_>:L?.2T^?ZK?)=35.B:VF&G,. VUAVMLO96R:DZ[8$5I2HUK M1FZVGA?*>,9ER@,J'3#=A0[1[[W0]Q.5%HG#E>GI="^$:1^'@D1.B_O#M+/[ MGA0M54DUV(UO:M/YDI8*FS'3B5*C:VOYD3R<8U6!(7/\9D"T[%I[!3&- QH= M3CZP!(Y #8':J4(^(J?%J4#MV8WTDEZA*^F_/CR1/_:GIA;,P$24V%@C)R2C M88.W^-\IYNV\.A,MD7%FX)V;A.;Y +I\\'0??#H&*)E80IA,..-/U&9+K Q_ M$OZE;*CAGX!_&*Z:F,NNOPF?)(="!4QS:2C:0P+PI#))!![X6P!7@6PE?%=6 MP=_;:@),&#"Q;RRUQ!SL"1CB.8&K:&IB[#JSW9.QW9/GKK,T *MZ"?!P.:&" MB6X2(]DSP#J38'_WB[9&_BN#YXA+__=#?_\4[VA"1RH-S<[%\3KM+[^R&&4U ! M4,+:F!E;^.5N\N'TC% N/H#_*U8 #^+^30:\ P$42,"D M5>]QQ_YG8?;WN>PKW"^'@D]B%2Y)R$E%HI*$*M&DHD@<2R:EE$9K*4;A5%)) M@1?\5][_!1"5J5*?IS&_5,-E9Y[VRYI<#JBF1$@'(\=NSQ_31@%P6 MVIE%B0+)8#MI'T^E4[MVR"D4?61''-N3E.D<)F@8\:[:[3 M7.3#H0=KLE0*:UC+66!FL-&$;ZV3&:JH2]3AFC)",BU7U)R#U[,M,EA5Z]V> MU00C#];DN 8[S)#EH8"U4DQ;G]'SC0:?>;"F>39E:_UFR<(#M[FJ%H>%=2X) M1QZN:;86@W&39KHXL^AP^216*+6,<.C!FI:FVBW7\"4O;C9!AJZRFUR[Q4NT M=/!0UQU1KJN8E!#HDFI21MJWV*:4/!PY6+4X-?!(6LCD!I0\S;M3QM7!R ,Z M%5M.BZ+6_E+$])2DEO+95G4+1Q+$VZ$% J_6C6QK(I ZIN>7=)NFMI6E7%&6E5H&CCPD:;6R M&N6&2\ CLU%];+E&;UZ=AD,/9HI[ /@F@9@6ZB0IE!HZHY:)<.@!]4U (F694&@]7 T27N<&3#K/46UH8I MX5ARGJ2[79-A31@F?4#]X830YX4./A';56SK<[DA(PLK,/* I-/5A.1GA1(G M8I.@LIQ18L9HP&<>D'1D8*/58CCK"T&1[U271JY8#H.TV0/.RXF\.,F-9'S& MC3MMH5.E2CK,M3HD/MWGVU9W7%?Q8%)-I\RF.N54N/@CN#-;E5,\CY$",[>H M9K!BJX(:WB ?/#7?99PJD5\PHI9O=7N*@ E<)8PM.Z 4*>)ERQKW9@+&8T;# M+.O%$1XZ4PZ>.FJ/!TV7G6A"?KYT)*^]2([E)AQZ\%1>TUOBM)TQQ8W2ZCOE MI3,<\>'0 V*M53'=XU>CB;CAR=NJF'S- MU6F/3LW)XO6VU.^/!BE\DP02HPZ=BTQF88[4^P^M>9ZZQ"MG, M+<*A!T^5&EDQV6_75J*,-?J=+2\M@G4X]&!9[;DOLEW:,05YJNO;#"L4-!$L MZPC\+&Q[:+)&DQ SJNLQJK]).:,F''HP@:!731-=15N)6C)'+;NE3M)H AY( M'C(VW_*=*N6K!9$9C_#J8C7J>M,F''K V< ^+BS:+:IJ,D 0:9B2)5=4^-1# MANT.[3Q."86>8'0*Z4*R[1(VW*[D3XY]I8*\H+6%O??VML5VTET#I"LO>F!A.9$%6 M"@K66SF\I#1WS@_##C25]]\9)\%AQ#>@FBKR'$S;=P/M#!9D:" 1Y.>LI)H# M5.34WE9*_*362P4U_);XYQ/&P+.Q=>:=;BL330TLK3[^M8.E!?5O!2BLZ M<,SACG*3L=9(98BV4%<%;9,5\$I[UCS3'KVC++_=--Z#IE0IL+6=]X/"'W:_ M0"+M+(B]^3:1GPPWQ[*<%;0"C)_G /S^9!2\W=2_P#?^Q D\8+9X?W\/=^UI MT&ZI3XX !3Q6GGO:]_TO+U<%%S'9,10P4;!PG^W]NC!+&_O?,?P19[D4D6*9 MY'_V'H/=5R]<"%AHZH>?//EJ?#J+(Q(.;>4-G_&X,.E.] 89%-; 7(\\_<\0S(7=]=S0JMUC?/?/*BA"_> M#Y5'GF,%OO9FH9D3F7!SV 9ES,=D(YA$YFDZX#[^9!OFA M[_NR#6(OE(KSODOM'GKB?NC@O>JFN(@USB@9[X$&'_D8[_-T?.3PNR[.4!P+ M?OB_W\AO7^82ZKRM"]A/,,E[@1MYU_&\DZ5YO.]2N;?-3SW2YX6(.&W^!U;K M_>U]*M9;S^NZJ^FRKQW):T&V 5( H[8-_I2_6]I,-FPPH]/)MAO:]5,H-MR[ MWN+(&8"?.6!!6TT]F7Q#FNU5:;:![6K@3T_' 4B]O3+U]N0<@'3P[;3;"TI9_RNDP8<)]2H)_RB3?7(OB>R96 M.)6*>]5_BD7Z, .OAH/;VS98*?L7C$;6([G:=?B[(TQ M&Z2NF@M@!9L=<<(R-M>G&+^WN(SL31+:(C# VF#2ZO=K48%^G?T9-7GH@Z^N,WHBB-,^9KOXJ]"G[7B8;2NSPNU^GD_-><*>2Z"?3LA MSMT^RWV42/C[2/]#'3NJ)YL$82(,?7"U-YKB^U9%O7PIKB\%]56)0UF/VZ(GE8 M4"QCR9[WJ@XY-'=A\3'P/^>?O)WG>R"AO?/7J/>]Y]T>#NZ0*A 9;FJ'#- M';#DSL35M"I8YV3_BCQG=\5-;IPU9U068XU:2MZD5J^*FF/@0'Q7 QX;GH+2,X_EI6&/\2*>&=2F7WN:$X5*8V70PE=(IO3R"Q8*3WWZ0W /. M<.=HY+ES3T0K+DW"GJO_.11;UNI$D/J$D_@U7EF GYZ/4 M=$Z;ALD13:?5SV=8V(CW75?6M>5HW8,[*[*HR%M?Y3ULY5T$FE\FA2OB14;M M2+F@W^3&%WF9["^TDQ>RLF]\C9=)'(L<7)$J WVU;ME3_?& M*0;L6O"B91S)F+XB2?X1C39J:\Q,$X=()Y()/L316%1;6%,XN&-U+I%1"4!/'M!\D<2,F_48D%I)7_JBA"C(0D J S ]!O MA(A;ZTK.J"]Y%:\W#+5D>=/M?!IB#+W3QJDKKW9P_HJY-PZ-EX]-B-P]>+XR M)^)XU!\M<+XK+C2=IEVGW,_;S7.[]ZH-04NGTXT!OEE-,6E>PS0L>XDBMC=^ M-.XBFB[R*)"HU(?SH4!1+_N8;[53ID;JPXZ8#^:K0J2U(1:C%EE)4IN)2,H\ M5F6*?FK>7DD$#IUR-/' I)+G<\I%'/9VH_$Y<5MUY)$]"$/VUQB'X*S+N4QO'BH^3B@C:O 5/Z?F MCM'2@,\^BPP92>P.USJQP0X1<'BL(0RS9>3M8]"VLLDO/^*DJO)];,Y3($T>B+ M[8&^:0[GC2*[T(&I ;V>R0<*<;\AMM/ M;K0].=TME,V9Q_8[S)*M!^8JA!'H]GO@DC<:GHA"L*XI.O&D[CO#_EWWW9Y_ MTH9EO?'MOSC<':=N:P--=I\>GJX61F=')(XOGVNMSIJ(OF1 +V&!FZ.JD'DD0!GBC M$P5XWB-^?#FPT\:\IER;U$9BOET0FG5YO>PL=0@J,+#S6#O!*SE:D:L;M[]& M%-AY$Q#QD1]85\94LVIYEI#Q>X-%?8-M"C0/(0+Z@0\A @5T(HL$!71>&UK\ MAD=WQ"Y6BY34]LP@+01\7BO[7C(T1*!'%UHBU'N6" KDO..8M-@&:&;)[= M\WM_*'2OU^TH,O9LB+$47*6?Z_04D9&&K#[ E4JFK$?I+QZG.4D8VY,F3FYJ M"V71%12<74D$!?W%Y -'G\6[@XITWM>Z4>#K/>PR"GR-#7/'QND9>R'Y98_G MO-4NEH#XW!X-9]7:.P4Y8^ '_5-"]P-%\9?% MG(LSDP6ATYU2>W2G*NM6-IIEX'F>Z6[]M+5JR/M!1..Q)]"ZP39J+[09_ M)^;KA.=8AIKX%Q[^=^M$>'*'1DR$&*ID49==?P>$[4;!\OI^:86"JE MZ&(]4C^K-AL,)F2J+.-!"AN-JKA@!JTFT/&@GY5]2!UI\W U8;E1ZT<[=]M] MH]23AQ6A%$*I4T?_EJTJKY.S'B,89*K:[2^#=%#@(72QP$!%P;]_Y"V_;]1Z M#,](KDH%7#^=)T,M"_KDC[2X06'(R!+\ M37=\?,$*J5B7QJW?\//GO-QRHW56N&@H'LO59L:*9%8A--'0 F2X]RS ZPR' MCL06C,$-Z?_\BV#PDT22Q"$0^HA.M%O@Z989BUU[Q:WAP)4&EPZF;ZG_1'O1 M_5KJ4$#JJ$X <"@BT3OZ)9G"YI:CLX:A1DZ+SXO@=PD5<_E,M7R:YO1>%9^Q MW9DD69E%AHJTC"N?\]05U1.[@KR>#V9J)>.32UXBDF%'>3+UP!Z]*S\)-\8P M8C4:B/IE<&/DQ_+R$/7+L-;(:8$@*D8.5+G+V]U.9^0*,A-P?7'5K27[38A; M[+H%Y6K! M9-I"?=JD%O/68@5A"CI/">IH+=\3*5?(_$/FW^=BGR,G!5*M+NLX30?JD,JU M*[*8X;/Z-CF?VI:AC_3M&;]VG__7A!'X$#(^NKF$C(+I,3!Z#-W^7K96\\?:^(>)% M4-[WYS,/"9&@'^G4?Q(_?X7D.*#E3%YC+RCV!!28I8W][[N_VG\4GO']9XYG M0.[Z[FI P!I+#3[[U5/#;?&=^7>2>&3.M"LO\";$G!> (R5KJAXCEQR> M:XE2DYI,*)J$8\$5HEK]-)E#,/) M=G-6<1>R5)JM)%(BWX[,S4?E,F5F-:&>G*J;:EVG"C.E7X_LE*GF(E4G M1KB<=-Q&83P9X%LXDGT[LEE9"5:0ZWDXV6I3>G^ZV>;[U2G=,_Q M17F[7%AUN[K9A@^%,/AZJ#_PR,*XZE1-1JS6NFN<36WE\*FI TI)_6JF8(UI M7!LT\>%D7E*3S$JB)?SM2'HZRC5;O94E;J36NE\516&:6TG)PY%D+34S32K5 M-'O48#DS2+YD-GDP\H"D#46N8^2 W)K!(DTR?4PMU'E=2AX22L$W0H_,.S;> M:ZQ+%9=;>V87CCPDU+0TH)J$Y+!")FTNR*I?:-8-.-'#U?>=#8Z7TXYJ&KYL MR/)RM13J*R!%#];D+T4S5>:4GD":OHZ1RT*[O5E)[.%(;)1LD+-4JBQDAJ-) MGEY0(N$W)>YP9$:;%$=IT1R)]25C#DOS95LB>3#R@$ZI16=-C=.X+;:](KY> M3B=R=@2?>4"G86ME\6.T&EJC>=";F94\5Z^O>JTDN74U@^[PB=C!;FD@7\T;9:)L9,2>(PG;5 M2>N[KB@'8RFUO:ZHE"J; 5M06C5R0=K$KO7!X(/E%O]3J]3#K M:>S!RN@NEVVW:TQ+R"LK?XU79W6F'!;@.IA">REB:G8RG9OMG&H8M)KW)]KJ MJ;[GZZ%Z=F"("R=I"-J,SHU;A3$VH9K[.G^OQV:;N-)M\-.DL% ;NJ7W_2I% MA8]]YC"@\T EUK"#,+%E]Y@M>V-B.)$%62DH6&_E\)+2E.!0XD]2D59- MIMK45W,99^H-NT1M"7OKZV^5U=>>/6@VU^VBO=0\'P8G>*&([( WIBU',;_M MYSPPDGRWOLG4Q04WH?G.E..9;?-;0@,:[1P\W7<#[;2:F6$#9=+_3C&'2@%! M/BL%G8F6D'7=U728@S<&YD!B">V!Q%^&G? G3N !2\/[.P%^)H .#Y1_*/Y_ MINDE)IJE)D8;,%8#6L$,: ,;^+>*%4 %"3["TQ(*-"N,L:&I"=E+*+(W26B+ MP !O@B3[.P'>)4,;9T_9A 7(FMAK"/!OP$M+@:WM+I4I_&'W"]RV<&I930DM MDZ?OB9_?DPG9U> 3QHYE.2OO>R)45$)M_UG[W%F-0/.TY+FG?=__\I*ND(Q/ M&BA49)2= K37M4/54 Y\9__!3C$,/WFE/KXP/)_&'*KGOKN?V-,+B9W^]LGH M#J!;IMX+.7NAG;UXO@.>.08$VELA^W]CT.K^OM.U84K6AVKND]D1OG@_5!YY MCA7XVIDUWJ-^FMU \.5G+:V?-LH?N]A3[P8JHXVXV$;@)-J(&&P$^T@0:"-B ML!% 1KQ;=QMM!(*F^]H(YI%%T!2'C2 >DTA]C<=&(&B*Q48@:(K)1B"M*38; M@: I%AN!H"DF&X&@*38;@: I%AN!H"DF&X&@*38;@: I%AO!/*;>+=F)-N+W M-N)W\]\_NB&]W*I9\&54F7KO7T[>!PW>!\1[H,%'5W*7*1\<-ZI\I+/< V>@ MT_&Q$7&OI^/]*YI[I0HZ+Y6=7+4C=2D0NL8+7=D#$KRWUR]+X1[^/$"(Y]-!?G0ZGHJ@$O15'P58 M?B8!AIN:_Y1VZHP3QL]DV@\20Q'"OH>PG^.AU"-[W3Q4>\Y*/AOCO'!ZQZC M_X6=XO?&5^)KWH$=:1':W#U7((F%>.@*)!9BG..,<]5\\X%$^IJY&$%AU5<% M45*/Y/QUQ1IL]]'GZ5(-X7A7T.5G81IXGA)/Y8._ZB"_:W/$;98* M5YPH%:&=#Q:KNF;(TGES5![IK8U]U*Z*H^ MT@RI+?6P87WF-/!%RQL6B7R0G$Z;4E*BOOT@D@_))/U.$_FKO5.ZU7,?E<)Z M?2CQ),0L[5='S7A 1;&6BPPK=C?.]?'^^Y^=U/"? MX-%V;O5J>'XGZ)EU@80\=YMN/,^$&RB*.!="<0L&('#K^N62GU]O5 M*EXTB(7#CB@9(DZ-YIEYMF>P7#+$*\XW1 MF9 G[K8>N>B1W=JFTA?*6$HKI9J#,I=K OHQP-0[WT72_9U'A$/QP:$X73_= MGL;SL9E)CX15?3 ?M4QL,V'Q,5OD2J(.B =OI0[]2Z>[E;J_XX=@)SZP$]?+ MKR]!T-IFB49+*R3%15H;XUAALE'6<;D8/X(YJ8[=Z,S3J;'(**905J:LU4Q# MS(%W8O0#>\YPN_L[?@AVKAYV+G.7=B;LB;W9->RGZ,Z6JYH!K:>6S"0]WX1F M5WC%AI ((=&-IO7$YR+O]K2>CPTOO+WN#9.EH21L-'.1+F:9I;2 GF=XOT<< M48'^^'[OQD\92J.ZE45&GG058;+OC6_M7?!OY"%[$6WM)=)2(E\DXM^;Y5^$ MO[>Q2,2_-[NUB'\1_U[SUMX)_T8?I7[AFC77$3M]EFK0E@8^\2> VL]UH5$U M:.0HOY7H[ AEX?TQP+TR?ASOJB-T(MT? R#&OWO&1XA_3^M&C(\8'S$^8OS[ M8X#[9?Q81H&AXLZW5MQYWR/[&IW5J&8SJJX(2%31/*\SD9_#*H_$3V*T,?-I MK2X),[&W*)NK%3.MZ1(',_>9!YJ\E9+-UWR:[_#J-,YY]==4B?DM GPJDR/+ M^IOEIF_B^?Q$4^IYM9 >\@ 2F&\_SE3( X6\Q54+B!P)_HE19OL5B_Z/,RFZ MF6#5;M4;=7/14-KC>7W^(TH9E'8 GGIMTUH/9-F5NYIQ=Z.7H4=MIQ@0\CZ#EL-V: M;J7!A!?JZ6HYG\QZ>GJL2P0.KSHHXH'!#[T<*#[ARB'C9-I@'.-MXGQ)\L?@ M$7=C*C6:F ,/[Y0$K#7OZ\MA9^MW5Q!.8)UA5&@80_XV&C; M&-:4DWR_*S+=PI :5[RJ3S8A;G -]ZM5X5T$ 0<<0..MSH(W$."/(W_#3$M M8EK$M(AIHV#:^ 69OV': YZ]F4#R<[2FNX_CY[BJYF*[P=^)^3KA.9:A)OZ% MA_]=K;,VXF5=H^?VVCNP?,*?RVTJS+92XJ8"YGB#@>#-I@L/&%($].>2#QR- M.H+?$)Q$EF%Y<^"#>L^=SRG<'P/.Z3.&)P8FNUD2=-I:-W2(2>=M/G?C1Q'A MT37@4;Q\R+>F 7WL6>8[E(;[M,GB=4M934#,$$>IK/""0H!#E6)^M,%2)BN-(/ZB^^ MBQOG=DO'0.'X1*O%19>U=/RI#?&K16$#!AY3#''/,1(^T!8$,.5 MQMH.>9&F7FJVO!(Y:A*XX?FI_"C9X3?FN1+,/VV(=$:]7C-92D[QNBR:0T/> M9L5)$\X;EH?A\ >&.)8*B;#@6K$ 62)79(G\%GR<,B#FZ\;(N++I:.+&2^.] MQ;RJ6/PBOC[JE<;/R(B7-O&)*)0<*3JNQ33P M0*OA$W4N:FD8A4+NJM)0^$=F1GB[\]^P@^*/_5@ 0F"[E)/N\E,& L6\8O!0 M !#D3RGP!=%Y\4GR7L(9)TJ!K>VPB,(?=K] X_0A83L)V;*]BXTM7 ?D-^]IVW+2TAC^_9 MY'5/R\=$9V* 0?")BAQX6L*?: EC-I<-%P9E>0G9U<#,8*, ![:0T)UPG^Z MVMS5/# B(2<\< Z-,< 5\*^YZ\P=-YP'6"M\F._XLI48@PYLX<.$?X MW(P#%F%OP'S!4^",#7!DP?-#ZH!WP#%O.R"\3ZL'0"/+ &0(&X""!_KA5L ' MR3MV@P^? )@Y^G#P'3CPH9KQ$*X4_#V@._C>!:NR-N"]EF%JX)?PZ2_7L#+ MA$<:(/HB,,"Z7R[">]7 =*0!QMEM(N0.L&6;/:'E&=P7N"K%\?S'W4D&Y_:I MW:F\D_AG/Q21'M9?3^/%0/#E)R_P7 WWI'T:QT0\H+FY5'\T[;238;*PF(D+;_W_S]Z7-B>N)&M_OQ'W M/Q ]<]Z8B0"/=J#/W(X0(/8=Q.(O"B$5("0DT,+VZ]\J26 P&+O=+,+61$P? M&Q=252Y/9F5E9:Z:K$ F:Z5!=;?5Q@ M,:64'#.K9%]B*%8@!>SH[8MNN9-R$A+6[64!,6:7/ MM(:U>C9&E18C@3X>";K\.)_GM1[OY$OC7+6JY!F1%9CCDSU5 MEN7\*CU:LD+\>"0[SO(Q9U&O<[GYW,H6\M(XWV\(B>.U)Y(YNI2:IG >C(#0 M?)[2\;Z!1F[7?F!)#QR-C&.Z2@I9CWOQS+:Q%]Q<-IA*8[2YC#0G-B6VWX_)1F2*KO&PR$9&%0XKN]Q 8K-1H3O=S!6_$* M^R,"H!O7)FD+6D, M9$<#M>$)XB+_Z)C"^1*CKI,%<\2G5\8SNTQG"]LSZ]T^7VGY3;6_B_D9!@M\09Q;XN?UA?XYH M2F./N5-Q%7/YHV]GZ=U(%1W;V'[@.OS>)P>W5O9V M8OX+<4_2/I:A%,>?XG^V9+Q)_(&U9<#M>3$4^*[<9E^ MBE/?;,FA8#_0DG\S>S9 MBGQ_6P36O*1D_J;-("N$?KP_WX0/SZKW]@3?MVB MXHG#V*L$T%6]WPB^GHA]7>B,(3AP'LK"QV0A R3W/J0A1\/XHF#A: M\3FV>EP\_O=(SR\FXW<\C/I3'4!1ADIP+C%>Y%)>[#F."4 +M0 MIK$HB[.?;7&5=O6GN=,>/\9\XER_D:ZTN%EC->!%,!@YBX56+I;1>0WJGA"/ M)IBK=)3SC,^]9?<>]PU"G7UPG;U\XL[O*VVHFF(EK-\?C$38\5S?R7QP5;Q-TO3=P7.U:D:LMBLRM M9D"WSJ!&HK.L:669MKE8G!;+6B:9'JQ8@4*F'B>C&'6!PFK,D0I MT*C42)0X6;;H@8((';9]C?.#+ZZ/X4[FRR#,U0(.'70?BX7,D=OBZB/Q2DEW M6HQ8' RP$C%,=,S,XGDBH2L4T)-(GMO.A%&'4%>_A:Y>+^KPV\HZUD>5JDIP M:W7=S5;Y 6>02;,!E16Z!53R7(SP,8,/IZ\"A>&'#^Y/[GVU/Q#P%$"ZW!O1 MKN9]N/KJW99[&\1JBK69U(:%-K_.\(,!6VQD#*TAQ+W819RAP]C%#6(7]]:! M$!N"B0W7\W8^! [J(MT=F+7:1(V-8K,<1LV(;F$$P<$-?"2)^&,'/FXOZ/>. MC/SI]8D_@KT#72:A+LN&@VXTWP?DSJ4-__-"J>,^KMU[X8&N%GF=TYO#(V16 MEX_QKJ!+FH.(S4H2-#JV];+G.P&%'1GO-80E! T6( MR"AYHAA<)TZI;[?4*TR6_6JNB.T!F[3/C!#0,#V!9H^1+6:,M!2*:2X*= MVEU[DNV]ZG.HR)WQ:B*O"PZBLG_0@*S=NH7&<*A((!J!4W"&$# <$WT1W0DS MMQ?$X,=(R!2XI#=4EW#G\10YIZ3_D97%K__"?[;?E^#L3&2[QMMJ05O3A)9U M6 OHX@;H\-H?0;V8'Y^HJ%SW;#MK]]___9_]V;]$%E#!),/\N;6B>\ORZQ81 MKD$=@=C !*(:$X?PS3]%;2FN+7^92?P)VUGHGSM+C @1H9ZH^%^1EQ\1.8YH MB6HQ[5'LH-:2]ZW#:DO^9WZQQ)^>="P >O;!4UVVV,;L)X$_,5?BRBO!)O?< M #$R-A%._:-=2Y\T'.AG*&70$FL']_C]CZ!NN 6NC&$$]0;V[C3X(BK^VF/P M6V)Y2-53Y/++"@[EY# ^B.-"@J1Q@4J2LB!*F"C$R402#&B"C!/QU^7EE;+#D=BLVI[DV[$Y7Q)BZ?%H-35&DX9WC^5P9(;N MKD1IWNWP4W*] MQ(-NG^R<)^%(?+="&GXAQ3H&4AE\>(GINU=C0R2\_7\>=4 M1^!*!:J!.Z4ROZ99+[_M55'#?KD8O1STNJ/1)P['@H;@JIOMDLF^H:[RI*O98:.3*+AAYSB2DV8W2E MTE.GBYA=7//%%BF[18*/EK]8Z+UAE2;7F+-JM]> ,W AQOI=TUZMRF)+^>$: MVW"Q0KVT2!HM'%2W/9$.AR['1CE6G!,.-I^2HI1HV(E^ @Y]77Y2P(<2)C$R MW.=2 R@SR00C#,0A)B1D0,D#; <_1PNU/LMD*L') MIBJ924M11]BTL1GF+)M>)0A.G."&X.CDMP-MO#WKS7ZZNU1:]$-;K)62*&I/5HY-JJM/#$FHYC::=; MBL7':SQ/N=)Z7%4T4ZJVV@-V@#FQMF7JP#HF!8KM2K,ZI_$AOW-PO;A]4 MEO2K2(Z-I5=AV74[W/K0B >RSYK=+:KNN)MN'N#^B; M2Y](,=&C$G1,?5+Z+X+NU/3MT;)/5%1]&D2@>RS:[[[[JQ?'I-YK3;WG#^T] M'Y6H'D*>;W>;V]]C*-;TT_-NEY!.[SJ6OJ/OOG@[5!Q8AN;8X,H^YF4"$"^[ M@C\]O8F[C91#3MR=$\Q3\FQ,/&3$C1A!/B7.GMJ&C+@1([R6V2$C[LX(_.EL M=<"0#[E^OKC?N$N"QZWI?JKS[._&: MKRX+R:=D_-%%X<]*O-_%JIQ;47EW(OOS0C(>&H4 &(7@-3AY[_#F"R[YO6.2 MJU^>" -KFWQ@L?U]\X"ON"2WXNZ/Y"@?\Z>W[NZP*L;!JX]OYPIO_?J'M.Z MWYMJ%RLRXUGN>R_G,NTQ\/N4\[Q?:8=/IJM^MM##P5VO-$2A$Q<5"T:B**JQ MD<6)/1:OY*W)K"LU!%J@X 8K2M)7Z6WC^B'WEN&+J:3G8]Q[.9=02<]U^-8J M2>RK)"'86<,8M!*]#>;TF*Q9&@L+O=RXKDIR!M;@)Z,,@:7C5;O5:,9IQKUT M$T,W-Q; MTJ^CQ;Z?%6KQ39RN#VFQ4*,SN=Z8:&"USJI#4RRO-S14?QLZ73ASKH_'Q;(; M[KV#>#1G)@R(A0&Q,P&QNQ?2ND<%L3=":G>G14"+BMW6G3QG?Q2P-.4-UFUQ MI?AXD*O6*YTTN13B7AR..=G1[G)9,/=&@P]DQEPJ(>*M8-W=5>3V8DANFY :/ M1O<.23X B0*1K15L$MTFN^NA212$Y*]@4R@0R6+!)M%MDLN"0*+00PH]I�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end